[
  {
    "id": "US20120107231A1",
    "text": "Metalloproteinase binding proteins AbstractProteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described. Claims (\n24\n)\n\n\n\n\n \n\n\n \n1\n.-\n77\n. (canceled)\n\n\n\n\n \n \n\n\n \n78\n. A method for treating cancer, the method comprising: administering, to a subject, a protein comprising a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence wherein the HC and the LC immunoglobulin variable domain sequences form an antigen binding site that binds to a human membrane-type-matrix metalloproteinase 14 (MMP-14) and wherein the HC immunoglobulin variable domain comprises HC complementarity determining region (CDR) 1, CDR2, and CDR3, wherein the HC CDR1 sequence comprises residues 31-35 of SEQ ID NO:156, the HC CDR2 sequence comprises residues 50-66 of SEQ ID NO:156, and the HC CDR3 sequence comprises residues 99-104 of SEQ ID NO:156; and the LC immunoglobulin variable domain comprises LC CDR1, CDR2, and CDR3, wherein the LC CDR1 sequence comprises residues 25-35 of SEQ ID NO:157, the LC CDR2 sequence comprises residues 51-57 of SEQ ID NO:157, and the LC CDR3 sequence comprises residues 90-99 of SEQ ID NO:157 in combination with one or more therapies for treating cancer.\n\n\n\n\n \n \n\n\n \n79\n. The method of \nclaim 78\n, wherein the one or more therapies for treating cancer are selected from the group consisting of: radiation therapy, chemotherapy, surgery and administration of a second agent.\n\n\n\n\n \n \n\n\n \n80\n. The method of \nclaim 79\n, wherein the radiation therapy is selected from the group consisting of: a radioisotope, a toxin short range radiation emitter, a β-emitter, an α-emitter, or a γ-emitter.\n\n\n\n\n \n \n\n\n \n81\n. The method of \nclaim 78\n, wherein the protein is administered prior to the administration of the one or more therapies for treating cancer or the protein is administered after the administration of the one or more therapies for treating cancer.\n\n\n\n\n \n \n\n\n \n82\n. The method of \nclaim 78\n, wherein the time between the sequential administration of the protein and the one or more additional therapies for treating cancer is minutes, hours, days, or weeks.\n\n\n\n\n \n \n\n\n \n83\n. The method of \nclaim 78\n, wherein the protein and the one or more therapies for treating cancer are administered as a single formulation or as two separate formulations.\n\n\n\n\n \n \n\n\n \n84\n. The method of \nclaim 78\n, wherein administration of the protein in combination with the one or more therapies for treating cancer permits administration of the one or more therapies for treating cancer at a dosage of at least 10% lower than would be used in the absence of the protein.\n\n\n\n\n \n \n\n\n \n85\n. The method of \nclaim 78\n, wherein the protein comprises a human antibody framework region or a primate antibody framework region.\n\n\n\n\n \n \n\n\n \n86\n. The method of \nclaim 78\n, wherein the protein is a humanized antibody or a primate antibody.\n\n\n\n\n \n \n\n\n \n87\n. The method of \nclaim 78\n, wherein the HC immunoglobulin variable domain sequence comprises SEQ ID NO: 156 and/or the LC immunoglobulin variable domain sequence comprises SEQ ID NO: 157.\n\n\n\n\n \n \n\n\n \n88\n. A method of treating cancer in a subject, the method comprising: administering, to a subject previously treated with one or more cancer therapies or undergoing treatment with one or more cancer therapies, a protein comprising a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence wherein the HC and the LC immunoglobulin variable domain sequences form an antigen binding site that binds to a human membrane-type-matrix metalloproteinase 14 (MMP-14) and wherein the HC immunoglobulin variable domain comprises HC complementarity determining region (CDR) 1, CDR2, and CDR3, wherein the HC CDR1 sequence comprises residues 31-35 of SEQ ID NO:156, the HC CDR2 sequence comprises residues 50-66 of SEQ ID NO:156, and the HC CDR3 sequence comprises residues 99-104 of SEQ ID NO:156; and the LC immunoglobulin variable domain comprises LC CDR1, CDR2, and CDR3, wherein the LC CDR1 sequence comprises residues 25-35 of SEQ ID NO:157, the LC CDR2 sequence comprises residues 51-57 of SEQ ID NO:157, and the LC CDR3 sequence comprises residues 90-99 of SEQ ID NO:157.\n\n\n\n\n \n \n\n\n \n89\n. The method of \nclaim 88\n, further comprising a step of selecting the subject that has been previously treated or is undergoing treatment with one or more cancer therapies.\n\n\n\n\n \n \n\n\n \n90\n. The method of \nclaim 88\n, wherein the selecting step comprises detecting MMP-14 expression in a sample obtained from the subject.\n\n\n\n\n \n \n\n\n \n91\n. The method of \nclaim 88\n, wherein the subject has been treated or is undergoing treatment with one or more therapies for treating cancer selected from the group consisting of: radiation therapy, chemotherapy, surgery and administration of an anti-cancer agent.\n\n\n\n\n \n \n\n\n \n92\n. The method of \nclaim 89\n, wherein the protein is administered minutes, hours, days or weeks after the subject has been treated with the one or more cancer therapies.\n\n\n\n\n \n \n\n\n \n93\n. The method of \nclaim 89\n, wherein the protein comprises a human antibody framework region or a primate antibody framework region.\n\n\n\n\n \n \n\n\n \n94\n. The method of \nclaim 88\n, wherein the protein is a humanized antibody or a primate antibody.\n\n\n\n\n \n \n\n\n \n95\n. The method of \nclaim 88\n, wherein the HC immunoglobulin variable domain sequence comprises SEQ ID NO: 156 and/or the LC immunoglobulin variable domain sequence comprises SEQ ID NO: 157.\n\n\n\n\n \n \n\n\n \n96\n. A kit comprising:\n\n(i) a protein comprising a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence wherein the HC and the LC immunoglobulin variable domain sequences form an antigen binding site that binds to a human membrane-type-matrix metalloproteinase 14 (MMP-14) and wherein the HC immunoglobulin variable domain comprises HC complementarity determining region (CDR) 1, CDR2, and CDR3, wherein the HC CDR1 sequence comprises residues 31-35 of SEQ ID NO:156, the HC CDR2 sequence comprises residues 50-66 of SEQ ID NO:156, and the HC CDR3 sequence comprises residues 99-104 of SEQ ID NO:156; and the LC immunoglobulin variable domain comprises LC CDR1, CDR2, and CDR3, wherein the LC CDR1 sequence comprises residues 25-35 of SEQ ID NO:157, the LC CDR2 sequence comprises residues 51-57 of SEQ ID NO:157, and the LC CDR3 sequence comprises residues 90-99 of SEQ ID NO:157; and\n \n(ii) at least one additional reagent for treating cancer in a subject.\n \n\n\n\n\n \n \n\n\n \n97\n. The kit of \nclaim 96\n, wherein the at least one additional reagent is an anti-cancer agent.\n\n\n\n\n \n \n\n\n \n98\n. The kit of \nclaim 96\n, further comprising a pharmaceutically acceptable carrier.\n\n\n\n\n \n \n\n\n \n99\n. The kit of \nclaim 96\n, further comprising instructions for selecting a subject that has been previously treated or is undergoing treatment with one or more cancer therapies.\n\n\n\n\n \n \n\n\n \n100\n. The kit of \nclaim 96\n, wherein the instructions for selecting a subject comprise instructions for detecting MMP-14 expression in a sample obtained from the subject. Description\n\n\n\n\nCROSS-REFERENCE TO RELATED APPLICATIONS\n\n\n \n \n \nThis application claims priority to U.S. Application Ser. No. 60/755,376, filed on Dec. 30, 2005; U.S. Application Ser. No. 60/805,567, filed on Jun. 22, 2006; and U.S. Application Ser. No. 60/870,566, filed on Dec. 18, 2006. The disclosures of the prior applications are considered part of (and are incorporated by reference in) the disclosure of this application.\n\n\n \nBACKGROUND\n\n\n \n \n \nThe membrane type (MT)—matrix metalloproteinases (MMPs) constitute a sub-group of membrane-anchored MMPs that are major mediators of pericellular proteolysis and physiological activators of pro-MMP-2. MT-MMPs activate the zymogenic form of MMP-2 (pro-MMP-2 or pro-gelatinase A) (Hernandez-Barrantes et al, 2002, Semin. Cancer Biol, 12:131-8; Zucker et al, 2003, Curr Top Dev Biol, 54: 1-74). MMP-2, in turn, can activate pro-MMP-9 (Toth et al, 2003, Biochem Biophys Res Commun, 308:386-95). The MT-MMPs comprise six members of plasma-tethered MMPs, which include four \ntype\n 1 transmembrane enzymes (MMP-14, -15, -16, and -24) and two glycosylphosphatidylinositol-anchored enzymes (MMP-17, and -25) (Zhao et al, 2004, J Biol Chem, 279: 8592-8601). In addition to being potent extracellular matrix (ECM)-degrading enzymes, the \ntype\n 1 transmembrane MT-MMPs can also initiate a cascade of zymogen activation on the cell surface.\n\n\n \nSUMMARY\n\n\n \n \n \nThis disclosure relates, inter alia, to proteins that bind MMP-14, herein referred to as “MMP-14 binding proteins,” and methods of identifying and using such proteins. These proteins include antibodies and antibody fragments (e.g., primate antibodies and Ribs, especially human antibodies and Fabs) that bind to and or inhibit MMP-14 (e.g., human MMP-14). The MMP-14 binding proteins can be used in the treatment of diseases, particularly human disease, such as cancer, in which excess or inappropriate activity of MMP-14 features. In many cases, the proteins have tolerable low or no toxicity.\n\n\n \n \n \n \nSome of these binding proteins also bind to and/or inhibit \nother type\n 1 transmembrane enzymes, such as MMP-16 and MMP-24. Ability to inhibit two or more of MMP-14, 16, and 24 is useful for treating diseases and conditions to which these MMPs collectively contribute.\n\n\n \n \n \n \nIn one aspect, the disclosure features a protein (e.g., an isolated protein) that hinds to MMP-14 (e.g., human MMP-14) and includes at least one immunoglobulin variable region. For example, the protein includes a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence. In one embodiment, the protein binds to and inhibits MMP-14, e.g., human MMP-14.\n\n\n \n \n \n \nThe protein can include one or more of the following characteristics: (a) a human CDR or to human framework region; (h) the HC immunoglobulin variable domain sequence comprises one or more CDRs that are at least 85, 88, 90, 92, 94, 95, 96, 97, 98, 99, or 100% identical to a CDR of a LC variable domain described herein; (c) the LC immunoglobulin variable domain sequence comprises one or more CDRs that are at least 85, 88, 90, 92, 94, 95, 96, 97, 98, 99, or 100% identical to a CDR of a HC variable domain described herein: (d) the LC immunoglobulin variable domain sequence is at least 85, 88, 90, 92, 94, 95, 96, 97, 98, 99, or 100% identical to a LC variable domain described herein; (e) the HC immunoglobulin variable domain sequence is at least 85, 88, 90, 92, 94, 95, 96, 97, 98, 99, or 100% identical to a HC variable domain described herein; (f) the protein binds an epitope hound by a protein described herein, or an epitope that overlaps with such epitope: and (g) a primate CDR or primate framework region.\n\n\n \n \n \n \nThe protein can bind to MMP-14, e.g., human MMP-14, with a binding affinity of at least 10\n5\n, 10\n6\n, 10\n7\n; 10\n8\n, 10\n9\n, 10\n10 \nand 10\n11 \nM\n−1\n. In one embodiment, the protein binds to MMP-14 with a K\noff \nslower than 1×10\n−3\n, 5×10\n−1 \ns\n−1\n, or 1×10\n−4\n. In one embodiment, the protein binds to MMP-14 with a K\non \nfaster than 1×10\n2\n, 1×10\n3\n, or 5×10\n3 \nM\n−1 \ns\n−1\n. In one embodiment, the protein inhibits human MMP-14 activity, e.g., with a Ki of less than 10\n−5\n, 10\n−6\n, 10\n−7\n, 10\n−8\n, 10\n−9\n, and 10\n−10 \nM. The protein can have, for example, an 100 of less than 100 nM, 10 nM or 1 nM. For example, the protein modulates MMP-14 binding to proMMP-2, e.g., by inhibiting activation of proMMP-2. The protein truly inhibit MMP-14 activation of pro-MMP2 in vitro in PMA-activated HT-1080 cells. The affinity of the protein for MMP-14 can be characterized by a K\nD \nof less than 100 nm, less than 10 nM, or less than 2.4 nM.\n\n\n \n \n \n \nIn one embodiment, the protein binds the catalytic domain of human MMP-14. e.g., the protein contacts residues in or near the active site of MMP-14.\n\n\n \n \n \n \nIn one embodiment, the protein also binds to MMP-16 and/or MMP-24, e.g., with a binding affinity of at least 10\n5\n, 10\n6\n, 10\n7\n, 10\n8\n, 10\n9\n, 10\n10 \nand 10\n11 \nM\n−1\n. For example, the protein binds to both MMP-14 and to MMP-16 or MMP-24 with a binding affinity of at least 10\n5\n, 10\n6\n, 10\n7\n, 10\n8\n, 10\n9\n, 10\n10 \nand 10\n11 \nM\n−1\n.\n\n\n \n \n \n \nIn a preferred embodiment, the protein is a human antibody having the light and heavy chains of antibodies picked from the list comprising M0031-C02, M0031-F01, M0033-1407, M0037-009, M0037-D01, M0038-E06, M0038-F0 M0038-F08, M0039-H08, M0040-A06, M0040-A11, and M0043-002. In a preferred embodiment, the protein is a human antibody having its heavy chain picked from the list comprising M0031-C02, M0031-F01, M0033-H07, to M0037-009, M0037-D0.1, M0038-E06, M0038-F01, M00384:08, M0039-H08, M0040-A06, M0040-A11, and MD043-G02. In a preferred embodiment, the protein is a human antibody having its light chain picked from the list comprising M0031-C02, M0031-F01, M00334107, M0037-009, M0037-D01, M0038-E06, M0038-F01, M0038-F08, M0039-H08, M0040-A06, M0040-A11, and M0043-002. In a preferred embodiment, the protein is a human antibody having one or more heavy chain CDRs picked from the corresponding CDRs of the list of heavy chains comprising M0031-C02, M0031-F01, M0033-H07, M0037-009, M0037-D01, M0038-E06, M0038-F01, M0038-F08, M0039-H08, M0040-A06, M0040-A11, and M0043-G002. In a preferred embodiment, the protein is a human antibody having one or more light chain CDRs picked from the corresponding CDRs oldie list or heavy chains comprising M0031-C02, M0031-F01, M0033-H07, M0037-009. M0037-D01, M0038-E06, M0038-F01, M0038-F08, M0039-H08, M0040-A06, M0040-A11, and M0043-002.\n\n\n \n \n \n \nIn one embodiment, the HC and LC variable domain sequences are components of the same polypeptide chain. In another, the HC and LC variable domain sequences are components of different polypeptide chains. For example, the protein is an IgG, e.g., IgG1, IgG2, IgG3, or IgG4. The protein can be a soluble Fab. In other implementations the protein includes a Fab2′, scFv, minibody, scFv::Fc fusion. Fah::HSA fusion. HSA::Fab fusion, Fab::HSA::Fah fusion, or other molecule that comprises the antigen combining site of one of the binding proteins herein. The VH and VL regions of these Fabs can be provided as IgG, Fab, Fab2, Fab2′, scFv, PEGylated Fab, PEGylated scFv, PEGylated Fab2, VH::CH1::HSA+LC, HSA::VH::CH1+LC, LC::HSA+VH::CH HSA::LC VH::CH1, or other appropriate construction.\n\n\n \n \n \n \nIn one embodiment, the protein is a human or humanized antibody or is non-immunogenic in a human. For example, the protein includes one or more human antibody framework regions, e.g., all human framework regions. In one embodiment, the protein includes a human Fc domain, or an Fc domain that is at least 95, 96, 97, 98, or 99% identical to a human Fc domain.\n\n\n \n \n \n \nIn one embodiment, the protein is a primate or primatizcd antibody or is non-immunogenic in a human. For example, the protein includes one or more primate antibody framework regions, e.g., all primate framework regions. In one embodiment, the protein includes a primate Fc domain, or an Fc domain that is at least 95, 96, 97, 98, or 99% identical to a primate Fc domain. “Primate” includes humans (\nHomo sapiens\n), chimpanzees (\nPan troglodytes \nand \nPan paniscus \n(bonobos)), gorillas (\nGorilla gibons\n, monkeys, lemurs, aye-ayes (\nDaubentonia madagaseariensis\n), and tarsiers.\n\n\n \n \n \n \nIn some embodiments, the affinity of the primate antibody for MMP-14 is characterized by a K\nD \nof less than 1.2 nM.\n\n\n \n \n \n \nIn certain embodiments, the protein includes no sequences from mice or rabbits (e.g., is not a murine or rabbit antibody).\n\n\n \n \n \n \nIn one embodiment, the protein is capable of binding to tumor cells expressing MMP-14, e.g., to H7-1080 (a human librosarcoma cell LNCaP (human prostate carcinoma), MDA-MB-231 (human, Caucasian, breast, adenocarcinoma), or PC3 (Human prostatic cancer cells) cells.\n\n\n \n \n \n \nIn one embodiment, protein is physically associated with a nanoparticle, and can be used to guide a nanoparticle to a cell expressing MMP-14 on the cell surface. In one embodiment, the protein causes effector cells (CDC or ADCC) to kill a cell which expresses MMP-14.\n\n\n \n \n \n \nA binding protein described herein can be provided as a pharmaceutical composition, e.g., including a pharmaceutically acceptable carrier. The composition can be at least 10, 20, 30, 50, 75, 85, 90, 95, 98, 99, or 99.9% free of other protein species.\n\n\n \n \n \n \nIn another aspect, the disclosure features a method of detecting an MMP-14 in a sample. The method includes: contacting the sample with an MMP-14 binding protein; and detecting an interaction between the protein and the MMP-14, if present. In some embodiments, the protein includes a detectable label. An MMP-14 binding protein can be used to detect MMP-14 in a subject. The method includes: administering an MMP-14 binding protein to a subject; and detecting the protein in the subject. In some embodiments, the protein further includes a detectable label. For example, the detecting comprises imaging the subject.\n\n\n \n \n \n \nIn another aspect, the disclosure features a method of modulating MMP-14 activity. The method includes: contacting an MMP-14 with an MMP-14 binding protein (e.g., in a human subject), thereby modulating MMP-14 activity.\n\n\n \n \n \n \nIn another aspect, the disclosure features a method of treating cancer (e.g., metastatic cancer). The method includes: administering, to a subject, an MMP-14 binding protein in an amount sufficient to treat a cancer in the subject. For example, the cancer is head and neck cancer, oral cavity cancer, laryngeal cancer, chondrosarcoma, breast cancer (which may be estrogen receptor positive (ER+), estrogen receptor negative (ER−), Her2 positive (Her2+), Her2 negative (Her2−), or a combination thereof, e.g., ER+/Her2+, ER+/Her2−, ER−/Her2+, or ER−/Her2-), laryngeal cancer, ovarian cancer, testicular carcinoma, melanoma, or brain tumors (e.g., astrocytomas, glioblastomas, gliomas).\n\n\n \n \n \n \nMMP-14 binding proteins are useful to modulate metastatic activity in a subject. The protein can be administered, to the subject, an MMP-14 binding protein in an amount effective to modulate metastatic activity. For example, the protein inhibits one or more of: tumor growth, tumor embolism, tumor mobility, tumor invasiveness, and cancer cell proliferation.\n\n\n \n \n \n \nThe methods disclosed herein relating to the treatment cancer (e.g., treating cancer and/or modulation of metastatic activity) can further include providing to the subject a second therapy that is an anti-cancer therapy, e.g., administration of a chemotherapeutic, e.g., an agent that antagonizes signaling through a VEGF pathway, e.g., bevacizumab (AVASTINg). In one embodiment, the second therapy includes administering 5-FU, leucovorin, and/or irinotecan, in one embodiment, the second therapy includes administering a Tiel inhibitor (e.g., an anti-Tiel antibody). In one embodiment, the second therapy is an inhibitor of plasmin (e.g., a kunitz domain disclosed in U.S. Pat. No. 6,010,880. such as a protein or polypeptide comprising the amino acid sequence\n\n\n \n \n\n\n\n\n\n\n\n\n\n\n(SEQ ID NO: 5)\n\n\n\n\n\n\nMHSFCAFKAETGPCRARFDRWFFNIFTRQCEEFIYGGCEGNQNRFESLEE\n\n\n\n\n\n\n \n\n\n\n\n\n\nCKKMCTRD.\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n \nInhibitors of MMP-14 (e.g., the MMP-14 binding proteins disclosed herein) can potentiate the activity of an agent that targets Her2 (e.g., a Her2-binding antibody such as trastuzumab). Accordingly, in one embodiment, the second therapy is an agent that binds Her2, such as a Her2-binding antibody (e.g., trastuzumab). In some such embodiments, the dose of the Her2 binding agent is reduced from the dose or the Her2 binding agent when administered not in combination with an MMP-14 binding protein (e.g., is at least 10%, 25%, 40%, or 50% less than the dose of the Her2 binding agent when administered not in combination with a MMP-14 binding protein)\n\n\n \n \n \n \nIn another aspect, the disclosure features a method of treating an ocular condition. The method includes: administering, to a subject, an MMP-14 binding protein in an amount sufficient to treat the ocular condition. In one embodiment, the method further includes administering a second agent an agent that antagonizes signaling through a VEGF pathway, e.g., bevacizumab or ranibizumab. In one embodiment where the second agent is a VEGF pathway inhibitor (e.g., bevacizumab or ranibizumab), the ocular condition is age-related macular degeneration, such as wet age-related macular degeneration.\n\n\n \n \n \n \nIn another aspect, the disclosure features a method of treating an inflammatory disease synovitis, rheumatoid arthritis). The method includes: administering, to a subject, an MMP-14 binding protein in an amount sufficient to treat the inflammatory disease. The method can further include providing to the subject a second therapy that is an anti-inflammatory therapy. For example, particularly for rheumatoid arthritis, the second therapy comprises administering one or more of the following agents: aspirin, naproxen, ibuprofen, etodolac, cortisone (corticosteroids), antacids, sucralfate, proton-pump inhibitors, misoprostol, gold (e.g., gold salts, gold thioglucose , gold thiomalate, oral gold), methotrexate, sutfasalazine, D-penicitlamine, azathioprine, cyclophosphamide, chlorambucil, cyclosporine, leflunomide, etanereept, in fliximab, anakinra, adalimumab, and/or hydroxychloroquine.\n\n\n \n \n \n \nIn another aspect, the disclosure features a method of treating osteoarthritis. The method includes: administering, to a subject, an MMP-14 binding protein in an amount sufficient to treat the osteoarthritis. The method can further include providing to the subject a second therapy that is an anti-osteoarthritis therapy.\n\n\n \n \n \n \nIn another aspect, the disclosure features a method of treating diabetes. The method includes: administering, to a subject, an MMP-14 binding protein in an amount sufficient to treat diabetes. The method can further include providing to the subject a second therapy that is a diabetes therapy. For example, the second therapy comprises administering one or more of the following agents: sullonylureas, meglitinides, biguanides, metformin, troglitazone, pioglitazone, rosiglitazone, acarbose, pramlintide, exenalide, glyburide/metformin (GLUCOVANCE®), rosiglitazone/metformin (AVANDAMET®), and/or glipizide/metformin (METAGLIP®).\n\n\n \n \n \n \nIn another aspect, the disclosure features a method of treating Alzheimer's Disease. The method includes: administering, to a subject, an MMP-14 binding protein in an amount sufficient to treat Alzheimer's Disease. The method can further include providing to the subject a second therapy that is an Alzheimer's Disease therapy. For example, the second therapy comprises administering one or more of the following agents: tacrine (COGNEX®), donepezil (ARICEPT®), rivastigmine (EXELON®), galantamine (REMINYL®), memantine (NAMENDA™), nonsteroidal anti-inflammatory drugs (NSAIDS), statins, folic acid, gingko biloha, vitamin E, vitamin B6, and/or vitamin B12.\n\n\n \n \n \n \nOther exemplary therapeutic methods that include administering an MMP-14 binding protein are described below. An MMP-14 binding protein described herein can be administered in combination with one or more other MMP inhibitors, e.g., small molecule inhibitors, e.g., broad specificity inhibitors. In one embodiment, the small molecule inhibitors are one or more of neovastat, marimastat. BAY 12-9566, or prinomastat. In another embodiment, the one or more MMP inhibitors include another MMP-14 binding protein.\n\n\n \n \n \n \nMMP-14 binding proteins are useful for targeted delivery of an agent to a subject (e.g., a subject who has or is suspected of having a tumor), e.g., to direct the agent to a tumor in the subject. For example, an MMP-14 binding protein that is coupled to an anti-tumor agent (such as a chemotherapeutic, toxin, drug, or a radionuclide (e.g., \n131\nI, \n90\nY, \n177\nLu)) can be administered to a subject who has or is suspected of having a tumor.\n\n\n \n \n \n \nIn another aspect, the disclosure features a method of imaging a subject. The method includes administering an MMP-14 binding protein to the subject. In some embodiments, the protein is one that does not substantially inhibit MMP-14 catalytic activity. The MMP-14 binding protein may include a detectable label (e.g., a radionuclide or an MRI-detectable label). In one embodiment, the subject has or is suspected of having a tumor. The method is useful for cancer diagnosis, intraoperative tumor detection, post-operative tumor detection, or monitoring tumor invasive activity.\n\n\n \n \n \n \nIn one aspect, the disclosure features the use of an MMP-14 binding protein described herein for the manufacture of a medicament for the treatment of a disorder described herein, e.g., a cancer (e.g., metastatic cancer, e.g., metastatic breast cancer), an inflammatory disease (e.g., synovitis, atherosclerosis), rheumatoid arthritis, osteoarthritis, an ocular condition (e.g., macular degeneration), diabetes, Alzheimer's Disease, cerebral ischemia, endometriosis, fibrin-invasive activity, or dysregulated or inappropriate angiogenesis. Still other disorders that can be treated using a medicament comprising an MMP-14 binding protein include: aortic aneurysms, periodontitis, autoimmune blistering disorders of the skin, dermal photoaging.\n\n\n \n \n \n \nThe details of one or more embodiments or the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.\n\n\n \n\n\nDESCRIPTION OF DRAWINGS\n\n\n \n \n \n \nFIGS. 1A and 1B\n show a series of graphs depicting the determination of Ki values of MMP-14 binding proteins.\n\n\n \n \n \n \n \nFIG. 2\n is a reproduction of a gelatin zymogram.\n\n\n \n \n \n \n \nFIG. 3\n shows a series of graphs depicting the binding of germlined antibodies (539C-M0038F01 Germline and 539C-M0033-H07 Germline) to MMP-14.\n\n\n \n \n \n \n \nFIG. 4\n shows a series of graphs depicting the determination of IC50 values (against 2 pM hMMP-14) for two germlined antibodies (539C-M0038F01 Germline and 539C-M0033-H07 Germline) as compared to the parental antibodies.\n\n\n \n \n \n \n \nFIG. 5\n shows reproductions of gelatin zymograms performed with germlined antibodies 539C-M0038F01 Geneart and 539C-M0033-H07 Geneart.\n\n\n \n \n \n \n \nFIG. 6A\n shows photomicrographs of three dimensional cultures of HUVEC treated with vehicle, M0038F01 at various doses, or suramin. \nFIG. 6B\n shows a graph summarizing measurements of tube length from the same experiment.\n\n\n \n \n \n \n \nFIG. 7\n shows a graph summarizing results of an experiment examining the effect of an MMP-14 binding antibody (M0038-F01) on growth of tumors derived from MDA-MB-23.1 cells orthotopically injected into the mammary fat pads of female Balb/c mice. The y-axis is tumor volume (in cubic millimeters) and the x-axis is time (in weeks), starting at initiation of dosing.\n\n\n \n \n \n \n \nFIG. 8\n shows a graph summarizing results of an experiment examining the effect of a range of doses of an MMP-14 binding antibody (M0038-1:01) on growth of tumors derived from MDA-MB-231 cells orthotopically injected into the mammary fat pads of female Balb/c mice. The y-axis is tumor volume (in cubic millimeters) and the x-axis is time (in weeks), starting at initiation of dosing.\n\n\n \n \n \n \n \nFIG. 9\n shows a graph summarizing results of an experiment examining the effect of a range of doses of an MMP-14 binding antibody (M0038-F01) on growth of MDA-MB-435 GFP breast tumors orthotopically transplanted into the mammary fat pads of female Balb/c mice (described in Example 15). The y-axis is tumor volume (in cubic millimeters) and the a-axis is time (in weeks), starting at initiation or dosing\n\n\n \n \n \n \n \nFIG. 10A\n shows a graph summarizing results of an experiment examining the effect of a range of doses of an MMP-14 binding antibody (M0038-F01) on growth of B16F1 melanoma tumors implanted subcutaneously (described in Example 16). The y-axis is tumor volume (in cubic millimeters) and the x-axis is time (in weeks), starting at initiation of dosing.\n\n\n \n \n \n \n \nFIG. 10B\n shows the quantification of the lung nodules after treatment with Dox, M0038F01 and isotype-matched antibody control on B16F1 melanoma metastasis. The y-axis is total number of lung nodules.\n\n\n \n \n \n \n \nFIG. 11\n shows a graph summarizing results from an experiment examining the effect of a range of doses of an MMP-14 binding antibody (M0038-F01) on growth of PC3 prostate tumors in mice (described in Example 17). The y-axis is tumor volume (in cubic millimeters) and the x-axis is time (in weeks), starting at initiation of dosing.\n\n\n \n \n \n \n \nFIG. 12\n shows a graph summarizing results from an experiment examining the effect of a range of doses of an MMP-14 binding antibody (M0038-F01 or “F01”) on growth of 31474 breast tumors in mice (described in Example 18). The y-axis is tumor volume (in cubic millimeters) and the x-axis is time (in days), starting at initiation of dosing.\n\n\n \n\n\nDETAILED DESCRIPTION\n\n\n \n \n \nMatrix metalloproteinases function in the physiological remodeling of the extracellular matrix. e.g., during tissue morphogenesis, growth, uterine cycling and postpartum involution, tissue repair, and angiogenesis. Three proteases that have these activities are MMP-14, MMP-16, and MMP-24. The disclosure provides MMP-14 binding proteins, including MMP-14 binding proteins that inhibit MMP-14 binding activity. The MMP-14 binding proteins taught by the disclosure may also hind, and in some embodiments also inhibit MMP-16 and/or MMP-24.\n\n\n \n \n \n \nThe term “binding protein” refers to a protein that can interact with a target molecule. This term is used interchangeably with “ligand.” An “MMP-14 binding protein” refers to a protein that can interact with MMP-14, and includes, in particular, proteins that preferentially interact with and/or inhibit MMP-14. For example, the MMP-14 binding protein is an antibody.\n\n\n \n \n \n \nThe term “antibody” refers to a protein that includes at least one immunoglobulin variable domain or immunoglobulin variable domain sequence. For example, an antibody can include a heavy (H) chain variable region (abbreviated herein as VH), and a light (L) chain variable region: (abbreviated herein as VL). In another example, an antibody includes two heavy (H) chain variable regions and two light (L) chain variable regions. The term “antibody” encompasses antigen-binding fragments of antibodies (e.g., single chain antibodies, Fab and sFab fragments, F(ab′)\n2\n, Fd fragments, Fv fragments, scFv, and domain antibodies (dAb) fragments (de Wildt et al.; Eur J. Immunol. 1996; 26(3):629-39.)) as well as complete antibodies. An antibody can have the structural features of IgA, IgG, IgE, IgD, IgM (as well as subtypes thereof). Antibodies may be from any source, but primate (human and non-human primate) and primatized are preferred\n\n\n \n \n \n \nThe VH and VL regions can be further subdivided into regions of hypervariability, termed “complementarity determining regions” (“CDR”), interspersed with regions that are more conserved, termed “framework regions” (“FR”). The extent of the framework region and CDRs has been precisely defined (see. Kabat, E A., et al. (1991) \nSequences of Proteins of Immunological Interest\n, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242, and Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917, see also www.hgmp.mre.ac.uk). Kabat definitions are used herein. Each VH and VL is typically composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3. CDR3, FR4.\n\n\n \n \n \n \nAs used herein, an “immunoglobulin variable domain sequence” refers to an amino acid sequence which can form the structure of an immunoglobulin variable domain such that one or more CDR regions are positioned in a conformation suitable for an antigen binding site. For example, the sequence may include all or part of the amino acid sequence of a naturally-occurring variable domain. For example, the sequence may omit one, two or more N- or C-terminal amino acids, internal amino acids, may include one or more insertions or additional terminal amino acids, or may include other alterations. In one embodiment, a polypeptide that includes immunoglobulin variable domain sequence can associate with another immunoglobulin variable domain sequence to form an antigen binding site, e.g., a structure that preferentially interacts with an MMP-14 protein, e.g., the MMP-14 catalytic domain.\n\n\n \n \n \n \nThe VH or VL chain of the antibody can further include all or part of a heavy or light chain constant region, to thereby form a heavy or light immunoglobulin chain, respectively. In one embodiment, the antibody is a tetramer of two heavy immunoglobulin chains and two light immunoglobulin chains, wherein the heavy and light immunoglobulin chains are inter-connected by, e.g., disulfide bonds. In IgGs, the heavy chain constant region includes three immunoglobulin domains, CH1, CH2 and CH3. The light chain constant region includes a CL domain. The variable region of the heavy and light chains contains a binding domain that interacts with an antigen. The constant regions of the antibodies typically mediate the binding of the antibody to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system. The light chains of the immunoglobulin may be of types kappa or lambda. In one embodiment, the antibody is glycosylated, antibody can be functional for antibody-dependent cytotoxicity and/or complement-mediated cytotoxicity.\n\n\n \n \n \n \nOne or more regions of an antibody can be human or effectively human. For example, one or more of the variable regions can be human or effectively human. For example, one or more of the CDRs can be human, e.g., HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3. Each of the light chain CDRs can be human. HC CDR3 can be human. One or more of the framework regions can be human, e.g., FR1, FR2, FR3, and FR4 of the HC or LC. For example, the Fc region can be human. In one embodiment, all the framework regions are human, e.g., derived from a human somatic cell, e.g., a hematopoictic cell that produces immunoglobulins or a non-hematopoictic cell. In one embodiment, the human sequences are germline sequences, e.g., encoded by a germline nucleic acid. In one embodiment, the framework (FR) residues of a selected Fab can be converted to the amino-acid type of the corresponding residue in the most similar primate germline gene, especially the human germline time. One or more of the constant regions can be human or effectively human. For example, at least 70, 75, 80, 85, 90, 92, 95, 98, or 100% aim immunoglobulin variable domain, the constant region, the constant domains (CH1, CH2, CH3. CL1), or the entire antibody can be human or effectively human.\n\n\n \n \n \n \nAll or part of an antibody can be encoded by an immunoglobulin gene or a segment thereof. Exemplary human immunoglobulin genes include the kappa, lambda, alpha (IgA1 and IgA2), gamma (IgG1, IgG2, IgG3, IgG4), delta, epsilon and mu constant region genes, as well as the many immunoglobulin variable region genes, Full-length immunoglobulin “light chains” (about 25 KDa or about 214 amino acids) are encoded by u variable region gene at the NH2 terminus (about 110 amino acids) and a kappa or lambda constant region gene at the COON— terminus. Full-length immunoglobulin “heavy chains” (about 50 KDa or about 446 amino acids), are similarly encoded by a variable region gene (about 116 amino acids) and one of the other aforementioned constant region genes, e.g., gamma (encoding about 330 amino acids). The length of human HC varies considerably because HC CDR3 varies from about 3 amino-acid residues to over 35 amino-acid residues.\n\n\n \n \n \n \nThe term “antigen-binding fragment” of a full length antibody refers to one or more fragments of a full-length antibody that retain the ability to specifically bind to a target of interest. Examples of binding fragments encompassed within the term “antigen-binding fragment” of a full length antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab′)\n2 \nfragment, a bivalent fragment including two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341:544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR) that retains functionality. Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules known as single chain Fv (say). See e.g., U.S. Pat. Nos. 5,260,203, 4,946,778, and 4,881,175: Bird et al, (1958) Science 242:423-426; and Huston et. al. (1988) \nProc. Natl. Acad. Sci. LISA \n85:5879-5883.\n\n\n \n \n \n \nAntibody fragments can be obtained using any appropriate technique including conventional techniques known to those with skill in the art. The term “monospecific antibody” refers to an antibody that displays a single binding specificity and affinity for a particular target, e.g., epitope. This term includes a “monoclonal antibody” or “monoclonal antibody composition,” which as used herein refer to a preparation of antibodies or fragments thereof of single molecular composition, irrespective of how the antibody was generated.\n\n\n \n \n \n \nAn “effectively human” immunoglobulin variable region is an immunoglobulin variable region that includes a sufficient number of human framework amino acid positions such that the immunoglobulin variable region does not elicit an immunogenic response in a normal human.\n\n\n \n \n \n \nAn “effectively human” antibody is an antibody that includes a sufficient number of human amino acid positions such that the antibody does not elicit an immunogenic response in a normal human.\n\n\n \n \n \n \nA “humanized” immunoglobulin variable region is an immunoglobulin variable region that is modified to include a sufficient number of human framework amino acid positions such that the immunoglobulin variable region does not elicit an immunogenic response in a normal human. Descriptions of “humanized” immunoglobulins include, for example, U.S. Pat. No. 6,407,213 and U.S. Pat. No. 5,693,762.\n\n\n \n \n \n \nAs used herein, “binding affinity” refers to the apparent association constant or K\na\n. The K\na \nis the reciprocal of the dissociation constant (K\nd\n). A binding protein May, for example, have a binding affinity of at least 10\n5\n, 10\n6\n, 10\n7\n, 10\n8\n, 10\n9\n, 10\n10 \nand 10\n11 \nM\n−1 \ntfor a particular target molecule, e.g., MMP-14, MMP-16, or MMP-24. Higher affinity binding of a binding protein to a first target relative to a second target can be indicated by a higher K\na \n(or a smaller numerical value K\na\n) for binding the first target than the K, (or numerical value K\nd\n) for binding the second target in such cases, the binding protein has specificity for the first target (e.g., a protein in a first conformation or mimic thereof) relative to the second target (e.g., the same protein in a second conformation or mimic thereof; or a second protein). Differences in binding affinity (e.g., for specificity or other comparisons) can be at least 1.5, 2, 3, 4, 5, 10, 15, 20, 37.5, 50, 70, 80, 91, 100, 500, 1000, or 10\n5 \ninf.\n\n\n \n \n \n \nBinding affinity can be determined by a variety of methods including equilibrium dialysis, equilibrium binding, gel filtration, ELISA, surface plasmon resonance, or spectroscopy (e.g., using a fluorescence assay). Exemplary conditions for evaluating binding affinity are in TRIS-buffer (50 mM TRIS. 150 mM NaCl, 5 mM CaCl\n2 \nat pH7.5). These techniques can be used to measure the concentration of bound and free binding protein as a function of binding protein (or target) concentration. The concentration abound binding protein ([Bound]) is related to the concentration of free binding protein ([Free]) and the concentration of binding sites for the binding protein on the target where (N) is the number of binding sites per target molecule by the following equation:\n\n\n \n \n \n[Bound]=\nN\n·[Free]/((1\n/Ka\n)+[Free]).\n\n\n\n \n \n \n \nIt is not always necessary to make an exact determination of K\na\n, though, since sometimes it is sufficient to obtain a quantitative measurement of affinity, e.g., determined using a method such as ELISA or FACS analysis, is proportional to K\na \nand thus can be used for comparisons, such as determining whether a higher affinity is, e.g., 2-fold higher, to obtain a qualitative measurement of affinity, or to obtain an inference of affinity, e.g., by activity in a functional assay, e.g., an in vitro or in vivo assay.\n\n\n \n \n \n \nAn “isolated composition” refers to a composition that is removed from at least 90% of at least one component of a natural sample from which the isolated composition can be obtained. Compositions produced artificially or naturally can be “compositions of at least” a certain degree of purity if the species or population of species of interests is at least 5, 10, 25, 50, 75, 80, 90, 92, 95, 98, or 99% pure on a weight-weight basis.\n\n\n \n \n \n \nAn “epitope” refers to the site on a target compound that is bound by a binding protein (e.g., an antibody such as a Fab or full length antibody). In the case where the target compound is a protein, the site can be entirely composed of amino acid components, entirely composed of chemical modifications of amino acids of the protein (e.g., glycosyl moieties), or composed of combinations thereof, Overlapping epitopes include at least one common amino acid residue, glycosyl group, phosphate group, sulfate group, or other molecular feature.\n\n\n \n \n \n \nCalculations of “homology” or “sequence identity” between two sequences (the terms are used interchangeably herein) are performed as follows. The sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). The optimal alignment is determined as the best score using the GAP program in the GCG software package with a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid “identity” is equivalent to amino acid or nucleic acid “homology”). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences.\n\n\n \n \n \n \nIn a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at least 70%, 80%, 90%, 92%, 95%, 97%, 98%, or 100% of the length of the reference sequence. For example, the reference sequence may be the length of the immunoglobulin variable domain sequence.\n\n\n \n \n \n \nAs used herein, the term “substantially identical” (or “substantially homologous”) is used herein to refer to a first amino acid or nucleic acid sequence that contains a sufficient number of to identical or equivalent (e.g., with a similar side chain, e.g., conserved amino acid Substitutions) amino acid residues or nucleotides to a second amino acid or nucleic acid sequence: such that the first and second amino acid or nucleic acid sequences have (or encode proteins having) similar activities, e.g., a binding activity, a binding preference, or a biological activity. In the case of antibodies, the second antibody has the same specificity and has at least 50%, at least 25%, or at least 10% of the affinity relative to the same antigen.\n\n\n \n \n \n \nSequences similar or homologous (e.g., at least about 85% sequence identity) to the sequences disclosed herein are also part of this application. In some embodiments, the sequence identity can be about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher. In addition, substantial identity exists when the nucleic acid segments hybridize under selective hybridization conditions (e.g., highly stringent hybridization conditions), to the complement of the strand. The nucleic acids may be present in whole cells, in a cell lysate, or in a partially purified or substantially pure form.\n\n\n \n \n \n \nAs used herein, the term “hybridizes under low stringency, medium stringency, high stringency, or very high stringency conditions” describes conditions for hybridization and washing. Guidance for performing hybridization reactions can be found in \nCurrent Protocols in Molecular Biology\n, John Wiley & Sons. N.Y. (1989), 6.3.1-6.3.6. Aqueous and nonaqueous methods are described in that reference and either can be used. Specific hybridization conditions referred to herein are as follows: (I) low stringency hybridization conditions in 6× sodium chloride/sodium citrate (SSC) at about 45° C., followed by two washes in 0.2×. SSC. 0.1% SDS at least at 50° C. (the temperature of the washes can be increased to 55° C. for low stringency conditions); (2) medium stringency hybridization conditions in 6×SSC at about 45° C., followed by one or more washes in 0.2×SSC, 0.1% SDS at 60° C.; (3) high stringency hybridization conditions in 6×SSC at about 45° C., followed by one or more washes in 0.2×SSC, 0.1% SDS at 65° C.; and (4) very high, stringency hybridization conditions are 0.5M sodium phosphate, 7% SDS at 65° C., followed by one or more washes at 0.2×SSC, 1% SDS at 65° C. Very high stringency conditions (4) are the preferred conditions and the ones that should be used unless otherwise specified. The disclosure includes nucleic acids that hybridize with low, medium, high, or very high stringency to a nucleic acid described herein or to a complement thereof, e.g., nucleic acids encoding a binding protein described herein. The nucleic acids can be the same length or within 30, 20, or 10% of the length of the reference nucleic acid. The nucleic acid can correspond to a region encoding an immunoglobulin variable domain sequence described herein.\n\n\n \n \n \n \nAn MMP-14 binding protein may have mutations (e.g., at least one, two, or four, and/or less than 15, 10, 5, or 3) relative to a binding protein described herein (e.g., a conservative or non-essential amino acid substitutions), which do not have a substantial effect on protein function. Whether or not a particular substitution will be tolerated, i.e., will not adversely affect biological properties, such as binding activity can be predicted, e.g., by evaluating whether the mutation is conservative or by the method of Bowie, et al. (1990) Science 247:1306-1310.\n\n\n \n \n \n \nA “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). If is possible for many framework and CDR amino acid residues to include one or more conservative substitutions.\n\n\n \n \n \n \nMotif sequences for biopolymers can include positions which can be varied amino acids. For example, the symbol “X” in such a context generally refers to any amino acid (e.g., any of the twenty natural amino acids or any of the nineteen non-cysteine amino acids). Other allowed amino acids can also be indicated for example, using parentheses and slashes. For example, “(A/W/F/N/Q)” means that alanine, tryptophan, phenylalanine, asparagine, and glutamine are allowed at that particular position.\n\n\n \n \n \n \nA “non-essential” amino acid residue is a residue that can be altered from the wild-type sequence of the binding agent, e.g., the antibody, without abolishing or more preferably, without substantially altering a biological activity, whereas changing an “essential” amino acid residue results in a substantial loss of activity.\n\n\n \n \n \n \nThe term “cognate ligand” refers to a naturally occurring ligand of an MMP-14, including naturally occurring variants thereof (e.g., splice variants, naturally occurring mutants, and isoforms).\n\n\n \n \n \n \nStatistical significance can be determined by any art known method. Exemplary statistical tests include: the Students T-test. Mann. Whitney U non-parametric test, and Wilcoxon non-parametric statistical test. Some statistically significant relationships have a P value of less than 0.05 or 0.02. Particular binding proteins may show a difference, e.g., in specificity or binding, that are statistically significant (e.g., P value<0.05 or 0.02). The terms “induce”, “inhibit”, “potentiate”, “elevate”, “increase”, “decrease” or the like, e.g., which denote distinguishable qualitative or quantitative differences between two states, and may refer to a difference, e.g., a statistically significant difference, between the two states.\n\n\n \nMMP-14 Binding Proteins\n\n\n \n \n \nThe disclosure provides proteins that bind to MMP-14 (e.g., human MMP-14) and include at least one immunoglobin variable region. For example, the MMP-14 binding protein includes a heavy chain (HC) immunoglobulin variable domain sequence and alight chain (LC) immunoglobulin variable domain sequence. A number of exemplary MMP-14 binding proteins are described herein.\n\n\n \n \n \n \nThe MMP-14 binding protein may be an isolated protein (e.g., at least 70, 80, 90, 95, or 99% free of other proteins).\n\n\n \n \n \n \nThe MMP-14 binding protein may additionally inhibit MMP-14, e.g., human MMP-14. In one embodiment, the protein hinds the catalytic domain of human MMP-14. e.g., the protein contacts residues in or near the active site of MMP-14.\n\n\n \n \n \n \nIn certain embodiments, the MMP-14 binding protein also binds to MMP-16 and/or MMP-24. Additionally, the MMP-14 binding protein may also inhibit MMP-16 and/or MMP-24.\n\n\n \n \n \n \nExemplary MMP-14 binding proteins include M0031-C02, M0031-F01, M0033-H07, M0037-009, M0037-D01, M0038-E06, M0038-F01, M0038-F08, M0039-H08, M0040-M6, M0040-A11, and M0043-G02.\n\n\n \n \n \n \nMMP-14 binding proteins may be antibodies. MMP-14 binding antibodies may have their HC and LC variable domain sequences included in a single polypeptide (e.g., scFv), or on different polypeptides (e.g., IgG or Fab).\n\n\n \nMatrix Metalloproteinases\n\n\n \n \n \nMMP-14\n\n\n \n \n \n \nMMP-14 is encoded by a gene designated as MMP14, matrix metalloproteinase-14 precursor. Synonyms for MMP-14 include matrix metalloproteinase 14 (membrane-inserted), membrane-type-1 matrix metalloproteinase, membrane-\ntype matrix metalloproteinase\n 1, MMP-14, MMP-X1, MT1MMP, MT1-MMP, MTMMP1, MT-\nMMP\n 1.\n\n\n \n \n \n \nMT-MMPs have similar structures, including a signal peptide, a prodomain, a catalytic domain, a hinge region, and a hemopexin domain (Wang, et al., 2004, J Biol Chem 279151148-55). According to SwissProt entry P50281, the signal sequence of MMP-14 precursor includes amino acid residues 1-20. The pro-peptide includes residues 21-111. Cys93 is annotated as a possible cysteine switch. Residues 112 through 582 make up the mature, active protein. The catalytic domain includes residues 112-317. The hemopexin domains includes residues 318-523. The transmembrane segment comprises residues 542 through 562.\n\n\n \n \n \n \nMMP-14 can be shed from cells or found on the surface of cells, tethered by a single transmembrane amino-acid sequence. See, e.g., Osnkowski et al. (2004, J Cell Physiol, 200:2-10).\n\n\n \n \n \n \nAn exemplary amino acid sequence of human MMP14 is shown in Table 1:\n\n\n \n \n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 1\n\n\n\n\n\n\n \n\n\n\n\n\n\nAmino-acid sequence of human MMP14\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nMSPAPRPPRCLLLPLLTLGTALASLGSAQSSSFSPEAWLQQYGYLPPGDL\n\n\n\n\n\n\n \n\n\n\n\n\n\nRTHTQRSPQSLSAAIAAMQKFYGLQVTGKADADTMKAMRRPRCGVPDKFG\n\n\n\n\n\n\n \n\n\n\n\n\n\nAEIKANVRRKRYAIQGLKWQHNEITFCTQNYTPKVGEYATYEAIRKAFRV\n\n\n\n\n\n\n \n\n\n\n\n\n\nWESATPLRFREVPYAYIREGHEKQADIMIFFAEGFHGDSTPFDGEGGFLA\n\n\n\n\n\n\n \n\n\n\n\n\n\nHAYFPGPNIGGDTHFDSAEPWTVRNEDLNGNDIFLVAVHELGHALGLEHS\n\n\n\n\n\n\n \n\n\n\n\n\n\nSDPSAIMAPFYQWMDTENFVLPDDDRRGIQQLYGGESGFPTKMPPQPRTT\n\n\n\n\n\n\n \n\n\n\n\n\n\nSRPSVPDKPKNPTYGPNICDGNFDTVAMLRGEMFVFKERWFWRVRNNQVM\n\n\n\n\n\n\n \n\n\n\n\n\n\nDGYPMPIGQFWRGLPASINTAYERKDGKFVFFKGDKHWVFDEASLEPGYP\n\n\n\n\n\n\n \n\n\n\n\n\n\nKHIKELGRGLPTDKIDAALFWMPNGKTYFFRGNKYYRFNEELRAVDSEYP\n\n\n\n\n\n\n \n\n\n\n\n\n\nKNIKVWEGIPESPRGSFMGSDEVFTYFYKGNKYWKFNNQKLKVEPGYPKS\n\n\n\n\n\n\n \n\n\n\n\n\n\nALRDWMGCPSGGRPDEGTEEETEVIIIEVDEEGGGAVSAAAVVLPVLLLL\n\n\n\n\n\n\n \n\n\n\n\n\n\nLVLAVGLAVFFFRRHGTPRRLLYCQRSLLDKV\n\n\n\n\n\n\n(SEQ ID NO: 2: Genbank Accession No. CAA83372.1).\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n \nAn exemplary amino acid sequence of mouse MMP14 is shown in Table 2.\n\n\n \n \n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 2\n\n\n\n\n\n\n \n\n\n\n\n\n\nAmino-acid sequence of mouse MMP14\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nMSPAPRPSRSLLLPLLTLGTALASLGWAQGSNFSPEAWLQQYGYLPPGDL\n\n\n\n\n\n\n \n\n\n\n\n\n\nRTHTQRSPQSLSAAIAAMQKFYGLQVTGKADLATMMAMRRPRCGVPDKFG\n\n\n\n\n\n\n \n\n\n\n\n\n\nTEIKANVRRKRYAIQGLKWQHNEITFCIQNYTPKVGEYATFEAIRKAFRV\n\n\n\n\n\n\n \n\n\n\n\n\n\nWESATPLRFREVPYAYIREGHEKQADIMILFAEGFHGDSTPFDGEGGFLA\n\n\n\n\n\n\n \n\n\n\n\n\n\nHAYFPGPNIGGDTHFDSAEPWTVQNEDLNGNDIFLVAVHELGHALGLEHS\n\n\n\n\n\n\n \n\n\n\n\n\n\nNDPSAIMSPFYQWMDTENFVLPDDDRRGIQQLYGSKSGSPTKMPPQPRTT\n\n\n\n\n\n\n \n\n\n\n\n\n\nSRPSVPDKPKNPAYGPNICDGNFDTVAMLRGEMFVFKERWFWRVRNNQVM\n\n\n\n\n\n\n \n\n\n\n\n\n\nDGYPMPIGQFWRGLPASINTAYERKDGKFVFFKGDKHWVFDEASLEPGYP\n\n\n\n\n\n\n \n\n\n\n\n\n\nKHIKELGRGLPTDKIDAALFWMPNGKTYFFRGNKYYRFNEEFRAVDSEYP\n\n\n\n\n\n\n \n\n\n\n\n\n\nKNIKVWEGIPESPRGSFMGSDEVFTYFYKGNKYWKFNNQKLKVEPGYPKS\n\n\n\n\n\n\n \n\n\n\n\n\n\nALRDWMGCPSGRRPDEGTEEETEVIIIEVDEEGSGAVSAAAVVLPVLLLL\n\n\n\n\n\n\n \n\n\n\n\n\n\nLVLAVGLAVFFFRRHGTPKRLLYCQRSLLDKV\n\n\n\n\n\n\nSEQ ID NO: 4: GenBank Accession No. NP_032634.2\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n \nAn exemplary MMP-14 protein can include the human or mouse MMP-14 amino acid sequence, a sequence that is 80%, 85%, 90%, 95%, 96%, 97%. 98%, or 99% identical to one of these sequences, or a fragment thereof, e.g., a fragment without the signal sequence or prodomain.\n\n\n \n \n \n \nTable 3 shows a sequence alignment of the exemplary human MMP-14 (hMMP-14) amino acid sequence with the exemplary mouse MMP-14 (mMMP-14) amino acid sequence. A “-” in the mMMP14 entries indicates that the amino acid is the same as shown for hMMP14,\n\n\n \n \n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 3\n\n\n\n\n\n\n \n\n\n\n\n\n\nComparison of human and murine MMP14\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\nhMMP14:\n\n\n1:\n\n\n50\n\n\nMSPAPRPFNC LLLPLLPLGT ALASLGSAQS SSFSPEAWLQ QYGYLFPGDL\n\n\n\n\n\n\nmMMP14:\n\n\n1:\n\n\n50\n\n\n-------S-S ---------- ------W--G -N-------- ----------\n\n\n\n\n\n\n \n\n\n\n\n\n\nhMMP14:\n\n\n51:\n\n\n100\n\n\nR\n QRSPQS LSAALAAMQK FYGLQVTGKA DADTMKAMRR PRCGVP\n \n\n\n\n\n\n\nmMMP14:\n\n\n51:\n\n\n100\n\n\n---------- ---------- ---------- -LA--M---- ----------\n\n\n\n\n\n\n \n\n\n\n\n\n\nhMMP14:\n\n\n101:\n\n\n150\n\n\nAEIKANVRRK RYAIQGLKWQ HNEIPFGIQN YPGKVGEYAT YEAIRKAFRV\n\n\n\n\n\n\nmMMP14:\n\n\n101:\n\n\n150\n\n\nT--------- ---------- ---------- ---------- F---------\n\n\n\n\n\n\n \n\n\n\n\n\n\nhMMP14:\n\n\n151:\n\n\n200\n\n\nWEAATPLRFR EVPYAYIREG HEKGADIMIF FAEGFHGDST PFDGEGGFLA\n\n\n\n\n\n\nmMMP14:\n\n\n151:\n\n\n200\n\n\n---------- ---------- ---------L ---------- ----------\n\n\n\n\n\n\n \n\n\n\n\n\n\nhMMP14:\n\n\n201:\n\n\n250\n\n\nHAYFPGPNIG GDTHFDSAEP WTVRNEDLNG NDIFLVAVHE LGHALGLEHS\n\n\n\n\n\n\nmMMP14:\n\n\n201:\n\n\n250\n\n\n---------- ---------- ---Q------ ---------- ----------\n\n\n\n\n\n\n \n\n\n\n\n\n\nhMMP14:\n\n\n251:\n\n\n300\n\n\nSDPSAIMAPF YQWMDTENFV LPDDDRRGIQ QLYGGESCFP TKMPPQPRTT\n\n\n\n\n\n\nmMMP14:\n\n\n251:\n\n\n300\n\n\nN------S-- ---------- ---------- ----SK--S- ----------\n\n\n\n\n\n\n \n\n\n\n\n\n\nhMMP14:\n\n\n301:\n\n\n350\n\n\nSRPSVPDKPK NPTYGPNICD GNFDTVAMLR GEMFVFKERW FWRVRNNQVM\n\n\n\n\n\n\nmMMP14:\n\n\n301:\n\n\n350\n\n\n---------- --A------- ---------- ---------- ----------\n\n\n\n\n\n\n \n\n\n\n\n\n\nhMMP14:\n\n\n351:\n\n\n400\n\n\nDGYPMPIGQF WRGLPASINT AYERKDGKFV FFKGDKHWVF DEASLEPGYP\n\n\n\n\n\n\nmMMP14:\n\n\n351:\n\n\n400\n\n\n---------- ---------- ---------- ---------- ----------\n\n\n\n\n\n\n \n\n\n\n\n\n\nhMMP14:\n\n\n401:\n\n\n450\n\n\nKHIKELGRGL PTDKIDAALF WMPNGKTVFP RGNKYYRFNE ELRAVDSEYP\n\n\n\n\n\n\nmMMP14:\n\n\n401:\n\n\n450\n\n\n---------- ---------- ---------- ---------- -F--------\n\n\n\n\n\n\n \n\n\n\n\n\n\nhMMP14:\n\n\n451:\n\n\n500\n\n\nKNIKVWEGIP ESPRGSFMGS DEVFTYFYKG NKYWKFNNQK LKVEPGYRKS\n\n\n\n\n\n\nmMMP14:\n\n\n451:\n\n\n500\n\n\n---------- ---------- ---------- ---------- ----------\n\n\n\n\n\n\n \n\n\n\n\n\n\nhMMP14:\n\n\n501:\n\n\n550\n\n\nALRDWMGCPS GGRFDEGTEE EREVIIIEVD EEGGGAVSAA AVVLPVLLLL\n\n\n\n\n\n\nmMMP14:\n\n\n501:\n\n\n550\n\n\n---------- -R-------- ---------- ---S------ ----------\n\n\n\n\n\n\n \n\n\n\n\n\n\nhMMP14:\n\n\n551:\n\n\n582\n\n\nLVLAVGLAVF FFRRHGTPRR LLYCQRSLLD (SEQ ID NO: 1)\n\n\n\n\n\n\nmMMP14:\n\n\n551:\n\n\n582\n\n\n---------- --------K- ---------- (SEQ ID NO: 3)\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n  indicates data missing or illegible when filed\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n \nThese exemplary hMMP-14 and mMMP-14 sequences are identical at 558 of 580 positions, about 96.2% identity. Despite a relatively high degree of similarity, their activity toward different substrates, including proMMP-2 and type I collagen, varies (Wang, et al., 2004, J Biol Chem, 279:51148-55).\n\n\n \n \n \n \nMMP-14-deficient mice were generated by gene targeting (Holmbeck, et al., 1999, Cell, 99:81-92). MMP-14 deficiency causes craniofacial dysmorphism, arthritis, osteopenia, dwarfism, And fibrosis or soft tissues, but the mice are viable. The expression of MMP-14 in tumors is reviewed in Sato et al. (Sato, et al., 2005, Cancer Sci, 96:212-7), Zucker et al. (Zucker and Vacirca, 2004, Cancer Metastasis Rev, 23:101-17), and Bauvois (Bauvois. 2004, Oncogene, 23:317-29), Increased expression of MT-MMPs has previously been reported to correlate with increasing grade of malignancy in gliomas, a relationship shared with alterations in epidermal growth factor receptor (EGFR) signaling. One mechanism of ECM-mediated invasiveness in gliomas may involve the induction of MT1-MMP (Van metier et al, 2004, Neuro-oncol., 6(3):188-99).\n\n\n \n \n \n \nMMP-14 is regulated by chemokines monocytc-cheinoattractam protein-11 ccl2 and interleukin-81CXCL8 in endothelial cells during angiogenesis (Galvez et. al, 2005, J Biol Chem, 280(2):1292-8). MMP-14 activity is also regulated by \nERK\n 1/2- and p38 MAPK-modulated TIMP-2 expression which controls TGF-beta1-induced pericellular collagenolysis (Munshi et al, 2004, J Biol Chem, 279(37):39042-50). Blockade of the ERK pathway suppress the expression of MMP-3, -9, and -14, and CD44 and markedly inhibits the invasiveness of tumor cells (Tanimura et al. 2003, Biochem Biophys Res Commun, 304(4):801-6).\n\n\n \n \n \n \nDuring angiogenesis, MMP-14 contributes to the specific up-regulation of VEGF-A through activation of Src tyrosine kinase pathways perhaps involving the cleavage of CD44 (Sounni et al, 2004, J Biol Chem, 279(14):13564-74).\n\n\n \n \n \n \nMMP-14 has a number of endogenous inhibitors. TIMP-2 binds MMP-14 and anchors MMP-14 to cell surface and acts as a “receptor” for proMMP-2 (progelatinase A), such that the latter can be activated efficiently in a localized fashion (Murphy, et al., 2003, Biochem Soc Symp, 65-80). TIMP-2. TIMP-3, and TIMP-4 inhibit MMP-14, but TIMP-1 does not (Lee, et al., 2003, J Biol Chem, 278:40224-30). TIMPs typically are slow, tight binding inhibitors.\n\n\n \n \n \n \nMMP-14 activates pro-MMP-2 causing a cascade of proteolysis that facilitates the mobility and invasiveness of tumor cells (Berno, et al., 2005. Endocr Relat Cancer, 12:393-406; Anilkumar, et. al., 2005, Faseb J, 19:1326-8: holt and Seiki, 2005, J Cell Physiol; Lopez de Cicco, et al., 2005, Cancer Res, 65:4162-71; El Bedoui, et al., 2005, Cardiovasc Res, 67:31725; Cao, et al., 2005, Thromb Haemost, 93:770-8; Sato, et al., 2005, Cancer Sci, 96:212-7; Dong, et al., 2005, Am J Pathol, 166:1173-86; Philip, et al., 2004, Glycoconj J, 21:429-41; Guo et al., 2005, Am J Pathol, 166:877-90; Grossman. 2005, Uml Oncol, 23:222; Gilles, et al., 2001, J Cell Sci, 114:2967-76). Studies propose that this activation process requires both active MT1-MMP and the TIMP-2-bound MT1-MMP (Strongin et al, 1995, J Biol Chem, 270, 5331-5338; Butler et al., 1998, J Biol Client, 273: 871-80; Kinoshita et al, 1995, J. Biol Chem, 273, 16098-103). The TIMP-2 in the latter complex binds, through its C-terminal domain, to the hemopexin domain of pro-MMP-2, which may localize the zymogen close to the active MT1-MMP (Butler et al, 1998. J Biol Chem, 273: 871-80: Kinoshita et al, 1998).\n\n\n \n \n \n \nIn addition to proMMP-2, MMP-14 cleaves other substrates, such as collagen triple-helical structure (Minond, et al. 2004, Biochemistry, 43:11474-81), fibrin (Kluft. 2003, Pathophysial Haemost Thromb. 33:425-9), Matrigel (Cao, et al., 2005, Thromb Haemost, 93:770-8), other extracellular matrix components (Sato, et al., 2005, Cancer Sci, 96:212-7), CD44 (Suenaga, et al., 2005, Oncogene, 24:859-68), and various other proteins (Hwang, et al., 2004, Biochim Biophys Acta, 1702:79-87). MMP-14 can promote the activation of \npro-collagenase\n 2 and -3, a potent collagenolytic protease (Knauper et al, 1996, J Biol Chem, 271:1.7124-31; Woessner et Nagase, 2000).\n\n\n \n \n \n \nMMP-14 has been implicated in many disease states, including, e.g.: tumor growth (Trisciuoglio, et al., 2005, j Cell Physiol), tumor embolism (Cao, et al., 1996, J. Biol Chem, 271:30174-80), angiogenesis (Haas, 2005, Can J Physiol Pharmacol, 83:1-7; (Handsley and Edwards, 2005, Int J Cancer, 115:849-60; (Roebuck, et al., 2005, Am J. Clin. Pathol, 123:405-14 (Pilorget, et al., 2005, J Cereb Blood Flow Metall), and cell proliferation (Aoki, et al., 2005, J Biochem (Tokyo). 137:95-9). Accordingly, proteins that bind and/or inhibit MMP-14 can be used to treat and/or diagnose these conditions.\n\n\n \n \n \n \nAs MMP-14 is implicated in the progression of laryngeal cancer, MMP-14 may serve as a reliable marker in estimating invasive and metastatic potency of laryngeal cancer. Suppressing expression of MMP-14 may inhibit the invasion and metastases of laryngeal cancer (Sun, Li, 2004, Chin Med Sci J, 19(3):170-3). Thus, MMP-14 binding proteins can be used to treat or prevent metastatic cancers. e.g., metastatic laryngeal cancer.\n\n\n \n \n \n \nMMP-14 is implicated in several non-oncological diseases including: rheumatoid arthritis (Itoh and Seiki, 2005, J Cell Physiol, (Distler, et al., 2005, Proc Natl Acad Sci USA. 102:2892-7); osteoarthritis (Tchetina et al., 2005, J Rheumatol, 32:876-86); diabetes (inter alia, (Savinoy, et al., 2005, J Biol Chem, 280:27755-8; Gebel, et al., 2005, Lab Invest, 85:597-607; Raymond, et al., 2004, J. Vasc Surg. 40:1190-8); and atherosclerosis (Stawowy, et al., 2005, Circulation, 111:2820-7; May, et al., 2005, Thromb Haemost, 93:710-5; Rajavashisth, et al., 1999, Circulation, 99:3103-9). The role of MMPs in development, normal processes, and cancer is reviewed in Folgucras et al., lot. J. Dev. Biol. 48:411-424 (2004). Accordingly, proteins that bind and/or inhibit MMP-14 are useful to treat and/or diagnose these conditions.\n\n\n \n \n \n \nMMP-16\n\n\n \n \n \n \nMatrix metalloproteinase-16 (also known as MMP-16, membrane type-3 matrix metalloproteinase, or MT3-MMP) is expressed in a variety of normal (Takino et al, 1995. J Biol Chem, 270: 23013-20; Yoshiyama ct at. 1998, Acta Neuropathol, 96: 347-50; Sholuda et. al, 2001, 947:337-40; Natall et al, 2003, Mol Cancer Res, 1:333-45) and tumor tissues (Natall et al, 2003, Mol Cancer Res. 1:333-45; Kitagawa et al, 1999.3 Urol, 162:905-9: Ohnishi et al, 2001, Eur J dermatol, 11:420-3). MMP-16 is involved in the remodeling of both the normal and diseased mammary gland either directly or indirectly by activation of other MMPs. Non invasive breast cancer (MCF-7) express notably less MMPs than invasive breast cancer (MDA-MB-231) (Kousidou et al. 2005, Int J Oncol, 26(4):1101-9 Szabova et al. 2005, J Cell Physiol, 205(1):123-32). MMP-16 plays a role in extracellular matrix turnover not only by activating proMMP-2 but also by acting directly on ECM macromolecules.\n\n\n \n \n \n \nMMP-16 is involved in capillary tube formation (Lafleur et al, 2002, J Cell Sci., 115(Pt 17):3427-38, et al. 2004, J Clin Endocrinol Metab, 89(11):5828-36; et al. 2002, J Cell Sci Plaisier et al, 2004, J Clin Endocrinol Metab, 89(11):5828-36) and matrix remodeling of blood vessels (Shofuda et al. 1997, J Biol Chem, 272(15):9749-54). MMP-16 is an alternate pro-invasive factor that drives fibrin-invasive activity (Kang et al, 2000, Faseb J, 14(15):2559-68; 2002, et al. J Exp Med, 195(3):295-308).\n\n\n \n \n \n \nMMP-16 shows increased expression in osteoarthritis (at P<0.01) (Kevorkian et al. 2004, Arthritis Rheum., 50(1):131-41). MMP-16 is intensely expressed in synovium of rheumatoid arthritis patients (Pap et al. 2000, Arthritis Rheum., 43(6):1226-32). Expression of MMP-16 is also increased in human atherosclerotic plaque (Uzui et al. 2002, Circulation, 106(24):3024-30).\n\n\n \n \n \n \nMMP-16 is expressed in the ovarian cancers (Stadlmann et al. 2003, Eur J Cancer, 39(17):2499-505). Expression of MMP-2, MMP-16, and VEGF is increased in testicular carcinoma (Konaka et al, 1999, J Urol, 161(1):342-8), and MMP-16 shows increased expression in the testicular cancer associated with increased metastatic potential (Koshida et al. 2000. Hinyokika Kiyo, 46(10):775-81). Expression of MMP-16 is higher in carcinomas, especially clear cell carcinoma, than in normal parenchyma.\n\n\n \n \n \n \nMMP-16 is expressed in primary and metastatic melanoma cells. Double immunofluorescence demonstrates a consistent colocalization of MMP-16/MMP-2 in metastatic melanoma cells. The colocalization of MMP-16 and MMP-2 in nodular and metastatic melanoma cells indicates that MT-MMPs and MMP-2 may cooperate in the invasive and metastatic process of melanoma cells (Ohnishi et al. 2001, Eur Dermatol, 11(5):420-3, lido et al. 2001, J Biol Chem, 276(22):187S6-94). Like MMP-14. MMP-16 is implicated in the progression of laryngeal cancer. Thus, MMP-14 binding proteins that also bind and/or inhibit MMP-16 can be used to treat or prevent metastatic cancers, e.g., metastatic laryngeal cancer.\n\n\n \n \n \n \nBasal MMP-16 mRNA expression has a pattern similar to that or MMP-14 but is not up-regulated by collagen (Gilles et al. 1997, Lab Invest, 76(5):651-60). MMP-14 is implicated in collagen-stimulated MMP-2 activation. This mechanism may be employed in vivo by both tumor-associated fibroblasts and EMT-derived carcinoma cells to facilitate increased invasion and/or metastasis. In human invasive breast carcinomas, there is a correlation between the expression of MMP-14 and -16, immunolocalization of MMP-14 and proMMP-2 activation (Ueno et al. 1.997, Cancer Res, 57(10):2055-60). MMP-16 and TIMP-2 mRNA expressions are significantly increased in diabetic rat kidneys (Wan et al., 2004, Di Yi Jun Yi Da Xue Xue Bao. 24(12): 1391-4).\n\n\n \n \n \n \nMMP-24\n\n\n \n \n \n \nMatrix metalloproteinasc-24 (also known as MMP-24, membrane type-5 matrix metalloproteinase, or MT5-MMP) has been identified and cloned from a human brain cDNA library (Llano et al., 1999, Cancer Res, 59(11):2570-6). While sharing similar domain structure with other MT-MMPs, the cytoplasmic tail of MMP-24 is the most divergent, having only 50% identity with those of MMP-14 and -16 (Poi D, 1999, J. Biol Chem, 274, 8925-32). MMP-24 is expressed predominantly in the brain and at low levels in the kidney, pancreas, and lung. MMP-24 has been shown to play a role in axonal growth (Hayashita-Kinoh et al., 2001, Cell Growth Differ, 12, 573-58). Human MMP-24 gene maps to 20q11.2, a region frequently amplified in tumors from diverse sources, suggesting that MMP-24 may play a role in the progression of cancer. The catalytic domain of MMP-24 exhibits a potent proteolytic activity against proMMP-2, leading to the generation of the Mr 62,000 active form of this enzyme. MMP-24 may contribute to the activation of pro MMP-2 in tumor tissues, in which it is overexpressed, thereby facilitating tumor progression (Pei D, 1999, J. Biol Chem, 274. 8925-32).\n\n\n \n \n \n \nMMP-24 transcripts are detected at high levels compared to normal brain tissue in a series of brain tumors including astrocytomas, glioblastomas and gliomas (Van inciter et al, 2004, Neuro-oncol, 3:188-99). MMP-24 is predominantly expressed in the brain. (Brain Res. 2000 Mar. 31; 860(1-2):174; Biol. Chem. 1999 Mar. 26; 274(13):8925-32; Lett. 1999 December 3:462(3):261-6).\n\n\n \n \n \n \nMMP-24 mRNA levels are higher in a series of brain tumors, including astrocytomas and glioblastomas, as compared to levels in normal brain tissue (Llano et al., 1999, Cancer Res, 59(11):2570-6).\n\n\n \n \n \n \nMMP-24-deficient mice are born without obvious morphological abnormalities. No apparent histological defects are observed in the nervous system. However, MMP-24 deficient mice do not develop neuropathic pain with mechanical allodynia after sciatic nerve injury, though responses to acute noxious stimuli am normal (Uekita et al, FEBS Lett. 2004 Jan. 16, 557(1-3):125-8).\n\n\n \n \n \n \nMMP-24 expression is increased in infected corneas. There is good correlation between to the overexpression of MMP-24 in the infected corneas and the inflammatory response. Inflammatory cells such as macrophages and PMNs may play a role in the upregulation of MT-MMPs during corneal infection, which in turn can cause the destruction of corneal tissue (Doug et al, Invest Ophthalmol V is Sci. 2001 December; 42(13):3223-7).\n\n\n \n \n \n \nMMP-24 expression is increased in diabetes. MMP-24 plays a role in the pathogenesis of renal tubular atrophy and end-stage renal disease (Romanic et al, 2001, Am Physiol Renal Physiol, August; 281(2):F309-17).\n\n\n \n \n \n \nMMP-24 is co-localized with senile plaques in Alzheimer brain, indicating possible roles in regulating patho-physiological processes associated with advanced age (Sekinc-Aizawa, 2001, Eur J Neurosci, 13(5):935-48).\n\n\n \nDisplay Libraries\n\n\n \n \n \nA display library is a collection of entities; each entity includes an accessible polypeptide component and a recoverable component that encodes or identifies the polypeptide component. The polypeptide component is varied so that different amino acid sequences are represented. The polypeptide component can be of any length, e.g. from three amino acids to over 300 amino acids. A display library entity can include more than one polypeptide component, for example, the two polypeptide chains of an sFab. In one exemplary implementation, a display library can be used to identify proteins that bind to MMP-14. In a selection, the polypeptide component of each member of the library is probed with MMP-14 (e.g., the catalytic domain of MMP-14 or other fragment) and if the polypeptide component binds to the MMP-14, the display library member is identified, typically by retention on a support.\n\n\n \n \n \n \nRetained display library members are recovered from the support and analyzed. The analysis can include amplification and a subsequent selection under similar or dissimilar conditions. For example, positive and negative selections can be alternated. The analysis can also include determining the amino acid sequence of the polypeptide component and purification of the polypeptide component for detailed characterization.\n\n\n \n \n \n \nA variety of formats can be used for display libraries. Examples include the following.\n\n\n \n \n \n \nPhage Display The protein component is typically covalently linked to a bacteriophage coat protein. The linkage results from translation of a nucleic acid encoding the protein component fused to the coat protein. The linkage can include a flexible peptide linker, a protease site, or an amino acid incorporated as a result of suppression of a stop codon. Phage display is described, for example, in U.S. Pat. No. 5,223,409; Smith (1985) \nScience \n228:1315-1317; WO 92/18619; WO 91/17271; WO 92/20791: WO 92/15679; WO 93/01288; WO 92/01047; WO 92/09690; WO 90/02809; de Haunt et al. (1999)) \nJ. Biol. Chem. \n274:18218-30; Hoogenboom et al. (1998) \nImmunotechnology \n4:1-20; Hoogenboom et al. (2000) \nImmunol Today \n2:371-8 and Fleet et al. (2005) \nNat. Biotechnol. \n23(3)344-8. Bacteriophage displaying the protein component can be grown and harvested using standard phage preparatory methods, e.g. PEG precipitation from growth media. Alley selection of individual display phages, the nucleic acid encoding the selected protein components can be isolated from cells infected with the selected phages or from the phage themselves, after amplification. Individual colonies or plaques can be picked, the nucleic acid isolated and sequenced.\n\n\n \n \n \n \nOther Display Formats. Other display formats include cell based display (see, e.g., WO 03/029456), protein-nucleic acid fusions (see, e.g., U.S. Pat. No. 6,207,446), ribosome display (See, e.g. Mattheakis et al. (1994) \nProc. Natl. Acad. Sci. USA \n91:9022 and Hanes et al. (2000) \nNat. Biotechnol. \n18:1287-92; Hanes et al. (2000) \nMethods Enzymol. \n328:404-30; and Schaffitzel et al. (1999) \nJ Immunol Methods. \n231(1-2):119-35), and \nE. coli \nperiplasmic display (\nJ Immunol Methods. \n2005 November 22:PKID: 16337958).\n\n\n \n \n \n \nScaffolds. Scaffolds useful for display include: antibodies (e.g., Fab fragments, single chain Fv molecules (scFV), single domain antibodies, camelid antibodies, and camelized antibodies): T-cell receptors; MEIC proteins; extracellular domains (e.g. fibronectin Type III repeats, EGF repeats); protease inhibitors (e.g., Kunitz domains, ecotin, BPTI, and so forth); TPR repeats; trifoil structures; zinc finger domains; DNA-binding proteins; particularly monomeric DNA binding proteins; RNA binding proteins; enzymes, e.g., proteases (particularly inactivated proteases), RNase; chaperones, e.g., thioredoxin and heat shock proteins; intracellular signaling domains (such as SH2 and SH3 domains); linear and constrained peptides; and linear peptide substrates. Display libraries can include synthetic and/or natural diversity. See, e.g., US 2004-0005709.\n\n\n \n \n \n \nDisplay technology can also be used to obtain binding proteins (e.g., antibodies) that bind particular epitopes of a target. This can be done, for example, by using competing non-target molecules that lack the particular epitope or are mutated within the epitope, e.g., with alaninc. Such non-target molecules can be used in a negative selection procedure as described below, as competing molecules when binding a display library to the target, or as a pre-elution agent, e.g., to capture in a wash solution dissociating display library members that are not specific to the target.\n\n\n \n \n \n \nIterative Selection. In one preferred embodiment, display library technology is used in an iterative mode. A first display library is used to identify one or more binding proteins for a target. These identified binding proteins are then varied using a mutagenesis method to form a second display library. Higher affinity binding proteins are then selected from the second library, e.g., by using higher stringency or more competitive binding and washing conditions.\n\n\n \n \n \n \nIn some implementations, the mutagenesis is targeted to regions at the binding interface. If, for example, the identified binding proteins are antibodies, then mutagenesis can be directed to the CDR regions of the heavy or light chains as described herein. Further, mutagenesis can be directed to framework regions near or adjacent to the CDRs in the case of antibodies, mutagenesis can also be limited to one or a few of the CDRs, e.g., to make precise step-wise improvements. Exemplary mutagenesis techniques include: error-prone PCR, recombination, DNA shuffling, site-directed mutagenesis and cassette mutagenesis.\n\n\n \n \n \n \nIn one example of iterative selection, the methods described herein are used to first identify a protein from a display library that binds MMP-14 with at least a minimal binding specificity for a target or a minimal activity, e.g., an equilibrium dissociation constant for binding of less than 1 nM, 10 nM, or 100 nM. The nucleic acid sequence encoding the initial identified proteins are used as a template nucleic acid for the introduction of variations, e.g., to identify a second protein that has enhanced properties (e.g., binding affinity, kinetics, or stability) relative to the initial protein.\n\n\n \n \n \n \nOff-Rate Selection. Since a slow dissociation rate can be predictive of high affinity, particularly with respect to interactions between polypeptides and their targets, the methods described herein can be used to isolate binding proteins with a desired (e.g., reduced) kinetic dissociation rate for a binding interaction to a target.\n\n\n \n \n \n \nTo select for slow dissociating binding proteins from a display library, the library is contacted to an immobilized target. The immobilized target is then washed with a first solution that removes non-specifically or weakly bound biomolecules. Then the bound binding proteins are eluted with a second solution that includes a saturating amount of free target or a target specific high-affinity competing monoclonal antibody, i.e., replicates of the target that are not to attached to the particle. The free target binds to biomolecules that dissociate from the target. Rebinding is effectively prevented by the saturating amount of free target relative to the much lower concentration of immobilized target.\n\n\n \n \n \n \nThe second solution can, have solution conditions that are substantially physiological or that are stringent. Typically, the solution conditions of the second solution are identical to the solution conditions of the first solution. Fractions of the second solution are collected in temporal order to distinguish early from late fractions. Later fractions include biomolecules that dissociate at a slower rate from the target than biomolecules in the early fractions.\n\n\n \n \n \n \nFurther, it is also possible to recover display library members that remain bound to the target even alter extended incubation. These can either be dissociated using chaotropic conditions or can be amplified while attached to the target. For example, phage hound to the target can be contacted to bacterial cells.\n\n\n \n \n \n \nSelecting or Screening for Specificity. The display library screening methOds described herein can include a selection or screening process that discards display library members that bind to a non-target molecule. Examples of non-target molecules include streptavidin on magnetic beads, blocking agents such as bovine serum albumin, non-fat bovine milk, any capturing or target immobilizing monoclonal antibody, or non-transfected cells which do not express the human MMP-14 target.\n\n\n \n \n \n \nIn one implementation, a so-called “negative selection” step is used to discriminate between the target and Mated non-target molecule and a related, but distinct non-target molecules. The display library or a pool thereof is contacted to the non-target molecule. Members of the sample that do not bind the non-target are collected and used in subsequent selections for binding to the target molecule or even for subsequent negative selections. The negative selection step can be prior to or after selecting library members that bind to the target molecule.\n\n\n \n \n \n \nIn another implementation, a screening step is used. After display library members are isolated for binding to the target molecule, each isolated library member is tested for its ability to bind to a non-target molecule (e.g., a non-target listed above). For example, a high-throughput ELISA screen can be used to obtain this data. The ELISA screen can also be used to obtain quantitative data for binding of each library member to the target as well as for cross species reactivity to related targets or subunits of the target (e.g., mouse MMP-14) and also under to different condition such as pH6 or pH 7.5. The non-target and target binding data are compared (e.g., using a computer and software) to identify library members that specifically bind to the target.\n\n\n \nOther Exemplary Expression Libraries\n\n\n \n \n \nOther types of collections of proteins (e.g., expression libraries) can be used to identify proteins with a particular property (e.g., ability to bind MMP-14 and/or ability to modulate MMP-14), including, e.g., protein arrays of antibodies (see, e.g., De Wildt et al. (2000) Nat. Biotechnol. 18:989-994), lambda-gt11 libraries, two-hybrid libraries and so forth.\n\n\n \nExemplary Libraries\n\n\n \n \n \nIt is possible to immunize a non-human primate and recover primate antibody genes that can be displayed on phage (see below). From such a library, one can select antibodies that bind the antigen used in immunization. See, for example, Vaccine. (2003) 22(2):257-67 or Immunogenetics. (2005) 57(10):730-8. Thus one could obtain primate antibodies that bind and inhibit MMP-14 by immunizing a chimpanzee or macaque and using a variety of means to select or screen for primate antibodies that bind and inhibit MMP-14. One can also make chimeras of primatized Fabs with human constant regions, sec Curr Opin Mol. Ther. (2004) 6(6):675-83. “PRIMATIZED antibodies, genetically engineered from cynomolgus macaque monkey and human components, are structurally indistinguishable from human antibodies. They may, therefore, be less likely to cause adverse reactions in humans, making them potentially suited for long-term, chronic treatment” Curr Opin Investig Drugs. (2001) 2(5):635-8.\n\n\n \n \n \n \nOne exemplary type of library presents a diverse pool of polypeptides, each of which includes an immunoglobulin domain, e.g., an immunoglobulin variable domain. Of interest are display libraries where the members of the library include primate or “primatized” (e.g., such as human, non-human primate or “humanized”,) immunoglobin domains (e.g., immunoglobin variable domains) or chimeric primatized Fabs with human constant regions. Human or humanized immunoglobin domain libraries may be used to identify human or “humanized” antibodies that, for example, recognize human antigens. Because the constant and framework regions of the antibody are human, these antibodies may avoid themselves being recognized and targeted as antigens when administered to humans. The constant regions may also be optimized to recruit effector functions of the human immune system. The in vitro display selection process surmounts the inability of a normal human immune system to generate antibodies against self-antigens.\n\n\n \n \n \n \nA typical antibody display library displays a polypeptide that includes a VH domain and a VL domain. An “immunoglobulin domain” refers to a domain from the variable or constant domain of immunoglobulin molecules. Immunoglobulin domains typically contain two β-sheets formed of about seven β-strands, and a conserved disulphide bond (see, e.g., A. F. Williams and A. N. Barclay, 1988\n, Ann. Rev. Immunol. \n6:381-405). The display library can display the antibody as a Fab fragment (e.g., using two polypeptide chains) or a single chain Fv (e.g., using a single polypeptide chain). Other formats can also be used.\n\n\n \n \n \n \nAs in the case of the Fab and other formats, the displayed antibody can include one or inure constant regions as pad of a light and/or heavy chain. In one embodiment, each chain includes one constant region, e.g., as in the case of a Fab in other embodiments, additional constant regions are displayed.\n\n\n \n \n \n \nAntibody libraries can be constructed by a number of processes (see, e.g., de Haard et al., 1999\n, J. Biol. Chem. \n274:18218-30; Hoogenboom et al., 1998\n, Immunotechnology \n4:1-20; Hoogenboom et al., 2000, \nImmunol. Today \n21:371-378, and Hae et al. (2005) \nNat. Biotechnol. \n23(3)344-8. Further, elements of each process can be combined with those of other processes. The processes can be used such that variation is introduced into a single immunoglobulin domain (e.g., VH or VL) or into multiple immunoglobulin domains (e.g., VH and VL). The variation can be introduced into an immunoglobulin variable domain, e.g., in the region of one or more of CDR1, CDR2, CDR3, FR1, FR2, FR3 and FR4, referring to such regions of either and both of heavy and light chain variable domains. The variation(s) may be introduced into all three CDRs of a given variable domain, or into CDR1 and CDR2, e.g., of a heavy chain variable domain. Any combination is feasible. In one process, antibody libraries are constructed by inserting diverse oligonucleotides that encode CDRs into the corresponding regions of the nucleic acid. The oligonucleotides can be synthesized using monomeric nucleotides or trinueleotides. For example, Knappik et al., 2000\n, J. Mol. Biol. \n296:57-86 describe a method for constructing CDR encoding oligonucleotides using trinucleotide synthesis and a template with engineered restriction sites for accepting the oligonucleotides.\n\n\n \n \n \n \nIn another process, an animal, e.g. a rodent, is immunized with MMP-14. The animal is optionally boosted with the antigen to further stimulate the response. Then spleen cells are isolated from the animal, and nucleic acid encoding VH and/or VL domains is amplified and cloned for expression in the display library.\n\n\n \n \n \n \nIn yet another process, antibody libraries are constructed from nucleic acid amplified from naïve germline immunoglobulin genes. The amplified nucleic acid includes nucleic acid encoding the VH and/or VL domain. Sources of immunoglobulin-encoding nucleic acids are described below. Amplification can include PCR, e.g., with primers that anneal to the conserved constant region, or another amplification method.\n\n\n \n \n \n \nNucleic acid encoding immunoglobulin domains can be obtained from the immune cells of, e.g., a primate (e.g., a human) mouse, rabbit, camel, or rodent. In one example, the cells are selected for a particular property, B cells at various stages of maturity can be selected. In another example, the B cells are naïve.\n\n\n \n \n \n \nIn one embodiment, fluorescent-activated cell sorting (FACS) is used to sort B cells that express surface-bound IgM, IgD, or IgG molecules. Further, B cells expressing different isotypes of IgG can be isolated. In another preferred embodiment, the B or T cell k cultured in vitro. The cells can be stimulated in vitro, e.g., by culturing with feeder cells or by adding mitogens or other modulatory reagents, such as antibodies to CD40, CD40 ligand or CD20, phorbol myristate acetate, bacterial lipopolysaccharide, concanavalin A, phytohemagglutinin, or pokeweed mitogen.\n\n\n \n \n \n \nIn another embodiment, the cells are isolated from a subject that has a disease of condition described herein, e.g., a cancer (e.g., metastatic cancer, e.g., metastatic breast cancer), an inflammatory disease (e.g., synovitis, atherosclerosis), rheumatoid arthritis, osteoarthritis, an ocular condition (e.g., macular degeneration), diabetes, Alzheimer's Disease, cerebral ischemia, endometriosis, fibrin-invasive activity, angiogenesis, or capillary tube formation In another embodiment, the cells are isolated from a transgenic non-human animal that includes a human immunoglobulin locus.\n\n\n \n \n \n \nIn one preferred embodiment, the cells have activated a program of somatic hypermutation. Cells can be stimulated to undergo somatic mutagenesis of immunoglobulin genes, for example, by treatment with anti-immunoglobulin, anti-CD40, and anti-CD38 antibodies (see, e.g., Bergthorsdottir et al., 2001\n, J. Immunol. \n166:2228). In another embodiment, the cells are naïve.\n\n\n \n \n \n \nThe nucleic acid encoding an immunoglobulin variable domain can be isolated from a natural repertoire by the following exemplary method. First, RNA is isolated from the immune cell. Full length (i.e., capped) mRNAs are separated (e.g. by degrading uncapped RNAs with calf intestinal phosphatase). The cap is then removed with tobacco acid pyrophosphatase and reverse transcription is used to produce the cDNAs.\n\n\n \n \n \n \nThe reverse transcription of the first (antisense) strand can be done in any manner with any suitable primer. See, e.g., de Haard et al., 1999\n, J. Biol. Chem. \n274:182.18-30. The primer binding region can be constant among different immunoglobulins, e.g., in order to reverse transcribe different isotypes of inummoglobulin. The primer binding region can also be specific ton particular isotype of immunoglobulin. Typically, the primer is specific for a region that is 3′ to a sequence encoding at least one CDR. In another embodiment, poly-dT primers may be used (and may be preferred for the heavy-chain genes).\n\n\n \n \n \n \nA synthetic sequence can be ligated to the 3′ end of the reverse transcribed strand. The synthetic sequence can be used as a primer binding site for binding of the forward primer during PCR amplification idler reverse transcription. The use of the synthetic sequence can obviate the need to use a pool of different forward primers to fully capture the available diversity.\n\n\n \n \n \n \nThe variable domain-encoding gene is then amplified, e.g., using one or more rounds. If multiple rounds are used nested primers can be used for increased fidelity. The amplified nucleic acid is then cloned into a display library vector.\n\n\n \nSecondary Screening Methods\n\n\n \n \n \nAfter selecting candidate library members that bind to a target; each candidate library member can be further analyzed, e.g., to further characterize its binding properties for the target, e.g., MMP-14, or for binding to other protein, e.g., another metalloproteinase. Each candidate library member can be subjected to one or more secondary screening assays. The assay can be for a binding property, a catalytic property, an inhibitory property, a physiological property (e.g., cytotoxicity, renal clearance, immunogenicity), a structural property (e.g., stability, conformation, oligomerization state) or another functional property. The same assay can be used repeatedly, but with varying conditions, e.g., to determine pH, ionic, or thermal sensitivities.\n\n\n \n \n \n \nAs appropriate, the assays can use a display library member directly, a recombinant polypeptide produced from the nucleic acid encoding the selected polypeptide, or a synthetic peptide synthesized based on the sequence of the selected polypeptide. In the case of selected Fabs, the Fabs can be evaluated or can be modified and produced as intact IgG proteins. Exemplary assays for binding properties include the following.\n\n\n \n \n \n \nELISA. Binding proteins can be evaluated using an ELISA assay. For example, each protein is contacted to a microtitre plate whose bottom surface has been coated with the target, e.g., a limiting amount of the target. The plate is washed with buffer to remove non-specifically bound polypeptides. Then the amount of the binding protein hound to the target on the plate is determined by probing the plate with an antibody that can recognize the binding protein, e.g. a tag or constant portion of the binding protein. The antibody is linked to a detection system (e.g., an enzyme such as alkaline phosphatase or horse radish peroxidase (HRP) which produces a colorimetric product when appropriate substrates are provided).\n\n\n \n \n \n \nHomogeneous Binding Assays. The ability of a binding protein described herein to bind a target can be analyzed using a homogenous assay, i.e., after all components of the assay are added, additional fluid manipulations are not required. For example, fluorescence resonance energy transfer (FRET) can be used as a homogenous assay (see, for example, Lakowiez et al., U.S. Pat. No. 5,631,169; Stavrianopoulos, et al., U.S. Pat. No. 4,868,103). A fluorophore label on the first molecule (e.g. the molecule identified in the fraction) is selected such that its emitted fluorescent energy can be absorbed by a fluorescent label on a second molecule (e.g., the target) if the second molecule is in proximity to the first molecule. The fluorescent label on the second molecule fluoresces when it absorbs to the transferred energy. Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, the spatial relationship between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the ‘acceptor’ molecule label in the assay should be maximal. A binding event that is configured for monitoring by FRET can be conveniently measured through standard fluorometric detection means, e.g., using a fluorimeter. By titrating the amount of the first or second binding molecule, a binding curve can be generated to estimate the equilibrium binding constant.\n\n\n \n \n \n \nAnother example of a homogenous assay is ALPHASCREEN™ (Packard Bioscience, Meriden Conn.). ALPHASCREEN™ uses two labeled beads. One bead generates singlet oxygen when excited by a laser. The other bead generates a light signal when singlet oxygen diffuses from the first bead and collides with it. The signal is only generated when the two heads are in proximity. One bead can be attached to the display library member, the other to the target. Signals are measured to determine the extent of binding.\n\n\n \n \n \n \nSurface Plasmon Resonance (SPR). The interaction of binding protein and a target can be analyzed using SPR. SPR or Biomolecular Interaction Analysis (BIA) detects biospceific interactions in real time, without labeling any of the interactants. Changes in the mass at the binding surface (indicative of a binding event) of the BRA chip result in alterations of the refractive index of light near the surface (the optical phenomenon of surface plasmon resonance (SPR)). The changes in the refractivity generate a detectable signal, which are measured as an indication of real-time reactions between biological molecules. Methods for using SPR are described, for example, in U.S. Pat. No. 5,641,640; Raether, 1988, Surface Plasmons Springer Verlag; Sjolander and Urbaniczky, 1991\n, Anal. Chem. \n63:2338-2345; Szabo et al. 1995\n, Curr. Opin. Struct. Biol. \n5:699-705 and on-line resources provide by BIAcore International AB (Uppsala, Sweden).\n\n\n \n \n \n \nInformation from SPR can be used to provide an accurate and quantitative measure of the equilibrium dissociation constant (K\nd\n) and kinetic parameters, including and K\non \nand K\noff\n, for the binding of a binding protein to a target. Such data can be used to compare different biomolecules. For example, selected proteins from an expression library can be compared to identify proteins that have high affinity for the target or that have a slow K\noff\n. This information can also be used to develop structure-activity relationships (SAR). For example, the kinetic and equilibrium binding parameters of matured versions of a parent protein can be compared to the parameters of the parent protein. Variant amino acids at given positions can be identified that correlate with particular binding parameters, e.g., high affinity and stow K\noff\n. This information can be combined with structural modeling (e.g., using homology modeling, energy minimization, or structure determination by x-ray crystallography or NMR). As a result, an understanding of the physical interaction between the protein and its target can be formulated and used to guide other design processes.\n\n\n \n \n \n \nCellular Assays. Binding proteins can be screened for ability to bind to cells which transiently or stably express and display the target of interest on the cell surface. For example, MMP-14 binding proteins can be fluorescently labeled and binding to MMP-14 in the presence to of absence of antagonistic antibody can be detected by a change in fluorescence intensity using flow cytometry e.g., a FACS machine.\n\n\n \nOther Exemplary Methods for Obtaining MMP-14 Binding Antibodies\n\n\n \n \n \nIn addition to the use of display libraries, other methods can be used to obtain a MMP-14 binding antibody. For example, MMP-14 protein or a region thereof can be used as an antigen in anon-human animal, e.g., a rodent.\n\n\n \n \n \n \nIn one embodiment, the non-human animal includes at least a part of a human immunoglobulin gene. For example, it is possible to engineer mouse strains deficient in mouse antibody production with large fragments of the human Ig loci. Using the hybridoma technology, antigen-specific monoclonal antibodies (Mabs) derived from the genes with the desired specificity may be produced and selected. Sec, e.g., XENOMOUSE™, Green et al., 1994\n, Nat. Gen. \n7:13-21; U.S. 2003-0070185, WO 96/34096, published Oct. 31, 1996, and PCT Application No. PCT/US96/05928, filed Apr. 29, 1996.\n\n\n \n \n \n \nIn another embodiment, a monoclonal antibody is obtained from the non-human animal, and then modified, e.g., humanized or deimmunized. Winter describes a CDR-grafting method that may be used to prepare the humanized antibodies (UK Patent Application GB 2.188638A, filed on Mar. 26, 1987; U.S. Pat. No. 5,225,539. All of the CDRs of a particular human antibody may be replaced with at least a portion of a non-human CDR or only some of the CDRs may be replaced with non-human CDRs. It is only necessary to replace the number of CDRs required for binding of the humanized antibody to a predetermined antigen.\n\n\n \n \n \n \nHumanized antibodies can be generated by replacing sequences of the Fv variable region that are not directly involved in antigen binding with equivalent sequences from human Fv variable regions. General methods for generating humanized antibodies are provided by Morrison, S. L., 1985\n, Science \n229:1202-1207, by Oi et al., 1986\n, Biotechniques \n4:214, and by Queen et al. U.S. Pat. No. 5,585,089, U.S. Pat. No. 5,693,761 and U.S. Pat. No. 5,693,762. Those methods include isolating, manipulating, and expressing the nucleic acid sequences that encode all or part of immunoglobulin Fv variable regions from at least one of a heavy or light chain. Numerous sources of such nucleic acid are available. For example, nucleic acids may be obtained from a hybridoma producing an antibody against a predetermined target, as described above. The to recombinant DNA encoding the humanized antibody, or fragment thereof, can then be cloned into an appropriate expression vector.\n\n\n \nReducing Immunogenicity of MMP-14 Binding Proteins\n\n\n \n \n \nImmunoglobin MMP-14 binding proteins (e.g., IgG or Fab MMP-14 binding proteins) may be modified to reduce immunogenicity. Reduced immunogenicity is desirable in MMP-14 binding proteins intended for use as therapeutics, as it reduces the chance that the subject will develop an immune response against the therapeutic molecule. Techniques usertil for reducing immunogenicity or MMP-14 binding proteins include deletion/modification of potential human T cell epitopes and ‘germlining’ of sequences outside of the CDRs (e.g., framework and Fe).\n\n\n \n \n \n \nAn MMP-14-binding antibody may be modified by specific deletion or human T cell epitopes or “deimmunization” by the methods disclosed in WO 98/52976 and WO 00/34317. Briefly, the heavy and light chain variable regions of an antibody are analyzed for peptides that bind to MHC Class II; these peptides represent potential T-cell epitopes (as defined in WO 98/52976 and WO 00/34317). For detection of potential T-cell epitopes, a computer modeling approach termed “peptide threading” can be applied, and in addition a database of human MHC class II binding peptides can be searched for motifs present in the VH and VL sequences, as described in WO 98/52976 and WO 00/34317. These motifs bind to any of the 18 major MHC class II DR allotypes and thus constitute potential T cell apitopes. Potential T-cell epitopes detected can be eliminated by substituting small numbers of amino acid residues in the variable regions, or preferably by single amino acid substitutions. As far as possible conservative substitutions are made often but not exclusively, an amino acid common at this position in human germline antibody sequences may be used. Human germline sequences are disclosed in Tomlinson, I. A. et al., 1992\n, J. Mol. Biol. \n227:776-798; Cook, G. P. et al., 1995\n, Immunol. Today Vol. \n16 (5): 237-242; Chothia, D. et al., 1992\n, J. Mol. Bio. \n227:799-817. The V BASE directory provides a comprehensive directory of human immunoglobulin variable region sequences (compiled by Tomlinson, I. A. et al. MRC Centre for Protein Engineering, Cambridge, UK).\n\n\n \n \n \n \nAfter the deimmunizing changes are identified, nucleic acids encoding V\nH \nand V\nL \ncan be constructed by mutagenesis or other synthetic methods (e.g., de novo synthesis, cassette replacement, and so forth). Mutagenized variable sequence can, optionally, be fused to a human constant region, e.g., human IgG1 or κ constant regions.\n\n\n \n \n \n \nIn some cases a potential T cell epitope will include residues which are known or predicted to be important for antibody function. For example, potential T cell epitopes are usually biased towards the CDRs. In addition, potential T cell epitopes can occur in framework residues important for antibody structure and binding. Changes to eliminate these potential epitopes will in some cases require more scrutiny, e.g., by making and testing chains with and without the change. Where possible, potential T cell epitopes that overlap the CDRs were eliminated by substitutions outside the CDRs. In some cases, an alteration within a CDR is the only option, and thus variants with and without this substitution should be tested in other cases, the substitution required to remove a potential T cell epitope is at a residue position within the framework that might be critical for antibody binding. In these cases, variants with and without this substitution should be tested. Thus, in some cases several variant deimmunized heavy and light chain variable regions were designed and various heavy/light chain combinations tested in order to identify the optimal deimmunized antibody. The choice of the final deimmunized antibody can then be made by considering the binding affinity of the different variants in conjunction with the extent of deimmunization, i.e., the number of potential T cell epitopes remaining in the variable region. Deimmunization can be used to modify any antibody, e.g., an antibody that includes a non-human sequence, e.g., a synthetic antibody, a murine antibody other non-human monoclonal antibody, or an antibody isolated from a display library.\n\n\n \n \n \n \nMMP-14 binding antibodies are “germlined” by reverting one or more non-germline amino acids in framework regions to corresponding germline amino acids of the antibody, so long as binding properties are substantially retained. Similar methods can also be used in the constant region, e.g., in constant immunoglobulin domains.\n\n\n \n \n \n \nAntibodies that bind to MMP-14, e.g., an antibody described herein, may be modified in order to make the variable regions of the antibody more similar to one or more germline sequences. For example, an antibody can include one, two, three, or more amino acid substitutions, e.g., in a framework, CDR, or constant region, to make it more similar to a reference germline sequence. One exemplary germlining method can include identifying one or more germline sequences that are similar (e.g., most similar in a particular database) to the sequence of the isolated antibody. Mutations (at the amino acid level) are then made in the isolated antibody, either incrementally or in combination with other mutations. For example, a nucleic acid library that includes sequences encoding some or all possible germline mutations is made. The mutated antibodies are then evaluated, e.g., to identify an antibody that has one or more additional germline residues relative to the isolated antibody and that is still useful (e.g., has a functional activity). In one embodiment, as many germline residues are introduced into an isolated antibody as possible.\n\n\n \n \n \n \nIn one embodiment, mutagenesis is used to substitute or insert one or more germline residues into a framework and/or constant region. For example, a germline framework and/or constant region residue can be from a germline sequence that is similar (e.g., most: similar) to the non-variable region being modified. After mutagenesis, activity (e.g., binding or other functional activity) of the antibody can be evaluated to determine lithe germline residue or residues are tolerated (i.e., do not abrogate activity). Similar mutagenesis can be performed in the framework regions.\n\n\n \n \n \n \nSelecting a germline sequence can be performed in different ways. For example, a germline sequence can be selected if it meets a predetermined criteria for selectivity or similarity, e.g., at least a certain percentage identity, e.g., at least 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 99.5% identity. The selection can be performed using at least 2, 3, 5, or 10 germline sequences. In the case of CDR1 and CDR2, identifying a similar germline sequence can include selecting one such sequence. In the case of CDR3, identifying a similar germline sequence can include selecting one such sequence, but may including using two germline sequences that separately contribute to the amino-terminal portion and the carboxy-terminal portion. In other implementations more than one or two germline sequences are used, e.g., to form a consensus sequence.\n\n\n \n \n \n \nIn one embodiment, with respect to a particular reference variable domain sequence, e.g., a sequence described herein, a related variable domain sequence has at least 30, 40, 50, 60, 70, 80, 90, 95 or 100% of the CDR amino acid positions that are not identical to residues in the reference CDR sequences, residues that are identical to residues at corresponding positions in a human germline sequence (i.e., an amino acid sequence encoded by a human germline nucleic acid).\n\n\n \n \n \n \nIn one embodiment, with respect to a particular reference variable domain sequence, e.g., a sequence described herein, a related variable domain sequence has at least 30, 50, 60, 70; 80, 90 or 100% of the FR regions identical to FR sequence from a human germline sequence, e.g., a germline sequence related to the reference variable domain sequence.\n\n\n \n \n \n \nAccordingly, it is possible to isolate an antibody which has similar activity to a given antibody of interest, but is more similar to one or more germline sequences, particularly one or more human germline sequences. For example, an antibody can be at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 99.5% identical to a germline sequence in a region outside the CDRs (e.g., framework regions). Further, an antibody can include at least 1, 2, 3, 4, or 5 germline residues in a CDR region, the germline residue being from a germline sequence of similar (e.g., most similar) to the variable region being modified. Germline sequences of primly interest are human germline sequences. The activity or the antibody (e.g., the binding activity as measured by K\nA\n) can be within a factor or 100, 10, 5, 2, 0.5, 0.1, and 0.001 of the original antibody.\n\n\n \n \n \n \nGermline sequences of human immunoglobin genes have been determined and are available from a number of sources, including the international ImMunoGeneTics information systemic (IMGT), available via the world wide web at imgt.cines.fr, and the V BASE directory (compiled by Tomlinson, I. A. et al. MRC Centre for Protein Engineering, Cambridge, UK, available via the world wide web at vbase.mre-cpecam.ac.uk).\n\n\n \n \n \n \nExemplary germline reference sequences for V\nkappa \ninclude: O12/O2, O18/O8, A20, A30, L14, L1, L15, L4/18a, L5/L19, L8, L23, L9, L24, L11, L12. O11/O1, A17, A1, A18, A2, A19/A3, A23, A27, A 11, L2/L16, L6, L20, L25, B3, B2, A26/A10, and A14. See, e.g., Tomlinson et al., 1995\n, EMBO J. \n14(18):4628-3.\n\n\n \n \n \n \nA germline reference sequence for the HC variable domain can be based on a sequence that has particular canonical structures, e.g., 1-3 structures in the H1 and H2 hypervariable loops. The canonical structures of hypervariable loops of an immunoglobulin variable domain can be inferred from its sequence, as described in Chothia et al., 1992\n, J. Mol. Biol. \n227:799-817; Tomlinson et al., 1992\n, J. Mol. Biol. \n227:776-798); and Tomlinson et al., 1995\n, EMBO J. \n14(18):4628-38. Exemplary sequences with a 1-3 structure include: DP-1, DP-8, DP-12, DP-2, DP-25, DP-15, DP-7, DP-4, DP-31, DP-32, DP-33, DP-35, DP-40, 7-2, hv3005, hv300513, DP-46, DP-47, DP-58, DP-49, DP-50, DP-51, DP-53, and DP-54.\n\n\n \nProtein Production\n\n\n \n \n \nStandard recombinant nucleic acid methods can be used to express a protein that binds to MMP-14. Generally, a nucleic acid sequence encoding the protein is cloned into a nucleic acid expression vector. Of course, if the protein includes multiple polypeptide chains, each chain can be cloned into an expression vector, e.g., the same or different vectors, that are expressed in the same or different cells.\n\n\n \n \n \n \nAntibody Production. Some antibodies, e.g., Fabs, can be produced in bacterial cells, e.g., \nE. coli \ncells. For example, if the Fab is encoded by sequences in a phage display vector that includes a suppressible stop codon between the display entity and a bacteriophage protein (or fragment thereof), the vector nucleic acid can be transferred into a bacterial cell that cannot suppress a stop codon. In this case, the Fab is not fused to the gene III protein and is secreted into the periplasm and/or media.\n\n\n \n \n \n \nAntibodies can also be produced in eukaryotic cells. In one embodiment, the antibodies (e.g., say's) are expressed in a yeast cell such as \nPichia \n(see, e.g., Powers et al., 2001, \nJ. Immunol. Methods. \n251:123-35) \nHanseula\n, or \nSacchuromyces. \n \n\n\n \n \n \n \nIn one preferred embodiment, antibodies are produced in mammalian cells. Preferred mammalian host cells for expressing the clone antibodies or antigen-binding fragments thereof include Chinese Hamster Ovary (CHO cells) (including dhfr-CHO cells, described in Urlaub and Chasin, 1980\n, Proc. Natl. Acad. Sci. USA \n77:4216-4220, used with a DHFR selectable marker, e.g., as described in Kaufman and Sharp, 1982, Mol. Biol. 159:601 621), lymphocytic cell lines, e.g., NS0 myeloma cells and SP2 cells, COS cells, HEK293T cells (\nJ. Immunol. Methods \n(2004) 289(1-2):65-80), and a cell from a transgenic animal, e.g., a transgenic mammal. For example, the cell is a mammary epithelial cell.\n\n\n \n \n \n \nIn addition to the nucleic acid sequence encoding the diversified immunoglobulin domain the recombinant expression vectors may carry additional sequences such as sequences that regulate replication of the vector in host cells (e.g., origins of replication) and selectable marker genes. The selectable marker gene facilitates selection of host cells into which the vector has been introduced (see e.g., U.S. Pat. Nos. 4,399,216, 4,634,665 and 5,179,017). For example, typically the selectable marker gene confers resistance to drugs, such as G418, hygromycin or methotrexate, on a host cell into which the vector has been introduced. Preferred selectable marker genes include the dihydrofolate reductase (DHFR) gene (for use in dhfr\n− \nhost cells with methotrexate selection/amplification) and the neo gene (for G418 selection).\n\n\n \n \n \n \nIn an exemplary system for recombinant expression of an antibody, or antigen-binding portion thereof, a recombinant expression vector encoding both the antibody heavy chain and the antibody light chain is introduced into dhfr CHO cells by calcium phosphate-mediated transfection. Within the recombinant expression vector, the antibody heavy and light chain genes are each operatively linked to enhancer/promoter regulatory elements (e.g., derived from SV40, CMV, adenovirus and the like, such as a CMV enhancer/AdMLP promoter regulatory element or an SV40 enhancer/AdMLP promoter regulatory element) to drive high levels of transcription of the genes. The recombinant expression vector also carries a DHFR gene, which allows for selection of CHO cells that have been transfected with the vector using methotrexate selection/amplification. The selected transformant host cells are cultured to allow for expression of the antibody heavy and light chains and intact antibody is recovered from the culture medium, Standard molecular biology techniques are used to prepare the recombinant expression vector, transfect the host cells, select for transformants, culture the host cells and recover the antibody from the culture medium. For example, some antibodies can be isolated by affinity chromatography with a Protein A or Protein G coupled matrix.\n\n\n \n \n \n \nFor antibodies that include an Fc domain, the antibody production system may produce antibodies in which the Fc region is glycosylated. For example, the Fc domain of IgG molecules is glycosylated at asparagine 297 in the CH2 domain. This asparagine is the site for modification with biantennary-type oligosaccharides. It has been demonstrated that this glycosylation is required for effector functions mediated by Fcg receptors and complement Clq (Burton and Woof, 1992\n, Adv. Immunol. \n51:1-84; Jeans et al., 1998, Mumma Rev. 163:59-76). In one embodiment, the Fc domain is produced in a mammalian expression system that appropriately glycosylates the residue corresponding to asparagine 297. The Fc domain can also include other eukaryotic post-translational modifications.\n\n\n \n \n \n \nAntibodies can also be produced by a transgenic animal. For example, U.S. Pat. No. 5,849,992 describes a method of expressing an antibody in the mammary gland of a transgenic mammal. A transgene is constructed that includes a milk-specific promoter and nucleic acids encoding the antibody or interest and a signal sequence for secretion. The milk produced by females of such transgenic mammals includes, secreted-therein, the antibody of interest. The antibody can be purified from the milk, or for some applications, used directly.\n\n\n \nCharacterization of MMP-14 Binding Proteins\n\n\n \n \n \nBinding of MMP-14 binding proteins to cells expressing MMP-14 can be characterized in a number assays known in the art, including FACS (Fluorescence Activated Cell Sorting), immunofluorescence, and immunocytochemistry. MMP-14 binding protein is contacted with cells and/or tissues which express or contain MMP-14, and binding is detected in accordance with the method being used. For example, a fluorescent detection system (e.g., fluorescent-labeled secondary antibody) employed for FACS and immunofluorescence analysis, or a enzymatic system is used for immunocytochemistry are generally used in these assays can be performed on non-perm. MMP-14 binding proteins can be characterized as to cellular binding by FACS (Fluorescence Activated Cell Sorting) using cells expressing MMP-14. Individual cells held in a thin stream of fluid are passed through one or more laser beams cause light to scatter and fluorescent dyes to emit light at various frequencies. Photomultiplier tubes (PMT) convert light to electrical signals and cell data is collected. Forward and side scatter are used for preliminary identification of cells. Forward and side scatter are used to exclude debris and dead cells. Fluorescent labeling allows investigation of cell structure and function. Cell autofluorescence is generated by labeling cell structures with fluorescent dyes. FACS collects fluorescence signals in one to several channels corresponding to different laser excitation and fluorescence emission wavelength. Immunofluorescence, the most widely used application, involves the staining of cells with antibodies conjugated to fluorescent dyes such as fluorescein and phycoerythrin (PE). This method can be used to label MMP-14 on the cell surface of MDA-MB-231 cells using biotinylated MMP-14 binding proteins. Biotin is used in this two-step detection systems in concert with conjugated steptavidin. Biotin is typically conjugated to proteins via primary amines (i.e., lysines). Usually, between 1.5 and 3 biotin molecules are conjugated to each antibody. A second fluorescently conjugated antibody (streptavidin/PE) is added which is specific for biotin.\n\n\n \n \n \n \nMMP-14 binding proteins can be characterized in cultured cells expressing the MMP-14 antigen. The method generally used is immunocytochemistry. Immunocytochemistry involves the use of antibodies that recognize parts of the receptor that are exposed to the outside environment when expressed at the cell surface (the ‘primary antibody’) if the experiment is carried out in intact cells, such an antibody will only bind to surface expressed receptors. Biotinylated or non-biotinylated MMP-14 binding proteins can be used. The secondary antibody is then either a streptavidin/HRP antibody (for biotinylated MMP-14 binding protein) or an anti-human IgG/HRP (for non-biotinylated MMP-14 binding protein). The staining can then be detected using an inverted microscope. The assay can be performed in the absence of MMP-14 binding protein and in presence of 10 μg/mL of MMP-14 binding protein.\n\n\n \n \n \n \nMMP-14 binding proteins can be characterized in assays that measure their modulatory activity toward MMP-14 or fragments thereof in vitro or in vivo. For example, MMP-14 can be combined with a substrate such as Mca-Pro-Len-Ala-Cys(Mob)-Trp-Ala-Arg-Dap(Dnp)-NH, under assay conditions permitting cleavage by MMP-14. The assay is performed in the absence of the MMP-14 binding protein, and in the presence of increasing concentrations of the MMP-14 binding protein. The concentration or binding protein at which 50% of the MMP-14 activity (e.g., binding to the substrate) is inhibited is the IC\n50 \nvalue (\nInhibitory Concentration\n 50%) or EC\n50 \n(\nEffective Concentration\n 50%) value for that binding protein. Within a series or group of binding proteins, those having lower IC\n50 \nor EC\n50 \nvalues are considered more potent inhibitors of MMP-14 than those binding proteins having higher IC\n50 \nor EC\n50 \nvalues. Exemplary binding proteins have an IC\n50 \nvalue of less than 800 nM, 400 nM, 100 nM, 25 nM, 5 nM, or 1 nM, e.g., as measured in an in vitro assay for inhibition of MMP-14 activity when the MMP-14 is at 2 pM.\n\n\n \n \n \n \nMMP-14 binding proteins may also be characterized with reference to the activity of MMP-14 on its substrates (e.g., activation of cell surface pro-MMP-2). Cleavage of cell surface pro-MMP-2 by MMP-14 releases active MMP-2, which can be detected by zymography. The method is based on a SDS gel impregnated with a protein substrate, which is degraded by the proteases resolved during the incubation period. Coomassie blue staining of the gels reveals proteolytic fragments as white bands on a dark blue background. Within a certain range, the band intensity can be related linearly to the amount of the protease loaded. Cells expressing both MMP-14 and MMP-2 are used in this assay. The assay is performed in the absence of the MMP-14 binding protein, and in the presence of increasing concentrations of the MMP-14 binding protein. The concentration of binding protein at which 50% of the MMP-2 activity (e.g., binding to the substrate) is inhibited is the IC\n50 \nvalue (\nInhibitory Concentration\n 50%) or EC\n50 \n(\nEffective Concentration\n 50%) value for that binding protein. Within a series or group of binding proteins, those having lower IC\n50 \nor EC\n50 \nvalues are considered more potent inhibitors of MMP-14 than those binding proteins having higher IC\n50 \nor EC\n50 \nvalues. Exemplary binding proteins have an IC\n50 \nvalue of less than 800 nM, 400 nM, 100 nM, 25 nM, 5 nM, or 1 nM, e.g., as measured in an in vitro assay for inhibition of MMP-14 activity.\n\n\n \n \n \n \nThe binding proteins can also be evaluated for selectivity toward MMP-14. For example, a MMP-14 binding protein can be assayed for its potency toward MMP-14 and a panel of MMPs and other enzymes. e.g., MMP-1, -2, -3, -7, -8, -9, -12, -13, -16, -17, -24, and TACE, and an IC\n50 \nvalue or EC\n50 \nvalue can be determined for each MMP. In one embodiment, a compound that demonstrates a low IC\n50 \nvalue or EC\n50 \nvalue for the MMP-14, and a higher IC\n50 \nvalue or EC\n50 \nvalue, e.g., at least 2-, 5-, or 10-fold higher, for another MMP within the test panel (e.g., MMP-1, -10) is considered to be selective toward MMP-14.\n\n\n \n \n \n \nMMP-14 binding proteins can be evaluated for their ability to inhibit MMP-14 in a cell based assay. The expansion of tumor cells inside a three-dimensional collagen-matrix can be significantly enhanced in response to MMP-14 overexpression (Hotary et al., 2003 Cell 114:33-45). Addition of an MMP-14 binding protein to this assay can be used to determine the inhibitory properties and other characteristics of the protein.\n\n\n \n \n \n \nA pharmacokinetics study in rat, mice, or monkey can be performed with MMP-14 binding proteins for determining MMP-14 half-life in the serum. Likewise, the effect of the binding protein can be assessed in vivo, e.g., in an animal model for a disease, for use as a therapeutic, for example, to treat a disease or condition described herein, e.g., a cancer (e.g., metastatic cancer. e.g., metastatic breast cancer), an inflammatory disease (e.g., synovitis, atherosclerosis), rheumatoid arthritis osteoarthritis, an ocular condition (e.g., macular degeneration), diabetes, Alzheimer's Disease, cerebral ischemia, endometriosis, fibrin-invasive activity angiogenesis, or capillary tube formation.\n\n\n \nPharmaceutical Compositions\n\n\n \n \n \nIn another aspect, the disclosure provides compositions, e.g., pharmaceutically acceptable compositions or pharmaceutical compositions, which include an MMP-14-binding protein, e.g., an antibody molecule, other polypeptide or peptide identified as binding to MMP-14 described herein. The MMP-14 binding protein can be formulated together with a pharmaceutically acceptable carrier. Pharmaceutical compositions include therapeutic compositions and diagnostic compositions, e.g., compositions that include labeled MMP-14 binding proteins for in vivo imaging.\n\n\n \n \n \n \nA pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. Preferably, the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal, or epidermal administration (e.g., by injection or infusion), although carriers suitable for inhalation and intranasal administration are also contemplated. Depending on the route of administration, the MMP-14 binding protein may be coated in a material to protect the compound from the action of acids and other natural conditions that may inactivate the compound.\n\n\n \n \n \n \nA pharmaceutically acceptable salt is a salt that retains the desired biological activity of the parent compound and does not impart any undesired toxicological effects (sec e.g., Berge, S. M., et al., 1977\n, J. Pharm. Sci. \n66:1-19). Examples of such salts include acid addition salts and base addition salts. Acid addition salts include those derived from nontoxic inorganic acids, such as hydrochloric, nitric, phosphoric sulfuric, hydrobromic, hydroiodic, phosphorous, and the like, as well as from nontoxic organic acids such as aliphatic mono- and dicarboxylic acids phenyl-substituted alkanoic acids, hydroxy alkanoic acids, aromatic acids, aliphatic and aromatic sullonic acids, and the like. Base addition salts include those derived from alkaline earth metals, such as sodium, potassium, magnesium calcium, and the like, as well as from nontoxic organic amines, such as N,N′-dibenzylethylenediamine, N-methylglucamine, chloroprocaine, choline, diethanolamine, ethylenediamine, procaine, and the like.\n\n\n \n \n \n \nThe compositions may be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage harms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions tablets, pills, powders, liposomes and suppositories. The fomi can depend on the intended mode of administration and therapeutic application. Many compositions are in the form of injectable or infusible solutions, such as compositions similar to those used for administration of humans with antibodies. An exemplary mode or administration is parenteral (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular) in one embodiment, the MMP-14 binding protein is administered by intravenous infusion or injection. In another preferred embodiment, the MMP-14 binding protein is administered by intramuscular or subcutaneous injection.\n\n\n \n \n \n \nThe phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion.\n\n\n \n \n \n \nThe composition can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable to high drug concentration. Sterile injectable solutions can be prepared by incorporating the binding protein in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The proper fluidity of a solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prolonged absorption of injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin.\n\n\n \n \n \n \nAn MMP-14 binding protein can be administered by a variety of methods, although for many applications, the preferred route/mode of administration is intravenous injection or infusion. For example, for therapeutic applications, the MMP-14 binding protein can be administered by intravenous infusion at a rate of less than 30, 20, 10, 5, or 1 mg/min to reach a dose of about 1 to 100 mg/m\n2 \nor 7 to 25 mg/m\n2\n. The route and/or mode of administration will vary depending upon the desired results. In certain embodiments, the active compound may be prepared with a carrier that will protect the compound against rapid release, such as a controlled release formulation, including implants, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthocsters, and polylactic acid. Many methods for the preparation of such formulations are available. Sec, e.g., Sustained and Controlled Release Drug Delivery Systems, J. R. Robinson, ed., 1973, Marcel Dekker, Inc., New York.\n\n\n \n \n \n \nPharmaceutical compositions can be administered with medical devices. For example, in one embodiment, a pharmaceutical composition disclosed herein can be administered with a device, e.g., a needleless hypodermic injection device, a pump, or implant.\n\n\n \n \n \n \nIn certain embodiments, an MMP-14 binding protein can be formulated to ensure proper distribution in vivo. For example, the blood-brain barrier (BBB) excludes many highly hydrophilic compounds. To ensure that the therapeutic compounds disclosed herein cross the BBB (if desired), they can be formulated, for example, in liposomes. For methods of manufacturing liposomes, see, e.g., U.S. Pat. Nos. 4,522,811; 5,374,548: and 5,399,331. The liposomes may comprise one or more moieties that are selectively transported into specific cells or organs, thus enhance targeted drug delivery (see, e.g., V. V. Ranade, 1989\n, J. Clin. Pharmocol. \n29:685).\n\n\n \n \n \n \nDosage regimens are adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies oldie therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms can be dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.\n\n\n \n \n \n \nAn exemplary, non-limiting range for a therapeutically or prophylactically effective amount of an antibody disclosed herein is 0.1-20 mg/kg, more preferably 1-10 mg/kg. An anti-MMP-14 antibody can be administered, e.g., by intravenous infusion, e.g., at a rate of less than 30, 20, 10, 5, or 1 mg/min to reach a dose of about 1 to 100 mg/m\n2 \nor about 5 to 30 mg/m\n2\n. For binding proteins smaller in molecular weight than an antibody, appropriate amounts can be proportionally less. Dosage values may vary with the type and severity of the condition to be alleviated. For a particular subject, specific dosage regimens can be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.\n\n\n \n \n \n \nThe pharmaceutical compositions disclosed herein may include a “therapeutically effective amount” or a “prophylactically effective amount” of an MMP-14 binding protein disclosed herein. A “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of the composition may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the protein to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the composition is outweighed by the therapeutically beneficial effects.\n\n\n \n \n \n \nA “therapeutically effective dosage” preferably modulates a measurable parameter, e.g., levels of circulating gel antibodies by a statistically significant degree or at least about 20% more preferably by at least about 40%, even more preferably by at least about 60%, and still more preferably by at least about 80% relative to untreated subjects. The ability of a compound to modulate a measurable parameter, e.g., a disease-associated parameter, can be evaluated in an animal model system predictive of efficacy in human disorders and conditions, e.g., a cancer (e.g., metastatic cancer, e.g., metastatic breast cancer), an inflammatory disease (e.g., synovitis, atherosclerosis), rheumatoid arthritis, osteoarthritis, an ocular condition (e.g., macular degeneration), diabetes, Alzheimer's Disease, cerebral ischemic, endometriosis, fibrin-invasive activity, angiogenesis, or capillary tube formation. Alternatively, this property of a composition can be evaluated by examining the ability of the compound to modulate a parameter in vitro.\n\n\n \n \n \n \nA “prophylactically effective amount” refers to an amount effective at dosages and for periods or time necessary, to achieve the desired prophylactic result. Typically, because a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.\n\n\n \nStabilization and Retention\n\n\n \n \n \nIn one embodiment, an MMP-14 binding protein is physically associated with a moiety that improves its stabilization and/or retention in circulation, e.g., in blood, scrum, lymph, or other tissues, e.g., by at least 1.5, 2, 5, 10, or 50 fold. For example, an MMP-14 binding protein can be associated with a polymer, e.g., a substantially non-antigenic polymers, such as polyalkylene oxides or polyethylene oxides. Suitable polymers will vary substantially by weight. Polymers having molecular number average weights ranging from about 200 to about 35,000 (or about 1,000 to about 15,000, and 2,000 to about 12,500) can be used. For example, an MMP-14 binding protein can be conjugated to a water soluble polymer, e.g., hydrophilic polyvinyl polymers, e.g. polyvinylalcohol and polyvinylpyrrolidone non-limiting list of such polymers include polyalkylene oxide homopolymers such as polyethylene glycol (PEG) or polypropylene glycols, polyoxyethylenated polyols, copolymers thereof and block copolymers thereof, provided that the water solubility of the'block copolymers is maintained.\n\n\n \n \n \n \nAn MMP-14 binding protein can also be associated with a carrier protein, e.g., a serum albumin, such as a human serum albumin. For example, a translational fusion can be used to associate the carrier protein with the MMP-14 binding protein.\n\n\n \nKits\n\n\n \n \n \nAn MMP-14 binding protein described herein can be provided in a kit, e.g., as a component of a kit. For example, the kit includes (a) an MMP-14 binding protein, e.g., a composition that includes an MMP-14 binding protein, and, optionally (h) informational material. The informational material can be descriptive, instructional, marketing or other material that relates to the methods described herein and/or the use elan MMP-14 binding protein for the methods described herein.\n\n\n \n \n \n \nThe informational material of the kits is not limited in its form, in one embodiment, the informational material can include information about production of the compound, molecular weight of the compound, concentration, date of expiration, batch or production site information, and so forth. In one embodiment, the informational material relates to using the binding protein to treat, prevent, or diagnosis of disorders and conditions, a cancer (e.g., metastatic cancer, e.g., metastatic breast cancer), an inflammatory disease (e.g., synovitis, atherosclerosis), rheumatoid arthritis, osteoarthritis, an ocular condition (e.g., macular degeneration), diabetes, Alzheimer's Disease, cerebral ischemia, endometriosis, fibrin-invasive activity; angiogenesis, or capillary tube formation.\n\n\n \n \n \n \nIn one embodiment, the informational material can include instructions to administer an MMP-14 binding protein in a suitable manner to perform the methods described herein, e.g., in a suitable dose, dosage form, or mode of administration (e.g., a dose, dosage form, or mode of administration described herein). In another embodiment, the informational material can include instructions to administer an MMP-14 binding protein to a suitable subject, e.g., a human, e.g., a human having, or at risk for, a disorder or condition described herein, e.g., a cancer (e.g., metastatic cancer, e.g., metastatic breast cancer), an inflammatory disease (e.g., synovitis, atherosclerosis), rheumatoid arthritis, osteoarthritis, an ocular condition (e.g., macular degeneration), diabetes, Alzheimer's Disease, cerebral ischemia, endometriosis, fibrin-invasive activity, angiogenesis, or capillary tube formation. For example, the material can include instructions to administer an MMP-14 binding protein to a patient with a disorder or condition described herein, e.g., a cancer (e.g., metastatic cancer, e.g., metastatic breast cancer), an inflammatory disease (e.g., synovitis, atherosclerosis), rheumatoid arthritis, osteoarthritis, an ocular condition (e.g., macular degeneration), diabetes, Alzheimer's Disease, cerebral ischemia, endometriosis, fibrin-invasive activity, angiogenesis, or capillary tube formation. The informational material of the kits is not limited in its form. In many cases, the informational material, e.g., instructions, is provided in print but may also be in other formats, such as computer readable material.\n\n\n \n \n \n \nAn MMP-14 binding protein can be provided in any form, e.g., liquid, dried or lyophilized form it is preferred that an MMP-14 binding protein be substantially pure and/or sterile. When an MMP-14 binding protein is provided in a liquid solution, the liquid solution preferably is an aqueous solution, with a sterile aqueous solution being preferred. When an MMP-14 binding protein is provided as a dried form, reconstitution generally is by the addition of a suitable solvent. The solvent, e.g. sterile water or buffer, can optionally be provided in the kit.\n\n\n \n \n \n \nThe kit can include one or more containers for the composition containing an MMP-14 binding protein. In some embodiments, the kit contains separate containers, dividers or compartments for the composition and informational material. For example, the composition can be contained in a bottle, vial, or syringe, and the informational material can be contained association with the container. In other embodiments, the separate elements of the kit are contained within a single, undivided container. For example, the composition is contained in a bottle, vial or syringe that has attached thereto the informational material in the form of a label. In some embodiments, the kit includes a plurality (e.g., a pack) of individual containers, each containing one or more unit dosage forms (e.g., a dosage form described herein) of an MMP-14 binding protein. For example, the kit includes a plurality of syringes, ampules, foil packets, or blister packs, each containing a single unit dose of an MMP-14 binding protein. The containers of the kits can be air tight, waterproof (e.g., impermeable to changes in moisture or evaporation), and/or light-tight.\n\n\n \n \n \n \nThe kit optionally includes a device suitable for administration of the composition, e.g., a syringe, inhalant, dropper (e.g., eye dropper), swab (e.g., a cotton swab or wooden swab), or any such delivery device. In one embodiment, the device is an implantable device that dispenses metered doses of the binding protein. The disclosure also features a method of providing a kit, e.g., by combining components described herein.\n\n\n \nTreatments\n\n\n \n \n \nProteins that bind to MMP-14 and identified by the method described herein and/or detailed herein have therapeutic and prophylactic utilities, particularly in human subjects. These binding proteins are administered to a subject to treat, prevent, and/or diagnose a variety of disorders, including e.g., a cancer (e.g., metastatic cancer, e.g., metastatic breast cancer), an inflammatory disease (e.g., synovitis, atherosclerosis), rheumatoid arthritis, osteoarthritis, an ocular condition (e.g., macular degeneration), diabetes, Alzheimer's Disease, cerebral ischemia, endometriosis, fibrin-invasive activity, angiogenesis, or capillary tube formation, or even to cells in culture, e.g. in vitro or ex vivo. Treating includes administering an amount effective to alleviate, relieve, alter, remedy, ameliorate, improve or affect the disorder, the symptoms of the disorder or the predisposition toward the disorder. The treatment may also delay onset, e.g. prevent onset, or prevent deterioration of a disease or condition.\n\n\n \n \n \n \nExemplary disorders include a cancer (e.g., metastatic cancer, e.g., metastatic breast cancer), an inflammatory disease (e.g., synovitis, atherosclerosis) rheumatoid arthritis, osteoarthritis, an ocular condition (e.g., macular degeneration), diabetes, Alzheimer's Disease, cerebral ischemia, endometriosis, fibrin-invasive activity, angiogenesis, or capillary tube formation. Some of these disorders are discussed above. Still other disorders that can be treated using an MMP-14 binding protein include: aortic aneurysms, periodontitis, autoimmune blistering disorders of the skin, dermal photoaging.\n\n\n \n \n \n \nAs used herein, an amount of an target-binding agent effective to prevent a disorder, or a prophylactically effective amount of the binding agent refers to an amount of a target binding agent, e.g., an MMP-14 binding protein, e.g., an anti-MMP-14 antibody described herein, which is effective, upon single- or multiple-dose administration to the subject, for preventing or delaying the occurrence of the onset or recurrence of a disorder, e.g., a disorder described herein.\n\n\n \n \n \n \nA binding agent described herein can be used to reduce angiogenesis in a subject, e.g., to treat a cancer (e.g., a solid tumor) or an angiogenesis-associated disorder. The method includes administering the binding to the subject, e.g., in an amount effective to modulate angiogenesis, a symptom of the disorder, or progression attic disorder. The agent (e.g., an MMP-14 binding protein, e.g., an anti-MMP-14 antibody) may be administered multiple times (e.g., at least two, three, five, or ten times) before a therapeutically effective amount is attained.\n\n\n \n \n \n \nMethods or administering MMP-14 binding proteins and other agents are also described in “Pharmaceutical Compositions.” Suitable dosages of the molecules used can depend on the ago and weight of the subject and the particular drug used. The binding proteins can be used as competitive agents to inhibit, reduce an undesirable interaction, e.g., between a natural or pathological agent and the MMP-14. The dose of the MMP-14 binding protein can be the amount sufficient to block 90%, 95%, 99%, or 99.9% of the activity of MMP-14 in the patient, especially at the site of disease. Depending on the disease, this may require 0.1, 1.0, 3.0, 6.0, or 10.0 mg/Kg. For an IgG, having a molecular mass of 150,000 g/mole (two binding sites), these doses correspond to approximately 18 nM, 180 nM, 540 nM, 1.08 μM, and 1.8 μM of binding sites for a 5 L blood volume.\n\n\n \n \n \n \nIn one embodiment, the MMP-14 binding proteins are used to inhibit an activity (e.g., inhibit at least one activity of, reduce proliferation, migration, growth or viability) of a cell, e.g., a cancer cell in vivo. The binding proteins can be used by themselves or conjugated to an agent. e.g., a cytotoxic drug, cytotoxin enzyme, or radioisotope. This method includes: administering the binding protein alone or attached to an agent (e.g., a cytotoxic drug), to a subject requiring such treatment. For example, MMP-14 binding proteins that do not substantially inhibit MMP-14 may be used to deliver nanoparticles containing agents, such as toxins, to MMP-14 associated cells or tissues, e.g., tumors.\n\n\n \n \n \n \nBecause the MMP-14 binding proteins recognize MMP-14-expressing cells and can bind to cells that are associated with (e.g., in proximity of or intermingled with) cancer cells, e.g., cancerous lung, liver, colon, breast, ovarian, epidermal, laryngeal, and cartilage cells, and particularly metastatic cells thereof, MMP-14 binding proteins can be used to inhibit (e.g., inhibit at least one activity, reduce growth and proliferation, or kill) any such cells and inhibit carcinogenesis. Reducing MMP-14 activity near a cancer can indirectly inhibit (e.g., inhibit at least one activity, reduce growth and proliferation, or kill) the cancer cells which may be dependent on the MMP-14 activity for metastasis, activation of growth factors, and so forth.\n\n\n \n \n \n \nAlternatively, the binding proteins bind to cells in the vicinity of the cancerous cells, but are sufficiently close to the cancerous cells to directly or indirectly inhibit (e.g., inhibit at least one activity, reduce growth and proliferation, or kill) the cancers cells. Thus, the MMP-14 binding proteins (e.g., modified with a toxin, e.g., a cytotoxin) can be used to selectively inhibit cells in cancerous tissue (including the cancerous cells themselves and cells associated with or invading the cancer).\n\n\n \n \n \n \nThe binding proteins may be used to deliver an agent (e.g., any of a variety of cytotoxic and therapeutic drugs) to cells and tissues where MMP-14 is present. Exemplary agents include a compound emitting radiation molecules of plants fungal, or bacterial origin, biological proteins, and mixtures thereof. The cytotoxic drugs can be intracellularly acting cytotoxic drugs, such as toxins short range radiation emitters, e.g., short range, high energy α-emitters.\n\n\n \n \n \n \nTo target MMP-14 expressing cells, particularly cancerous cells, a prodrug system can be used. For example, a first binding protein is conjugated with a prodrug which is activated only when in close proximity with a prodrug activator. The prodrug activator is conjugated with a second binding protein preferably one which binds to a non competing site on the target molecule. Whether two binding proteins bind to competing or non competing binding sites can be determined by conventional competitive binding assays. Exemplary drug prodrug pairs are described in Blakely et al., (1996) Cancer Research, 56:3287 3292.\n\n\n \n \n \n \nThe MMP-14, binding proteins can be used directly in vivo to eliminate antigen-expressing cells via natural complement-dependent cytotoxicity (CDC) or antibody dependent cellular cytotoxicity (ADCC). The binding proteins described herein can include complement binding effector domain, such as the Fc portions from IgG1, -2, or -3 or corresponding portions of IgM which bind complement. In one embodiment, a population of target cells is ex vivo treated with a binding agent described herein and appropriate effector cells. The treatment can be supplemented by the addition of complement or serum containing complement. Further, phagocytosis of target cells coated with a binding protein described herein can be improved by binding of complement proteins. In another embodiment target, cells coated with the binding protein which includes a complement binding effector domain are lysed by complement.\n\n\n \n \n \n \nMethods of administering MMP-14 binding proteins are described in. “Pharmaceutical Compositions.” Suitable dosages of the molecules used will depend on the age and weight of the subject and the particular drug used. The binding proteins can be used as competitive agents to inhibit or reduce an undesirable interaction, e.g., between a natural or pathological agent and the MMP-14.\n\n\n \n \n \n \nThe MMP-14 binding protein can be used to deliver macro and micromolecules, e.g., a gene into the cell for gene therapy purposes into the endothelium or epithelium and target only those tissues expressing the MMP-14. The binding proteins may be used to deliver a variety of cytotoxic drugs including therapeutic drugs, a compound emitting radiation, molecules of plants, fungal, or bacterial origin, biological proteins, and mixtures thereof. The cytotoxic drugs can be intracellularly acting cytotoxic drugs, such as short range radiation emitters, including, for example, short range, high energy α emitters, as described herein.\n\n\n \n \n \n \nIn the case of polypeptide toxins recombinant nucleic acid techniques can be used to construct a nucleic acid that encodes the binding protein (e.g., antibody or antigen-binding fragment thereof) and the cytotoxin (or a polypeptide component thereof) as translational fusions. The recombinant nucleic acid is then expressed, e.g., in cells and the encoded fusion polypeptide isolated.\n\n\n \n \n \n \nAlternatively, the MMP-14 binding protein can be coupled to high, energy radiation emitters, for example, a radioisotope, such as \n131\nI, a γ-emitter, which, when localized at a site, results in a killing of several cell diameters. See, e.g., S. E. Order, “Analysis, Results, and Future Prospective of the Therapeutic Use of Radiolaheled Antibody in Cancer Therapy”, \nMonoclonal Antibodies for Cancer Detection and Therapy\n, R. W. Baldwin et al. (eds.), pp 303 316 (Academic Press 1985). Other suitable radioisotopes include a emitters, such as \n212\nBi, \n213\nBi, and \n211\nAt, and b emitters; such as \n186\nRe and \n90 \nY. Moreover, \n177\nLu may also be used as both an imaging and cytotoxic agent.\n\n\n \n \n \n \nRadioimmunotherapy (RIT) using antibodies labeled with \n131\nI, \n90\nY, and \n177\nLu is under intense clinical investigation. There are significant differences in the physical characteristics of these three nuclides and as a result, the choice of radionuclide is very critical in order to deliver maximum radiation dose to a tissue of interest. The higher beta energy particles of \n90\nY may be good for bulky tumors. The relatively low energy beta particles of \n131\nI are ideal, but in vivo dehalogenation of radioiodinated molecules is a major disadvantage for internalizing antibody. In contrast, \n177\nLu has low energy beta particle with only 0.2-0.3 mm range and delivers much lower radiation dose to bone marrow compared to \n90\nY. In addition, due to longer physical half-life (compared to \n90 \nY), the residence times are higher. As a result, higher activities (more mCi amounts) of \n177\nLu labeled agents can be administered with comparatively less radiation dose to marrow. There have, been several clinical studies investigating the use of \n177\nLu labeled antibodies in the treatment of various cancers. (Mulligan T et al., 1995\n, Clin. Canc. Res. \n1: 1447-1454; Meredith R F, et al., 1996\n, J. Nucl. Med. \n37:1491-1496; Alvarez R D, et al., 1997\n, Gynecol. Oncol. \n65: 94-101).\n\n\n \n \nExemplary. Diseases and Conditions\n\n\n \n \n \n \nThe MMP-14 binding proteins described herein are useful to treat diseases or conditions in which MMP-14 is implicated, e.g., a disease or condition described herein, or to treat one or more symptoms associated therewith. In some embodiments, the MMP-14 binding protein (e.g., MMP-14 binding IgG or Fab) inhibits MMP-14 activity, and may amber inhibit, MMP-16, and/or MMP-24. MMP-14 binding proteins which inhibit MMP-16 and/or MMP-24 are particularly useful for the treatment of disorders in which these metalloproteases are also implicated.\n\n\n \n \n \n \nExamples of such diseases and conditions include a cancer (e.g., metastatic cancer, e.g., metastatic breast cancer), inflammatory disease (e.g., synovitis, rheumatoid arthritis, osteoarthritis), atherosclerosis, ocular conditions (e.g., macular degeneration), diabetes, Alzheimer's Disease, cerebral ischemia, endometriosis, fibrin-invasive activity, angiogenesis, and capillary tube formation. A therapeutically effective amount of a MMP-14 binding protein is administered to a subject having or suspected of having a disorder in which MMP-14 is implicated, thereby treating (e.g., ameliorating or improving a symptom or feature of a disorder, slowing, stabilizing or halting disease progression) the disorder.\n\n\n \n \n \n \nThe MMP-14 binding protein is administered in a therapeutically effective amount. A therapeutically effective amount of an MMP-14 binding protein, is the amount which is effective, upon single or multiple dose administration to a subject, in treating a subject, e.g., curing, alleviating, relieving or improving at least one symptom of a disorder in a subject to a degree beyond that expected in the absence of such treatment. A therapeutically effective amount of the composition may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the compound to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the composition is outweighed by the therapeutically beneficial effects.\n\n\n \n \n \n \nA therapeutically effective amount can be administered, typically an amount of the compound which is effective, upon single or multiple close administration to a subject, in treating a subject, e.g., curing, alleviating, relieving or improving at least one symptom of a disorder in a subject, to a degree beyond that expected in the absence of such treatment. A therapeutically effective amount of the composition may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability or the compound to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the composition is outweighed by the therapeutically beneficial effects. A therapeutically effective dosage preferably modulates a measurable parameter, favorably, relative to untreated subjects. The ability of a compound to inhibit a measurable parameter can be evaluated in an animal model system predictive of efficacy in a human disorder.\n\n\n \n \n \n \nDosage regimens can be adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated: each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.\n\n\n \nCancer\n\n\n \n \n \nMatrix metalloproteases (MMPs), such as MMP-14, MMP-16, and MMP-24, are believed to contribute to cancer by cleaving components of the ECM and basement membranes, thereby allowing cancer cells to penetrate and infiltrate the subjacent stromal matrix. Additionally, a number of growth-factor receptors, cell adhesion molecules, chemokines, cytokines, apoptotic ligands, and angiogenic factors are substrates of MMPs. Hence, MMP activity may cause activation of growth factors, suppression of tumor cell apoptosis, destruction of chemokine gradients developed by host immune response, or release of angiogenic factors. MMPs may facilitate tumor growth by promoting the release of cell proliferation factors such as insulin-like growth factors which are bound to specific binding proteins (IGFBPs) (Manes et al., 1997 J. Biol. Chem. 272: 25706-25712).\n\n\n \n \n \n \nCollagenases, including MMP-2, have been found at elevated levels in melanoma and in cancers of the colon, breast, lung, prostate, and bladder. Usually, these elevated levels correlate with higher tumor grade and invasiveness. MMP-2 levels are significantly elevated in the serum of patients with metastatic lung cancer, and in those patients with high levels, response to chemotherapy is diminished.\n\n\n \n \n \n \nLikewise, MMP-14, which cleaves proMMP-2 to release active MMP-2, is elevated in numerous cancers and can contribute to the growth of tumors, tumor embolism, and the mobility, invasiveness and metastasis of cancer (e.g., CNS tumors (e.g., gliomas), head and neck cancer, oral cavity cancer, laryngeal cancer, chondrosarcoma, breast cancer).\n\n\n \n \n \n \nMMP-16 and MMP-24 are also elevated in numerous cancers and can contribute, to both the growth of tumors and the invasiveness and metastasis of cancer (e.g., breast cancer, laryngeal cancer, ovarian cancer, testicular carcinoma, melanoma, brain tumors (e.g., astrocytomas, glioblastomas, gliomas).\n\n\n \n \n \n \nAccordingly, the disclosure provides methods of treating (e.g., slowing, eliminating, or reversing tumor growth, preventing or reducing, either in number or size, metastases, reducing or eliminating tumor cell invasiveness, providing an increased interval to tumor progression, or increasing disease-free survival time) cancer (e.g. breast cancer, including Her2+, Her2−, ER+, ER−, Her2+/ER+, Her2+/ER−, Her2−/ER+, and Her2−/ER− breast cancer), head and neck cancer, oral cavity cancer, laryngeal cancer, chondrosarcoma, ovarian cancer, testicular carcinoma, melanoma, brain tumors (e.g., astrocytomas, glioblastomas, gliomas)) by administering an effective amount of an MMP-14 binding protein (e.g., an anti-MMP-14 IgG or Fab). In some embodiments, the MMP-14 binding protein inhibits MMP-14 activity. The MMP-14 binding protein may further inhibit MMP-16 and/or MMP-24.\n\n\n \n \n \n \nIn certain embodiments, the MMP-14 binding protein is administered as a single agent treatment. In other embodiments, the MMP-14 binding protein is administered in combination with a an additional anti-cancer agent.\n\n\n \n \n \n \nAlso provided are methods of preventing or reducing risk of developing cancer, by administering an effective amount of an MMP-14 binding protein to a subject at risk of developing cancer, thereby reducing the subject's risk of developing a cancer.\n\n\n \n \n \n \nThe disclosure further provides methods of modulating (e.g. reducing or preventing) angiogenesis at a tumor site by administering an effective amount of an MMP-14 binding protein, thereby reducing or preventing angiogenesis at the tumor site. The MMP-14 binding protein may be administered as a single agent therapy or in combination with additional agents.\n\n\n \n \n \n \nAlso provided are methods for reducing extracellular matrix (ECM) degradation by a tumor, comprising administering an effective amount of an MMP-14 binding protein to a subject, thereby reducing ECM degradation by a tumor in the subject.\n\n\n \n \n \n \nThe disclosed methods are useful in the prevention and treatment of solid tumors, soft tissue tumors, and metastases thereof. Solid tumors include malignancies (e.g., sarcomas, adenocarcinomas, and carcinomas) attic various organ systems, such as those of lung, breast, lymphoid, gastrointestinal (e.g., colon), and genitourinary (e.g., renal, urothelial, or testicular tumors) tracts, pharynx, prostate, and ovary. Exemplary adenocarcinomas include colorectal cancers, renal-cell carcinoma, liver cancer, non-small cell carcinoma of the lung, and cancer of the small intestine. Additional exemplary solid tumors include: fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, gastrointestinal system carcinomas, colon carcinoma, pancreatic cancer, breast cancer, genitourinary system carcinomas, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, endocrine system carcinomas, testicular tumor, lung carcinoma, small cell lung carcinoma, non-small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, and retinoblastoma. Metastases of the aforementioned cancers can also be treated or prevented in accordance with the methods described herein.\n\n\n \n \n \n \nGuidance for determination of a therapeutically effective amount for treatment of cancer may be obtained by reference to in vivo models of the cancer to be treated. For example, the amount of a MMP-14 binding protein that is a therapeutically effective amount in a rodent or Libechov minipig model of cancer may be used to guide the selection of a dose that is a therapeutically effective amount. A number of rodent models of human cancers are available, including nude mouse/tumor xenograft systems (e.g., melanoma xenografts; see, e.g., Trikha et al. Cancer Research 62:2824-2833 (2002)) and murine models of breast cancer or glioma (e.g., Kuperwasser et al., Cancer Research 65, 6130-6138, (2005): Bradford et al., Br. J Neurosurg. 3(2):197-210 (1989)). A melanoblastoma-bearing Libechov minipig (McLiM) is available as an animal model of melanoma (e.g., Boisgard et al., Eur J Nucl Med Mol Imaging 30(6):826-34 (2003)).\n\n\n \nSynovitis\n\n\n \n \n \nSynovitis is a condition characterized by inflammation of the synovium, a tissue normally only a few cell layers thick. In synovitis, the synovium can become thickened, more cellular, and engorged with fluid. Synovitis can cause pain and inflammation within the affected joint, and is commonly seen in arthritic conditions (e.g., rheumatoid arthritis).\n\n\n \n \n \n \nActive synovial MMP-2 is associated with radiographic erosions in patients with early synovitis (Goldbach-Mansky et. al, 2000, Arthritis Res, 2:145-153). Synovial tissue expressions of MMP-2MMP-14, and TIMP-2 are virtually undetectable in normal synovial tissue samples. The synovial tissue samples of patients with erosive disease have significantly higher levels of active MMP-2 than did those of patients without erosions. This may reflect augmented activation of MMP-2 by the relatively high levels of MMP-14 and low levels of TIMP-2 seen in these tissues. Thus, active MMP-2 can contribute to the development and/or progression of rheumatoid arthritis and osteoarthritis.\n\n\n \n \n \n \nThe disclosure provides methods of treating (e.g., ameliorating, stabilizing, reducing, or eliminating a symptom of synovitis such as pain, joint swelling, synovial thickening, increased synovial fluid) synovitis by administering a therapeutically effective amount of a MMP-14 binding protein. Also provided are methods which combine MMP-14 binding protein therapy with additional therapies. Current therapies for synovitis include anti-inflammatory medications (e.g. NSAIDS and ibuprofen), cortisone injections into the joint, and surgical treatment (e.g., synovectotny). One or more of these treatments can be used in combination with an MMP-14 binding protein (e.g., an inhibitory MMP-14 binding protein, e.g., an anti-MMP-14 IgG or Fab) to treat this condition.\n\n\n \n \n \n \nGuidance for determination of a therapeutically effective amount of an MMP-14 binding protein may be obtained from an animal model of synovitis. Rodent models of synovitis are available, including a rat model of synovitis-like inflammation (Cirino et al., J. Rheumatot. 21(5):824-9 (1994)), and a model of carrageenan synovitis in male Wistar rats (Walsh et al. Lab Invest. 78(12):1513-21 (1998)).\n\n\n \nRheumatoid-Arthritis and Associated Conditions\n\n\n \n \n \nRheumatoid arthritis (RA) is an autoimmune, chronic inflammatory disease that causes joint swelling and pain and normally results in joint destruction, RA generally follows a relapsing/remitting course, with “flares” of disease activity interspersed with remissions of disease symptoms. RA is associated with a number of additional inflammatory disorders, including Sjogren's syndrome (dry eyes and mouth caused by inflammation of tear and saliva glands), pleuritis (inflammation of the pleura that causes pain upon deep breath and coughing), rheumatoid nodules (nodular sites of inflammation that develop within the lungs), pericarditis (inflammation of the pericardium that causes pain when lying down or leaning forward), Felty syndrome (splenomegaly and leucopenia observed in conjunction with RA, making the subject prone to infection), and vasculitis (an inflammation of the blood vessels which can block blood flow). MMP-14 and MMP-16 have been implicated in rheumatoid arthritis.\n\n\n \n \n \n \nSymptoms of active RA include fatigue, lack of appetite, low grade fever, muscle and joint aches, and stiffness. Muscle and joint stiffness are usually most notable in the morning and after periods of inactivity. During flares, joints frequently become red, swollen, painful, and tender, generally as a consequence of synovitis.\n\n\n \n \n \n \nTreatment for rheumatoid arthritis involves a combination of medications, rest, joint strengthening exercises, and joint protection. Two classes of medications are used in treating rheumatoid arthritis: anti-inflammatory “first-line drugs,” and Disease-Modifying Antirheumatic Drugs (DMARDs).” The first-line drugs, include NSAIDS (e.g., aspirin, naproxen, ibuprofen, and etodolac) and cortisone (corticosteroids). DMARDS, such as gold (e.g., gold salts, gold thioglucose, gold thiomalate, oral gold), methotrexate, sulfasalazine, D-penicillamine, azathioprine, cyclophosphamide, chlorambucil, and cyclosporine, leflunomide, etanereept, infliximab, anakinra, and adalimumab, and hydroxychloroquine, promote disease remission and prevent progressive joint destruction, but they are not anti-inflammatory agents.\n\n\n \n \n \n \nThe disclosure provides methods of treating (e.g., ameliorating; stabilizing, or eliminating one or more symptoms or ameliorating or stabilizing the subject's score on a RA scale) rheumatoid arthritis by administering a therapeutically effective amount of a MMP-14 binding protein to a subject having or suspected of having RA. Additionally provides are methods of treating RA by administering a therapeutically effective amount of a MMP-14 binding protein and at least one NSAID and/or DMARDS.\n\n\n \n \n \n \nFurther provided are methods of treating (e.g., ameliorating, stabilizing, or eliminating one or more symptoms) rheumatoid arthritis associated disorders (Sjogren's syndrome, pleuritis, pulmonary rheumatoid nodules, pericarditis, Felty syndrome, and vasculitis) by administering a therapeutically effective amount of an MMP-14 binding protein.\n\n\n \n \n \n \nScales useful for assessing RA and symptoms of RA include the Rheumatoid Arthritis Severity Scale (BASS; Bardwell et al., (2002) \nRheumatology \n41(1):38-45), SF-36 Arthritis Specific Health Index (ASHI: Ware et al., (1999) \nMed Care. \n37(5 Suppl):MS40-50), Arthritis Impact Measurement Scales or Arthritis Impact Measurement Scales 2 (AIMS or AIMS2; Meenan et al. (1992) \nArthritis Rheum. \n35(1):1-10); the Stanford Health Assessment Questionnaire (HAQ), HAQII, or modified HAQ (see, e.g., Pincus et al. (1983) Arthritis Rheum. 26(11):1346-53).\n\n\n \n \n \n \nGuidance for the determination of the dosage that delivers a therapeutically effective amount of a MMP-14 binding protein may be obtained from animal models of rheumatoid arthritis, such as collagen-induced arthritis (CIA), which is induced, typically in rodents, by immunization with autologous or heterologous type II collagen in adjuvant (Williams et al. Methods Mol. Med. 98:207-16 (2004)).\n\n\n \nAtherosclerosis\n\n\n \n \n \nInduction of MMP-14 is linked to the rupture of atherosclerotic plaques associated with acute coronary syndrome (ACS) (Ray et al, 2004, Circ Res, 95:1082-90). MMP-14 can cause highly focal degradation of the fibrous cap structure of atherosclerotic plaques because of its cell membrane location and the ability to activate several other members of the MMP family including MMP-2. Accordingly, the disclosure provides methods of treating (e.g., eliminating, ameliorating, or stabilizing a symptom of atherosclerosis, reducing or stabilizing the size or number of atherosclerotic plaques, including plaques in coronary arteries, carotid arteries, and the aorta, reducing or stabilizing arterial stenosis, including coronary artery and carotid artery stenosis, or reducing risk of myocardial infarction) atherosclerosis in a subject having or suspected of having atherosclerosis by administering a therapeutically effective amount of a MMP-14 binding protein (e.g., an inhibitory MMP-14 binding protein, e.g., an anti-MMP-14 IgG or Fab).\n\n\n \n \n \n \nCurrent treatments for atherosclerosis include cholestyramine, colestipol, nicotinic acid, gemfibrozil, probucol, atorvastatin, lovastatin, aspirin, ticlopidine, clopidogrel (inhibitors of platelet clumping) and anti-coagulants. The disclosure also includes methods of treating atherosclerosis by administering a therapeutically effective amount of a MMP-14 binding protein (e.g., an inhibitory MMP-14 binding protein, e.g., an anti-MMP-14 IgG or Fab) in addition to another atherosclerosis therapy (e.g., cholestyramine, colestipol, nicotinic acid, gemfibrozil, probucol, atorvastatin, lovastatin, aspirin, ticlopidine, clopidogrel, or anti-coagulants).\n\n\n \n \n \n \nGuidance for determining the dosage of MMP-14 binding protein that provides a therapeutically effective amount of the MMP-14 binding protein may be obtained from an animal model of atherosclerosis, such as a hypercholesterolaemic rabbit (Booth et al. NMR Biomed. 3(2):95-100 (1990)), or a apoE-knockout mouse (Ozaki et al., J Clin Invest. 1.10(3): 331-340 (2002)).\n\n\n \nOcular Conditions\n\n\n \n \n \nMacular Degeneration. Macular degeneration progressively destroys the macula, the central portion of the retina, impairing central vision, leading to difficulty with reading, driving, and/or other daily activities that require fine central vision. While there are a number of different forms of macular degeneration, the most common is age-related macular degeneration (AMD). AMD presents as either “dry” or “wet”, with the wet type being far more common. In wet AMD, fluid leaking from newly formedssubretinal blood vessels (subretinal neovascularization) distorts the macula and impairs vision. Symptoms of AMD include loss or impairment in central vision (generally slowing in dry AMD and rapidly in wet AMD) and abnormal visual perception of straight lines (e.g., straight lines appear wavy). Supplements of zinc and the antioxidants vitamin C, vitamin E and beta-carotene reportedly slow the progression of wet AMD.\n\n\n \n \n \n \nThe disclosure provides methods of treating (e.g., ameliorating vision, stabilizing vision degradation, or reducing the rate of vision degradation) AMD (wet AMD or dry AMD) by administering a therapeutically effective amount of a MMP-14 binding protein (e.g., an inhibitory MMP-14 binding protein, e.g., an anti-MMP-14 tgG or Fab) to a subject having or suspected of having AMD. Also provided are methods of treating AMD by administering a therapeutically effective amount of a MMP-14 binding protein with another AMD treatment (e.g., zinc, vitamin C, vitamin E and/or beta-carotene).\n\n\n \n \n \n \nGuidance regarding the efficacy and dosage an MMP-14 binding protein which will deliver a therapeutically effective amount of the protein can be obtained from an animal model of macular degeneration, e.g., a \nCoturnix coturnix \njaponica (Japanese quail) model of macular degeneration (U.S. Pat. No. 5,854,015), or wound creation on the Bruch's membrane of a C57BL/6J mouse, e.g., with a krypton laser (US App. No. 20030181531).\n\n\n \n \n \n \nCorneal Disease. Peak expression of MMP-14 and -16 shows a good correlation with the overall inflammatory response in intracorneal diseases (Dong et al, 2000, Invest Ophthalmol Vis Sci, 41(13):4189-94). Keratoconus is a progessive disease where the cornea thins and changes shape. The resulting distortion (astigmatism) frequently causes nearsightedness. Keratoconus may also cause swelling and scarring of the cornea and vision loss.\n\n\n \n \n \n \nThe disclosure provides methods of treating (e.g., improving or stabilizing vision, or improving, stabilizing, reducing eliminating, or preventing corneal scarring) keratoconus in a subject having or suspected of having keratoconus by administering an effective amount of a MMP-14 binding protein (e.g., an inhibitory MMP-14 binding protein, e.g., an anti-MMP-14 IgG or Fab).\n\n\n \n \n \n \nGuidance regarding the efficacy and dosage an MMP-14 binding protein which will deliver a therapeutically effective amount of the protein can be obtained from an animal model of keratoconus, e.g., the inbred SKC mouse line, which serves as a model for a subset of keratoconus (Tachibana et al. Investig Ophthalmol Visual Sci, 43:51-57 (2002)).\n\n\n \n \n \n \nCorneal infection. Also provided are methods of treating (e.g., preventing, reducing, stabilizing or climinamig corneal scarring as a result of the infection) corneal infection by administering an effective amount of a MMP-14 binding protein (e.g., an inhibitory MMP-14 binding protein, e.g., an anti-MMP-14 IgG or Fab) to a subject having or suspected of having a cortical infection. Additionally, methods are provided for treatment of corneal infection by administering a MMP-14 binding protein and a therapeutic agent which treats the infectious agent (e.g., an antibiotic or anti-viral agent).\n\n\n \n \n \n \nGuidance regarding the efficacy and dosage an MMP-14 binding protein which will deliver a therapeutically effective amount of the protein can be obtained from an animal model of corneal infection, e.g., a rabbit model of experimental keratomycosis, in which keratitis is induced with a standardized inoculum of \nCandida albicans \n(SC 5314) placed on a debrided cornea (Goldblum et al. Antimicrob Agents Chemother 49:1359-1363 (2005)).\n\n\n \nOsteoarthritis\n\n\n \n \n \nOsteoarthritis, also known as degenerative arthritis, is characterized by the breakdown and eventual loss of die cartilage of one or more joints. Osteoarthritis commonly affects the hands, feet, spine, and large weight-bearing joints, such as the hips and knees. MMP-14 and MMP-16 have been implicated in osteoarthritis. The disclosure provides methods of treating (e.g., stabilizing, reducing, or eliminating joint pain, stabilizing or improving performance on general health or osteoarthritis scales) osteoarthritis by administering a therapeutically effective amount of a MMP-14 binding protein (e.g., an inhibitory MMP-14 binding protein, e.g., an anti-MMP-14 IgG or Fab) to a subject having or suspected of having osteoarthritis.\n\n\n \n \n \n \nCurrent medical treatment of osteoarthritis includes conservative measures (e.g., rest, weight reduction, physical and occupational therapy) and medications such as acetaminophen, pain-relieving creams applied to the skin over the joints such as capsaicin, salycin, methyl salicylate, and menthol, nonsteroidal anti-inflammatoty drugs (NSAIDs) such as aspirin, ibuprofen, naburnetone, and naproxen, and Cox-2 inhibitors. The disclosure further provides methods of treating osteoarthritis by administering a therapeutically effective amount of a MMP-14 binding protein (e.g., an inhibitory MMP-14 binding protein, e.g., an anti-MMP-14 IgG or Fab) and another osteoarthritis therapy (e.g. acetaminophen, a topical pain-relieving cream, a nonsteroidal anti-inflammatory drug (NSAID) such as aspirin, ibuprofen, nabumetone, or naproxen, or a Cox-2 inhibitor).\n\n\n \n \n \n \nScales useful for the assessment or osteoarthritis include the Knee Injury and Osteoarthritis Outcome Score (KOOS; Roos et al. (1998) \nJ. Orthop. Sports Phys. Ther. \n28(2):88-96), Western Ontario and McMaster Universities Osteoarthritis index (WOMAC; Roos et al. (2003) \nHealth Qual. Life Outcomes \n1(1):17), and the 36-item Short Form General Health Scale (SF-36 GHS), as well as other assessment tools known in the art.\n\n\n \n \n \n \nGuidance regarding the efficacy and dosage an MMP-14 binding protein which will deliver a therapeutically effective amount of the protein can be obtained from an animal model of osteoarthritis, e.g., injection of mono-iodoacetate (MIA) into the femorotibial joint of rodents which promotes loss of articular cartilage similar to that noted in human osteoarthritis (Guzman et al. Toxicol Pathol. 31(6):619-24 (2003)), or transection of the anterior cruciate ligament (ACL) in canines to induce osteoarthritis (Fife and Brandt J Clin Invest. 84(5): 1432-1439 (1989)).\n\n\n \nDiabetes\n\n\n \n \n \nThere are two major types of diabetes mellitus, called type I (sometimes known as insulin dependent diabetes mellitus (IDDM), or juvenile onset diabetes mellitus) and type 2 (sometimes known as non-insulin dependent diabetes mellitus (NIDDM) or adult onset diabetes mellitus). MMP-14 and MMP-24 have been implicated in diabetes. Pro-MMP2 is efficiently activated in the fibrovascular tissues of proliferative diabetic retinopathy (PDR), probably through interaction with MMP-14 and TIMP2, suggesting that MMP2 and MT1-MMP may be involved in the formation of the fibrovascular tissues and in the pathogenesis of PDR.\n\n\n \n \n \n \nThe disclosure provides methods of treating (e.g., reducing or eliminating dependence on exogenous insulin, reducing fasting serum glucose levels, e.g., 6 hour fasting serum glucose, to below 150, 140, 130, 126, 120, 110, or 100 mg/dL) diabetes (type I or type 2) by administering a therapeutically effective amount of a MMP-14 binding protein (e.g., an inhibitory MMP-14 binding protein, an anti-MMP-14 IgG or Fab) to a subject having or suspected of having diabetes mellitus.\n\n\n \n \n \n \nThe disclosure further provides methods of treating diabetes by administering a therapeutically effective amount of a MMMP-14 binding protein in addition to another diabetes mellitus treatment agent. A number of additional treatment agents are known, including agents that increase the insulin output by the pancreas (e.g., sulfonylureas (e.g., chlorpropamide and tolbutamide, glyburide, glipizide, and glimepiride) and meglitinides (e.g., repaglinide and nateglinide), agents that decrease hepatic glucose production (e.g., biguanides, metformin), insulin sensitizing agents (e.g. troglitazone, pioglitazonc, rosiglitazone), agents that decrease the absorption of carbohydrates from the intestine (e.g., acarbose), agents that effect glycemic control (e.g., pramlintide, exenatide), and combination medications such as glyburide/metformin (GLUCOVANCE®), rosiglitazoneimetformin (AVANDAMET®), and glipizide/metformin (METAGLIP®).\n\n\n \n \n \n \nAlso provided are methods of treating disorders secondary to diabetes, such as proliferative diabetic retinopathy (PDR) and microangiopathy. Accordingly, the disclosure provides a method of treating (e.g., preventing stabilizing, reducing, or eliminating vision deterioration) PDR by administering a therapeutically effective amount of a MMP-14 binding protein (e.g., an inhibitory MMP-14 binding protein, e.g., an anti-MMP-14 IgG or Fab) to a subject having or suspected of having PDR. Also provided are methods of treating (e.g., preventing, stabilizing, reducing, or eliminating a symptom) microangiopathy by administering a MMP-14 binding protein (e.g. an inhibitory MMP-14 binding protein, e.g., an anti-MMP-14 IgG or Fab) to a subject having or suspected of having microangiopathy.\n\n\n \n \n \n \nGuidance regarding the efficacy and dosage an MMP-14 binding protein which will deliver a therapeutically effective amount of the protein can be obtained from an animal model of diabetes, e.g., the ob/ob mouse (Kerouz et al. J. Clin. Invest. 100:3164-3172 (1997)), the db/db mouse (Koenig and Cerami Proc Natl Acad Sci USA. 72(9): 3687-3691 (1975)), the Zucker fatty rat (Orci et al. Proc Natl Acad Sci USA. 87(24):9953-7 (1990)), or rats made diabetic by daily low-dose intraperitoneal streptozotocin (STZ) (Nie et al. J Clin Invest. 105:955-965 (2000)).\n\n\n \nAlzheimer's Disease\n\n\n \n \n \nAlzheimer's Disease (AD) is a progressive, neurodegenerative disease characterized in the brain by abnormal clumps (amyloid plaques) and tangled bundles of fibers (neurofibrillary tangles) composed of misplaced proteins. Symptoms of AD include memory loss, language deterioration, impaired ability to mentally manipulate visual information, poor judgment, confusion, restlessness, and mood swings. Eventually AD destroys cognition, personality, and the ability to function. The early symptoms of AD, which include forgetfulness and loss of concentration, are often missed because they resemble natural signs of aging. Current medical treatments for AD include as tacrine (COGNEX®), donepezil (ARICEPT®), rivastigmine (EXELON®), and galantamine (REMINYL®), memantine (NAMENDA™), other drugs that may affect AD progression include nonsteroidal anti-inflammatory drugs (NSAIDS), statins, folic acid, gingko biloba, and vitamins E, 86, and 1312.\n\n\n \n \n \n \nThe disclosure provides methods of treating (e.g., stabilizing, ameliorating, eliminating, or preventing a symptom of AD or slowing or eliminating disease progression) by administering a therapeutically effective, amount of a MMP-14 binding protein (e.g., an inhibitory MMP-14 binding protein, e.g. an anti-MMP-14 IgG or Fab) to a subject having or suspected of having AD. Also provided are methods for treatment of AD by administering to a subject having or suspected of having AD a therapeutically of amount of a MMP-14 binding protein and an additional AD treatment (e.g., tacrine COGNEX®), donepezil (ARICEPT®), rivastigmine (EXELON®)), and galantamine (REMINYL®), memantine (NAMENDA™)).\n\n\n \n \n \n \nGuidance regarding the efficacy and dosage an MMP-14 binding protein which will deliver a therapeutically effective amount of the protein can be obtained from an animal model of AD. For example, transgenic mice expressing a human or mouse APP or presenilin can be used. Some of these transgenic mice develop a progressive neurologic disorder generally within a year from birth (see, e.g., U.S. Pat. Nos. 5,877,399; 6,037,521; 5,894.078; 5,850,003; and 5,898,094). Certain transgenic animal models have been described, for example, in U.S. Pat. Nos. 5,612,486; 5,387,742; 5,720,936; 5,877,015, and 5,811,633, and in Ganes et. al. (1995) Nature 373:523.\n\n\n \nMammary Gland Remodeling\n\n\n \n \n \nMammary morphogenesis involves epithelial “invasion” of adipose tissue; a process akin to invasion by breast cancer cells, although the former is a highly regulated developmental process. Mammary gland branching morphogenesis is dependent, in pan, on the extracellular matrix (ECM), ECM-receptors (e.g., integrins), ECM-degrading enzymes (e.g., MMPs) and MMP inhibitors (tissue inhibitors of metalloproteinases (TIMPs)). Increased MMP-14 expression is associated with increased mammary carcinogenesis and MMP-2 contributes to mammary gland branching morphogenesis during puberty. Accordingly, provided herein are methods of inhibiting inappropriate mammary gland remodeling and for prophylaxis or treatment of, precancerous lesions/activity in breast tissue.\n\n\n \n \n \n \nThe disclosure provides methods of inhibiting (e.g., preventing, reducing, or eliminating) inappropriate mammary gland remodeling by administering a therapeutically effective amount of a MMP-14 binding protein (e.g., an inhibitory MMP-14 binding protein, e.g., an anti-MMP-14 IgG or Fab) to a subject having or suspected of having inappropriate mammary gland remodeling. Also provided are methods for prophylaxis or treatment (e.g., reducing risk of developing breast cancer, or preventing, eliminating, reducing, or stabilizing precancerous breast lesions) precancerous breast lesions or activity by administering a therapeutically effective amount of a MMP-14 binding protein (e.g., an inhibitory MMP-14 binding protein, e.g., an anti-MMP-14 IgG or Fab) to a subject having or suspected of having breast tissue precancerous lesions or activity.\n\n\n \n \n \n \nGuidance regarding the efficacy and dosage an MMP-14 binding protein which will deliver a therapeutically effective amount of the protein can be obtained from an animal model of mammary carcinogenesis, such as transgenic mice overexpressing MMP-14 in mammary gland under the control of the mouse mammary tumor virus long terminal repeat-promoter (Ha et al. Cancer Research 61:984-990, (2001)), or transgenic mice model in which rat stromelysin-1 expression is augmented in breast tissue (Lochter et al. J Biol Chem 272:5007-5015 (1997)) can be used.\n\n\n \nCerebral Ischemia\n\n\n \n \n \nExpression of MMP-2, MMP-14 and MMP-16 are increased within 1 hour after middle cerebral artery occlusion in the ischemic core (Chang et al. 2003, J Cereb Blood Flow Metab., 23(12):1408-19). The expression patterns are consistent with secretion of proMMP-2 and its activators in the ischemic core, perhaps from separate cell compartments. The rapid and coordinate appearance of pro-MMP-2 and its activation apparatus suggest that in the primate striatum this protease may participate in matrix injury during focal cerebral ischemia.\n\n\n \n \n \n \nThe disclosure provides methods of treating (e.g., reducing or eliminating a symptom of cerebral ischemia, such as a deficit/impairment in speech, movement, vision, or understanding) cerebral ischemia by administering a therapeutically effective amount of a MMP-14 binding protein (e.g., an inhibitory MMP-14 binding protein, e.g., an anti-MMP-14 IgG or Fab) to a subject having or suspected of having cerebral ischemia.\n\n\n \n \n \n \nCurrent medical treatment of cerebral ischemia includes anticoagulation with heparin and heparin-like agents (low molecular heparin and heparinoid), and aspirin. The disclosure further provides methods of treating cerebral ischemia by administering a therapeutically effective amount of a MMP-14 binding protein (e.g., an inhibitory MMP-14′ binding protein, e.g., an anti-MMP-14 EgG or Fab) and an additional cerebral ischemia treatment to a subject having or suspected of having cerebral ischemia.\n\n\n \n \n \n \nGuidance regarding the efficacy and dosage an MMP-14 binding protein which will deliver a therapeutically effective amount of the protein can be obtained from an animal model of cerebral ischemia, e.g., acute stroke model middle cerebral artery occlusion (MCAO) and the direct distal MCAO model (Schneider et al. J. Clin. Invest, 115:2083-2098 (2005); Taguchi et al. J. Clin. Invest. 114:330-338 (2004)).\n\n\n \nEndometriosis\n\n\n \n \n \nEndometriosis involves the proliferation of endometrial tissue outside of the Endometrial cavity, typically throughout the peritoneum and can cause significant pain (e.g., pelvic pain, pain upon defecation, dyspareunia) and infertility. Lesions may be “classical” (pigmented, e.g., dark blue, dark brown, or black and may be cystic) or “non-classical” (generally non-pigmented). Non-classical lesions are commonly found in patients with more ‘aggressive’ disease (e.g., Significant pain). MMP-2 and MMP-14 mRNA expression levels in clinically aggressive pigmented lesions are significantly higher than those in normal eutopic endometrium.\n\n\n \n \n \n \nCurrent endometriosis treatments include progestational agents, including acetate, norethynodrel, megestrol acetate, dydrogesterone, norethisterone, and lynestrenol; danazol, a synthetic; 3-isoxazole derivative of 17 ethinyl-testosterone, gonadotropin-releasing hormone (GaRH), destruction of lesions, e.g., with laparoscopy.\n\n\n \n \n \n \nThe disclosure provides methods for treating (e.g., reducing, stabilizing, or eliminating a symptom of endometriosis such as pain or infertility) endometriosis in a subject having or suspected of having endometriosis by administering a therapeutically effective amount of a MMP-14 binding protein (e.g., an inhibitory MMP-14 binding protein, e.g., an anti-MMP-14 IgG or Fab). Also provided are methods for treating endometriosis by in a subject having or suspected of having endometriosis by administering a therapeutically effective amount of a MMP-14 binding protein and an additional endometriosis treatment (e.g., a progestational agent (acetate, norethynodrel, megestrol acetate, dydrogesterone, norethisterone, and lynestrenol), danazol, gonadotropin-releasing hormone (GnRH), or laparoscopic lesion removal/destruction).\n\n\n \n \n \n \nGuidance regarding the efficacy and dosage an MMP-14 binding protein which will deliver a therapeutically effective amount of the protein can be obtained from an animal model of endometriosis, e.g., surgically-induced endometriosis involving autotransplantation of biopsies of uterus into the abdomen (Berkley et al. (2004) \nProc. Natl. Acad. Set. USA \n101:11094-98).\n\n\n \nFibrin-Invasive Activity\n\n\n \n \n \nCross-linked fibrin is deposited in tissues surrounding wounds, inflammatory sites, or tumors and serves not only as a supporting substratum for trafficking cells, but also as a structural barrier to invasion. Invading cells can use proteinases to access the fibrin matrix with proteolysis purposefully restricted to the pericellular milieu of the ingressing cells. MMP-14 may participate fibrin-invasive events, as fibroblasts from MMP-14-null mice display an early defect in invasion. However, MMP-14-deleted fibroblasts can circumvent this early deficiency and exhibit compensatory fibrin-invasive activity. The MMP-14-independent process is sensitive to MMP inhibitors that target membrane-anchored MMPs (Notary et al., 2002 J Exp Med. 195(3):295-308).\n\n\n \n \n \n \nThe disclosure provides methods of modulating fibrin invasive activity by administering a therapeutically effective amount of a MMP-14 binding protein (e.g., a Fab or IgG, that inhibits MMP-14) to a subject in need of fibrin invasive activity modulation. In some embodiments, the MMP-14 binding protein further binds MMP-16, or further binds and inhibits MMP-16.\n\n\n \n \n \n \nGuidance regarding the efficacy and dosage an MMP-14 binding protein which will deliver a therapeutically effective amount of the protein can be obtained from a model of fibrin invasive activity, e.g., a cell invasion assay (Trikha et al. Cancer Research 62:2824-2833 (2002)).\n\n\n \nAngiogenesis and Capillary Tube Formation.\n\n\n \n \n \nThe role of MMPs in angiogenesis is dual and complex. The relevance of these enzymes as positive regulators of tumor angiogenesis has been largely demonstrated. However MMPs have also been reported to act as inhibitors of angiogenesis, by recent descriptions of mechanisms by which these enzymes negatively regulate angiogenesis have contributed to increase the functional complexity of this proteolytic system in cancer. A number of MMPs are able to cleave the precursors of angiostatin and endostatin, and generate the active forms of these endogenous inhibitors of angiogenesis (Cornelius et al., 1998; Ferreras et al., 2000). Human endothelial cell (EC) tube formation induced by the chemokines CCL2 and CXCL8 is highly dependent on MMP-14 activity.\n\n\n \n \n \n \nThe disclosure provides methods of modulating (e.g., inhibiting) inappropriate angiogenesis or capillary tube formation by administering a therapeutically effective amount of a MMP-14 binding protein (e.g., an anti-MMP-14 IgG or Fab that inhibits MMP-14) to a subject in need of modulation of inappropriate angiogenesis or capillary tube formation. Also provided are methods in which inappropriate angiogenesis or capillary tube formation is modulated by administering a MMP-14 binding protein and an additional angiogenesis or capillary tube formation modulating agent, such as a VEGF or Tiel inhibitor.\n\n\n \n \n \n \nGuidance regarding the efficacy and dosage an MMP-14 binding protein which will deliver a therapeutically effective amount of the protein can be obtained from a model of angiogenesis, e.g., a Matrigel-based angiogenesis assay in nude rats, or in a model of capillary tube formation, e.g., endothelial MC-based sprouting assay (Trikha et al. Cancer Research 62:2824-2833 (2002)) or a capillary tube formation assay or an angiogenesis assay as described in U.S. Ser. No. 11/199,739 and PCT/US2005/0284, both filed Aug. 9, 2005.\n\n\n \nCombination Therapies\n\n\n \n \n \nThe MMP-14 binding proteins described herein, e.g., anti-MMP-14 Fabs or IgGs, can be administered in combination with one or more of the oilier therapies for treating a disease or condition associated with MMP-14 activity, e.g., a disease or condition described herein. For example, an MMP-14 binding protein can be used therapeutically or prophylactically with surgery, another MMP-14 inhibitor, e.g., a small molecule inhibitor, another anti-MMP-14 Fab or IgG (e.g., another Fab or IgG described herein), peptide inhibitor, or small molecule inhibitor. Examples of MMP-14 inhibitors that can be used in combination therapy with an MMP-14 binding protein described herein include neovastat, marimastat, BAY 12-9566 and prinomastat.\n\n\n \n \n \n \nOne or more small-molecule MMP inhibitors can be used in combination with one or more MMP-14 binding proteins described herein. For example, the combination can result in a lower dose of the small-molecule inhibitor being needed, such that side effects are reduced.\n\n\n \n \n \n \nThe MMP-14 binding proteins described herein can be administered in combination with one or more of the other therapies for treating cancers, including, but not limited to: surgery; radiation therapy, and chemotherapy. For example, proteins that inhibit MMP-14 or that inhibit a downstream event of MMP-14 activity (e.g., cleavage of pro-MMP-2 to MMP-2) can also be used in combination with other anti-cancer therapies, such as radiation therapy, chemotherapy, surgery, or administration of a second agent. For example, the second agent can be a Tie-1 inhibitor (e.g., Tie-1 binding proteins; see e.g., U.S. Ser. No. 11/199,739 and PCT/US2005/0284, both filed Aug. 9, 2005). As another example, the second agent can be one that targets or negatively regulates the VEGF signaling pathway. Examples of this latter class include VEGF antagonists (e.g., anti-VEGF antibodies such as bevacizumab) and VEGF receptor antagonists (e.g., anti-VEGF receptor antibodies). One particularly preferred combination includes bevacizumab. As a further example, the second agent is an inhibitor of plasmin, such as a kunitz domain-containing protein or polypeptide (e.g., a plasmin-inhibiting kunitz domain disclosed in U.S. Pat. No. 6,010,880, such as a protein or polypeptide comprising the amino acid sequence MHSFCAFKAETGPCRARFDRWFFNIFTRQCEEFIYGGCEGNQNRFESLEECKKMCTRD (SEQ ID NO:)). As another example, the second agent is an agent that binds to Her2, such as a Her2-binding antibody (e.g., trastuzumab). The combination can further include 5-FU and leucovorin and/or irinotecan.\n\n\n \n \n \n \nInhibitors of MMP-14 (e.g., the MMP-14 binding proteins disclosed herein) can potentiate the activity of an agent that targets Her2 (e.g., a Her2-binding antibody such as trastuzumab). Accordingly, in one combination therapy for the treatment of breast cancer, the second therapy is an agent that binds Her2, such as a Her2-binding antibody (e.g., trastuzumab). When an MMP-14 binding protein is used in a combination therapy with a Her2 binding agent, the dose of the Her2 binding agent may be reduced from the dose of the Her2 binding agent when administered not in combination with an MMP-14 binding protein (e.g., is at least 10%, 25%, 40%, or 50% less than the dose of the Her2 binding agent when administered not in combination with a MMP-14 binding protein). For example, the dose of trastuzumab, when administered in a combination therapy with an MMP-14 binding protein is less than about 4.0, 3.6, 3.0, 2.4, or 2 mg/kg as an initial (loading) dose, and less than about 2.0, 1.8, 1.5, 1.2, or 1 mg/kg in subsequent doses.\n\n\n \n \n \n \nThe MMP-14 binding proteins described herein can also be administered in combination with one or more other therapies for treating ocular disorders, such as surgical or medical (e.g., administration of a second agent) therapies. For example, in treatment of age-related macular degeneration (e.g., wet age-related macular degeneration), an MMP-14 binding protein may be administered in conjunction with (e.g., before, during; or after) laser surgery (laser photocoagulation or photocoagulation therapy). As another example, the MMP-14 binding protein can be administered in combination with a second agent, such as a VEGF antagonist (e.g., an anti-VEGF antibody such as bevacizumab or ranibizumab) or a VEGF receptor antagonist (e.g., anti-VEGF receptor antibodies).\n\n\n \n \n \n \nThe term “combination” refers to the use of the two or more agents or therapies to treat the same patient, wherein the use or action of the agents or therapies overlap in lime. The agents or therapies can be administered at the same time (e.g., as a single Formulation that is administered to a patient or as two separate formulations administered concurrently) or sequentially in any order. Sequential administrations are administrations that are given at different times. The time between administration ° Nile one agent and another agent can be minutes, hours, days, or weeks. The use of an MMP-14 binding protein described herein can also be used to reduce the dosage of another therapy, e.g., to reduce the side-effects associated with another agent that is being administered, e.g., to reduce the side-effects elan anti-VEGF antibody such as bevacizurraib. Accordingly, a combination can include administering a second agent at a dosage at least 10, 20, 30, or 50% lower than would be used in the absence oldie MMP-14 binding protein.\n\n\n \n \n \n \nIn addition, a subject can be treated, for an angiogenesis-associated disorder, e.g., a cancer, by administering to the subject a first and second agent. For example; the first agent modulates early stage angiogenesis and the second agent modulates a subsequent stage of angiogenesis or also modulates early stage angiogenesis. The first and second agents can be administered using a single pharmaceutical composition or can be administered separately. In one embodiment, the first agent is a VEGF pathway antagonist (e.g., an inhibitor of a VEGF (e.g., VEGF-A, -B, or -C) or a VEGF receptor (e.g., KDR or VEGF receptor III (Flt4)) or a bFGF pathway antagonist (e.g., an antibody that binds to bFGF or a bFGF receptor). Other VEGF pathway antagonists are also described, herein and elsewhere. In one embodiment, the second agent inhibits or decreases the mobility or invasiveness of tumor cells. For example, the second agent comprises au MMP-14 binding protein. For example, the second agent is an MMP-14 binding protein described herein.\n\n\n \n \n \n \nOnce a tumor reaches a certain size (e.g., ˜1-2 mm), the tumor requires new vasculature prior to increasing its mass. An early stage of tumor angiogenesis can include a signal from the tumor, e.g., secretion of VEGF, to stimulate the growth of new blood vessels from the host and infiltration of the tumor by the vessels. VEGF can, for example, stimulate proliferation of endothelial cells that are then assembled into blood vessels. A late stage of tumor growth can include metastasis, mobility and invasiveness of tumor cells. This mobility and invasiveness may involve the action of matrix metalloproteinases, e.g., MMP-14, MMP-16, or MMP-24. Thus, an effective therapy to treat angiogenesis-related disorders can involve a combination of an agent that modulates an early stage angiogenesis (e.g., VEGF pathway antagonists, e.g., anti-VEGF (e.g., bevacizumab) or anti-VEGF receptor (e.g., anti-KDR) antibodies; or antagonists of other pro-angiogenic pathways, e.g., anti-bFGF antibodies or anti-bFGF receptor (e.g., anti-bFGF receptor-1, -2, -3) antibodies) and an agent that modulates a late stage of tumor growth can include metastasis mobility and invasiveness of tumor cells s (e.g., antagonists of MMP-14, MMP-16, or MMP-24 (e.g., anti-MMP-14 antibodies (e.g., an antibody disclosed herein)), of MMP-16 (e.g., anti-MMP-14 antibodies that cross react with MMP-16), or of MMP-24 (e.g., anti-MMP-14 antibodies that cross react with MMP-24). One or more of these agents can be used in combination. One or more of these agents may also be used in combination with other anti-cancer therapies, such as radiation therapy or chemotherapy.\n\n\n \n \n \n \nExemplary VEGF receptor antagonists include inhibitors of a VEGF (e.g., VEGF-A, -B, or -C, for example bevacizumab), modulators of VEGF expression (e.g., INGN-241, oral tetrathiomolybdate, 2-methoxycstradioi, 2-methoxyestradiot nanocrystal dispersion, bevasiranib sodium, PTC-299, Veglin), inhibitors of a VEGF receptor (e.g., 1:011 or VEGF receptor III (flt4), for example anti-KDR antibodies, VEGFR2 antibodies such as CDP-791, IMC-112113, VEGFR2 blockers such as CT-322), VEGFR3 antibodies such as mF4-31C1 from Imclone Systems, modulators of VEGFR expression (e.g., VEGFR1 expression modulator Sirna-027) or inhibitors of VEGF receptor downstream signaling.\n\n\n \n \n \n \nExemplary inhibitors of VEGF include bevaciztnnab, pegaptanib, ranibizumab, NEOVASTAT®, AE-941, VEGF Trap, and PI-88.\n\n\n \n \n \n \nExemplary VEGF receptor antagonists include inhibitors of VEGF receptor tyrosine-kinase activity. 4-[4-(1-Amino-1-methylethyl)phenyl]-2-[4-(2-morpholin-4-yl-ethyl)phenylamino]pyrimidine-5-carbonitrile (JNJ-17029259) is one of a structural class of 5-cyanopyrimidines that are orally available, selective, nanomolar inhibitors of the vascular endothelial growth factor receptor-2 (VEGF-R2). Additional examples include: PTK-787/ZK222584 (Astra-Zeneca), SU5416, SU11248 (Pfizer), and ZD6474 ([N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine]), vandetanib, cediranib, AG-013958, CP-547632, E-7080, XL-184, L-21649, and ZK-304709. Other VEGF antagonist agents are broad specificity tyrosine kinase inhibitors, e.g., SU6668 (see, e.g., Bergers, B. et al., 2003 J. Clin. Invest. 111:1287-95), sorafenib, sunitinib, pazopanib, vinalanib, AEE-788, AMG-706, axitinib, BIBF-1120, SU-14813, XL-647, XL-999, ABT-869, BAY-57-9352, BAY-73-4506, BMS-582664, CEP-7055, CHIR-265, OSI-930, and TK1-258. Also useful are agents that down regulate VEGF receptors on the cell surface, such as fenretinide, and agents which inhibit VEGF receptor downstream signaling, such as squalamine.\n\n\n \n \n \n \nThe second agent or therapy can also be another anti-cancer agent or therapy. Non-limiting examples of anti-cancer agents include, e.g., anti-microtubule agents, topoisomerase inhibitors, antimetabolites, mitotic inhibitors, alkylating agents, intercalating agents, agents capable of interfering with a signal transduction pathway, agents that promote apoptosis, radiation, and antibodies against other tumor-associated antigens (including naked antibodies, immunotoxins and radioconjugates). Examples attic particular classes of anti-cancer agents are provided in detail as follows: antitubulin/antimicrombule, paclitaxel, vincristine, vinblastine, vindesine, vinorelbin, taxotere; topoisomerase I inhibitors, e.g., irinotecan, topotecan camptothecin, doxorubicin, etoposide, mitoxantrone, daunorubicin, idarubicin, teniposide, amsacrine, epirubicin, merbarone, piroxantrone hydrochloride; antimetabolites, e.g., 5 fluorouracil (5 FU), methotrexate, 6 mercaptopurine, 6 thioguanine, fludarabine phosphate, cytarabine/Ara C, trimetrexate, gemcitabine, acivicin, alanosine, pyrazofurin, N-Phosphoracetyl-L-Asparate=PALA pentostatin, 5 azacitidine, 5 Aza 2′ deoxycytidine, ara A, cladrihine, 5 fluorouridine, FUDR, tiazofurin, N-[5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2-thenoyl]-glutamic acid; alkylating agents, e.g., cisplatin, carboplatin, mitomycin C, BCNU=Carmustine, melphalan, thiotepa, busulfan, chlorambucil, plicamycin, dacarbazine, ifosfamide phosphate, cyclophosphamide, nitrogen mustard, uracil mustard, pipobroman, 4 ipomeanol; agents acting via other mechanisms of action, e.g., dihydrolenperone, spiromustine, and desipeptide; biological response modifiers, e.g., to enhance anti-tumor responses, such as interferon; apoptotic agents, such as actinomycin D; and anti-hormones, for example anti-estrogens such as tamoxifen or, for example antiandrogens such as 4′-cyano-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methyl-3′-(trifluoromethyl)propionanilide.\n\n\n \n \n \n \nA combination therapy can include administering an agent that reduces the side effects of other therapies. The agent can be an agent that reduces the side effects of anti-cancer treatments. For example, the agent can be leucovorin.\n\n\n \n \n \n \nCombination therapies that include administering an MMP-14 binding protein or other binding protein described herein can also be used to treat a subject having or at risk for another angiogenesis related disorder (e.g., a disorder other than cancer, e.g., disorders that include undesired endothelial cell proliferation or undesirable inflammation, e.g., rheumatoid arthritis).\n\n\n \nDiagnostic Uses\n\n\n \n \n \nProteins that bind to MMP-14 and identified by the method described herein and/or detailed herein have in vitro and in vivo diagnostic utilities. The MMP-14 binding proteins described herein (e.g., the proteins that bind and inhibit, or the proteins that bind but do not inhibit MMP-14) can be used, e.g., for in vivo imaging, e.g., during a course of treatment for a disease or condition in which MMP-14 is active, e.g., a disease or condition described herein, or in diagnosing a disease or condition described herein.\n\n\n \n \n \n \nIn one aspect, the disclosure provides a diagnostic method for detecting the presence of an MMP-14, in vitro or in vivo (e.g., in vivo imaging in a subject). The method can include localizing MMP-14 within a subject or within a sample from a subject. With respect to sample evaluation, the method can include, for example: (i) contacting a′ sample with MMP-14 binding protein; and (ii) detecting location of the MMP-14 binding protein in the sample.\n\n\n \n \n \n \nAn MMP-14 binding protein can also be used to determine the qualitative or quantitative level of expression of MMP-14 in a sample. The method can also include contacting a reference sample (e.g., a control sample) with the binding protein, and determining a corresponding assessment of the reference sample. A change, e.g., a statistically significant change, in the formation of the complex in the sample or subject relative to the control sample or subject can be indicative of the presence of MMP-14 in the sample. In one embodiment, the MMP-14 binding protein does not cross react with another metalloproteinase.\n\n\n \n \n \n \nThe MMP-14 binding proteins are also useful for in vivo tumor imaging. Better clinical endpoints are needed to monitor the efficacy of drugs, such as MMP-inhibitors, that are designed to block enzymatic function (Zucker et al, 2001, Nature Medicine 7:655-656). Imaging of tumors in vivo by using labeled MMP-14 binding proteins could be of help to target the delivery of the binding protein to tumors for cancer diagnosis, intraoperative tumor detection, and for investigations of drug delivery and tumor physiology. MMP-14 binding proteins can be used to monitor native enzymatic activity in vivo at invasive sites. Another exemplary method includes: (i) administering the MMP-14 binding protein to a subject; and (iii) detecting location of the MMP-14 binding protein in the subject. The detecting can include determining location or time of formation of the complex.\n\n\n \n \n \n \nThe MMP-14 binding protein can be directly or indirectly labeled with a detectable substance to facilitate detection of the bound or unbound antibody. Suitable detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials and radioactive materials.\n\n\n \n \n \n \nComplex formation between the MMP-14 binding protein and MMP-14 can be detected by evaluating the binding protein bound to the MMP-14 or unbound binding protein. Conventional detection assays can be used, e.g., an enzyme-linked immunosorbent assays (ELISA), a radioimmunoassay (RIA) or tissue immunohistochemistry. Further to labeling the MMP-14 binding protein, the presence of MMP-14 can be assayed in a sample by a competition immunoassay utilizing standards labeled with a detectable substance and an unlabeled MMP-14 binding protein. In one example of this assay, the biological sample, the labeled standards, and the MMP-14 binding protein are combined and the amount of labeled standard bound to the unlabeled binding protein is determined. The amount of MMP-14 in the sample is inversely proportional to the amount of labeled standard bound to the MMP-14 binding protein.\n\n\n \n \n \n \nFluorophore and chromophore labeled proteins can be prepared. Because antibodies and other proteins absorb light having wavelengths up to about 310 nm, the fluorescent moieties should be selected to have substantial absorption at wavelengths above 310 nm and preferably above 400 nm. A variety of suitable fluorescers and chromophores are described by Stryer, 1968, \nScience \n162:526 and Brand, L. et al., 1972\n, Annu. Rev. Biochem. \n41:843 868. The proteins can be labeled with fluorescent chromophore groups by conventional procedures such as those disclosed in U.S. Pat. Nos. 3,940,475, 4,289,747, and 4,376,110. One group of fluorescers having a number of the desirable properties described above is the xanthene dyes, which include the fluoresceins and rhodamines. Another group of fluorescent compounds are the naphthylamines. Once labeled with a fluorophore or chromophore, the protein can be used to detect the presence or localization of the MMP-14 in a sample, e.g., using fluorescent microscopy (such as confocal or deconvolution microscopy).\n\n\n \n \n \n \nHistological Analysis. Immunohistochemistry can be performed using the proteins described herein. For example, in the case of an antibody, the antibody can be synthesized with a label (such as a purification or epitope tag), or can be detectably labeled, e.g., by conjugating a label or label-binding group. For example, a chelator can be attached to the antibody. The antibody is then contacted to a histological preparation, e.g., a fixed section of tissue that is on a microscope slide. After an incubation for binding, the preparation is washed to remove unbound antibody. The preparation is then analyzed, e.g. using microscopy, to identify if the antibody bound to the preparation.\n\n\n \n \n \n \nOf course, the antibody (or other polypeptide or peptide) can be unlabeled at the time of binding. After binding and washing, the antibody is labeled in order to render it detectable.\n\n\n \n \n \n \nProtein Arrays. The MMP-14 binding protein can also be immobilized on a protein array. The protein array can be used as a diagnostic tool, e.g., to screen medical samples (such as isolated cells, blood, sera, biopsies, and the like). Of course, the protein array can also include other binding proteins, e.g., that bind to MMP-14 or to other target molecules.\n\n\n \n \n \n \nMethods of producing polypeptide arrays are described, e.g., in De Wildt et al., 2000\n, Nat. Biotechnol. \n18:989-994; Lucking et al., 1999\n, Anal. Biochem. \n270:103-111; Ge, 2000\n, Nucleic Acids Res. \n28, e3, I-VII: MacBeath and Schreiber, 2000\n, Science \n289:1760-1763: WO 01/40803 and WO 99/51773A1. Polypeptides for the array can be spotted at high speed, e.g., using commercially available robotic apparati, e.g., from Genetic MicroSystems or BioRobotics. The array substrate can be, for example, nitrocellulose, plastic, glass, e.g., surface-modified glass. The array can also include a porous matrix, e.g., acrylamide, agarose, or another polymer.\n\n\n \n \n \n \nFor example the array can be an array of antibodies, e.g., as described in De Wildt, supra. Cells that produce the proteins can be grown on a filter in an arrayed format. Polypeptide production is induced, and the expressed polypeptides are immobilized to the filter at the location oldie cell. A protein array can be contacted with a labeled target to determine the extent of binding of the target to each immobilized polypeptide. Information about the extent of binding at each address of the array can be stored as a profile, e.g., in a computer database. The protein array can be produced in replicates and used to compare binding profiles, e.g., of a target and a non-target.\n\n\n \n \n \n \nFACS (Fluorescence Activated Cell Sorting). The MMP-14 binding protein can be used to label tells, e.g., cells in a sample (e.g., a patient sample). The binding protein is also attached (or attachable) to a fluorescent compound. The cells can then be sorted using to fluorescence activated cell sorter (e.g., using a sorter available from Becton Dickinson Immunocytometry Systems, San Jose Calif.; see also U.S. Pat. Nos. 5,627,037; 5,030,002; and 5,137,809). As cells pass through the sorter, a laser beam excites the fluorescent compound while a detector counts cells that pass through and determines whether a fluorescent compound is attached to the cell by detecting fluorescence. The amount of label bound to each cell can be quantified and analyzed to characterize the sample.\n\n\n \n \n \n \nThe sorter can also deflect the cell and separate cells bound by the binding protein from those cells not bound by the binding protein. The separated cells can be cultured and/or characterized.\n\n\n \n \n \n \nIn vivo Imaging. Also featured is a method for detecting the presence of a MMP-14 expressing tissues in vivo. The method includes (i) administering to a subject (e.g., a patient having, e.g., a cancer (e.g., metastatic cancer, e.g. metastatic breast cancer), an inflammatory disease (e.g., synovitis, atherosclerosis), rheumatoid arthritis, osteoarthritis, an ocular condition (e.g., macular degeneration), diabetes, Alzheimer's Disease, cerebral ischemia, endometriosis, fibrin-invasive activity, angiogenesis, or capillary tube formation) an anti-MMP-14 antibody, conjugated to a detectable marker; (ii) exposing the subject to a means for detecting said detectable marker to the MMP-14 expressing tissues or cells. For example, the subject is imaged, e.g., by NMR or other tomographic means.\n\n\n \n \n \n \nExamples of labels useful for diagnostic imaging include radiolabels such as \n131 \nI, \n111\nIn, \n123\nI, \n99m\nTc, \n32\nP, \n125\nI, \n3\nH, \n14\nC, and \n188\nRh, fluorescent labels such as fluorescein and rhodamine, nuclear magnetic resonance active labels, positron emitting isotopes detectable by a positron emission tomography (“PET”) scanner, chemiluminescers such as luciferin, and enzymatic markers such as peroxidase or phosphatase. Short range radiation emitters, such as isotopes detectable by short range detector probes can also be employed. The protein can be labeled with such reagents; for example, see Wensel and Meares, 1983\n, Radioimmunoimaging and Radionnmunotherapy\n, Elsevier, New York for techniques relating to the radiolabeling of antibodies and D. Colcher et al., 1986\n, Meth. Enzymol. \n121: 802 816.\n\n\n \n \n \n \nThe binding protein can be labeled with a radioactive isotope (such as \n14\nC, \n3\nH, \n35\nS, \n125\nI, \n32\nP, \n131\nI). A radiolabeled binding protein can be used for diagnostic tests, e.g., an in vitro assay. The specific activity of a isotopically-labeled binding protein depends upon the half life, the isotopic purity of the radioactive label, and how the label is incorporated into the antibody.\n\n\n \n \n \n \nIn the case of a radiolabeled binding protein, the binding protein is administered to the patient, is localized to cells bearing the antigen with which the binding protein reacts, and is detected or “imaged” in vivo using known techniques such as radionuclear scanning using e.g., a gamma camera or emission tomography. See e.g., A. R. Bradwell et al., “Developments in Antibody Imaging”, \nMonoclonal Antibodies Jar Cancer Detection and Therapy\n, R. W. Baldwin et al., (eds.), pp 65 85 (Academic Press 1985): Alternatively, a positron emission transaxial tomography scanner, such as designated Pet VI located at Brookhaven National Laboratory, can be used where the radiolabel emits positrons (e.g., \n11\nC, \n18\nF, \n15\nO and \n13\nN).\n\n\n \n \n \n \nMRI Contrast Agents. Magnetic Resonance Imaging (MRI) uses NMR to visualize internal features of living subject, and is useful for prognosis, diagnosis, treatment, and surgery, MRI can be used without radioactive tracer compounds for obvious benefit. Some MRI techniques are summarized in EP-A-0 502 814. Generally, the differences related to relaxation time constants T1 and T2 of water protons in different environments is used to generate an image. However, these differences can be insufficient to provide sharp high resolution images.\n\n\n \n \n \n \nThe differences in these relaxation time constants can be enhanced by contrast agents. Examples of such contrast agents include a number of magnetic agents paramagnetic agents (which primarily alter T1) and ferromagnetic or superparamagnetic (which primarily alter 12 response). Chelates EDTA, DTPA and NTA chelates) can be used to attach (anti reduce toxicity) of some paramagnetic substances (e.g., Fe\n3+\n, Mn\n+2\n, Gd\n+3\n). Other agents can be in the form of particles. e.g., less than 10 mm to about 10 nM in diameter). Particles can have ao ferromagnetic, anti ferromagnetic, or superparamagnetic properties. Particles can include, e.g., magnetite (Fe\n3\nO\n4\n), γ-Fe\n2\nO, ferrites, and other magnetic mineral compounds of transition elements. Magnetic particles may include: one or more magnetic crystals with and without nonmagnetic material. The nonmagnetic material can include synthetic or natural polymers (such as sepharose, dextran, dextrin, starch and the like.\n\n\n \n \n \n \nThe MMP-14 binding protein can also be labeled with an indicating group containing of the NMR active \n19\nF atom, or a plurality of such atoms inasmuch as (i) substantially all of naturally abundant fluorine atoms are the \n19\nF isotope and, thus, substantially all fluorine containing compounds are NMR active; (ii) many chemically active poly fluorinated compounds such as trifluoracetic anhydride are commercially available at relatively low cost; and (iii) many fluorinated compounds have been found medically acceptable for use in humans such as the perfluorinated polyethers utilized to carry oxygen as hemoglobin replacements. After permitting such time for incubation, a whole body MRI is carried out using an apparatus such as one of those described by Pykett, 1982\n, Sci. Am. \n246:78 SS to locate and image tissues expressing MMP-14.\n\n\n \n \n \n \nThe contents of all references, pending patent applications and published patents, cited throughout this application are hereby expressly incorporated by reference. The following examples provide further illustrate and are not limiting.\n\n\n \nEXAMPLES\n\n\nExample 1\n\n\nSelection and Screening of Anti-MMP-14 Fabs and IgGs\n\n\n \n \n \nTwo strategies were employed to identify anti-MMP-14 antibodies. Strategy 1: A 100-fold excess of the FAB310 library (e.g., an amount of the library that should contain 100 copies of each library member) was depicted of streptavidin-binding antibodies by incubating the library with 200 μL of streptavidin beads for 1 hour at room temperature (RT) with rotation. 500 nM of biotinylated MMP-14 was coupled to streptavidin beads by incubation with 100 μL of streptavidin beads. The MMP-14 beads were then incubated with the streptavidin-depleted library for 1 hour at RT with rotation. The beads were then rinsed three times with 2% MTRIS/0.1% Tween, transferred to a fresh tube and washed an additional three times with 2% mTRIS/0.1% Tween, and transferred to a fresh tube and washed a final time with \nRound\n 1 TRIS buffer (50 mM TRIS; 50 mM CaCl\n2\n; 150 mM NaCl, pH 7.5).\n\n\n \n \n \n \nMMP-14 binding antibodies were (Muted from the beads by re-suspension in 1 \nmL\n 2% MTRIS containing 2.5 μM TIMP-2 and incubation for 1 hour at RT with rotation. The beads were then washed three times with 2% MTRIS/0.1% Tween, transferred to a fresh tube and washed three times with TRIS/0.1% Tween, and transferred to a fresh tube and washed a final time with TRIS. 1 mL output was used for infection of 9 mL TG1 bacteria (grown to OD\n600\n=0.5). The beads were further eluted by suspension in 1 \nmL\n 100 mM TEA for 10 minutes. The supernatant was neutralized with 500 μl TRIS/HCl pH 7.5, 1 mL of the second elution was used for infection of 9 mL TG1 bacteria (grown to OD\n600\n=0.5).\n\n\n \n \n \n \nInfections were carried out for 30 minutes at 37° C. in water bath, then amplified in a total volume of 25 \nmL\n 2×TY/AG at 30° C. overnight with 250 RPM shaking.\n\n\n \n \n \n \nTwo additional rounds of selection were carried out under the same conditions as the first round, except that the streptavidin beads were loaded with 100 nM biotinylated MMP-14 and the number of washes were doubled (6 times with 2% MTRIS/0.1% Tween, 6 times with TRIS/0.1% Tween and 2 times with TRIS), and \nRound\n 2/3 Tris buffer (50 \nmM TRIS\n 5 mM CaCl\n2\n; 150 mM NaCl pH=7.5) was used for incubation and wash.\n\n\n \n \n \n \nStrategy II: Round I-strategy II on bMMP-14 with depletion on Carboxilic beads-TIMP-2-bMMP-14 complex.\n\n\n \n \n \n \nTIMP-2 was coupled to carboxylic beads, then complexed with a combination of biotinylated MMP-14 (500 nM each). The complexed beads were incubated with a 100 fold excess of FAB310 library that had been previously depleted by incubation with streptavidin beads and carboxylic heads. Elution/washing was carried out as for \nStrategy\n 1.\n\n\n \n \n \n \nTwo additional rounds of selection were carried out, essentially as described for \nStrategy\n 1 except that only 100 nM of each or MMP-14 were used in the bead complexes.\n\n\n \nPre Screening Phage ELISA\n\n\n \n \n \n384-well plates were coated with biotinylated BSA (2 μg/ml in 50 mM TRIS: 5 mM NaCl\n2\n; 150 mM NaCl, pH 7.5), then washed 3 times with 50 mM TRIS; 5 mM CaCl\n2\n; 150 mM NaCl, pH 7.5; 0.1% Tween. Streptavidin was captured on the coated plates by incubation with 10 μg/mL streptavidin in 50 mM TRIS mM CaCl\n2\n; 150 mM NaCl pH 7.5: 0.5% Gelatin, followed by a wash with 50 mM TRIS; 5 \nmM CaCl\n \n \n \n2 \n150 mM; 0.1% Tween. On the day the assay was to be performed, biotinylated MMP-14 (1 μg/ml) was captured in 50 mM TRIS; 5 mM CaCl\n2\n; 150 mM NaCl, pH 7.5.\n\n\n \n \n \n \n95 clones were picked from each of \nRound\n 2 and \nRound\n 3 of each selection strategy, producing 12 masterplates. ELISA was run on the MiniTrak-5 deck according to SOP.\n\n\n \n \n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 4\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nPhage on Fab ELISA pre-screening\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nRound\n\n\nStrategy\n\n\nHitrate > 3 BG\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nM0003 - R2\n\n\nI - TIMP elution\n\n\n61/95\n\n\n\n\n\n\n \n\n\nM0004 - R2\n\n\nI - \nTEA elution\n \n\n\n32/95\n\n\n\n\n\n\n \n\n\nM0006 - R2\n\n\nII\n\n\n27/95\n\n\n\n\n\n\n \n\n\nM0009 - R3\n\n\nI - TIMP elution\n\n\n86/95\n\n\n\n\n\n\n \n\n\nM0010 - R3\n\n\nI - TEA elution\n\n\n73/95\n\n\n\n\n\n\n \n\n\nM0012 - \nR3\n \n \nII\n \n \n\n\n63/95\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \nExample 2\n\n\nDNA Sequences Of MMP-14 Binding Anti-MMP-14 Fabs\n\n\n \n \n \nExemplary Fabs that bind to human MMP-14 were identified and designated as: M0030-A04, M0030-D08, M0031-A02, M0031. A04, M0031-C02, M0031-F01, M00314110, M 0032-B07, M0032-1309, M0033-F02, M0033-H07, M0035-F02, M0036-D02, M0036-F02, M0036-H08, M0037-A08, M0037-1310, M0037-H093, M0037-009, M0037-D01, M0037-H09, M0038-B06, M0038-F08, M0039-B06, M0038-D06, M0038-E05, M0038-E06, M0038-E12, M0038-F01, M0038-F08, M0038-H06, M0039-B07, M0039-D02, M0039-D10, M0039-G05, M0039-G07, M0039-H08, M0040-A03, M0040-A06, M0040-A08, M0040-A11, M0040-B06, M0040-1308, M0040-C10, M0040-D08, M0040-F03, M0040-G04, M00404-104, M0040-H09, M0041-A05, M0041-B03, M0041-B11, M0041-C11, M0041-D03, M0041-D08, M0041-E11, M0041-H09, M0041-H11, M0042-1307, M0042-G12, M0043-A09, M0043-C03, M0043-F01, M0043-G01, M0043-G02, M0044-B03, M0044-D08, M0044-E01, and M0044-E05. The DNA sequences of these Fab light chain variable regions (LV) and heavy chain variable regions (HV) are shown in Table 5.\n\n\n \n \n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 5\n\n\n\n\n\n\n \n\n\n\n\n\n\nDNA sequences of variable regions of\n\n\n\n\n\n\nMMP-14 binding antibodies\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n> M0030-A04 LV\n\n\n\n\n\n\nCAG AGC GAA TTG ACT CAG CCA CCC TCA GCG TCT GGG\n\n\n\n\n\n\nACC CCC GGG CAG AGG GTC ACT ATC TCT TGT TCT GGA\n\n\n\n\n\n\nAGC AGC TCC AAC ATC GGA ATT AAT TTT GTT ACC TGG\n\n\n\n\n\n\nTAC CAG CAG CTC CCA GGA ACG GCC CCC AAA CTC CTC\n\n\n\n\n\n\nATC TAT ACT AAT AAT CAG CGG CCC TCT GGG GTC CCT\n\n\n\n\n\n\nGAC CGA TTC TCT AGC TCC AAG TCT GGC GCC TCA GCC\n\n\n\n\n\n\nTCC CTG GCC ATC AGT GGG CTC CAG TCT GAG GAT GAG\n\n\n\n\n\n\nGCT GCT TAT TAC TGT GCA GCA TGG GAT GAC AAC CTG\n\n\n\n\n\n\nAAC GGT CCG GTG TTC GGC GGC GGG ACC AAG CTG ACC\n\n\n\n\n\n\nGTC CTA (SEQ ID NO: 6)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0030-A04 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT GTT TAC GAG ATG AAT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC TAT TCT TCT GGT GGC CGT ACT GAT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA GAG GCC CAT TAC TAT GAT AGT AGT GGT CCG\n\n\n\n\n\n\nCCT GAC TAC TGG GGC CAG GGA ACC CTG GTC ACC GTC\n\n\n\n\n\n\nTCA AGC (SEQ ID NO: 7)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0030-D08 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG\n\n\n\n\n\n\nTCT GCA TCT GTA GGA GAC AGA GTC ACC ATG ACT TGC\n\n\n\n\n\n\nCGG GCA GGT CAG AAC ATT AAA TCC TAT TTA AAT TGG\n\n\n\n\n\n\nTAT CAG CAG AAG CCA GGG AAA GCC CCT CAG GTC CTG\n\n\n\n\n\n\nATC TAT GCT GCA TCC ACT TTA CAA AGT GGG GTC TCA\n\n\n\n\n\n\nTCA AGG TTC CGT GGC AGT GGA TCT GGG ACA CAT TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGC GAT CTG CAA CCT GGA GAT TCT\n\n\n\n\n\n\nGCG ACT TAC TAC TGT CAA CAA AGT TTC AGT ACC CCT\n\n\n\n\n\n\nCGC AGT TTT GGC CAG GGG ACC AAG CTG GAG ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 8)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0030-D08 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT ATT TAC CAG ATG TAT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC GTT CCT TCT GGT GGC CTT ACT AAG TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA GAG AGA TTA CGA TAT TTT GAC TGG TCA GAT\n\n\n\n\n\n\nCGT GTG GGG GAA TCG GGT GAC TAC TGG GGC CAG GGA\n\n\n\n\n\n\nACC CTG GTC ACC GTC TCA AGC (SEQ ID NO: 9)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0031-A02 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG\n\n\n\n\n\n\nTCT GCA TCT GTA GGA GAC AGA GTC ACC GTC ACT TGC\n\n\n\n\n\n\nCGG GCA AGT CAG AGC ATT AGC AGT TAT TTA AAT TGG\n\n\n\n\n\n\nTAT CAG CAG AAA CCA GGG AAA GCC CCT AAA CTC CTG\n\n\n\n\n\n\nATC TAT GCT GCA TCC AGT TTG CAA AGT GGG GTC CCA\n\n\n\n\n\n\nTCA AGG TTC AGT GGC AGT GGA TCT GGG ACA GAT TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGC AGT CTG CAA CCT GAA GAT TTT\n\n\n\n\n\n\nGCA ACT TAC TAC TGT CAA CAG AGT TAC AGT ATC CCG\n\n\n\n\n\n\nCTC ACT TTC GGG GGA GGG ACC AAG GTG GCG ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 10)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0031-A02 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TCC TCT AAT TAC TGG ATG CTT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT GGT ATC GTT TCT TCT GGT GGC CGT ACT AAT TAT\n\n\n\n\n\n\nGGT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGG TTT AGC AGC TCG TTA GGG GCT TTT GAT ATC\n\n\n\n\n\n\nTGG GGC CAA GGG ACA ATG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 11)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0031-A04 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA GGC ACC CTG\n\n\n\n\n\n\nTCA TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC\n\n\n\n\n\n\nAGG GCC AGT CAG AGT CTT AGG AAC AGC TAC TTA GCC\n\n\n\n\n\n\nTGG TAT CAG CAG AAA CCT GGC CAG GCT CCC AGG CTC\n\n\n\n\n\n\nCTC ATC TAT GAT GCA TCC AAC AGG GCC ACT GGC ATC\n\n\n\n\n\n\nCCA GCC AGG TTC AGT GGC AGT GGG TCT GGG ACA GAC\n\n\n\n\n\n\nTTC ACT CTC ACC ATC AGC AGC CTA GAG CCT GAA GAT\n\n\n\n\n\n\nTTT GCA GTT TAT TAC TGT CAG CAG CGT AGC AAC TGG\n\n\n\n\n\n\nCCT CCG TAC ACT TTT GGC CAG GGG ACC AAG CTG GAG\n\n\n\n\n\n\nATC AAA (SEQ ID NO: 12)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0031-A04 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT AAT TAC GTT ATG CTT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC CGT CCT TCT GGT GGC CCT ACT AAG TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCT AGG GAC TGG CCC TCT TAC TAC TAC TAC GGT ATG\n\n\n\n\n\n\nGAC GTC TGG GGC CAA GGG ACC ACG GTC ACC GTC TCA\n\n\n\n\n\n\nAGC (SEQ ID NO: 13)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0031-C02 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA CTC TCC CTG\n\n\n\n\n\n\nCCC GTC ACC CCT GGA GAG CCG GCC TCC ATC TCC TGC\n\n\n\n\n\n\nAGG TCT AGT CAG AGC CTC CTG CAT AGT AAT GGA TAC\n\n\n\n\n\n\nTAC TAT TTG GAT TGG TAC CTG CAG AAG CCA GGG CAG\n\n\n\n\n\n\nTCT CCA CAA CTC CTG ATC TAT TTG GGT TCT TAT CGG\n\n\n\n\n\n\nGCC TCC GGG GTC CCT GAC AGG TTC AGT GGC AGT GGA\n\n\n\n\n\n\nTCA GGC ACA GAT TTT ACA CTG AAA ATC AGC AGT GTG\n\n\n\n\n\n\nGAG GCT GAA GAT GTT GGG GTT TAT TAC TGC ATG CAA\n\n\n\n\n\n\nGCT CTA CAA ACT CCT CTC ACT TTC GGC GGA GGG ACC\n\n\n\n\n\n\nAGG GTG GAC ATC AAA (SEQ ID NO: 14)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0031-C02 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CCT TAC CCT ATG GGT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC GTT TCT TCT GGT GGC CTT ACT CTT TAC\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACT GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA GGG GGA CGG CTT TAC GAT ATT TTG ACT GGT\n\n\n\n\n\n\nCAA GGG GCC CCG TTT GAC CAC TGG GGC CAG GGA ACC\n\n\n\n\n\n\nCTG GTC ACC GTC TCA AGC (SEQ ID NO: 15)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0031-F01 LV\n\n\n\n\n\n\nCAG AGC GAA TTG ACT CAG CCA CCC TCA GTG TCT GGG\n\n\n\n\n\n\nACC CCC GGG CAG AGG GTC ACC ATC TCT TGT TCT GGA\n\n\n\n\n\n\nACC AGC GCC AAC ATC GGA CGT AAT GCT GTA CAC TGG\n\n\n\n\n\n\nTAC CAG CAG CTC CCA GGA ACG GCC CGC AAA CTC CTC\n\n\n\n\n\n\nATT CAT AGT AAT AAC CGG CGG CCC TCA GGG GTC CCT\n\n\n\n\n\n\nGAC CGA TTC TCT GGC TCC AAG TCT GGC ACC TCA GCC\n\n\n\n\n\n\nTCC CTG GCC ATC AGT GGG CTC CAG TCT GAG GAT GAG\n\n\n\n\n\n\nGCT GAT TAT TAC TGT GCA GCA TGG GAG AAC AGC CTG\n\n\n\n\n\n\nAAT GCC TTT TAT GTC TTC GGA ACT GGG ACC AAG GTC\n\n\n\n\n\n\nACC GTC CTA (SEQ ID NO: 16)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0031-F01 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT ACT TAC GAG ATG CAT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC TAT TCT TCT GGT GGC TGG ACT GGT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA TCT CAA CAG TAT TAC GAT TTT TCC TCT CGC\n\n\n\n\n\n\nTAC TAC GGC ATG GAC GTC TGG GGC CAA GGG ACC ACG\n\n\n\n\n\n\nGTC ACC GTC TCA AGC (SEQ ID NO: 17)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0031-H10 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG\n\n\n\n\n\n\nTCT GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC\n\n\n\n\n\n\nCGG GCA AGT CAG AGC ATT AGC AGC TAT TTA AAT TGG\n\n\n\n\n\n\nTAT CAG CAG AAA CCA GGG AAA GCC CCT AAG CTC CTG\n\n\n\n\n\n\nATC TAT GCT GCA TCC AGT TTG CAA AGT GGG GTC CCA\n\n\n\n\n\n\nTCA AGG TTC AGT GGC AGT GGA TCT GGG ACA GAT TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGC AGT CTG CAA CCT GAA GAT TTT\n\n\n\n\n\n\nGCA ACC TAC TTC TGC CAA CAG AGT TAT AGT AAT CCT\n\n\n\n\n\n\nTTC ACT TTC GGC CCT GGG ACC AAA GTG GAT ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 18)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0031-H10 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CAG TAC GTT ATG TGG TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC GTT CCT TCT GGT GGC GTT ACT AAG TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AAA GAC GTC TTC GGT AGT ATT GGT TAT TAC TAC\n\n\n\n\n\n\nGTA CCG TTT TTT GAC TAC TGG GGC CAG GGA ACC CTG\n\n\n\n\n\n\nGTC ACC GTC TCA AGC (SEQ ID NO: 19)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0032-B07 LV\n\n\n\n\n\n\nCAG AGC GTC TTG ACT CAG GAG CCC TCA TTG ACT GTG\n\n\n\n\n\n\nTCC CCA GGA GGG ACA GTC ACT CTC ACC TGT GCT TCC\n\n\n\n\n\n\nAAC ACT GGA GCA GTC ACC AGT GGT TCC TAT GCA AAC\n\n\n\n\n\n\nTGG TTC CAG CAA AAA CCT GGA CTA ACA CCC AGG GCA\n\n\n\n\n\n\nCTG ATT TAT AGT GGA ACT AAC AAA TAT TCG TGG ACC\n\n\n\n\n\n\nCCT GCC CGA TTC TCA GGC TCC CTC TTT GGG GGC AAG\n\n\n\n\n\n\nGCA GCC CTG ACA CTG TCA GGT GTG CTG CCT GAG GAC\n\n\n\n\n\n\nGAG GCT GAG TAT TAC TGC CTC GTC TAC TAT GGT GGT\n\n\n\n\n\n\nGTT TGG GTG TTC GGC GGA GGG ACC AAG CTG ACC GTC\n\n\n\n\n\n\nCTA (SEQ ID NO: 20)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0032-B07 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CCT TAC CTT ATG CAT TGG\n\n\n\n\n\n\nGTT CGC CAA GGT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC TAT CCT TCT GGT GGC ATT ACT CAG TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA TTT TTC CCT AGT CAC AGG GAC TAT ACG GCG\n\n\n\n\n\n\nTTC GAC ACC TGG GGC CGG GGA ACC CTG GTC ACC GTC\n\n\n\n\n\n\nTCA AGC (SEQ ID NO: 21)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0032-B09 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCT TCC GTG\n\n\n\n\n\n\nTCT GCA TCT GTT GGA GAC ACA GTC ACC ATC ACC TGT\n\n\n\n\n\n\nCGG GCG AGT CAG CGT ATT AGC ACC TGG TTA GCC TGG\n\n\n\n\n\n\nTAT CAG CAC AAA CCA GGG AAA GCC CCT AAA CTC CTC\n\n\n\n\n\n\nATA TAT GCT GGA CCC AGT TTG CAG AGT GGG GTC CCA\n\n\n\n\n\n\nTCA AGG TTC AGC GGC AGT GGA TCT GGG ACA GAA TTC\n\n\n\n\n\n\nACT CTC ACA ATC AGC AGC CTG CAC CCT GAA GAT TTT\n\n\n\n\n\n\nGCA ACT TAT TAC TGT CAA CAA CTT AAT CAC TAC CCG\n\n\n\n\n\n\nATG ACC TTC GGC CAA GGG ACA CGA CTG GAG ATT AAA\n\n\n\n\n\n\n(SEQ ID NO: 22)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0032-B09 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT ATT TAC AAG ATG GTT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC GGT TCT TCT GGT GGC CAT ACT CGT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA GCT CCT TAC TAC TAC TAC ATG GAC GTC TGG\n\n\n\n\n\n\nGGC AAA GGG ACC ACG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 23)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0033-F02 LV\n\n\n\n\n\n\nCAG AGC GTC TTG ACT CAG CCT GCC TCC GTG TCT GGG\n\n\n\n\n\n\nTCT CCT GGA CAG TCG ATC ACC ATC TCC TGC ACT GGA\n\n\n\n\n\n\nACC AGC AGT GAC GTT GGT GGT TAT AAC TAT GTC TCC\n\n\n\n\n\n\nTGG TAC CAA CAA CAC CCA GGC AAA GCC CCC AAA CTC\n\n\n\n\n\n\nATG ATT TAT GAT GTC AGT AAT GGG CCC TCA GGG GTT\n\n\n\n\n\n\nTCT AAT CGC CTC TCT GGC TCC AAG TCT GGC AAC ACG\n\n\n\n\n\n\nGCC TCC CTG ACC ATC TCT GGG CTC CAG GCT GAG GAC\n\n\n\n\n\n\nGAG GCT GAT TAT TAC TGC AGC TCA TAT ACA AGC AGC\n\n\n\n\n\n\nAGC ACA GGT GTT CGG CGG AGG GAC CAA GCT GAC CGT\n\n\n\n\n\n\nCCT A (SEQ ID NO: 24)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0033-F02 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CAG TAC GCT ATG AAT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TGG ATC GTT TCT TCT GGT GGC TAT ACT CAT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ATG GCT GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGC CTC GTA GCA GCT CGT AAA CTT GAC TAC TGG\n\n\n\n\n\n\nGGC CAG GGC ACC CTG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 25)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0033-H07 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG\n\n\n\n\n\n\nTCT GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC\n\n\n\n\n\n\nCGG GCG AGT CAG GGC ATT AGG AAT TTT TTA GCC TGG\n\n\n\n\n\n\nTAT CAG CAG AAA CCA GGG AAA GTT CCT AAG CTC CTG\n\n\n\n\n\n\nGTC TTT GGT GCA TCC GCT TTG CAA TCG GGG GTC CCA\n\n\n\n\n\n\nTCT CGG TTC AGT GGC AGT GGA TCT GGG ACA GAT TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGC GGC CTG CAG CCT GAG GAT GTT\n\n\n\n\n\n\nGCA ACT TAT TAC TGT CAA AAG TAT AAC GGT GTC CCG\n\n\n\n\n\n\nCTC ACT TTC GGC GGA GGG ACC AAG GTG GAG ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 26)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0033-H07 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT GTT TAC GGT ATG GTT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT GTT ATC TCT TCT TCT GGT GGC TCT ACT TGG TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACC GCC TTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA CCG TTC AGT AGA AGA TAC GGC GTC TTT GAC\n\n\n\n\n\n\nTAC TGG GGC CAG GGC ACC CTG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 27)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0035-F02 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA GCC ACC CTG\n\n\n\n\n\n\nTCT TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC\n\n\n\n\n\n\nAGG GCC AGT CAG AGT GTT AGC AAT TAC TTA GCC TGG\n\n\n\n\n\n\nTAC CAA CAA AAA CCT GGC CAG GCT CCC AGG CTC CTC\n\n\n\n\n\n\nATC TAT GAT GCA TCC AAC AGG GCC ACT GGC ATC CCA\n\n\n\n\n\n\nGCC AGG TTC AGT GGC AGT GGG TCT GGG ACA GAC TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGC AGC CTA GAG CCT GAA GAT TTT\n\n\n\n\n\n\nGCA GTT TAT TAC TGT CAG CAG CGT AGC AAC TGG CCG\n\n\n\n\n\n\nCTC ACT TTC GGC GGA GGG ACC AAG GTG GAG ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 28)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0035-F02 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT TTT TAC CGT ATG GAG TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC GTT CCT TCT GGT GGC TTT ACT CGT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA TTT CAC GTA TTA CGA TAT TTT GAC TGG TTT\n\n\n\n\n\n\nGGT AAC ACC CAG GAT ACT GAT GCT TTT GAT ATC TGG\n\n\n\n\n\n\nGGC CAG GGC ACC CTG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 29)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0036-D02 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA GCC ACC CTG\n\n\n\n\n\n\nTCT TTG TCT CCA GGG GAA AAA GCC ACC CTC TCC TGC\n\n\n\n\n\n\nAGG GCC AGT CAG ACT GTT TAC AAC TAC TTA GCC TGG\n\n\n\n\n\n\nTAC CAG CAA AAA CCT GGC CAG GCT CCC AGG CTC CTC\n\n\n\n\n\n\nATC TAT GAC GCA TTC AAC AGG GCC ACT GGC ATC CCT\n\n\n\n\n\n\nGCC AGG TTC AGT GGC AGT GGG TCT GGG ACA GAC TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGC AGC CTG GAG CCT GAA GAT TTT\n\n\n\n\n\n\nGCA GTT TAT TAC TGT CAG CAG CGT GGC AAC TGG CCC\n\n\n\n\n\n\nCGG ACG TTC GGC CAA GGG ACC AAG GTG GAA ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 30)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0036-D02 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT TTT TAC AAG ATG ACT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT GGT ATC TAT CCT TCT GGT GGC CGT ACT GTT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACC GCC ATG TAT TAC TGT\n\n\n\n\n\n\nGCA AGA GGG CCC CAT TAC TAT GAT AGC CCG GGT GCT\n\n\n\n\n\n\nTTT GAT ATC TGG GGC CAA GGG ACA ATG GTC ACC GTC\n\n\n\n\n\n\nTCA AGC (SEQ ID NO: 31)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0036-F02 LV\n\n\n\n\n\n\nCAG TAC GAA TTG ACT CAG CCA CCC TCG TTG TCC GTG\n\n\n\n\n\n\nTCC CCA GGA CAG ACA GCC AGC ATC ACC TGC TCT GGA\n\n\n\n\n\n\nGAG AAA TTG GGG GAA AAA TTT GCT TCC TGG TAT CAA\n\n\n\n\n\n\nCGG AGG CCC GGC CAG TCT CCT CTA TTG ATC ATC TAT\n\n\n\n\n\n\nCAG GAT AAC AAG CGG CCC TCA GGG ATC CCT GAG CGG\n\n\n\n\n\n\nTTC TCT GGC TCC AAT TCT GGA AAC ACA GCC GCT CTG\n\n\n\n\n\n\nACC ATC ACC GGG ACC CAG GCT ATG GAT GAC GCT GAC\n\n\n\n\n\n\nTAT TAC TGT CAG GGG TGG GAG AGC ACC ACA GCG GTC\n\n\n\n\n\n\nTTC GGC GGA GGG ACC AAG TTG ACC GTC GTA\n\n\n\n\n\n\n(SEQ ID NO: 32)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0036-F02 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CGT TAC ACT ATG GGT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT CGT ATC TAT TCT TCT GGT GGC AAT ACT GTT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACA GCC ACA TAT TAC TGT\n\n\n\n\n\n\nGCA CGG ACC CGT AGA GAT GGC TAC AAC CCC TTT GAC\n\n\n\n\n\n\nTAC TGG GGC CAG GGA ACC CTG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 33)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0036-H08 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG\n\n\n\n\n\n\nTCT GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC\n\n\n\n\n\n\nCGG GCA AGT CAG AGC ATT AGC AGC TAT TTA AAT TGG\n\n\n\n\n\n\nTAT CAG CAG AAA CCA GGG AAA GCC CCT AAG CTC CTG\n\n\n\n\n\n\nATC TAT GCT GCA TCC AGT TTG CAA AGT GGG GTC CCA\n\n\n\n\n\n\nTCA AGG TTC AGT GGC AGT GGA TCT GGG ACA GAT TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGC AGT CTG CAA CCT GAA GAT TTT\n\n\n\n\n\n\nGCA ACT TAC TAC TGT CAA CAG AGT TAC AGT CTC CCC\n\n\n\n\n\n\nGTG ACG TTT GGC CAA GGG TCC AAG GTG GAA ATC AAA\n\n\n\n\n\n\nCGA ACT (SEQ ID NO: 34)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0036-H08 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CGT TAC TGG ATG GTT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TAT ATC TAT TCT TCT GGT GGC ATG ACT GGT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCA AGG GGG GGG GAA TAT AGT GGT TTC TTA GGG GTT\n\n\n\n\n\n\nTGG GGC CAG GGC ACC CTG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 35)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0037-A08 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCT TCC GTG\n\n\n\n\n\n\nTCT GGT TCT GTA GGA GAC AGA GTC ACC ATC ACT TGT\n\n\n\n\n\n\nCGG GCG AGT CAG GGT GTT AGC AGT TAC TTA GCC TGG\n\n\n\n\n\n\nTAT CAG CAG AAA CCA GGG AAA GGC CCT AAG CTC CTG\n\n\n\n\n\n\nATC TAT GGT GCA TCC ACT TTG CAA AAT GGG GTC CCA\n\n\n\n\n\n\nTCA AGG TTC AGC GGC AGT GGA TCT GGG ACA GAT TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGC AGC CTG CAG CCT GAA GAT TTT\n\n\n\n\n\n\nGCG ACT TAC CAT TGT CAA CAG GTT CAC AGT TTC CCT\n\n\n\n\n\n\nCCG ACG TTC GGT CAG GGG ACC AAG GTG GAA ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 36)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0037-A08 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CAT TAC ATG ATG ATG TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT GGT ATC TCT TCT TCT GGT GGC CGT ACT GGT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGT TTC GGG AAT AGT GGG AGC TAC TCT TGG CGT\n\n\n\n\n\n\nGCT TTT GAT ATC TGG GGC CAA GGG ACC ACG GTC ACC\n\n\n\n\n\n\nGTC TCA AGC (SEQ ID NO: 37)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0037-B10 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG\n\n\n\n\n\n\nTCT GCA TCT GTG GGA GAC AGA GTC GCC ATC ACT TGC\n\n\n\n\n\n\nCGC GCA AGT CAG AGC ATC GAC ACC TAT TTA AAT TGG\n\n\n\n\n\n\nTAT CAG CAG AAA CCA GGG AAA GCC CCT AAA CTC CTG\n\n\n\n\n\n\nATC TAT GCT GCA TCC AAG TTG GAA GAC GGG GTC CCA\n\n\n\n\n\n\nTCA AGA TTC AGT GGC AGT GGA ACT GGG ACA GAT TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGA AGT CTG CAA CCT GAA GAT TTT\n\n\n\n\n\n\nGCA AGT TAT TTC TGT CAA CAG AGC TAC TCT AGT CCA\n\n\n\n\n\n\nGGG ATC ACT TTC GGC CCT GGG ACC AAG GTG GAG ATC\n\n\n\n\n\n\nAAA (SEQ ID NO: 38)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0037-B10 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT GTT TAC TAT ATG GGT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TAT ATC GGT TCT TCT GGT GGC TGG ACT GAG TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA GAC CTC TCG GCA GTG GCT GGT CTA GGG GGT\n\n\n\n\n\n\nGCT TTT GAT ATC TGG GGC CAA GGG ACA ATG GTC ACC\n\n\n\n\n\n\nGTC TCA AGC (SEQ ID NO: 39)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0037-C03 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCT TCC GTG\n\n\n\n\n\n\nTCT GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGT\n\n\n\n\n\n\nCGG GCG AGT CAG GGT ATT AGC AGC TGG TTA GCC TGG\n\n\n\n\n\n\nTAT CAG CAG AAA CCA GGG AAA GCC CCT AAG CTC CTG\n\n\n\n\n\n\nATC TAT GCT GCA TCC AGT TTG CAA AGT GGG GTC CCA\n\n\n\n\n\n\nTCA AGG TTC AGC GGC AGT GGA TCT GGG ACA GAT TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGC AGC CTG CAG CCT GAA GAT TTT\n\n\n\n\n\n\nGCA ACT TAC TAT TGT CAA CAG GCT AAC AGT TTC CCC\n\n\n\n\n\n\nTTC GTA ACT TTT GGC CAG GGG ACC AAG CTG GAG ATC\n\n\n\n\n\n\nAAA (SEQ ID NO: 40)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0037-C03 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT ATG TAC CTT ATG ATT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT GTT ATC TCT TCT TCT GGT GGC CAG ACT AAA TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA ACC GAT TTG ACT GGT TAT TCA GCG GGA GCT\n\n\n\n\n\n\nTTT GAT ATC TGG GGC CAA GGG AGA ATG GTC ACC GTC\n\n\n\n\n\n\nTCA AGC (SEQ ID NO: 41)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0037-C09 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA CTC TCC CTG\n\n\n\n\n\n\nCCC GTC ACC CTT GGA GAG TCG GCC TCC GTC TCC TGC\n\n\n\n\n\n\nAGG TCT AGT CAG AGC CTC CTT CAT GAA AAT GGA CAC\n\n\n\n\n\n\nAAC TAT TTG GAT TGG TAC CTG CAG AAG CCA GGG CAG\n\n\n\n\n\n\nTCT CCA CAG CTC CTG ATC TAT TTG GGT TCT AAT CGG\n\n\n\n\n\n\nGCC TCC GGG GTC CCT GAC AGG TTC AGT GGC AGT GGA\n\n\n\n\n\n\nTCA GGC ACA GAT TTT ACA CTG AAA ATC AGC AGA GTG\n\n\n\n\n\n\nGAG GCT GAG GAT GTT GGG GTT TAT TAC TGC ATG CAA\n\n\n\n\n\n\nTCT CTA AAG ACT CCT CCG ACG TTC GGC CCA GGG ACC\n\n\n\n\n\n\nAAG GTG GAA ATC AAA (SEQ ID NO: 42)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0037-C09 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CAT TAC GAG ATG TTT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC TCT CCT TCT GGT GGC CAG ACT CAT TAT\n\n\n\n\n\n\nGTT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACT GTC GTG TAT TAC TGT\n\n\n\n\n\n\nGCC ACA GAT CGG ACG TAT TAC GAT TTT TGG AGT GGT\n\n\n\n\n\n\nTAT GGG CCC CTG TGG TAC TGG GGC CAG GGA ACC CTG\n\n\n\n\n\n\nGTC ACC GTC TCA AGC (SEQ ID NO: 43)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0037-D01 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG\n\n\n\n\n\n\nTCT GCA TCT GTC GGA GAC AGA GTC ACC ATC ACT TGC\n\n\n\n\n\n\nCGG GCA AGT CAG GGC ATT AGA AAT GAT TTA GGC TGG\n\n\n\n\n\n\nTAT CAG CAG AAA CCA GGG AAA GCC CCT AAG CGC CTG\n\n\n\n\n\n\nATC TAT GTT GCA TCC AGT TTG CAA AGT GGG GTC CCA\n\n\n\n\n\n\nTCA AGG TTC AGC GGC AGT GGA TCT GGG ACA GAA TTC\n\n\n\n\n\n\nACT CTC ACA ATC AGC AGC CTG CAG CCT GAA GAT TTT\n\n\n\n\n\n\nGCA ACT TAT TAC TGT CTA CAG CAT AAT AGT TAC CCG\n\n\n\n\n\n\nTGG ACG TTC GGC CAA GGG ACC AAG GTG GAA ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 44)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0037-D01 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT ATG TAC ATG ATG ATT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC TAT CCT TCT GGT GGC AAT ACT ATG TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCC ACA GGT GTA TTA CGA TAT TTT GAC TGG GAT GCT\n\n\n\n\n\n\nGGG AGC GGT ATG GAC GTC TGG GGC CAA GGG ACC ACG\n\n\n\n\n\n\nGTC ACC GTC TCA AGC (SEQ ID NO: 45)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0037-H09 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA CTC TCC CTG\n\n\n\n\n\n\nCCC GTC ACC CCT GGA GAG CCG GCC TCC ATC TCC TGC\n\n\n\n\n\n\nAGG TCT AGT CAG AGC CTC CTG CAT GGT AAT GGA AAC\n\n\n\n\n\n\nAAC TAT TTG GAT TGG TAC CTG CAG AAG CCA GGG CAG\n\n\n\n\n\n\nTCT CCA CAA CTC CTG ATC TAT TTG GGT TCC AAT CGG\n\n\n\n\n\n\nGCC TCC GGG GTC CCT GAC AGG TTC AGT GGC AGT GGA\n\n\n\n\n\n\nTCA GGC ACA GAT TTT ACA CTG AAA ATC AGC AGT GTG\n\n\n\n\n\n\nGAG GCT GAA GAT GTT GGC GTT TAT TAC TGC ATG CAA\n\n\n\n\n\n\nGGT CTA CAA ACT CCT CAC ACT TTT GGC CAG GGG ACC\n\n\n\n\n\n\nCAG CTG GAG ATC AAA (SEQ ID NO: 46)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0037-H09 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CGT TAC TGG ATG GAT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC CGT TCT TCT GGT GGC ATG ACT GGT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGGG AGA CAC CGT ACG GGC CGC GGG GCT TTT GAT ATC\n\n\n\n\n\n\nTGG GGC CAA GGG ACC ACG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 47)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0038-B06 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG\n\n\n\n\n\n\nTCT GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC\n\n\n\n\n\n\nCGG GCA AGT CAG AGC ATT AGC AGC TAT TTA AAT TGG\n\n\n\n\n\n\nTAT CAG CAG AAA CCA GGG AAA GCC CCT AAG CTC CTG\n\n\n\n\n\n\nATC TAT GCT GCA TCC AGT TTG CAA AGT GGG GTC CCA\n\n\n\n\n\n\nTCA AGG TTC CGT GGC AGT GGA TCT GGG ACA GAT TTC\n\n\n\n\n\n\nAGT CTC ACC ATC AGC AGT CTG CAA CCT GAA GAT TTT\n\n\n\n\n\n\nGCA ACT TAC TAC TGT CAA CAG ACT TAC AGT GGC CTT\n\n\n\n\n\n\nCCC ACT TTT GGT GGA GGG ACC GTG GTG GAG ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 48)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0038-B06 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT TCT TAC GTT ATG GGT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT GTT ATC TCT CCT TCT GGT GGC TGG ACT ACT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACA GCC ACA TAT TAC TGT\n\n\n\n\n\n\nGCG AGT CGG GGA GTG GTT ACC AAC CTT GAC TAC TGG\n\n\n\n\n\n\nGGC CAG GGA ACC CTG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 49)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0038-C05 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG\n\n\n\n\n\n\nTCT GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC\n\n\n\n\n\n\nCGG GCA AGT CAG AGC ATT AGC AGC TAT TTA AAT TGG\n\n\n\n\n\n\nTAT CAG CAG AAA CCA GGG AAA GCC CCT AAG CTC CTG\n\n\n\n\n\n\nATC TAT GCT GCA TCC AGT TTG CAA AGT GGG GTC CCA\n\n\n\n\n\n\nTCA AGG TTC AGT GGC AGT GGG TCT GGG ACA GAC TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGC AGA CTG GAG CCT GAA GAT TTT\n\n\n\n\n\n\nGCA GTG TAT TAT TGT CAG CAG TAT GGT AGC TCA CCC\n\n\n\n\n\n\nACG TTC GGC CAA GGG ACC AAG GTG GAA ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 50)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0038-C05 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT TCT TAC ATT ATG GTT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT GTT ATC TAT CCT TCT GGT GGC CCT ACT TAT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGG GAC CCC CGG CTG GAA CGT TTC TAC TTT GAC\n\n\n\n\n\n\nTAC TGG GGC CAG GGC ACC CTG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 51)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0038-C06 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA GGC ACC CTG\n\n\n\n\n\n\nTCT TTG TCT CCA GGG GAC AGA GCC ACC CTC TCC TGC\n\n\n\n\n\n\nAGG GCC AGT CAG AGT GTT GGC AGC GAC TAC TTA GCC\n\n\n\n\n\n\nTGG TAC CAG CAG AAA CCT GGC CAG GCT CCC AGG CTC\n\n\n\n\n\n\nCTC ATC TTT GCT GCG TCC ACC AGG GCC ACC GGC ATC\n\n\n\n\n\n\nCCA GAC AGG TTC AGT GGC AGT GGG TCT GCG ACA GAC\n\n\n\n\n\n\nTTC ACT CTC ACC ATC AGC AGC CTG GAA CCT GAA GAT\n\n\n\n\n\n\nTTT GCA GTG TAT TTC TGT CAG CAG TAT GCT AGC CCA\n\n\n\n\n\n\nCCT CGG ACG TTC GGC CAA GGG ACC AAG GTG GAA ATC\n\n\n\n\n\n\nAAA (SEQ ID NO: 52)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0038-C06 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT ATG TAC GGT ATG CAT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC TAT TCT TCT GGT GGC TAT ACT GGT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGG GGG AGG GCC GTT GAC CTC TGG GGC CAG GGA\n\n\n\n\n\n\nACC CTG GTC ACC GTC TCA AGC (SEQ ID NO: 53)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0038-D06 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA GCC ACC CTG\n\n\n\n\n\n\nTCT TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC\n\n\n\n\n\n\nAGG GCC AGT CAG AGT GTT AGC AGC TAC TTA GCC TGG\n\n\n\n\n\n\nTAC CAA CAG AAA CCT GGC CAG GCT CCC AGG CTC CTC\n\n\n\n\n\n\nATC TAT GAT GCA TCC AAC AGG GCC ACT GGC ATC CCA\n\n\n\n\n\n\nGCC AGG TTC AGT GGC AGT GGG TCT GGG ACA GAC TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGC AGC CTA GAG CCT GAA GAT TTT\n\n\n\n\n\n\nGCA GTT TAT TAC TGT CAG CAG CGT AGC AAC TGG CCT\n\n\n\n\n\n\nCTC ACC TTC GGC CAA GGG ACA CGA CTG GAG ATT AAA\n\n\n\n\n\n\n(SEQ ID NO: 54)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0038-D06 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TCA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT TGG TAC TAT ATG GGT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TAT ATC GGT TCT TCT GGT GGC ATG ACT GGT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACA GCC ACA TAT TAC TGT\n\n\n\n\n\n\nGCG ATG GTG GGC TTC CTC CCG ACC GTT GAC TAC TGG\n\n\n\n\n\n\nGGC CAG GGA ACC CTG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 55)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0038-E05 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCT TCT GTG\n\n\n\n\n\n\nTCT GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGT\n\n\n\n\n\n\nCGG GCG AGT CAG CAT ATT AGC AAC TGG CTA GCC TGG\n\n\n\n\n\n\nTAT CAG CAG AAA CCA GGG GAG GCC CCT AAA CTC CTG\n\n\n\n\n\n\nATC TCT GCT GCA TCC AGT TTG CAA AGT GGG GTC CCA\n\n\n\n\n\n\nTCA AGG TTC AGT GGC AGT GGA TCT GGG ACA GAT TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGC AGT CTG CAA CCT GAA GAT TTT\n\n\n\n\n\n\nGCA ACT TAC TAC TGT CAA CAG AGT TAC AGT ACC CCG\n\n\n\n\n\n\nCTC ACT TTC GGC GGA GGG ACC AAG GTG GAG ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 56\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0038-E05 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CCT TAC CAT ATG ACT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC TCT TCT TCT GGT GGC CAT ACT GAG TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG ACA GCA TGG GCG GGA TTT ACT TTT AAC GTC TGG\n\n\n\n\n\n\nGGC CAA GGG ACA ATG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 57)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0038-E06 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA GGC ACC CTG\n\n\n\n\n\n\nTCC TTG TCT CCA GGG GAC AGA GCC ACC CTC TCC TGC\n\n\n\n\n\n\nGGG GCC AGC CAG CTT GTT GTC AGC AAC TAC ATA GCC\n\n\n\n\n\n\nTGG TAC CAG CAA AAA CCT GGC CAG GCT CCC AGA CTC\n\n\n\n\n\n\nCTC ATG TAT GCT GGA TCC ATC AGG GCC ACT GGC ATC\n\n\n\n\n\n\nCCA GAC AGG TTC AGT GGC AGT GGG TCT GGG ACA GAC\n\n\n\n\n\n\nTTC ACT CTC ACC ATC AGC AGA CTA GAA CCT GAA GAT\n\n\n\n\n\n\nTTT GCA ATA TAT TAC TGT CAG CAG CGT AGC AAC TGG\n\n\n\n\n\n\nCCT TGG ACG TTC GGC CAA GGG ACC AAG GTG GAA ATC\n\n\n\n\n\n\nAAA (SEQ ID NO: 58)\n\n\n\n\n\n\n \n\n\n\n\n\n\nM0038-E06 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CCT TAC GTT ATG CAT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC TCT CCT TCT GGT GGC TGG ACT TAT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ATG GCT GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA GGG ACT GGA GCC TAC GGT ATG GAC CTG TGG\n\n\n\n\n\n\nGGC CAA GGG ACC ACG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 59)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0038-E12 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG\n\n\n\n\n\n\nTCT GCA TCT GTA GGA GAC AGC GTC ACC ATC ACT TGC\n\n\n\n\n\n\nCGG GCA AGT CAG AAC ATT AAC AGT TAT TTA AAT TGG\n\n\n\n\n\n\nTAT CAG CAG AAA CCA GGA AAA GCC CCT AAG CTC CTG\n\n\n\n\n\n\nATC TAT GTT GCA TCC AAT TTG CAA AGG GGG GTC CCA\n\n\n\n\n\n\nTCA AGG TTC GGT GGC AGT GGA TCT GGG ACA GAT TTC\n\n\n\n\n\n\nACT CTC ACC ATC ACC AGT CTG CAA CCT GAA GAT TTT\n\n\n\n\n\n\nGCA ACT TAC TCC TGT CAG CAG ACT TAC AGT ACC CCC\n\n\n\n\n\n\nCTC ACT TTC GGC GGA GGG ACC AAG GTG GAG ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 60)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0038-E12 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT AAG TAC TGG ATG ATG TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT GTT ATC TAT CCT TCT GGT GGC ATT ACT TAT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACT GCA GTC TAC TAT TGT\n\n\n\n\n\n\nGCG AGA CTA CCT TCT TGG GGG TTT GAT GCT CTT GAT\n\n\n\n\n\n\nATC TGG GGC CAA GGG ACA ATG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 61)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0038-F01 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG\n\n\n\n\n\n\nTCT GCA TTT GTA GGA GAC AAA GTC ACC ATC ACT TGC\n\n\n\n\n\n\nCGG GCA AGT CAG AGT GTT GGC ACC TAT TTA AAT TGG\n\n\n\n\n\n\nTAT CAG CAG AAA GCA GGG AAA GCC CCT GAG CTC CTG\n\n\n\n\n\n\nATC TAT GCT ACA TCC AAT TTG CGA AGT GGG GTC CCA\n\n\n\n\n\n\nTCA AGG TTC AGT GGC AGT GGA TCT GGG ACA GAT TTC\n\n\n\n\n\n\nACT CTC ACC ATC AAC ACT CTG CAA CCT GAA GAT TTT\n\n\n\n\n\n\nGCA ACT TAC TAC TGT CAA CAG AGT TAC AGT ATC CCT\n\n\n\n\n\n\nCGG TTT ACT TTC GGC CCT GGG ACC AAA GTG GAT ATC\n\n\n\n\n\n\nAAA (SEQ ID NO: 62)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0038-F01 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CTT TAC TCT ATG AAT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC TAT TCT TCT GGT GGC TCT ACT CTT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA GGT CGG GCT TTT GAT ATC TGG GGC CAA GGG\n\n\n\n\n\n\nACA ATG GTC ACC GTC TCA AGC (SEQ ID NO: 63)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0038-F08 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA GGC ACC CTG\n\n\n\n\n\n\nTCT TTG TCT CCA GGG GAA GAG GCC ACC CTC TCC TGC\n\n\n\n\n\n\nAGG GCC AGT CAG AGT GTT AGC AGC AGC TAC TTA GCC\n\n\n\n\n\n\nTGG TAC CAG CAG AAA CCT GGC CAG GCT CCC AGG CTC\n\n\n\n\n\n\nCTC ATC TAT GGT GCA TCC AGC AGG GCC ACT GGC ATC\n\n\n\n\n\n\nCCA GAC AGG TTC AGT GGC AGT GGG TCT GGG ACA GAC\n\n\n\n\n\n\nTTC ACT CTC ACC ATC AGC AGA CTG GAG CCT GAA GAT\n\n\n\n\n\n\nTTT GCA GTG TAT TAC TGT CAG CAC TAT GGT GGC TCA\n\n\n\n\n\n\nCAG GCT TTC GGC GGA GGG ACC AAG GTG GAG ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 64)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0038-F08 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CGT TAC AAG ATG TGG TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT GGT ATC CGT CCT TCT GGT GGC CTT ACT CGT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA CGC GGT GAC TAC GTC GGG GGG TTT GAC TAC\n\n\n\n\n\n\nTGG GGC CAG GGA ACC CTG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 65)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0038-H06 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA GGC ACC CTG\n\n\n\n\n\n\nTCT TTG TCT CCA GGG GAA GGA GCC ACC CTC TCC TGC\n\n\n\n\n\n\nAGG GCC AGT CAG ATT ATA AAT CCT TTT TAC GTA GCC\n\n\n\n\n\n\nTGG TAT CAA CAG AGA CCT GGC CAG GCT CCC AGG CTC\n\n\n\n\n\n\nCTC ATC TAT GCT TCA TCC AGG AGG GCC GGT GGC ATC\n\n\n\n\n\n\nCCA GAC AGA TTC AGT GGC AGT GCG TCT GGG ACA GAC\n\n\n\n\n\n\nTTC ACT CTC ACA ATC AGC AGA CTG GAG CCT GAA GAT\n\n\n\n\n\n\nTTT GCA GTC TAT TAC TGT CAA TAC TTT TAT AAC TCC\n\n\n\n\n\n\nATG TGG ACG TTC GGC CAA GGG GCC AAG GTG GAG ATC\n\n\n\n\n\n\nAGA (SEQ ID NO: 66)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0038-H06 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT TGG TAC AAT ATG ACT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT CGT ATC TCT CCT TCT GGT GGC GAT ACT TTT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCT AGA GCT GCG ATA GCA CCT CGT CCG TAC GGT ATG\n\n\n\n\n\n\nGAC GTC TGG GGC CAA GGG ACC ACG GTC ACC GTC TCA\n\n\n\n\n\n\nAGC (SEQ ID NO: 67)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0039-B07 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA CTC TCC CTG\n\n\n\n\n\n\nTCT GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC\n\n\n\n\n\n\nCGG GCG AGT CAG GGC ATT AGC AAT TAT TTA GCC TGG\n\n\n\n\n\n\nTAT CAG CAG AAA CCA GGG AAA GTT CCT AAG CTC CTG\n\n\n\n\n\n\nATC TAT GCT GCA TCC ACT TTG CAA TCA GGG GTC CCA\n\n\n\n\n\n\nTCT CGG TTC AGT GGC AGT GGA TCT GGG ACA GAT TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGC AGT CTG CAG CCT GAA GAT GTT\n\n\n\n\n\n\nGCA ACT TAT TAC TGT CAA AAG TAT AAC AGT GCC CGC\n\n\n\n\n\n\nCTC ACT TTC GGC GGA GGG ACC AAG GTG GAG ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 68)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0039-B07 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CTT TAC CCT ATG CTT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT GGT ATC TCT CCT TCT GGT GGC CAG ACT TTT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCA AGG ATG GCT TAT TAC TCT GGA TAC TTC GAT CTC\n\n\n\n\n\n\nTGG GGC CGT GGC ACC CTG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 69)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0039-D02 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG\n\n\n\n\n\n\nTCT GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC\n\n\n\n\n\n\nCGG GCA AGT CAG AGC ATT AGC AGC TAT TTA AAT TGG\n\n\n\n\n\n\nTAT CAG CAG AAA CCA GGG AAA GCC CCT AAG CTC CTG\n\n\n\n\n\n\nATC TAC GAT GCA TCC AAT TTG GAA CAC GGG GTC CCA\n\n\n\n\n\n\nTCA AGG TTC AGT GGA AGT GGA TCT GGG ACA GAT TTT\n\n\n\n\n\n\nACT TTC ACC ATC AGC AGC CTG CAG CCT GAA GAT ATT\n\n\n\n\n\n\nGCA ACA TAT TAC TGT CAA CAG TTT GAT GAT CTC CCG\n\n\n\n\n\n\nCTC ACT TTC GCC GGA GGG ACG AAG GTG GAG CTC AAA\n\n\n\n\n\n\nCGA ACT (SEQ ID NO: 70)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0039-D02 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CTT TAC GTT ATG ATT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT GGT ATC TAT TCT TCT GGT GGC GAT ACT TAT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGG GGG CAG CAG CTG GGG GGG GGT GCT TTT GAT\n\n\n\n\n\n\nATC TGG GGC CAA GGG ACA ATG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 71)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0039-D10 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA GAC ACC GTG\n\n\n\n\n\n\nTCT TTC TCT CCA GGG GAA AGA GCC TCC CTC TCA TGC\n\n\n\n\n\n\nCGG GCC AGT CAG AGT GTC CGC AGC GAC TTA GCC TGG\n\n\n\n\n\n\nTAC CAA CAG AAG CCT GGC CAG GCT CCC AGG CTG CTC\n\n\n\n\n\n\nATC TAT GGT GCA TCC AAC AGG GCC ACT GGC ATC CCA\n\n\n\n\n\n\nGTC AGG TTC AGT GGC AGT GGG TCT GGG ACA GAC TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGC AGA CTG GAG CCT GAA GAT TTT\n\n\n\n\n\n\nGCA GTG TAT TAC TGT CAG CAG TAT GGT AGC TCA CCC\n\n\n\n\n\n\nCTA TTC ACT TTC GGC CCT GGG ACC AAA GTG GAT ATC\n\n\n\n\n\n\nAAA (SEQ ID NO: 72)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0039-D10 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT ATG TAC AAT ATG GCT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TGG ATC TAT TCT TCT GGT GGC CTT ACT TTG TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTA TAT TAC TGT\n\n\n\n\n\n\nGCG AAA GGC TCC AAT ACG TAC TAC TTT GAT GCT AGT\n\n\n\n\n\n\nGGC CTC GGT GCT TTT AAT ATG TGG GGC CAA GGG ACA\n\n\n\n\n\n\nATG GTC ACC GTC TCA AGC (SEQ ID NO: 73)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0039-G05 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCC TTC CTG\n\n\n\n\n\n\nTCT GCA TCT ATA GGA GAC AGA GTC ACC ATC ACT TGC\n\n\n\n\n\n\nCGG GCC AGT CAG GGC ATT AAC ACT TTT TTA GCC TGG\n\n\n\n\n\n\nTAT CAG CAA AAA CCA GGG ATA GCC CCT AAG CTC CTG\n\n\n\n\n\n\nATC TAT GCT GCA TCC ACT CTG CAA AGT GGG GTC CCA\n\n\n\n\n\n\nTCA AGG TTC AGC GGC AGT GGA TCT GGG ACA GAA TTC\n\n\n\n\n\n\nACT CTC ACA ATC AGC AGT CTG CAG CCT GAA GAT TTT\n\n\n\n\n\n\nGCA ACT TAT TAC TGT CAG CAG CTT AAT GGT TAC CGC\n\n\n\n\n\n\nAGC TTC GGA CAA GGG ACA CGA CTA GAG ATG AAA\n\n\n\n\n\n\n(SEQ ID NO: 74)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0039-G05 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT AAT TAC GAG ATG GGT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TGG ATC TAT TCT TCT GGT GGC TAT ACT TCT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACA GCC ACG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA GAT CCG TAT TAC TAT GAT AGT AGT GGT TAT\n\n\n\n\n\n\nTAC TAC TAC TAC TAC TAC TAC ATG GAC GTC TGG GGC\n\n\n\n\n\n\nAAA GGG ACC ACG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 75)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0039-G07 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA GGC ACC CTG\n\n\n\n\n\n\nTCT TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC\n\n\n\n\n\n\nAGG GCC AGT CAG AGT GTT AAC AGC AGG TTC TTG GCC\n\n\n\n\n\n\nTGG TAC CAG CAG AAA CCT GGC CAG GCT CCC AGG CTC\n\n\n\n\n\n\nCTC ATC TAT AGT ACA TCC ACC AGG GCC ACT GGC ATC\n\n\n\n\n\n\nCCA GAC AGG TTC AGT GGC AGT GGG TCC GGG ACA GAC\n\n\n\n\n\n\nTTC ACT CTC ACC ATC AGC AGA CTG GAG CCT GAA GAT\n\n\n\n\n\n\nTTT GCG GTG TAT TAC TGT CAG CGA TAT GGT AGC TCA\n\n\n\n\n\n\nCCT ACG TGG ACG TTC GGC CAA GGG ACC AAG GTG GAA\n\n\n\n\n\n\nATC AAA (SEQ ID NO: 76)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0039-G07 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CGT TAC GTT ATG GAT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT CGT ATC TCT CCT TCT GGT GGC CAT ACT GAT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCC AGA GAA ACG GTT CGG GGA GTT TAC TTT GAC TAC\n\n\n\n\n\n\nTGG GGC CAG GGA ACC CTG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 77)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0039-H08 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA GCC ACC CTG\n\n\n\n\n\n\nTCT GTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC\n\n\n\n\n\n\nAGG GCC AGT GAG AGT GTT AAA AAC AAC TTA GCC TGG\n\n\n\n\n\n\nTAT CAG CAG AAA CCT GGC CAG GCT CCC AGG CTC CTC\n\n\n\n\n\n\nATC TAT GGT GTT TCC ACC AGG GCC CCT GGT ATC CCA\n\n\n\n\n\n\nGCC AGG TTC AGT GGC AGT GGG TCT GGG ACA GAC TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGC AGC CTA GAG CCT GAA GAT TTT\n\n\n\n\n\n\nGCA GTT TAT TAC TGT CAG CAG CGT AGC AAC TGG CCT\n\n\n\n\n\n\nCCG GTC ACC TTC GGC CAA GGG ACA CGA CTG GAG ATT\n\n\n\n\n\n\nAAA (SEQ ID NO: 78)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0039-H03 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT GCT TAC AAT ATG GGT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC TCT TCT TCT GGT GGC TAT ACT GGT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA GAT CTT TAC AGG GGC TTT GAC TAC TGG GGC\n\n\n\n\n\n\nCAG GGA ACC CTG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 79)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-A03 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCT TTT GTG\n\n\n\n\n\n\nTCT GCA TCT GTC GGA GAC AGA GTC ACC ATC TCT TGT\n\n\n\n\n\n\nCGG GCG AGT CAC AAT ATT AAC ACC TGG TTA GCC TGG\n\n\n\n\n\n\nTAT CAG CAG AAA CCA GGG AAA GCC CCT AAC CTC CTG\n\n\n\n\n\n\nATC TAT TCT GCA TCC AAT TTG CAA GGT GGG GTC CCA\n\n\n\n\n\n\nTCT AGG TTC AGC GGC AGT GGA TCT GGG ACA GAC TTC\n\n\n\n\n\n\nACT CTG ACT ATC AGC AGC CTG CAG CCT GGA GAT TTT\n\n\n\n\n\n\nGCG ACT TAC TAT TGT CAA CAG GCT AGC AGT TTC CCT\n\n\n\n\n\n\nATC ACC TTC GGC CAA GGG ACA CGA CTG GAG ATT AAA\n\n\n\n\n\n\n(SEQ ID NO: 80)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-A03 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CGT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT AAT TAC ATG ATG ATT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TGG ATC TCT CCT TCT GGT GGC TAT ACT TTT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA GGA TAT TAC GAT ATT TTG ACT GGT ATG GTG\n\n\n\n\n\n\nGGC GGC GGT GCT TTT GAT ATC TGG GGC CAA GGG ACC\n\n\n\n\n\n\nACG GTC ACC GTC TCA AGC (SEQ ID NO: 81)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-A06 LV\n\n\n\n\n\n\nCAG GAC ATC GTC ATG ACT CAA ACC CCT CCT AGT TTA\n\n\n\n\n\n\nCCG GTT AAC CCG GGT GAA CCT GCC TCC ATC TCC TGC\n\n\n\n\n\n\nAGG TCT AGT CAG AGC CTC CTG CAT AGA AAT GGA TAC\n\n\n\n\n\n\nAAC TAT TTG GAT TGG TAC CTG CAG AAG CCA GGG CAG\n\n\n\n\n\n\nTCT CCA CAG CTC CTG ATC CAT TTG GGT TCT TAT CGG\n\n\n\n\n\n\nGCC TCC GGG GTC CCT GAC AGG TTC AGT GGC AGT GGA\n\n\n\n\n\n\nTCA GGC ACA GAT TTT ACA CTG AAA ATC AGC AGA GTG\n\n\n\n\n\n\nGAG GCT GAG GAT GTT GGG GTT TAT TAC TGC ATG CAA\n\n\n\n\n\n\nCCT CTA CAA ACT CCA TTC ACT TTC GGC CCT GGG ACC\n\n\n\n\n\n\nAAA GTG GAT ATC AAA (SEQ ID NO: 82)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-A06 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT TAT TAC GGT ATG TAT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC TCT TCT TCT GGT GGC TAT ACT GAT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCA AGG AGG ATT AAG TAT TAC GAT ATT GAA GGG GAA\n\n\n\n\n\n\nGGT GCT TTT GAT ATC TGG GGC CAA GGG ACA ATG GTC\n\n\n\n\n\n\nACC GTC TCA AGC (SEQ ID NO: 83)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-A08 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA CTC TCC CTG\n\n\n\n\n\n\nCCC GTC ACC CCT GGA GAG CCG GCC TCC ATC TCC TGC\n\n\n\n\n\n\nAGG TCT AGT CAG AGC CTC CTG CAT AGT AAT GGA TAC\n\n\n\n\n\n\nAAC TAT TTG GAT TGG TAC CTG CAG AAG CCA GGG CAG\n\n\n\n\n\n\nTCT CCA CAG CTC CTG ATC TAT TTG GGT TCT AAT CGG\n\n\n\n\n\n\nGCC TCC GGG GTC CCT GAC AGG TTC AGT GGC AGT GGA\n\n\n\n\n\n\nTCA GGC ACA GAT TTT ACA CTG AAA ATC AGC AGA GTG\n\n\n\n\n\n\nGAG GCT GAG GAT GTT GGG GTT TAT TAC TGC ATG CAA\n\n\n\n\n\n\nGCT CTA CAA CCT TTC ACT TTC GGC GGA GGG ACC AAG\n\n\n\n\n\n\nGTG GAG ATC AAA (SEQ ID NO: 84)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-A08 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT GCT TAC ATG ATG GGT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT GGT ATC TCT TCT TCT GGT GGC CTT ACT TCT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA CCA GCG CTG ATT TAC TAT GAT AGT AGT GGC\n\n\n\n\n\n\nCCA AGT GAT GCT TTT GAT ATC TGG GGC CAA GGG ACA\n\n\n\n\n\n\nATG GTC ACC GTC TCA AGC (SEQ ID NO: 85)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-A11 LV\n\n\n\n\n\n\nCAG AGC GCT TTG ACT CAG CCT CCC TCC GCG TCC GGG\n\n\n\n\n\n\nTCT CCT GGA CAG TCA GTC ACC ATC TCC TGC ACT GGA\n\n\n\n\n\n\nACC AGC AGT GAC GTT GGT GCT TAT AAC TAT GTC TCC\n\n\n\n\n\n\nTGG TAC CAA CAG CAC CCA GAC AAA GCG CCC AAA CTC\n\n\n\n\n\n\nATT ATT TAT AAT GTC AAT GAG CGG CCC TCA GGG GTC\n\n\n\n\n\n\nCCT GAT CGC TTC TCT GGC TCC AAG TCT GGC AAC ACG\n\n\n\n\n\n\nGCC TCC CTG ACC GTC TCT GGG CTC CAG GCT GAG GAT\n\n\n\n\n\n\nGAG GCT GAT TAT TAC TGT ACC TCA TAT GCA GGC AGC\n\n\n\n\n\n\nAAC AAA ATC GGG GTC TCC GGA ACT GGG ACC AAG GTC\n\n\n\n\n\n\nACC GTC CTA (SEQ ID NO: 86)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-A11 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CAT CAC GTT ATG TTT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT CGT ATC GTT CCT TCT GGT GGC GCT ACT ATG TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG CAT TAC TGT\n\n\n\n\n\n\nGCG AGA GAT CGA CCG CTC TAT GAT AGT AGT GGT TAC\n\n\n\n\n\n\nGTT GAC TAC TGG GGC CAG GGA ACC CTG GTC ACC GTC\n\n\n\n\n\n\nTCA AGC (SEQ ID NO: 87)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-B06 LV\n\n\n\n\n\n\nCAG TAC GAA TTG ACT CAG CCA CCC TCA GCG TCT GGG\n\n\n\n\n\n\nACC CCC GGG CAG AGG GTC ACC ATC TCT TGT TCT GGA\n\n\n\n\n\n\nAGC AGC TCC AAC ATC GGA AGG AAT TAT GTA TAC TGG\n\n\n\n\n\n\nTAC CAG CAG GTC CCA GGA ACG GCC CCC AAA CTC CTC\n\n\n\n\n\n\nATC TAT AGT AAT AAT CAG CGG CCC TCA GGG GTC CCT\n\n\n\n\n\n\nGAC CGA TTC TCT GGC TCC AAG TCT GGC ACC TCA GCC\n\n\n\n\n\n\nTCC CTG GTC ATC AGT GGG CTC CGG TCC GAG GAT GAG\n\n\n\n\n\n\nGCT GAT TAT TAC TGT GCA GCA TGG GAT GCC AGC CTG\n\n\n\n\n\n\nCGT GGG GTG TTC GGC GGA GGG ACC AAG CTG ACC GTC\n\n\n\n\n\n\nCTA (SEQ ID NO: 88)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-B06 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT GTT TAC CCT ATG GTT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TAT ATC TCT CCT TCT GGT GGC TTT ACT TTT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA GTG CCC GGG GGC AGC AGA CAG GAT TTT GAT\n\n\n\n\n\n\nATC TGG GGC CAA GGG ACA ATG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 89)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-B08 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG\n\n\n\n\n\n\nTCT GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC\n\n\n\n\n\n\nCGG GCA AGT CAG AGC ATT AGC AGC TAT TTA AAT TGG\n\n\n\n\n\n\nTAT CAG CAG AAA CCA GGG AAA GCC CCT AAG CTC CTG\n\n\n\n\n\n\nATC TAT GCT GCA TCC AGT TTG CAA AGT GGG GTC CCA\n\n\n\n\n\n\nTCA AGG TTC AGT GGC AGT GGA TCT GGG ACA GAT TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGC AGT CTG CAA CCT GAA GAT TTT\n\n\n\n\n\n\nGCA ACT TAC TAC TGT CAA CAG AGT TAC AGT ACC CCT\n\n\n\n\n\n\nCGA ACG TTC GGC CAA GGG ACC AAG GTG GAA ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 90)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-B08 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT TAT TAC AAT GAT ATG GCT\n\n\n\n\n\n\nTGG GTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG\n\n\n\n\n\n\nGTT TCT TCT ATC TCT CCT TCT GGT GGC AAG ACT GAG\n\n\n\n\n\n\nTAT GCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT\n\n\n\n\n\n\nAGA GAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG\n\n\n\n\n\n\nAAC AGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC\n\n\n\n\n\n\nTGT GCG AGG AGT GGA AGC TAC ACT CAA CAT TTT GAC\n\n\n\n\n\n\nTAC TGG GGC CAG GGA ACC CTG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 91)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-C10 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA GCC ACC CTG\n\n\n\n\n\n\nTCT GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC\n\n\n\n\n\n\nCGG GCA AGT CAG ACC ATT AGC ACC TAT TTA AAT TGG\n\n\n\n\n\n\nTAT CAA CAC AAA CCA GGG AAA GCC CCT GAG CTC CTG\n\n\n\n\n\n\nATT TAT GCT GCA TCC AGT TTG CAA AGT GGG GTC CCA\n\n\n\n\n\n\nTCA AGG TTC AGT GGC AGT GGA TCT GGG ACA GAT TTC\n\n\n\n\n\n\nACT CTC CGC ATC AGC AGT CTG CAA CCT GAA GAT TTT\n\n\n\n\n\n\nGCA ACT TAC TAC TGT CAA CAG AGT TAC ACT ACC CCG\n\n\n\n\n\n\nTGG ACG TTC GGC CAA GGG ACC AAG GTG GAA ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 92)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-C10 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CGT TAC ATG ATG GTT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC GTT TCT TCT GGT GGC AAG ACT TGG TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACC GCC ATG TAT TAC TGT\n\n\n\n\n\n\nGCC AGA TGG GAC TGG GGA CCT TTT GAC TAC TGG GGC\n\n\n\n\n\n\nCAG GGA ACC CTG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 93)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-D08 LV\n\n\n\n\n\n\nCAG AGC GCT TTG ACT CAA TCA CCC TCT GCC TCT GCT\n\n\n\n\n\n\nTCA CTG GGA TCC TCG GTC AAG CTC ACC TGC ACT CTG\n\n\n\n\n\n\nGCC AGT GAG CAC AGT GGC TAC ATC ATC GCA TGG CAT\n\n\n\n\n\n\nCAG CAG CAA CCA GGG AAG GCC CCT CGG TTC TTG ATG\n\n\n\n\n\n\nAAA CTT GAC GGT ACT GGC AAC TTC AAC AAG GGC AGC\n\n\n\n\n\n\nGGA GTT CCT GAT CGC TTC TCA GGC TAC AGC TCT GGG\n\n\n\n\n\n\nGCT GAC CGC TAC CTC ACC ATC TCC AAC CTC CAG TCT\n\n\n\n\n\n\nGAG GAT GAG GCT GAT TAT TAC TGT GAG ACC TGG GAC\n\n\n\n\n\n\nAGT ACC ACT CTT TGG GTG TTC GGC GGG GGG ACC AAG\n\n\n\n\n\n\nCTG ACC GTC CTA (SEQ ID NO: 94)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-D08 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CAT TAC GGT ATG ACT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC GTT CCT TCT GGT GGC TAT ACT GCT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACA GCC GTG TAT TAC TGT\n\n\n\n\n\n\nACC ACA GGT CTC AGC AGC AGC GGT ACA CGG TGG TTC\n\n\n\n\n\n\nGAC GCC TGG GGC CAG GGA ACC CTG GTC ACC GTC TCA\n\n\n\n\n\n\nAGC (SEQ ID NO: 95)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-F03 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA CTC TCC CTG\n\n\n\n\n\n\nCCC GTC ACC CCT GGA GAG CCG GCC TCC ATC TCC TGC\n\n\n\n\n\n\nAGG TCT GGT CAG AGC CTC CTG CAT AGT AAT GGA TAC\n\n\n\n\n\n\nAAC TAT TTG AAT TGG TAC CTG CAG AAG CCA GGG CAG\n\n\n\n\n\n\nTCT CCA CAG CTC CTG ATC TAT TTG GGT TCT TAT CGG\n\n\n\n\n\n\nGCC TCC GGG GTC CCT GAC AGG TTC AGT GGC AGT GGA\n\n\n\n\n\n\nTCA GGC ACA GAT TTT ACA CTG AAA ATC AGC AGA GTG\n\n\n\n\n\n\nGAG GCT GAG GAT GTT GGG CTT TAT TAC TGC ATG CAA\n\n\n\n\n\n\nGCT CTA CAA ACT CCT CTC ACT TTC GGC GTA GGG ACC\n\n\n\n\n\n\nAAG GTG GAG ATC AAA (SEQ ID NO: 96)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-F03 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTGG GGA TTC ACT TTC TCT ATG TAC GTT ATG TCT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC TCT TCT TCT GGT GGC AAT ACT GGT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AAG AGT TCG TTA TAT TAC GAT ATT TTG GCT GGC\n\n\n\n\n\n\nCCT GGG TTT GAC TAC TGG GGC CAG GGA ACC CTG GTC\n\n\n\n\n\n\nACC GTC TCA AGC (SEQ ID NO: 97)\n\n\n\n\n\n\n \n\n\n\n\n\n\nM0040-G04 LV\n\n\n\n\n\n\nCAG AGC GTC TTG ACT CAG CCA CCC TCA GCG TCT GGG\n\n\n\n\n\n\nACC CCC GGG CAG AGG GTC ACC ATC TCA TGT TCT GGA\n\n\n\n\n\n\nAGC AGG ACC AAC ATC GGA AGT GAT TAT GTA TAT TGG\n\n\n\n\n\n\nTAC CAG CAA CTC CCA GGA ACG GCC CCC AAA CTC CTC\n\n\n\n\n\n\nATC TAT AGG AAT AAT GAG CGG CCC TCA GGG GTC CCT\n\n\n\n\n\n\nGAC CGA TTC TCT GGC TTC AAG TCT GGC ACC TCA GCC\n\n\n\n\n\n\nTCC CTG GCC ATC AGT GGG CTC CGG TCC GAG GAT GAG\n\n\n\n\n\n\nGCT GAT TAT TAC TGT GCA TCA TGG GAT GAC AGG CTG\n\n\n\n\n\n\nAGT GGT CCG GTT TTC GGC GGA GGG ACC AAG CTG ACC\n\n\n\n\n\n\nGTC CTA (SEQ ID NO: 98)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-G04 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CAG TAC CAT ATG CTT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT GTT ATC GTT TCT TCT GGT GGC TTT ACT TTT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA AGC TAC GGT GGA GAT GCT TTT GAT ATC TGG\n\n\n\n\n\n\nGGC CAA GGG ACA ATG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 99)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-H04 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA GAC TCC CTG\n\n\n\n\n\n\nGCT GTG TCT CTG GGC GAG AGG GCC ACC CTC AAC TGC\n\n\n\n\n\n\nAGG TCC AGC CAG AGT GTT TTA TAC AGC CCC AAC AAT\n\n\n\n\n\n\nAAG AAC TAC TTA GCT TGG TAC CAG CAG AAA GCA GGA\n\n\n\n\n\n\nCAG CCA CCT AAG CTG CTC ATT TAC TGG GCA TCT TTC\n\n\n\n\n\n\nCGG GAA TCC GGG GTC CCT GAG CGA TTC AGT GGC AGC\n\n\n\n\n\n\nGGG TCT GGG ACA GAT TTC ACT CTC ACC ATC AGC AGC\n\n\n\n\n\n\nCTG CAG GCT GAA GAT GTG GCA GTT TAT TAC TGT CAG\n\n\n\n\n\n\nCAA TAT CAT ACT CCT CCC TGG ACG TTC GGC CAA GGG\n\n\n\n\n\n\nACC AAG GTG GAA ATC AAA (SEQ ID NO: 100)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-H04 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT TCT TAC GAT ATG GTT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC TCT CCT TCT GGT GGC AAT ACT CAG TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AAA GTG GCA GCT ATG GCC CCG TGG TAC TTT GAC\n\n\n\n\n\n\nTAC TGG GGC CAG GGA ACC CTG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 101)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-H09 LV\n\n\n\n\n\n\nCAG AGC GAA TTG ACT CAG GAC CCT GCT GTG TCT GTG\n\n\n\n\n\n\nGCC TTG GGA CAG GCA GTC ATC ATC ACA TGC CAA GGA\n\n\n\n\n\n\nGAC AGC CTC AGA ACC TAT TAT CCA AGC TGG TAC CAA\n\n\n\n\n\n\nCAG AAG CCA GGA CAG GCC CCT ACA CTT CTC GTC TAT\n\n\n\n\n\n\nGGT AAA AAC AAG CGG CCC TCA GGG GTC CCA GAC CGA\n\n\n\n\n\n\nTTC TCT GGC TCC AGG TCA GGA GAC ACA GCT TCC TTG\n\n\n\n\n\n\nATC ATC ACT GGG GCT CAG GCG GAA GAT GAC GCT GAC\n\n\n\n\n\n\nTAT TAT TGT AAC TCC CGG GAC GGC AGT GGT CAC CTT\n\n\n\n\n\n\nTTT GTC TTC GGA CCT GGG ACC ACG GTC ACC GTC CTC\n\n\n\n\n\n\n(SEQ ID NO: 102)\n\n\n\n\n\n\n \n\n\n\n\n\n\n<M0040-H09 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CTT TAC CCT ATG CAG TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TAT ATC CGT TCT TCT GGT GGC AAG ACT CAT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCT GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA GTA GGA ATG GGC AGT GGC TGG TAC ACG GGG\n\n\n\n\n\n\nTAC TTC GAT CTC TGG GGC CGT GGC ACC CTG GTC ACC\n\n\n\n\n\n\nGTC TCA AGC (SEQ ID NO: 103)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-A05 LV\n\n\n\n\n\n\nCAA GAC ATG CAG ATG ACC CAG TCT CCA TCC TCC CTG\n\n\n\n\n\n\nTCT GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC\n\n\n\n\n\n\nCGG GCA AGT CAG AAC ATT AAC AGC TAT TTA AAT TGG\n\n\n\n\n\n\nTAT CAG CAG AAA CCA GGG AAA GCC CCT AAG CTC CTG\n\n\n\n\n\n\nATC TAT GCT GCA TCC AGT TTG CAA AGT GGG GTC CCA\n\n\n\n\n\n\nTCA AGG TTC AGT GGC AGT GGA TCT GGG ACA GAT TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGC AGT CTG CAA CCT GAA GAT TTT\n\n\n\n\n\n\nGTA ACT TAC TAC TGT CAA CAG AGT TAC AGT ACC CCT\n\n\n\n\n\n\nAAG ACG TTC GGC CAA GGG ACC AAG GTG GAA ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 104)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0040-A05 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT GTT TAC ACT ATG CAT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT GTT ATC TAT CCT TCT GGT GGC CTT ACT ATT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCA CGG AAT AGG GGT TAC TAT GCC CCT ATG GAC GTC\n\n\n\n\n\n\nTGG GGC CAA GGG ACC ACG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 105)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0041-B03 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA GCC ACC CTG\n\n\n\n\n\n\nTCT GCA TCT GTA GGA GAC AGA GTC ACC ATC TCT TGC\n\n\n\n\n\n\nCGG GCC AGT CAG AAT ATT AGT AAT TGG TTG GCC TGG\n\n\n\n\n\n\nTAT CAG CAG AAG CCA GGC AAA GCC CCT AAA CTC CTC\n\n\n\n\n\n\nATC TAC ACT GCA TCC ACT TTG CAC CGT GGG GTC CCA\n\n\n\n\n\n\nTCA AGG TTC AGC GGC AGT GGA TCT GGG ACA GAT TTC\n\n\n\n\n\n\nACT CTC ACT ATC ACC AGC CTG CAG CCT GAA GAT TTT\n\n\n\n\n\n\nGCA ACT TAC TAT TGT CAA CAG GCT AAC ACT TTC CCT\n\n\n\n\n\n\nTGG ACG TTC GGC CAA GGG ACC AAG GTG GAA ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 106)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0041-B03 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT ATG CAC ATG ATG TGG TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT GTT ATC TCT TCT TCT GGT GGC TTT ACT TCT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA CTA AGG TAC AGT AAT TTC GTA GGC GGT CTG\n\n\n\n\n\n\nGAC GTC TGG GGC CAA GGG ACC ACG GTC ACC GTC TCA\n\n\n\n\n\n\nAGC (SEQ ID NO: 107)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0041-B11 LV\n\n\n\n\n\n\nCAG AGC GTC TTG ACT CAG GAC CCT GCT GTG TCT GTG\n\n\n\n\n\n\nGCC TTG GGA CAG ACA GTC AGG ATC ACA TGC CAA GGA\n\n\n\n\n\n\nGAC AGC CTC AGA AGC TAT TCT GCA AGT TGG TAC CAG\n\n\n\n\n\n\nCGG AAG CCA GGA CAG GCC CCT TTA CTT GTC ATC TAT\n\n\n\n\n\n\nCGT AAA ACC AAC CGG CCC TCA GGG ATC CCA GAC CGG\n\n\n\n\n\n\nTTC TCT GGC TCC AGC TCA GGA AAC ACA GCT TCC TTG\n\n\n\n\n\n\nACC ATC ACT GGG GCT CAG GCG GAA GAT GAG TCT GAC\n\n\n\n\n\n\nTAT TAC TGT AAC TCC CGG GAC AGC AGT GGT AAC CAC\n\n\n\n\n\n\nCTA TTC GGC GGA GGG ACC AAA CTG ACC GTC CTA\n\n\n\n\n\n\n(SEQ ID NO: 108)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0041-B11 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CAG TAC TCT ATG CAT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC GTT CCT TCT GGT GGC ATG ACT GCT TAT\n\n\n\n\n\n\nGCT GAC TGC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AAA ATT TCA CGG GGA AAT GAT GCT TTT GAT ATC\n\n\n\n\n\n\nTGG GGC CAA GGG ACA ATG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 109)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0041-C11 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG\n\n\n\n\n\n\nTCT GCA TCT GTT GGA GAC AGA GTC ACC ATC ACT TGC\n\n\n\n\n\n\nCGG GCA AGT CAG CGA ATT GGC AGC TAC TTG AAT TGG\n\n\n\n\n\n\nTAT CAG CAA AAT TCG GGA AAA GCC CCA AGG CTC CTG\n\n\n\n\n\n\nATC TAT GGT GCA TCC AAT TTG GAA AGT GGG GTC CCT\n\n\n\n\n\n\nTCA AGG TTC AGT GGC CGT GGA TCT GGG ACA GAC TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGC AGT CTG CAA CCT GAA GAT TTT\n\n\n\n\n\n\nGCG ACT TAC TAC TGT CAA CAG AGT AAC AGT ACC CCT\n\n\n\n\n\n\nCAC ACG TTC GGC CAA GGG ACC AAG GTG GAA ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 110)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0041-C11 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CAG TAC CCT ATG TCT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC GGT CCT GGT GGC TGG ACT TGG TAT GCT\n\n\n\n\n\n\nGAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA GAC\n\n\n\n\n\n\nAAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC AGC\n\n\n\n\n\n\nTTA AGG GCT GAG GAC ACT GCA GTC TAC TAT TGT GCG\n\n\n\n\n\n\nAGG ACC GCT ACA CGG ATT TTT GGA GTG GTT ATT ATG\n\n\n\n\n\n\nGGT CGC GCT TTT GAT ATC TGG GGC CAA GGG ACA ATG\n\n\n\n\n\n\nGTC ACC GTC TCA AGC (SEQ ID NO: 111)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0041-D03 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCT TCA CTG\n\n\n\n\n\n\nTCT GCA TCT GTA GGA GAC AGA ATC ACC GTC ACT TGC\n\n\n\n\n\n\nCGG GCA AGT CAG AGC ATT ACC AAC TAT TTA AAT TGG\n\n\n\n\n\n\nTAT CAG CAG AAA CCA GGG AAA GCC CCT AAG CTC CTG\n\n\n\n\n\n\nATC TAT GCT GCA TCC ACT TTG CAA AGT GGG GTC CCA\n\n\n\n\n\n\nTCA AGG TTC AGT GGC AGT GGG TCT GGG ACA GAC TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGC AGA CTG GAG CCT GAA GAT TTT\n\n\n\n\n\n\nCCA GTA TAT TAC TGT CAG CAG TAT GGT AGC TCA CCG\n\n\n\n\n\n\nACG TTC GGC CAA GGG ACC AAG GTG GAA GTC AAA\n\n\n\n\n\n\n(SEQ ID NO: 112)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0041-D03 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGG GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT TTT TAC AAT ATG ACT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC TAT TCT TCT GGT GGC AAT ACT GAT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTA TAT TAC TGT\n\n\n\n\n\n\nGCT AGA GAT TCC CTC TCC CAC TAC TAC TAC GGT ATG\n\n\n\n\n\n\nGAC GTC TGG GGC CAA GGG ACC ACG GTC ACC GTC TCA\n\n\n\n\n\n\nAGC (SEQ ID NO: 113)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0041-D08 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA GGC ACC CTG\n\n\n\n\n\n\nTCT TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC\n\n\n\n\n\n\nAGG GCC AGT CAG AGT GTT AGC AGC AGC TAC TTA GCC\n\n\n\n\n\n\nTGG TAC CAG CAG AAA CCT GGC CAG GCT CCC AGG CTC\n\n\n\n\n\n\nCTC ATC TAT GGT GCA TCC AGC AGG GCC ACT GGC ATC\n\n\n\n\n\n\nCCA GAC AGG TTC AGT GGC AGT GGG TCT GGG ACA GAC\n\n\n\n\n\n\nTTC ACT CTC ACC ATC AGC AGA CTG GAG CCT GAA GAT\n\n\n\n\n\n\nTTT GCA GTG TAT TAC TGT CAG CAG TAT GGT ACC TCA\n\n\n\n\n\n\nTCG ACG TTC GGC CAA GGG ACC AAG GTG GAA ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 114)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0041-D08 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT TCT TAC CGT ATG TCT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT GGT ATC TCT TCT TCT GGT GGC TTT ACT ATG TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGG GAT ATT TTG ACT GGT TAT TCC TAC GGT ATG\n\n\n\n\n\n\nGAC GTC TGG GGC CAA GGG ACC ACG GTC ACC GTC TCA\n\n\n\n\n\n\nAGC (SEQ ID NO: 115)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0041-E11 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCT TCC CTG\n\n\n\n\n\n\nTCT GCA TTT GTA GGA GAC AGA GTC ATC ATC ACT TGC\n\n\n\n\n\n\nCGG GCA AGC CAG GAC ATT AGT GTT TAT GTA AAT TGG\n\n\n\n\n\n\nTAT CAG CAG AGC TCA GGC AAA GCC CCT AAA CTC CTA\n\n\n\n\n\n\nATC TAT GGT GCA TCC AGT TTG CAA AGT GGG GTC CCA\n\n\n\n\n\n\nTCA AGG TTC AGT GGC AGT GGA TCT GGG ACA GAT TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGC AGT CTG CAA CCT GAA GAT TTT\n\n\n\n\n\n\nGCA AGT TAC TTC TGT CAA CAG AGT TAT AAT TTG CCT\n\n\n\n\n\n\nTTC ACC TTC GGC GGA GGA ACC AAC GTG CAG ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 116)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0041-E11 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CAG TAC AAT ATG CAG TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT GGT ATC GTT CCT TCT GGT GGC TGG ACT CCT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCA AGA GGG GTG CGC TAC GGG CTT GAC TAC TGG GGC\n\n\n\n\n\n\nCAG GGA ACC CTG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 117)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0041-H09 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA GGC ACC CTG\n\n\n\n\n\n\nTCT TTG TCT CCA GGG GAG AGA GCC ACC CTT TCC TGC\n\n\n\n\n\n\nAGG GCC AGT CAG AGT CTT AGC GGC GAC TAC TTA GCC\n\n\n\n\n\n\nTGG TAT CAG CAG AAA ATT GGC CAG GCT CCC AGG CTC\n\n\n\n\n\n\nCTC ATA TTT GGT GCA TCT AGG AGA CCC ACT GGC ATC\n\n\n\n\n\n\nCCA GAC AGG TTC AGT GGC AGT GGG TCT GGG ACA GAC\n\n\n\n\n\n\nTTC GCT CTC ACC ATC AGC AGA CTG GAG CCT GAA GAT\n\n\n\n\n\n\nTTT GCA GTG TAT TAC TGT CAG CAG TAT GGT AGT TTA\n\n\n\n\n\n\nATC ACC TTC GGC CAA GGG ACA CGG CTG GAG ATT AAA\n\n\n\n\n\n\n(SEQ ID NO: 118)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0041-H09 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT GTT TAC GAG ATG ACT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT GGT ATC GGT TCT TCT GGT GGC ATG ACT TTT TAT\n\n\n\n\n\n\nGCC GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCC CGG ATA AGG TAT AGT GGG AGC TAT GGG TGG CAC\n\n\n\n\n\n\nTAC ATG GAC GTC TGG GGC AAA GGG ACC ACG GTC ACC\n\n\n\n\n\n\nGTC TCA AGC (SEQ ID NO: 119)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0041-H11 LV\n\n\n\n\n\n\nCAG AGC GAA TTG ACT CAG GAC CCT GCT GTG TCT GTG\n\n\n\n\n\n\nGCC TTG GGA CAG ACA GTC AGG ATC ACA TGC CAA GGA\n\n\n\n\n\n\nGAC AGC CTC AGA AGC TAT TAT GCA AGC TGG TAC CAG\n\n\n\n\n\n\nCAG AAG CCA GGA CAG GCC CCT GTA CTT GTC ATC TAT\n\n\n\n\n\n\nGGT AAA AAC AAC CGG CCC TCA GGG ATC CCA GAC CGA\n\n\n\n\n\n\nTTC TCT GGC TCC AGC TCA GGA AAC ACA GCT TCC TTG\n\n\n\n\n\n\nACC ATC ACT GGG GCT CAG GCG GAA GAT GAG GCT GAC\n\n\n\n\n\n\nTAT TAC TGT AAC TCC CGG GAC AGC AGT GGT AAC CAT\n\n\n\n\n\n\nGTG GTA TTC GGC GGA GGG ACC AAG CTG ACC GTC CTA\n\n\n\n\n\n\n(SEQ ID NO: 120)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0041-H11 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT ATG TAC CCT ATG AAT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC TCT TCT TCT GGT GGC TGG ACT AAG TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA GTT TTT TTC GGC TAT GAT AGT AGT GGT TAC\n\n\n\n\n\n\nCCT TAC TAC TAC TAC GGT ATG GAC GTC TGG GGC CAA\n\n\n\n\n\n\nGGG ACC ACG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 121)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M00420B07 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA CTC TCC CTG\n\n\n\n\n\n\nCCC GTC ACC CCT GGA GAG CCG GCC TCC ATC TTC TGC\n\n\n\n\n\n\nAGG TCT AGT CAG AGC CTC CTA CAT AGT AAT GGA TAC\n\n\n\n\n\n\nAAC TAT TTG GAT TGG TAT GTG CAG AAG CCA GGA CAG\n\n\n\n\n\n\nTCT CCA CAG CTC CTG ATC TAT TTG GGT TCT GGT CGG\n\n\n\n\n\n\nGCC TCC GGG GTC CCT GAC AGG TTC AGT GGC AGT GGA\n\n\n\n\n\n\nTCA GGC ACA GAT TTT ACA CTG AAA ATC AAC AGA GTG\n\n\n\n\n\n\nGAG GCT GAG GAT GTT GGG GTT TAT TAC TGC ATG CAA\n\n\n\n\n\n\nGCT CTA CAA ACT CCG TGG ACG TTC GGC CAA GGG ACC\n\n\n\n\n\n\nAAG GTG GAA ATC AAA (SEQ ID NO: 122)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0042-B07 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CCT TAC TCT ATG TTT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT GTT ATC TAT CCT TCT GGT GGC GGT ACT ATT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC CCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA AGT AGA GAG TCT TGT GAT GCT GAT ACT TGC\n\n\n\n\n\n\nTAC CAA TAT TTC CAG GAG TGG GGC CAG GGC ACC CTG\n\n\n\n\n\n\nGTC ACC GTC TCA AGC (SEQ ID NO: 123)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0042-G12 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA GGC ACC CTG\n\n\n\n\n\n\nTCT TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC\n\n\n\n\n\n\nAGG GCC AGT CAG AGT GTT AGC AGC AGC TAC TTA GCC\n\n\n\n\n\n\nTGG TAC CAG CAG AAA CCT GGC CAG GCT CCC AGG CTC\n\n\n\n\n\n\nCTC ATC TAT GGT GCA TCC ATC AGG GCC ACT GGC ATC\n\n\n\n\n\n\nCCA GAC AGG TTC AGT GGC AGT CGG TCT GGG ACA GAC\n\n\n\n\n\n\nTTC ACT CTC ACC ATC AGC AGA CTG GAG CCT GAA GAT\n\n\n\n\n\n\nTTT GCA GTG TAT TAC TGT CAG CAG TAT GGT AGC TCA\n\n\n\n\n\n\nCCC CCG TAC ACT TTT GGC CAG GGG ACC AAG CTG GAG\n\n\n\n\n\n\nATC AAA (SEQ ID NO: 124)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0042-G12 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CAT TAC CCT ATG TTT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT GGT ATC TCT TCT TCT GGT GGC TAT ACT ATT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA GGG GGA AGA CGA CAG ACG CGG CGT ACC AGC\n\n\n\n\n\n\nGAC TAC TAC TAC GGT ATG GAC GTC TGG GGC CAA GGG\n\n\n\n\n\n\nACC ACG GTC ACC GTC TCA AGC (SEQ ID NO: 125)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0043-A09 LV\n\n\n\n\n\n\nCAG AGC GTC TTG ACT CAG CCA CCC TCG GTG TCC AAG\n\n\n\n\n\n\nGAC TTG AGA CAG ACC GCC ACA CTC ACC TGC ACT GGG\n\n\n\n\n\n\nAAC AGC AAC AAT GTT GGC TAC CAA GGA GCA GCT TGG\n\n\n\n\n\n\nCTG CAG CAG CAC CAG GGC CAC CCT CCC AAA GTC CTT\n\n\n\n\n\n\nTCG TAC AGG AAT AAC AAC CGG CCC TCA GGG ATC TCA\n\n\n\n\n\n\nGAG AGA TTT TCT GCG TCC AGG TCA GGA AAT ACA GCC\n\n\n\n\n\n\nTCC CTG ACC ATT ACT GGA CTC CAG CCT GAG GAC GAG\n\n\n\n\n\n\nGCT GAC TAT TAC TGC TCA GCG TGG GAC AGC AGC CTC\n\n\n\n\n\n\nACT GCT TGG GTC TTC GGC GGA GGG ACC AAG CTG ACC\n\n\n\n\n\n\nGTC CTA (SEQ ID NO: 126)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0043-A09 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT TTT TAC GAT ATG ACT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC TGG TCT TCT GGT GGC GTT ACT GAT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACA GCC GTG TAT TAC TGT\n\n\n\n\n\n\nACG AGA GCT AGT AGT GGT TAT TAT GAT GCT TTT GAT\n\n\n\n\n\n\nATC TGG GGC CAA GGG ACA ATG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 127)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0043-C03 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA GCC TCC CTG\n\n\n\n\n\n\nTAT TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC\n\n\n\n\n\n\nAGG GCC AGT CAG AGT GTT AGC AGC AAC TTA GCC TGG\n\n\n\n\n\n\nTAC CAG CAG AAA CCT GGC CAG GCT CCC AGG CTC CTC\n\n\n\n\n\n\nATC TAT GGT GCA TCC ACC AGG GCC ACT GGT ATC CCA\n\n\n\n\n\n\nGCC AGG TTC AGT GGC AGT GGG TCT GGG ACA GAG TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGC AGC CTG CAG TCT GCA GAT TTT\n\n\n\n\n\n\nGCC GTT TAT TAC TGT CAG CAG TAT GAT AAC TGG CCT\n\n\n\n\n\n\nCCC CTC ACT TTC GGC GGA GGG ACC AAG GTG GAG ATC\n\n\n\n\n\n\nAAA (SEQ ID NO: 128)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0043-C03 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT TAT TAC GCT ATG GAT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC GGT TCT TCT GGT GGC GAT ACT GTT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACA GCC ACG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA GAC CCT CGG CAG CCC GGA GTC TTT GAC TAC\n\n\n\n\n\n\nTGG GGC CAG GGA ACC CTG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 129)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0043-F01 LV\n\n\n\n\n\n\nCAG AGC GCT TTG ACT CAG CCT GCT TCC GTG TCT GGG\n\n\n\n\n\n\nTCT CCT GGA CAG TCG ATC ACC ATC TCC TGC ACT GGA\n\n\n\n\n\n\nACC AGC AGT GAC ATT GGT GCT TAT AGG TAT GTC TCC\n\n\n\n\n\n\nTGG TAC CAA CAG CGC CCA GGC AAA GCC CCC AAA CTC\n\n\n\n\n\n\nATG ATT TTT GAT GTC ACT AAG CGG CCC TCA GGG GTT\n\n\n\n\n\n\nTCT AAT CGC TTC TCT GGC TTC AAG TCT GGC AAC ACG\n\n\n\n\n\n\nGCT TCC CTG ACC ATC TCT GGG CTC CAG GCT GAG GAC\n\n\n\n\n\n\nGAG GCC GAT TAT TAC TGC AGC TCA TTT ACA AGT GGC\n\n\n\n\n\n\nAGC ACT TTC GTC TTC GGA ACT GGG ACC AAG GTC ACC\n\n\n\n\n\n\nGTC CTA (SEQ ID NO: 130)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0043-F01 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT AAG TAC TCT ATG TAT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC TCT TCT TCT GGT GGC TAT ACT GCT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACT GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG ATT CCT TGG GGT AGT GGG AGT TCC TGG GGC CAG\n\n\n\n\n\n\nGGA ACC CTG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 131)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0043-G01 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCT GCC ATG\n\n\n\n\n\n\nTCT GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGT\n\n\n\n\n\n\nCGG GCG AGT CAG GGT ATT AGC AGC TGG TTA GCC TGG\n\n\n\n\n\n\nTAT CAG CAG AAA CCA GGG AAA GCC CCT AAG CTC CTG\n\n\n\n\n\n\nATC TAT GCT GCA TCC AGT TTG CAA AGT GGG GTC CCA\n\n\n\n\n\n\nTCA AGG TTC AGC GGC AGT GGA TCT GGG ACA GAT TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGC AGC CTG CAG CCT GAA GAT TTT\n\n\n\n\n\n\nGCA ACT TAC TAT TGT CAA CAG GCT AAC AGT TTC CCG\n\n\n\n\n\n\nCTC ACT TTC GGC GGA GGG ACC AAG GTG GAG ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 132)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0043-G01 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT TTT TAC TCT ATG CAT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT GGT ATC TCT TCT TCT GGT GGC GTT ACT AAG TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA GCA CGG TCA ACT CGT GGC TTT GAC TAC TGG\n\n\n\n\n\n\nGGC CAG GGA ACC CTG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 133)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0043-G02 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA GGC ACC CTG\n\n\n\n\n\n\nTCT TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC\n\n\n\n\n\n\nAGG GCC AGT CAG AGT GTT AGC AGC AGC TAC TTA GCC\n\n\n\n\n\n\nTGG TAC CAG CAG AAA CCT GGC CAG GCT CCC AGG CTC\n\n\n\n\n\n\nCTC ATC TAT GGT GCA TCC AGC AGG GCC ACT GGC ATC\n\n\n\n\n\n\nCCA GAC AGG TTC AGT GGC AGT GGG TCT GGG ACA GAC\n\n\n\n\n\n\nTTC ACT CTC ACC ATC AGC AGA CTG GAG CCT GAA GAT\n\n\n\n\n\n\nTTT GCA GTG TAT TAC TGT CAG TCG GGG GTC ACT TTC\n\n\n\n\n\n\nGGC GGA GGG ACC AAG GTG GAG ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 134)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0043-G02 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT TGG TAC CCT ATG TTT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT GGT ATC TAT TCT TCT GGT GGC CCT ACT GAT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCA AAA GAT ACC CTA GGG AGG TAT TAC GAT TTT TGG\n\n\n\n\n\n\nAGT GGT TAT TCC TAC GGT ATG GAC CTC TGG GGC CAA\n\n\n\n\n\n\nGGG ACC ACG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 135)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0043-B03 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCT TCC GTG\n\n\n\n\n\n\nTCT GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGT\n\n\n\n\n\n\nAGG GCG AGT CAG AAT ATT TAC AGT TGG TTA GCC TGG\n\n\n\n\n\n\nTAT CAG CAG AGA CCA GGG AAA GCC CCT AAG CTC CTG\n\n\n\n\n\n\nATC TAC GCT GCA TCC AGT TTA CAT AGT GGG GTC CCA\n\n\n\n\n\n\nTCA AGG TTC AGC GGC AGT GGA TCT GGG ACA GAT TTC\n\n\n\n\n\n\nACT CTC ACC ATC AGC AGC CTG CAG CCT GAA GAT TTT\n\n\n\n\n\n\nGCA ACT TAC TAT TGT CAA CAG GCT AAG AGT TTC CCT\n\n\n\n\n\n\nGTG ACT TTC GGC GGA GGG ACC AAG GTG GAA ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 136)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0044-B03 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CAG TAC CAT ATG ATG TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC GGT TCT CTC GGC TAT ACT AAG TAT GCT\n\n\n\n\n\n\nGAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA GAC\n\n\n\n\n\n\nAAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC AGC\n\n\n\n\n\n\nTTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT GCG\n\n\n\n\n\n\nGGA GCA GTG GCT GGT ACC GGG GCC TTT GAC TAC TGG\n\n\n\n\n\n\nGGC CAG GGA ACC CTG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 137)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0044-D08 LV\n\n\n\n\n\n\nCAG TAC GAA TTG ACT CAG CCA CTC TCA GTC TCA GTG\n\n\n\n\n\n\nGCC CTG GGA CAG ACG GCC AGT ATT TCC TGT TGG GGA\n\n\n\n\n\n\nCAT AAC ATT AGA ATT AAA AAT GTA CAC TGG TAC CAG\n\n\n\n\n\n\nCAG AAG CCA GGC CAG GCC CCT GTG GTG GTC ATG TAT\n\n\n\n\n\n\nATC CCT GAG CGG TTC TCT GGC TCC ACC TCG GGG AAC\n\n\n\n\n\n\nACG GCC ACC CTG ACC ATC AGT GGA GCC CAA GCC GGG\n\n\n\n\n\n\nGAT GAG GCT GAC TAT TAT TGT CAA GTG TGG GAC AGC\n\n\n\n\n\n\nAGC ACT GTG GTG TTC GGC GGA GGG ACC AAG CTG ACC\n\n\n\n\n\n\nGTC CTA (SEQ ID NO: 138)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0044-D08 LV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT AAG TAC CCT ATG TCT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TCT ATC TGG CCT TCT GGT GGC CAT ACT TTT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AAA AAT CCC GGG CTA CGG TAT GCT TTT GAT AAC\n\n\n\n\n\n\nTGG GGC CGA GGG ACA ATG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 139)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0044-E01 LV\n\n\n\n\n\n\nCAG TAC GAA TTG ACT CAG CCA CCC TCA ACG TCT GGG\n\n\n\n\n\n\nACC CCC GGG CAG ACG GTC ACC ATC TCT TGT TCT GGA\n\n\n\n\n\n\nAGC ATC TCC AAC ATC GGA AGA AAT TCT GTA AAC TGG\n\n\n\n\n\n\nTAC CAG CAG CTC CCA GGA ACG GCC CCC AAA CTC CTC\n\n\n\n\n\n\nATG TTT AGG AAT AAT GAG CGG CCC TCA GGG GTC CCT\n\n\n\n\n\n\nGAC CGA TTC TCT GGC TCC AAG TCT GGC ACC TCG GCC\n\n\n\n\n\n\nTCC CTG GCC ATC AGT GGG CTC CGG TCC GAG GAT GAG\n\n\n\n\n\n\nGCT GAT TAT TAC TGT GCA GCA TGG GGT GAC AGC CTG\n\n\n\n\n\n\nAGT GGT TCT TAT GTC TTC GGA ACT GGG ACC AAG GTC\n\n\n\n\n\n\nACC GTC CTA (SEQ ID NO: 140)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0044-E01 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT TAT TAC GCT ATG GGT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT TAT ATC GTT CCT TCT GGT GGC GAG ACT CGT TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA GAT GGT TAT TAC GAT TTT TGG AGT GGT TAT\n\n\n\n\n\n\nTGG TCC TAC TAC TAC TAC GGT ATG GAC GTC TGG GGC\n\n\n\n\n\n\nCAA GGG ACC ACG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 141)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0044-E05 LV\n\n\n\n\n\n\nCAA GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG\n\n\n\n\n\n\nTCT GCA TCC GTG GGA GAC AGA CTC ACC ATC ACT TGC\n\n\n\n\n\n\nCGG GCA AGT CAG AGC ATT AGC AGC TAT TTA AAT TGG\n\n\n\n\n\n\nTAT CAG CAA AAA CCA GGG GAA GCC CCT AAG CTC CTC\n\n\n\n\n\n\nATC TAT GCT GCA TCC GCT TTG CAA AGT GGG GTC CCG\n\n\n\n\n\n\nTCA AGG TTC AGT GGC AGT GGA CTT GGG ACA GTT TTC\n\n\n\n\n\n\nACT CTC ACC ATC ACC AGC CTG CAA CCT GAA GAT TCT\n\n\n\n\n\n\nGCA ACT TAC TAT TGT CAA CAG AGT TAC AGT CCC CCG\n\n\n\n\n\n\nGTC ACT TTC GGC GGA GGG ACC AAG GTG GAT ATC AAA\n\n\n\n\n\n\n(SEQ ID NO: 142)\n\n\n\n\n\n\n \n\n\n\n\n\n\n> M0044-E05 HV\n\n\n\n\n\n\nGAA GTT CAA TTG TTA GAG TCT GGT GGC GGT CTT GTT\n\n\n\n\n\n\nCAG CCT GGT GGT TCT TTA CGT CTT TCT TGC GCT GCT\n\n\n\n\n\n\nTCC GGA TTC ACT TTC TCT CGT TAC CCT ATG TCT TGG\n\n\n\n\n\n\nGTT CGC CAA GCT CCT GGT AAA GGT TTG GAG TGG GTT\n\n\n\n\n\n\nTCT CGT ATC TCT TCT TCT GGT GGC TGG ACT CAG TAT\n\n\n\n\n\n\nGCT GAC TCC GTT AAA GGT CGC TTC ACT ATC TCT AGA\n\n\n\n\n\n\nGAC AAC TCT AAG AAT ACT CTC TAC TTG CAG ATG AAC\n\n\n\n\n\n\nAGC TTA AGG GCT GAG GAC ACG GCC GTG TAT TAC TGT\n\n\n\n\n\n\nGCG AGA GAG GGT TCT AGT GGG AGC CGT CGT GGT GAC\n\n\n\n\n\n\nTAC TGG GGC CAG CGA ACC CTG GTC ACC GTC TCA AGC\n\n\n\n\n\n\n(SEQ ID NO: 143)\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \nExample 3\n\n\nDNA Sequences of MMP-14 Inhibiting Anti-MMP-14 Fabs\n\n\n \n \n \nExemplary Fabs that bind to and inhibit human MMP-14 were identified and include: M0031-C02, M0031-F01, M0033-1107, M0037-009, M0037-D01, M0038-E06, M0038-F01, M0038-F08, M0039-H08, M0040-A06, M0040-A and M0043-G02. The DNA sequences of these antibodies are shown in Table 5.\n\n\n \nExample 4\n\n\nAmino Acid Sequences of MMP-14 Binding Fabs that Inhibit MMP-14\n\n\n \n \n \nThe amino acid sequences of exemplary Fab heavy chain (HC) and light chain (LC) variable regions that bind to and inhibit human MMP-14, the DNA sequence of which are provided in Example 3, are shown in Table 6. In Table 6, the standard numbering of the HC V domain is shown. The length of HC CDR3 varies considerably. By convention, the second cysteine is numbered 92 and the W of the conserved WG motif of FR4 is number 103. If there are more than 9 residues between C92 and W03, then residues after 102 are numbered 102a, 102b, etc. Table 7 shows the germline (GL) Vlight and JLight assignments.\n\n\n \n \n \n \nTable 8 shows the LCs of the 12 inhibitory Fabs aligned to their germline VS genes. In the germline sequence, FR regions are bold in the isolate sequences, departures from OL are shown bold. Table 9 shows the departures from GL as mutations from the isolate to GL, i.e. the mutation that is needed to restore GL sequence to the isolate. In one embodiment, the departures from germline in the FR regions are reverted to GL. Residues at or near the FR-CDR junctions may be involved in interactions with the antigen and so reversions of these residues is more likely to affect affinity than is the reversion of residues far from the junctions.\n\n\n \n \n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 6\n\n\n\n\n\n\n \n\n\n\n\n\n\nAmino-acid sequences of Fabs that bind and inhibit human MMP-14\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n1 M0031-C02 SC = SC-001 Round = SC-001-SR-003\n\n\n\n\n\n\n\n\n\n\nHC\n\n\n \n\n\n\n\n\n\n \n\n\n1   5    0     5    0     5    0     5    0     5    0\n\n\n\n\n\n\n 1\n\n\nEVQLLESGGG LVQPGGSLRL SCAASGFTFS PYPMGWVRQA PGKGLEWVSS\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n5    5     6    6     7    7     8 8   8 8  8 8  9  9\n\n\n\n\n\n\n \n\n\n1 a  5     0    5     0    5     0 2abc3 5  7 9  2  5\n\n\n\n\n\n\n 51\n\n\nIVSSGGLTLY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARGG\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n     1          1 1     1\n\n\n\n\n\n\n \n\n\n9    0          0 0     1\n\n\n\n\n\n\n \n\n\n7    2abcd efghi3 5     0\n\n\n\n\n\n\n101\n\n\nRLYDILTGQG APFDYWGQGT LVTVSS\n\n\n\n\n\n\n \n\n\n(SEQ ID NO: 144)\n\n\n\n\n\n\n \n\n\n\n\n\n\nLC\n\n\n \n\n\n\n\n\n\n  1\n\n\nQDIQMTQSPL SLPVTPGEPA SISCRSSQSL LHSNGYYYLD WYLQKPGQSP\n\n\n\n\n\n\n \n\n\n\n\n\n\n 51\n\n\nQLLIYLGSYR ASGVPDRFSG SGSGTDFTLK ISSVEAEDVG VYYCMQALQT\n\n\n\n\n\n\n \n\n\n\n\n\n\n101\n\n\nPLTFGGGTRV DIK\n\n\n\n\n\n\n \n\n\n(SEQ ID NO: 145)\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n2 M0031-F01 SC = SC-001 Round = SC-001-SR-003\n\n\n\n\n\n\n\n\n\n\nHC\n\n\n \n\n\n\n\n\n\n  1\n\n\nEVQLLESGGG LVQPGGSLRL SCAASGFTFS TYEMHWVRQA PGKGLEWVSS\n\n\n\n\n\n\n \n\n\n\n\n\n\n 51\n\n\nIYSSGGWTGY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARSQ\n\n\n\n\n\n\n \n\n\n\n\n\n\n101\n\n\nQYYDFSSRYY GMDVWGQGTT VTVSS\n\n\n\n\n\n\n \n\n\n(SEQ ID NO: 146)\n\n\n\n\n\n\n \n\n\n\n\n\n\nLC\n\n\n \n\n\n\n\n\n\n  1\n\n\nQSELTQPPSV SGTPGQRVTI SCSGTSANIG RNAVHWYQQL PGTAPKLLIH\n\n\n\n\n\n\n \n\n\n\n\n\n\n 51\n\n\nSNNRRPSGVP DRFSGSYSGT SASLAISGLQ SEDEADYYCA AWENSLNAFY\n\n\n\n\n\n\n \n\n\n\n\n\n\n101\n\n\nVFGTGTKVTV L\n\n\n\n\n\n\n \n\n\n(SEQ ID NO: 147)\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n3 M0033-H07 SC = SC-001 Round = SC-001-SR-003\n\n\n\n\n\n\n\n\n\n\nHC\n\n\n \n\n\n\n\n\n\n  1\n\n\nEVQLLESGGG LVQPGGSLRL SCAASGFTFS VYGMVWVRQA PGKGLEWVSV\n\n\n\n\n\n\n \n\n\n\n\n\n\n 51\n\n\nISSSGGSIWY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TALYYCARPF\n\n\n\n\n\n\n \n\n\n\n\n\n\n101\n\n\nSRRYGVFDYW GQGTLVTVSS\n\n\n\n\n\n\n \n\n\n(SEQ ID NO: 148)\n\n\n\n\n\n\n \n\n\n\n\n\n\nLC\n\n\n \n\n\n\n\n\n\n  1\n\n\nQDIQMTQSPS SLSASVGDRV TITCRASQGI RNFLAWYQQK PGKVPKLLVF\n\n\n\n\n\n\n \n\n\n\n\n\n\n 51\n\n\nGASALQSGVP SRFSGSGSGT DFTLTISGLQ PEDVATYYCQ KYNGVPLTFG\n\n\n\n\n\n\n \n\n\n\n\n\n\n101\n\n\nGGTKVEIK\n\n\n\n\n\n\n \n\n\n(SEQ ID NO: 149)\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n4 M0037-C09 SC = SC-001 Round = SC-001-SR-003\n\n\n\n\n\n\n\n\n\n\nHC\n\n\n \n\n\n\n\n\n\n  1\n\n\nEVQLLESGGG LVQPGGSLRL SCAASGFTFS HYEMFWVRQA PGKGLEWVSS\n\n\n\n\n\n\n \n\n\n\n\n\n\n 51\n\n\nISPSGGQTHY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCATDR\n\n\n\n\n\n\n \n\n\n\n\n\n\n101\n\n\nTYYDFWSGYG PLWYWGQGTL VTVSS\n\n\n\n\n\n\n \n\n\n(SEQ ID NO: 150)\n\n\n\n\n\n\n \n\n\n\n\n\n\nLC\n\n\n \n\n\n\n\n\n\n  1\n\n\nQDIQMTQSPL SLPVTLGESA SVSCRSSQSL LHENGENYLD WYLQKPGQSP\n\n\n\n\n\n\n \n\n\n\n\n\n\n 51\n\n\nQLLIYLGSNR ASGVPDRFSG SGSGTDFTLK ISRVEAEDVG VYYCMQSLKT\n\n\n\n\n\n\n \n\n\n\n\n\n\n101\n\n\nPPTFGPGTKV EIK\n\n\n\n\n\n\n \n\n\n(SEQ ID NO: 151)\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n5 M0037-D01 SC = SC-001 Round = SC-001-SR-003\n\n\n\n\n\n\n\n\n\n\nHC\n\n\n \n\n\n\n\n\n\n  1\n\n\nEVQLLESGGG LVQPGGSLRL SCAASGFTFS MYMMIWVRQA PGKGLEWVSS\n\n\n\n\n\n\n \n\n\n\n\n\n\n 51\n\n\nIYPSGGNTMY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCATGV\n\n\n\n\n\n\n \n\n\n\n\n\n\n101\n\n\nLRYFDWDAGS GMDVWGQGTT VTVSS\n\n\n\n\n\n\n \n\n\n(SEQ ID NO: 152)\n\n\n\n\n\n\n \n\n\n\n\n\n\nLC\n\n\n \n\n\n\n\n\n\n  1\n\n\nMDIQMTQSPS SLSASVGDRV TITCRASQGI RNDLGWYQQK PGKAPKRLIY\n\n\n\n\n\n\n \n\n\n\n\n\n\n 51\n\n\nVASSLQSGVP SRFSGSGSGT EFTLTISSLQ PEDFATYYCL QHNSYPWTFG\n\n\n\n\n\n\n \n\n\n\n\n\n\n101\n\n\nQGTKVEIK\n\n\n\n\n\n\n \n\n\n(SEQ ID NO: 153)\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n6 M0038-E06 SC = SC-001 Round = SC-001-SR-003\n\n\n\n\n\n\n\n\n\n\nHC\n\n\n \n\n\n\n\n\n\n  1\n\n\nEVQLLESGGG LVQPGSSLRL SCAASGFTFS PYVMHWVRQA PGKGLEWVSS\n\n\n\n\n\n\n \n\n\n\n\n\n\n 51\n\n\nISPSGGWTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED MAVYYCARGT\n\n\n\n\n\n\n \n\n\n\n\n\n\n101\n\n\nGAYGMDVWGQ GTTVTVSS\n\n\n\n\n\n\n \n\n\n(SEQ ID NO: 154)\n\n\n\n\n\n\n \n\n\n\n\n\n\nLC\n\n\n \n\n\n\n\n\n\n  1\n\n\nQDIQMTQSPG TLSLSPGDRA TLSCGASQLV VSNYIAWYQQ KPGQAPRLLM\n\n\n\n\n\n\n \n\n\n\n\n\n\n 51\n\n\nYAGSIRATGI PDRFSGSGSG TDFTLTISRL EPEDFAIYYC QQRSNWPWTF\n\n\n\n\n\n\n \n\n\n\n\n\n\n101\n\n\nGQGTKVEIK\n\n\n\n\n\n\n \n\n\n(SEQ ID NO: 155)\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n7 M0038-F01 SC = SC-001 Round = SC-001-SR-003\n\n\n\n\n\n\n\n\n\n\nHC\n\n\n \n\n\n\n\n\n\n  1\n\n\nEVQLLESGGG LVQPGGSLRL SCAASGFTFS LYSMNWVRQA PGKGLEWVSS\n\n\n\n\n\n\n \n\n\n\n\n\n\n 51\n\n\nIYSSGGSTLY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARGR\n\n\n\n\n\n\n \n\n\n\n\n\n\n101\n\n\nAFDIWGQGTM VTVSS\n\n\n\n\n\n\n \n\n\n(SEQ ID NO: 158)\n\n\n\n\n\n\n \n\n\n\n\n\n\nLC\n\n\n \n\n\n\n\n\n\n  1\n\n\nQDIQMTQSPS SLSAFVGDKV TITCRASQSV GTYLNWYQQK AGKAPELLIY\n\n\n\n\n\n\n \n\n\n\n\n\n\n 51\n\n\nATSNLRSGVP SRFSGSGSGT DFTLTINTLQ PEDFATYYCQ QSYSIPRFTF\n\n\n\n\n\n\n \n\n\n\n\n\n\n101\n\n\nGPGTKVDIK\n\n\n\n\n\n\n \n\n\n(SEQ ID NO: 157)\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n8 M0038-F08 SC = SC-001 Round = SC-001-SR-003\n\n\n\n\n\n\n\n\n\n\nHC\n\n\n \n\n\n\n\n\n\n  1\n\n\nEVQLLESGGG LVQPGGSLRL SCAASGFTFS RYKMWWVRQA PGKGLEWVSG\n\n\n\n\n\n\n \n\n\n\n\n\n\n 51\n\n\nIRPSGGLTRY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARRG\n\n\n\n\n\n\n \n\n\n\n\n\n\n101\n\n\nDYVGGFDYWG QGTLVTVSS\n\n\n\n\n\n\n \n\n\n(SEQ ID NO: 158)\n\n\n\n\n\n\n \n\n\n\n\n\n\nLC\n\n\n \n\n\n\n\n\n\n  1\n\n\nQDIQMTQSPG TLSLSPGERA TLSCRASQSV SSSYLAWYQQ KPGQAPRLLI\n\n\n\n\n\n\n \n\n\n\n\n\n\n 51\n\n\nYGASSRATGI PDRFSGSGSG TDFTLTISRL EPEDFAVYYC QHYGGSQAFG\n\n\n\n\n\n\n \n\n\n\n\n\n\n101\n\n\nGGTKVETK\n\n\n\n\n\n\n \n\n\n(SEQ ID NO: 159)\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n9 M0039-H08 SC = SC-001 Round = SC-001-SR-003\n\n\n\n\n\n\n\n\n\n\nHC\n\n\n \n\n\n\n\n\n\n  1\n\n\nEVQLLESGGG LVQPGGSLRL SCAASGFTFS AYNMGWVRQA PGKGLEWVSS\n\n\n\n\n\n\n \n\n\n\n\n\n\n 51\n\n\nISSSGGYTGY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDL\n\n\n\n\n\n\n \n\n\n\n\n\n\n101\n\n\nYRGFDYWGQG TLVTVSS\n\n\n\n\n\n\n \n\n\n(SEQ ID NO: 160)\n\n\n\n\n\n\n \n\n\n\n\n\n\nLC\n\n\n \n\n\n\n\n\n\n  1\n\n\nQDIQMTQSPA TLSVSPGERA TLSCRASESV KNNLAWYQQK PGQAPRLLIY\n\n\n\n\n\n\n \n\n\n\n\n\n\n 51\n\n\nGVSTRAPGIP ARFSGSGSGT DFTLTISSLE PEDFAVYYCQ QRSNWPPVTF\n\n\n\n\n\n\n \n\n\n\n\n\n\n101\n\n\nGQGTRLEIK\n\n\n\n\n\n\n \n\n\n(SEQ ID NO: 161)\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n10 M0040-A06 SC = SC-001 Round = SC-001-SR-003\n\n\n\n\n\n\n\n\n\n\nHC\n\n\n \n\n\n\n\n\n\n  1\n\n\nEVQLLESGGG LVQPGGSLRL SCAASGFTFS YYGMYWVRQA PGKGLEWVSS\n\n\n\n\n\n\n \n\n\n\n\n\n\n 51\n\n\nISSSGGYTDY ADSVNGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARRI\n\n\n\n\n\n\n \n\n\n\n\n\n\n101\n\n\nKYYDIEGEGA FDIWSQGTMV TVSS\n\n\n\n\n\n\n \n\n\n(SEQ ID NO: 162)\n\n\n\n\n\n\n \n\n\n\n\n\n\nLC\n\n\n \n\n\n\n\n\n\n  1\n\n\nQDIVMTQTPP SLPVNPGEPA SISCRSSQSL LHRNGYNYLD WYLQKPGQSP\n\n\n\n\n\n\n \n\n\n\n\n\n\n 51\n\n\nQLLIHLGSYR ASGVPDRRSG SGSGTDFTLK ISRVEAEDVG VYYCMQPLQT\n\n\n\n\n\n\n \n\n\n\n\n\n\n101\n\n\nPETFGPGTKV DIK\n\n\n\n\n\n\n \n\n\n(SEQ ID NO: 163)\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n11 M0040-A11 SC = SC-001 Round = SC-001-SR-003\n\n\n\n\n\n\n\n\n\n\nHC\n\n\n \n\n\n\n\n\n\n  1\n\n\nEVQLLESGGG LVQPGGSLRL SCAASGFTFS HYVMFWVRQA PGKGLEWVSR\n\n\n\n\n\n\n \n\n\n\n\n\n\n 51\n\n\nIVPSGGATMY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDR\n\n\n\n\n\n\n \n\n\n\n\n\n\n101\n\n\nPLYDSSGYVD YWGQGTLVTV SS\n\n\n\n\n\n\n \n\n\n(SEQ ID NO: 164)\n\n\n\n\n\n\n \n\n\n\n\n\n\nLC\n\n\n \n\n\n\n\n\n\n  1\n\n\nQSALTQPPSA SGSPGQSVTI SCTGTSSDVG AYNYVSWYQQ HPDKAPKLII\n\n\n\n\n\n\n \n\n\n\n\n\n\n 51\n\n\nYNVNERPSGV PDRFSGSKSG NTASLTVSGL QAEDEADYYC TSYAGSNKIG\n\n\n\n\n\n\n \n\n\n\n\n\n\n101\n\n\nVSGTGTKVTV L\n\n\n\n\n\n\n \n\n\n(SEQ ID NO: 165)\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n12 M0043-G02 SC = SC-001 Round = SC-001-SR-003\n\n\n\n\n\n\n\n\n \n\n\nHC\n \n \n \n \n\n\n \n\n\n\n\n\n\n  1\n\n\nEVQLLESSGG LVQPGGSLRL SCAASGFTFS WYPMFWVRQA PGKGLEWVSG\n\n\n\n\n\n\n \n\n\n\n\n\n\n 51\n\n\nIYSSGGPTDY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDT\n\n\n\n\n\n\n \n\n\n\n\n\n\n101\n\n\nLGRYYDFWSG YSYGMDVWGQ GTTVTVSS\n\n\n\n\n\n\n \n\n\n(SEQ ID N0: 166)\n\n\n\n\n\n\n \n\n\n\n\n\n\n \nLC\n \n\n\n \n\n\n\n\n\n\n  1\n\n\nQDIQMTQSPG TLSLSPGERA TLSCRASQSV SSSYLAWYQQ KPGQAPRLLI\n\n\n\n\n\n\n \n\n\n\n\n\n\n 51\n\n\nYGASSRATGI PDRFSGSGSG TDFTLTISRL EPEDFAVYYC QSGVTFGGGT\n\n\n\n\n\n\n \n\n\n\n\n\n\n101\n\n\nKVEIK\n\n\n\n\n\n\n \n\n\n(SEQ ID NO: 167)\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n \n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 7\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nTypes of the light chains of inhibitory Fabs\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nIsolate\n\n\n \nJ\n \n \nV_Class\n \n \n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n1\n\n\nM0031-C02\n\n\nJK4\n\n\nVK-A3-\nVK2_8_A3\n \n\n\n\n\n\n\n2\n\n\nM0031-F01\n\n\nJL1\n\n\nVL1-16-\nVL1_1c\n \n\n\n\n\n\n\n3\n\n\nM0033-H07\n\n\nJK4\n\n\nVK-A20-\nVK1_5_A20\n \n\n\n\n\n\n\n4\n\n\nM0037-C09\n\n\nJK1\n\n\nVK-A3-\nVK2_8_A3\n \n\n\n\n\n\n\n5\n\n\nM0037-D01\n\n\nJK1\n\n\nVK-A30-\nVK1_6_A30\n \n\n\n\n\n\n\n6\n\n\nM0038-E06\n\n\nJK1\n\n\nVK-A27-\nVK3_1_A27\n \n\n\n\n\n\n\n7\n\n\nM0038-F01\n\n\nJK3\n\n\nVK-O2-\nVK1_2_O2\n \n\n\n\n\n\n\n8\n\n\nM0038-F08\n\n\nJK4\n\n\nVK-A27-\nVK3_1_A27\n \n\n\n\n\n\n\n9\n\n\nM00390H08\n\n\nJK5\n\n\nVK-L6-\nVK3_5_L5\n \n\n\n\n\n\n\n10\n\n\nM0040-A06\n\n\nJK3\n\n\nVK-A3-\nVK2_8_A3\n \n\n\n\n\n\n\n11\n\n\nM0040-A11\n\n\nJL1\n\n\nVL2_2c\n\n\n\n\n\n\n12\n\n\nM0043-G02\n\n\nJK4\n\n\nVK-A27-VK3_1_A27\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n \n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 8\n\n\n\n\n\n\n \n\n\n\n\n\n\nAlignment of LCs of inhibitory Fabs with their germline sequences\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n \n\n\nFR1                     \nCDR1            FR2            CDR2\n \n\n\n\n\n\n\n \n\n\n          1    1    2  2 2    33     3333    4    4    5\n\n\n\n\n\n\n \n\n\n1    5    0    5    0  3 5    01acdef2345    0    5    0\n\n\n\n\n\n\nVKIIA3-JK1\n\n\n-\nDIVMTQSPLSLPVTPGEPASISC\nRSSQSLLHSNGYNYLD\nWYLQKPGQSPQLLIY\nLGSNR\n\n\n\n\n\n\n \n\n\n\n\n\n\nM0037-C09\n\n\n \nQ\nDI\nQ\nMTQSPLSLPVTLGESASVSCRSSQSLLHENGHNYLDWYLQKPGQSPQLLIYLGSNR\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n  \nFR3                             CDR3   FR4\n \n\n\n\n\n\n\n \n\n\n                                             1    1\n\n\n\n\n\n\n \n\n\n5 5  6    6    7    7    8    8  8 9    9    0    0\n\n\n\n\n\n\n \n\n\n5 7  0    5    0    5    0    5  8 0    5    0    5\n\n\n\n\n\n\nVKIIA3-JK1\n\n\n \nA\nS\nGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC\nMQ\nAL\nQT\nPWTFGTGTKVEIK\n \n\n\n\n\n\n\n(SEQ ID NO: 168)\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nM0037-C09\n\n\nASGVPDRFSGSGSGTDFTLKISRVDAEDVGVYYC\nMQSLK\nTP\nP\nTFG\nP\nGTKVEIK\n\n\n\n\n\n\n(SEQ ID NO: 151)\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nFR1                     CDR1            FR2            CDR2\n\n\n\n\n\n\n \n\n\n          1    1    2  2 2    33     3333    4    4    5   5\n\n\n\n\n\n\n \n\n\n1    5    0    5    0  3 5    01acdef2345    0    5    0   4\n\n\n\n\n\n\nVKIIA3-JK4\n\n\n-\nDIVMTQSPLSLPVTPGEPASISC\nRSSQSLLHSNGYNYLD\nWYLQKPGQSPQLLIY\nLGSNR\n\n\n\n\n\n\n \n\n\n\n\n\n\nM0031-C02\n\n\n \nQ\nDI\nQ\nMTQSPLSLPVTPGEPASISCRSSQSLLHSNGY\nY\nYLDWYLQKPGQSPQLLIYLGSYR\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n  FR3                             CDR3   \nFR4\n \n\n\n\n\n\n\n \n\n\n                                             1    1\n\n\n\n\n\n\n \n\n\n5 5  6    6    7    7    8    8  8 9    9    0    0\n\n\n\n\n\n\n \n\n\n5 7  0    5    0    5    0    5  8 0    5    0    5\n\n\n\n\n\n\nVKIIA3-JK4\n\n\nASGV\nPDRFSGSGSGTDFTLKISRMEAEDVGVYYC\nMQALQTP\nLTFGGGTKVEIK\n \n\n\n\n\n\n\n(SEQ ID NO: 169)\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nM0031-C02\n\n\nASGVPORFSGSGSGTDFTLKIS\nS\nVEAEDVGVYYCMQALQTPLTFGGGT\nR\nV\nD\nIK\n\n\n\n\n\n\n(SEQ ID NO: 145)\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nFR1                     CDR1            \nFR2            CDR2\n \n\n\n\n\n\n\n \n\n\n          1    1    2  2 2    33     3333    4    4    5\n\n\n\n\n\n\n \n\n\n1    5    0    5    0  3 5    01acdef2345    0    5    0\n\n\n\n\n\n\nVKIIA3-JK3\n\n\n-\nDIVMTQSPLSLPVTPGEPASISC\nRSSQSLLHSNGYNYLD\nWYLQKPGQSPQLLIY\nLGSNR\n\n\n\n\n\n\n \n\n\n\n\n\n\nM0040-A06\n\n\n \nQ\nDIVMTQ\nT\nP\nP\nSLPV\nN\nPGEPASISCRSSQSLLH\nR\nNGYNYLDWYLQKPGQSPQLLI\nH\nLGS\nY\nR\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n  \nFR3                             CDR3   FR4\n \n\n\n\n\n\n\n \n\n\n                                            1    1\n\n\n\n\n\n\n \n\n\n5 5  6    6    7    7    8    8  8 9    9    0    0\n\n\n\n\n\n\n \n\n\n5 7  0    5    0    5    0    5  8 0    5    0    5\n\n\n\n\n\n\nVKIIA3-JK3\n\n\nAS\nGVPDRFSGSGSGTDFTLKISRVEAEDVGVYY\nCMQALQTP\nFTFGPGTKVDIK\n \n\n\n\n\n\n\n(SEQ ID NO: 170)\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nM0040-A06\n\n\nASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQ\nP\nLQTPFTFGPGTKVDIK\n\n\n\n\n\n\n(SEQ ID NO: 163)\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n FR1                    \nCDR1       FR2            CDR2\n \n\n\n\n\n\n\n \n\n\n          1    1    2  2 2    3    3    4    4    5   5\n\n\n\n\n\n\n \n\n\n 1   5    0    5    0  3 5    0    5    0    5    0   4\n\n\n\n\n\n\nVK3L6-JK5\n\n\n-\nEIVLTQSPATLSLSPGERATLSC\nRASQSVSSYLA\nWYQQKPGQAPRLLIY\nDASNR\n\n\n\n\n\n\n \n\n\n\n\n\n\nM0039-H08\n\n\n \nQD\nI\nQM\nTQSPATLS\nV\nSPGERATLSCRAS\nE\nSV\nKNN\nLAWYQQKPGQAPRLLIY\nGVSTR\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n  FR3                             CDR3    FR4\n\n\n\n\n\n\n \n\n\n                                              1    1\n\n\n\n\n\n\n \n\n\n5    6    6    7    7    8    8    9    9     0    0\n\n\n\n\n\n\n \n\n\n5    0    5    0    5    0    5    0    5a    0    5\n\n\n\n\n\n\nVK3L6-JK5\n\n\nAT\nGIPARFSGSGSGTDFTLTISSLEPEDFAVYYC\nQQRSNWP-\nITFGQGTRLEIK\n \n\n\n\n\n\n\n(SEQ ID NO: 171)\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nM0039-H08\n\n\nA\nP\nGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWP\nPV\nTFGQGTRLEIK\n\n\n\n\n\n\n(SEQ ID NO: 145)\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n FR1                    \nCDR1       FR2            CDR2\n \n\n\n\n\n\n\n \n\n\n          1    1    2  2 2    33    3    4    4    5   5\n\n\n\n\n\n\n \n\n\n 1   5    0    5    0  3 5    01a   5    0    5    0   4\n\n\n\n\n\n\nVKIIIA27-JK1\n\n\n-\nEIVLTQSPGTLSLSPGERATLSC\nRASQSVSSSYLA\nWYQQKPGQAPRLLIY\nGASSR\n\n\n\n\n\n\n \n\n\n\n\n\n\nM0038-E06\n\n\n \nQD\nI\nQM\nTQSPGTLSLSPG\nD\nRATLSC\nG\nASQ\nL\nV\nV\nSNY\nI\nAWYQQKPGQAPRL\nLM\nY\nAG\nS\nI\nR\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n  FR3                             CDR3   FR4\n\n\n\n\n\n\n \n\n\n                                             1    1\n\n\n\n\n\n\n \n\n\n5    6    6    7    7    8    8    9    9    0    0\n\n\n\n\n\n\n \n\n\n5    0    5    0    5    0    5    0    5    0    5\n\n\n\n\n\n\nVKIIIA27-JK1\n\n\nAT\nGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC\nQQYGSS\nPWTFGQGTKVEIK\n \n\n\n\n\n\n\n(SEQ ID NO: 172)\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nM0038-E06\n\n\nATGIPDRFSGSGSGTDFTLTISRLEPEDFA\nI\nYYCQQ\nRSNWP\nWTFGQGTKVEIK\n\n\n\n\n\n\n(SEQ ID NO: 155)\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n FR1                    CDR1       \nFR2            CDR2\n \n\n\n\n\n\n\n \n\n\n          1    1    2  2 2    33    3    4    4    5   5\n\n\n\n\n\n\n \n\n\n 1   5    0    5    0  3 5    01a   5    0    5    0   4\n\n\n\n\n\n\nVKIIIA27-JK4\n\n\n-\nEIVLTQSPGTLSLSPGERATLSC\nRASQSVSSSYLA\nWYQQKPGQAPRLLIY\nGASSR\n\n\n\n\n\n\n \n\n\n\n\n\n\nM0038-F08\n\n\n \nQD\nI\nQM\nTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYOQKPGQAPRLLIYGASSR\n\n\n\n\n\n\n \n\n\n\n\n\n\nM0043-G02\n\n\n \nQD\nI\nQM\nTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSR\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n  FR3                             CDR3   FR4\n\n\n\n\n\n\n \n\n\n                                            1    1\n\n\n\n\n\n\n \n\n\n5    6    6    7    7    8    8    9    9    0    0\n\n\n\n\n\n\n \n\n\n5    0    5    0    5    0    5    0    5    0    5\n\n\n\n\n\n\nVKIIIA27-JK4\n\n\nAT\nGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC\nQQYGSSP\nLTFGGGTKVEIK\n \n\n\n\n\n\n\n(SEQ ID NO: 173)\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nM0038-F08\n\n\nATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQ\nH\nYGGS\nQA\n-FGGGTKVEIK\n\n\n\n\n\n\n(SEQ ID NO: 159)\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nM0043-G02\n\n\nATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQ\nS\n--G\nVT\n--FGGGTKVEIK\n\n\n\n\n\n\n(SEQ ID NO: 167)\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n FR1                    \nCDR1       FR2            CDR2\n \n\n\n\n\n\n\n \n\n\n          1    1    2  2 2    3    3    4    4    5   5\n\n\n\n\n\n\n \n\n\n 1   5    0    5    0  3 5    0    5    0    5    0   4\n\n\n\n\n\n\nVKIA20-JK4\n\n\n-\nDIQMTQSPSSLSASVGDRVTITC\nRASQGISNYLA\nWYQQKPGKVPKLIIY\nAASTL\n\n\n\n\n\n\nM0033-H07\n\n\n \nQ\nDIQMTQSPSSLSASVGDRVTITCRASQGI\nR\nN\nF\nLAWYQQKPGKVPKL\nLVFG\nAS\nAL\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n  \nFR3                             CDR3   FR4\n \n\n\n\n\n\n\n \n\n\n                                             1    1\n\n\n\n\n\n\n \n\n\n5    6    6    7    7    8    8    9    9    0    0\n\n\n\n\n\n\n \n\n\n5    0    5    0    5    0    5    0    5    0    5\n\n\n\n\n\n\nVKIA20-JK4\n\n\nQS\nGVPSRFSGSGSGTDFTLTISSLQPEDVATYYC\nQKYNSAP\nLTFGGGTKVEIK\n \n\n\n\n\n\n\n(SEQ ID NO: 174)\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nM0033-H07\n\n\nQSGVPSRFSGSGSGTDFTLTIS\nG\nLQPEDVATYYCQKY\nNGVPL\nTFGGGTKVEIK\n\n\n\n\n\n\n(SEQ ID NO: 149)\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n  FR1                    \nCDR1       FR2            CDR2\n \n\n\n\n\n\n\n \n\n\n          1    1    2  2 2    3    3    4    4    5   5\n\n\n\n\n\n\n \n\n\n 1   5    0    5    0  3 5    0    5    0    5    0   4\n\n\n\n\n\n\nVKIA30-JK1\n\n\n-\nDIQMTQSPSSLSASVGDRVTITC\nRASQGIRNDLG\nWYQQKPGKAPKRLIY\nAASSL\n\n\n\n\n\n\n \n\n\n\n\n\n\nM0037-D01\n\n\n \nQ\nDIQMTQSPSSLSASVGDRVTITCRASQGIRNDLSWYQQKPGKAPKRLIY\nV\nASSL\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n  \nFR3                             CDR3   FR4\n \n\n\n\n\n\n\n \n\n\n                                             1    1\n\n\n\n\n\n\n \n\n\n5    6    6    7    7    8    8    9    9    0    0\n\n\n\n\n\n\n \n\n\n5    0    5    0    5    0    5    0    5    0    5\n\n\n\n\n\n\nVKIA30-JK1\n\n\nQS\nGVPSRFSGSGSGTEFTLTISSLQPEDFATYYC\nLQHNSY\nPWTFGQGTKVEIK\n \n\n\n\n\n\n\n(SEQ ID NO: 175)\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nM0037-D01\n\n\nQSGVPSRFSGSGSGTEFTLTI5SLQPEDFATYYCLQHNSYPWTFGQGTKVEIK\n\n\n\n\n\n\n(SEQ ID NO: 153)\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n FR1                    \nCDR1       FR2            CDR2\n \n\n\n\n\n\n\n \n\n\n          1    1    2  2 2    3    3    4    4    5   5\n\n\n\n\n\n\n \n\n\n 1   5    0    5    0  3 5    0    5    0    5    0   4\n\n\n\n\n\n\nVKI02-JK3\n\n\n-\nDIQMTQSPSSLSASVGDRVTITC\nRASQSISSYLN\nWYQQKPGKAPKLLIY\nAASSL\n\n\n\n\n\n\n \n\n\n\n\n\n\nM0038-F01\n\n\n \nQ\nDIQMTQSPSSLSA\nF\nVGDKVTITCRASQS\nVGT\nYLNWYQQK\nA\nGKAP\nE\nLLIYA\nT\nS\nN\nL\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n  FR3                             CDR3    FR4\n\n\n\n\n\n\n \n\n\n                                             1    1\n\n\n\n\n\n\n \n\n\n5    6    6    7    7    8    8    9    9    0    0\n\n\n\n\n\n\n \n\n\n5    0    5    0    5    0    5    0    5    0    5\n\n\n\n\n\n\nVKI02-JK3\n\n\nQS\nGVPSRFSGSGSGTDFTLTISSLQPEDFATYYC\nQQSYSTP-\nFTFGPGTKVDIK\n \n\n\n\n\n\n\n(SEQ ID NO: 176)\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nM0038-F01\n\n\n \nR\nSGVPSRFSGSGSGTDFTLTI\nNT\nLQPEDFATYYCQQSYS\nI\nP\nR\nFTFG\nP\nGTKVDIK\n\n\n\n\n\n\n(SEQ ID NO: 157)\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nFR1                   \nCDR1         FR2            CDR2\n \n\n\n\n\n\n\n \n\n\n         1   1    2  2 2    33  3  3    4    4    5   5\n\n\n\n\n\n\n \n\n\n1   5   91   5    0  3 5    01ab2  5    0    5    0   4\n\n\n\n\n\n\nVL1_lc-JL1\n\n\n \nQSVLTQPPSASGTPGQRVTISC\nSGSSSNIGSNTVN\nWYQQLPGTAPKLLIY\nSNNQR\n\n\n\n\n\n\n \n\n\n\n\n\n\nM0031-F01\n\n\nQS\nE\nLTQPPSVSGTPGQRVTISCSG\nT\nSANIG\nRNA\nV\nH\nWYQQLPGTAPKLLI\nH\nSNN\nR\nR\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n  FR3                             CDR3      FR4\n\n\n\n\n\n\n \n\n\n                                                1    1\n\n\n\n\n\n\n \n\n\n5    6    6    7    7    8    8    9    9   9   0    0\n\n\n\n\n\n\n \n\n\n5    0    5    0    5    0    5    0    \n5abc6\n   0    5\n\n\n\n\n\n\nVL1_1c-JL1\n\n\nPS\nGVPDRFSGSKSGTSASLAISGLQSEDEADYYC\nAAWDDSLNG-\nYVFGTGTKVTVL\n \n\n\n\n\n\n\n(SEQ ID NO: 177)\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nM0031-F01\n\n\nPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAW\nEN\nSLN\nAF\nYVFGTGTKVTVL\n\n\n\n\n\n\n(SEQ ID NO: 147)\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\nFR1                   CDR1          \nFR2            CDR2\n \n\n\n\n\n\n\n \n\n\n         1   1    2  2 2    33   3  3    4    4    5   5\n\n\n\n\n\n\n \n\n\n1   5   91   5    0  3 5    01abc2  5    0    5    0   4\n\n\n\n\n\n\nVL2 2c-JL1\n\n\n \nQSALTQPPSASGSPGQSVTISC\nTGTSSDVGGYNYVS\nWYQQHPGKAPKLMIY\nEVSKR\n\n\n\n\n\n\n \n\n\n\n\n\n\nM0040-A11\n\n\nQSALTQPPSASGSPGQSVTISCTGTSSDVG\nA\nYNYVSNYQQHP\nD\nKAPK\nLI\nIY\nN\nV\nNE\nR\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n  FR3                             CDR3     FR4\n\n\n\n\n\n\n \n\n\n                                               1    1\n\n\n\n\n\n\n \n\n\n5    6    6    7    7    8    8    9    9  9   0    0\n\n\n\n\n\n\n \n\n\n5    0    5    0    5    0    5    0    5ab6   0    5\n\n\n\n\n\n\nVL2_2c-JL1\n\n\nPS\nGVPDRFSGSKSGNTASLTVSGLQAEDEADYYC\nSSYAGSNNF\nYVFGTGTKVTVL\n \n\n\n\n\n\n\n(SEQ ID NO: 178)\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nM0040-A11\n\n\nPSGVPDRFSGSKSGNTASLTVSG\nL\nQAEDEADYYC\nT\nSYAGSN\nKIG\nV\nS\nGTGTKVTVL\n\n\n\n\n\n\n(SEQ ID NO: 165)\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n \n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 9\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nNon Germline Residues in Inhibitory Fabs\n\n\n\n\n\n\n\n\n\n\nIsolate\n\n\nHC FR3\n\n\nLC FRs\n\n\nLC CDRs\n\n\n\n\n\n\n \n\n\n\n\n\n\nM0031-C02\n\n\n \n\n\nQ(−1)Δ, Q3V,\n\n\nY31fN, Y53N\n\n\n\n\n\n\n \n\n\n \n\n\nS77R, R103K,\n\n\n\n\n\n\n \n\n\n \n\n\nD105E\n\n\n\n\n\n\nM0031-F01\n\n\n \n\n\nE3V, V11A, H49Y\n\n\nT26S, A28S, R31aS, A32T,\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nH34N, R53Q, E92D,\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nN93D, A95bG, F95cΔ\n\n\n\n\n\n\nM0033-H07\n\n\nV89L\n\n\nQ(−1)Δ, V48I,\n\n\nR30S, F32Y, G50A,\n\n\n\n\n\n\n \n\n\n \n\n\nF49Y, G77S\n\n\nA53T, G93S, V94A\n\n\n\n\n\n\nM0037-C09\n\n\n \n\n\nQ(−1)Δ, Q3V,\n\n\nE31aS, H31eY, S91A,\n\n\n\n\n\n\n \n\n\n \n\n\nL15P, S18P, V21I,\n\n\nK93Q\n\n\n\n\n\n\n \n\n\n \n\n\nP96W, P100Q\n\n\n\n\n\n\nM0037-D01\n\n\n \n\n\nQ(−1)Δ\n\n\nV50A\n\n\n\n\n\n\nM0038-E06\n\n\nT87M\n\n\nQ(−1)Δ, D1E, Q3V,\n\n\nG24R, L28S, N31aS,\n\n\n\n\n\n\n \n\n\n \n\n\nM4L, D17E, M48I,\n\n\nI33L, A50G, G51A, I53S,\n\n\n\n\n\n\n \n\n\n \n\n\nI85V\n\n\nR91Y, S92G, N93S, W94S\n\n\n\n\n\n\nM0038-F01\n\n\n \n\n\nQ(−1)Δ, F14S,\n\n\nV291, G30S, T31S, T51A,\n\n\n\n\n\n\n \n\n\n \n\n\nK18R, A40P, E45K,\n\n\nN53S, I94T, R96Δ\n\n\n\n\n\n\n \n\n\n \n\n\nN76S, T77S\n\n\n\n\n\n\nM0038-F08\n\n\n \n\n\nQ(−1)Δ, D1E, Q3V,\n\n\nH90Q, Q95P, A96L, Δ97T\n\n\n\n\n\n\n \n\n\n \n\n\nM4L\n\n\n\n\n\n\nM0039-H08\n\n\n \n\n\nQ(−1)Δ, D1E, Q3V,\n\n\nE27Q, K30S, N31S,\n\n\n\n\n\n\n \n\n\n \n\n\nM4L, V13L, V96I\n\n\nN32Y, G50D, V51A,\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nT53N, P56T, P95aΔ\n\n\n\n\n\n\nM0040-A06\n\n\n \n\n\nQ(−1)Δ, T7S, P9L,\n\n\nR31aS, Y53N, P91A\n\n\n\n\n\n\n \n\n\n \n\n\nN14T, H49Y\n\n\n\n\n\n\nM0040-A11\n\n\n \n\n\nD41G, I47M, S98F\n\n\nA31aG, N50E, N52K,\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nT89S, K95aN, I95bF,\n\n\n\n\n\n\n \n\n\n \n\n\n \n\n\nG96Y,\n\n\n\n\n\n\nM0043-G02\n\n\n \n\n\nQ(−1)Δ, D1E, Q3V,\n\n\nS90Q, Δ91Y, Δ92G,\n\n\n\n\n\n\n \n\n\n \n\n\nM4L\n\n\nΔ96L, Δ97T\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \nExample 5\n\n\nIC\n50 \nValues for MMP-14 Inhibition of MMP-141 Binding Fabs and IgGs\n\n\n \n \n \nThe IC\n50 \nvalues for MMP-14 inhibition (MMP-14 was at 2 pM) of exemplary MMP-14 binding Fabs and IgGs are provided in Table 10.\n\n\n \n \n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 10\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nIC\n50 \nValues\n\n\n\n\n\n\n\n\n\n\n \n\n\nM name\n\n\nIC50 (nM) - Fab\n\n\nIC50 (nM) - IgG\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nM0040-A06\n\n\n 8.6 ± 1.3\n\n\n1.7 ± 0.6\n\n\n\n\n\n\n \n\n\nM0040-A11\n\n\n23.2 ± 2.4\n\n\n6.7 ± 0.5\n\n\n\n\n\n\n \n\n\nM0031-C02\n\n\n56.0 ± 4.6\n\n\n8.0 ± 1.1\n\n\n\n\n\n\n \n\n\nM0037-C09\n\n\n11.5 ± 1.9\n\n\n4.2 ± 0.8\n\n\n\n\n\n\n \n\n\nM0037-D01\n\n\n 4.3 ± 0.8\n\n\n1.7 ± 0.3\n\n\n\n\n\n\n \n\n\nM0038-E06\n\n\n16.6 ± 1.2\n\n\n7.2 ± 1.2\n\n\n\n\n\n\n \n\n\nM0031-F01\n\n\n25.3 ± 4.0\n\n\n15.2 ± 4.2 \n\n\n\n\n\n\n \n\n\nM0038-F01\n\n\n 3.8 ± 0.3\n\n\n2.0 ± 0.7\n\n\n\n\n\n\n \n\n\nM0038-F08\n\n\n31.1 ± 3.7\n\n\n23.0 ± 9.7 \n\n\n\n\n\n\n \n\n\nM0043-G02\n\n\n 9.3 ± 1.1\n\n\n 0.3 ± 0.07\n\n\n\n\n\n\n \n\n\nM0033-H07\n\n\n11.5 ± 1.2\n\n\n5.1 ± 1.7\n\n\n\n\n\n\n \n\n\nM0039-H08\n\n\n23.0 ± 2.8\n\n\n7.4 ± 2.0\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \nExample 6\n\n\nK\ni \nvalues for MMP-14 Inhibition by Anti-MMP-14 IgGs\n\n\n \n \n \nThe K\ni \nvalues for MMP-14 inhibition by exemplary IgGs are presented in Table 11. K\ni \nstudies were performed using an enzymatic assay at substrate [Mca-Pro-Lcu-Ala-Cys(Mob)-Trp-Ala-Arg-Dap(Dup)-NH\n2] \nconcentrations of 10 μM, 14 μM and 18 μM. These concentrations were chosen based on the finding that the K\n10\n, for the reaction was 6 μM, and that substrate inhibition occurred at 15-20 μM substrate. The concentration of MMP-14 was 2 nM.\n\n\n \n \n \n \nFive MMP-14 binding IgGs were selected for K\ni \nstudies: M0043-G02. M0037-D01, M037-009, M0038-F01, M0033-H07. The results with each IgG is depicted in \nFIG. 1(\n \na\n)-\n1\n(\nc\n), respectively. The highest K\ni \nmeasured for each of these antibodies is shown in Table 11.\n\n\n \n \n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 11\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nK\ni \nof Human Antibodies that inhibit MMP-14\n\n\n\n\n\n\n\n\n\n\n \n\n\nIsolate\n\n\nK\ni\n \n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nM0043-G02\n\n\n1.2 nM\n\n\n\n\n\n\n \n\n\nM0037-D01\n\n\n2.9 nM\n\n\n\n\n\n\n \n\n\nM0037-C09\n\n\n8.6 nM\n\n\n\n\n\n\n \n\n\nM0038-F01\n\n\n1.2 nM\n\n\n\n\n\n\n \n\n\nM0033-H07\n\n\n4.0 nM\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \nExample 7\n\n\nCross-reactivity of MMP-14 Binding IgGs and Fabs Against Other MMPs and TACE\n\n\n \n \n \nThe cross-reactivity of exemplary anti-MMP-14 IgGs and Fabs with other human MMPs and TACE (TNF-alpha converting enzyme) was examined. MMP and TACE enzymatic activity was monitored in the absence and presence of 1 μM anti-MMP-14 IgG antibody. Inhibition (Y) of activity ranged from approximately 50-80% of the reaction rate observed in the absence of antibody. “X” indicates no inhibition was observed. Cross-reactivity was not determined for MMP-17 because protein activity could not be detected.\n\n\n \n \n \n \nFor the studies summarized in Table 12, six anti-MMP-14 IgGs were selected for cross-reactivity testings: M0043-G02, M0040-A06, M0037-D01, M037-009, M0038-F0.1, M0033-1-107. The results are shown in Tables 5-7.\n\n\n \n \n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 12\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nCross Reactivity of Anti-MMP-14\n\n\n\n\n\n\nIgGs with Other MMPs and TACE\n\n\n\n\n\n\n\n\n\n\n \n\n\nM0043-\n\n\nM0040-\n\n\nM0037-\n\n\nM0037-\n\n\nM0038-\n\n\nM0033-\n\n\n\n\n\n\nMMP\n\n\nG02\n\n\nA06\n\n\nD01\n\n\nC09\n\n\nF01\n\n\nH07\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n1\n\n\nN\n\n\nN\n\n\nN\n\n\nN\n\n\nN\n\n\nN\n\n\n\n\n\n\n2\n\n\nY\n\n\nY\n\n\nN\n\n\nN\n\n\nN\n\n\nN\n\n\n\n\n\n\n3\n\n\nN\n\n\nY\n\n\nN\n\n\nN\n\n\nN\n\n\nN\n\n\n\n\n\n\n7\n\n\nN\n\n\nY\n\n\nN\n\n\nN\n\n\nN\n\n\nN\n\n\n\n\n\n\n8\n\n\nN\n\n\nY\n\n\nN\n\n\nN\n\n\nN\n\n\nN\n\n\n\n\n\n\n9\n\n\nY\n\n\nY\n\n\nN\n\n\nN\n\n\nN\n\n\nN\n\n\n\n\n\n\n10\n\n\nN\n\n\nN\n\n\nN\n\n\nN\n\n\nN\n\n\nN\n\n\n\n\n\n\n12\n\n\nY\n\n\nY\n\n\nN\n\n\nN\n\n\nN\n\n\nN\n\n\n\n\n\n\n13\n\n\nY\n\n\nY\n\n\nN\n\n\nN\n\n\nN\n\n\nN\n\n\n\n\n\n\n16\n\n\nY\n\n\nY\n\n\nY\n\n\nY\n\n\nY\n\n\n \nY\n \n\n\n\n\n\n\n17\n\n\n—\n\n\n—\n\n\n—\n\n\n—\n\n\n—\n\n\n—\n\n\n\n\n\n\n24\n\n\nY\n\n\nY\n\n\nY\n\n\nY\n\n\nN\n\n\nY\n\n\n\n\n\n\nTACE\n\n\nN\n\n\nN\n\n\nN\n\n\nN\n\n\nN\n\n\nN\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \nExample 8\n\n\nCross-Reactivity of MMP-14 Binding Fabs and IgGs with MMP-16\n\n\n \n \n \nFor the studies summarized in Tables 13 and 14, 1.00 nM anti-MMP-14 Fab/IgG were incubated with 5 nM MMP16 for 30 minutes at 30° C., 10 μM of substrate was added, and the MMP-16 activity was measured.\n\n\n \n \n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 13\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nAnti hMMP-14 Fab cross-reactivity with MMP-16\n\n\n\n\n\n\n\n\n\n\n \n\n\nAnti MMP-14 Fab\n\n\nMMP-16\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n \n\n\nM0043-G02\n\n\nY\n\n\n70% inhibition\n\n\n\n\n\n\n \n\n\nM0039-H08\n\n\nX\n\n\n\n\n\n\n \n\n\nM0038-F08\n\n\nX\n\n\n\n\n\n\n \n\n\nM0031-C02\n\n\nX\n\n\n\n\n\n\n \n\n\nM0037-C09\n\n\nX\n\n\n\n\n\n\n \n\n\nM0037-D01\n\n\nX\n\n\n\n\n\n\n \n\n\nM0038-E06\n\n\nX\n\n\n\n\n\n\n \n\n\nM0038-F01\n\n\nX\n\n\n\n\n\n\n \n\n\nM0033-F01\n\n\nX\n\n\n\n\n\n\n \n\n\nM0040-A11\n\n\nX\n\n\n\n\n\n\n \n\n\nM0040-A06\n\n\nX\n\n\n\n\n\n\n \n\n\nM0033-H07\n\n\nX\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nX: Does not inhibit MMP-16 at [l] = 100 nM level\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 14\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nAnti hMMP-14 IgG cross-reactivity against MMP-16\n\n\n\n\n\n\n\n\n\n\n \n\n\nAnti MMP-14 IgG\n\n\nMMP-16\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n \n\n\nM0043-G02\n\n\nY\n\n\n94% inhibition\n\n\n\n\n\n\n \n\n\nM0039-H08\n\n\nX\n\n\n\n\n\n\n \n\n\nM0038-F08\n\n\nX\n\n\n\n\n\n\n \n\n\nM0031-C02\n\n\nX\n\n\n\n\n\n\n \n\n\nM0037-C09\n\n\nX\n\n\n\n\n\n\n \n\n\nM0037-D01\n\n\nX\n\n\n\n\n\n\n \n\n\nM0038-E06\n\n\nX\n\n\n\n\n\n\n \n\n\nM0038-F01\n\n\nX\n\n\n\n\n\n\n \n\n\nM0033-F01\n\n\nX\n\n\n\n\n\n\n \n\n\nM0040-A11\n\n\nX\n\n\n\n\n\n\n \n\n\nM0040-A06\n\n\nX\n\n\n\n\n\n\n \n\n\nM0033-H07\n\n\nX\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nX: Does not inhibit MMP-16 at [l] = 100 nM level\n\n\n\n\n\n\n\n\n\n\n\n\n \nExample 9\n\n\nCross-Reactivity of MMP-14 Binding Fabs with MMP-16 and MMP-24\n\n\n \n \n \nFor the studies summarized in Table 15, 1 μM of anti-MMP-14 Fab/IgG (100 nM final inhibitor concentration) were incubated with 5 nM of MMP-16 or 5 nM of MMP-24 for 30 minutes at 30° C., 10 μM of substrate was added, and the MMP-16 activity was measured.\n\n\n \n \n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 15\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nAnti-hMMP 14 Fab Cross-reactivity Against MMP-16 and MMP-24\n\n\n\n\n\n\n\n\n\n\n \n\n\nAnti-MMP-14 Fab\n\n\nMMP-16\n\n\nMMP-24\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n \n\n\nM0043-G02\n\n\nX\n\n\nY\n\n\n74% inhibition\n\n\n\n\n\n\n \n\n\nM0039-H08\n\n\nX\n\n\nX\n\n\n\n\n\n\n \n\n\nM0038-F08\n\n\nX\n\n\nX\n\n\n\n\n\n\n \n\n\nM0031-C02\n\n\nX\n\n\nY\n\n\n54% inhibition\n\n\n\n\n\n\n \n\n\nM0037-C09\n\n\nX\n\n\nY\n\n\n72% inhibition\n\n\n\n\n\n\n \n\n\nM0037-D01\n\n\nX\n\n\nY\n\n\n71% inhibition\n\n\n\n\n\n\n \n\n\nM0038-E06\n\n\nX\n\n\nX\n\n\n\n\n\n\n \n\n\nM0038-F01\n\n\nX\n\n\nX\n\n\n\n\n\n\n \n\n\nM0033-F01\n\n\nX\n\n\nX\n\n\n\n\n\n\n \n\n\nM0040-A11\n\n\nX\n\n\nY\n\n\n58% inhibition\n\n\n\n\n\n\n \n\n\nM0040-A06\n\n\nX\n\n\nY\n\n\n65% inhibition\n\n\n\n\n\n\n \n\n\nM0033-H07\n\n\nX\n\n\nX\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nX: Do not inhibit MMP-16 or MMP-24 at [l] = 100 nM level\n\n\n\n\n\n\n \n\n\nY: partially inhibit at [l] = 100 nM level\n\n\n\n\n\n\n\n\n\n\n\n\n \nExample 10\n\n\nBinding of MMP-14 IgGs to Tumor Cells Expressing MMP-14\n\n\n \n \n \nThe ability of twelve biotinylated-MMP-14 binding IgGs is to bind to tumor cells expressing MMP-14 was evaluated using both immunocytochemistry (ICC) and Dow cytometry. The cell lines tested were HT-1080 (a human fibrosarcoma cell line), LNCaP (human, prostate, carcinoma), MDA-MB-231 (human, Caucasian, breast, adenocarcinoma), or PC3 (Human prostatic cancer cells) cells. MMP-14 is expressed on HT-1080 cells (Cancer Res. (2005) 65(23):10959-69). MMP-14 is expressed on PC-3 cells (Oncol Rep. (2006) 15(1):199-206). LNCaP express MMP-14 (Endocrinology (2003) 144(5):1656-1663) at a relatively low level. FGF-1 significantly induced MMP-1.4 expression in LNCaP prostate carcinoma cells (Prostate. (2004) 58(1):66-75). MMP-14 is expressed by MDA-MB-231 cells (Int J. Cancer. (2005) 114(4):544-554).\n\n\n \n \n \n \nCells (2×10\n5\n) were cultivated on cell culture slides in complete medium. At confluency, cells were washed with PBS and fixed with 4% paraformaldehyde for 30 minutes at room temperature. Endogenous peroxidases were blocked with 3% hydrogen peroxide for 20 minutes. Nonspecific binding sites were blocked by incubation with 10% heat inactivated \nhuman serum\n 10% normal rabbit serum for 30 minutes at room temperature. Cells were then incubated with biotinylated or non-biotinylated MMP-14 binding proteins at 10 μg/ml for 2 hours at room temperature. Streptavidin IgG/HRP (1/200, where the MMP-14 binding proteins were biotinylated) or anti human IgG/HRP (1/200, for non-biotinylated MMP-14 binding proteins) was then added for 60 minutes at room temperature. Binding was detected with the substrate AEC+(25 minutes at room temperature in the dark). Slides were then dried and mounted using Paramount mounting medium.\n\n\n \n \n \n \nThe results are summarized in Table 16.\n\n\n \n \n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 16\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\nBinding of Anti-MMP-14 IgGs to Tumor Cells Expressing MMP-14\n\n\n\n\n\n\n\n\n\n\n \n\n\nAntibody Staining\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n \n\n\nM0033-H07\n\n\n+++\n\n\n\n\n\n\n \n\n\nM0043-G02\n\n\n−\n\n\n\n\n\n\n \n\n\nM0038-F08\n\n\n++\n\n\n\n\n\n\n \n\n\n \n\n\n(only positive in immunocytochemistry, ICC)\n\n\n\n\n\n\n \n\n\nM0037-C09\n\n\n−\n\n\n\n\n\n\n \n\n\nM0038-F01\n\n\n+++\n\n\n\n\n\n\n \n\n\nM0038-E06\n\n\n−\n\n\n\n\n\n\n \n\n\nM0031-C02\n\n\n−\n\n\n\n\n\n\n \n\n\nM0040-A06\n\n\n−\n\n\n\n\n\n\n \n\n\nM0037-D01\n\n\n−\n\n\n\n\n\n\n \n\n\nM0040-A11\n\n\n−\n\n\n\n\n\n\n \n\n\nM0039-H08\n\n\n++\n\n\n\n\n\n\n \n\n\nM0031-F01\n\n\n+\n\n\n\n\n\n\n \n\n\n \n\n\n(only positive in ICC)\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \nExample 11\n\n\nInhibition of Pro-MMP-2 Activation by MMP-14 by MMP-14 Binding IgGs\n\n\n \n \n \nThe ability of anti-MMP-14 IgGs to inhibit the activation of pro-MMP-2 by MMP-14 was examined by gelatin zymogram experiments performed with PMA-activated HT-1080 cells. M0033-H07 and M0038-F01 were tested for their ability to inhibit MMP-14 in this assay. HT1080 cells (well-known to express MMP-14 and MMP-2) were seeded at 5×10\n5 \ncells/well at \nDay\n 0. At \nDay\n 1, the cells were cultured in a serum-free medium in presence of either GM6001 (a broad-spectrum hydroxamate-based matrix metalloproteinase inhibitor) at 10 μM, or a commercial polyclonal anti-human MMP-14 antibody (this antibody binds, but does not inhibit MMP-14) at. 10 μg/ml (negative control), or M00384:01 at 10 μM, or M0033-H07 at 10 μg/ml. HT-1.080 cells cultured in the presence of 20 ng/ml of PMA were used us a positive control.\n\n\n \n \n \n \nAfter 3 days of incubation, conditioned media were collected and gelatinolytic activities were analyzed by gelatin zymography as described previously (Maquoi et al, J Biol Chem 2000; 275:1:1368-78). The results are shown in \nFIG. 2\n. When HT-1080 cells are activated with a phorbol ester, pro-MMP-2 is activated into MMP-2 (lane 1). In presence of GM6001 (10 μM) (lane 2), activation of pro-MMP-2 is completely abolished but expression of pro-MMP-9 is paradoxically stimulated, as described in the literature (Maquoi E et al, 1999, Ann N Y Acad. Sci., 30878:744-6). As expected, the commercial polyclonal anti-MMP-14 antibody does not affect expression or activation of gelatinases (lane 3). Interestingly, M0038-F01 completely inhibits pro-MMP-2 activation by MMP-14 (lane 4), while M0033-H07 partly inhibited pro-MMP-14 activation by MMP-14 (lane 5). No stimulation of pro-MMP-9 expression was observed in both conditions.\n\n\n \nExample 12\n\n\nGermlining of M0038-F01 and M0033-H07\n\n\n \n \n \nThe sequences of M0038-F01 and M0033-H07 were compared with human germline sequence and modified where possible to achieve identity with the germline. Sequences of the germlined antibodies, designated M0038-F01 germline and M0033-H07 germline are shown in Table 17 (underlined portions indicate the signal sequence).\n\n\n \n \n \n \nGermlined antibodies were tested for binding affinity and MMP-14 inhibitory activity in comparison with the parental antibodies.\n\n\n \n \n \n \nBinding of M0038F01 germline and 539C-M0033-H07 germline to biotinylated human MMP-14 (bhMMP-14) was tested in an ELISA format essentially as described in previous examples. 539C-M0038-F01 germline was tested against bhMMP-14 both directly adsorbed to the ELISA plate and bound to the plate via streptavidin, 539C-M0033-H07 germline was tested against directly adsorbed bhMMP-14 only. Results, shown in \nFIG. 3\n, indicate that both germlined antibodies retain binding to WIMP-14.\n\n\n \n \n \n \nIC\n50\n's were determined for both germlined antibodies, using 2 pM MMP-14. Results, shown in \nFIG. 4\n, demonstrate that the IC50's of the germlined antibodies (the panels labeled “Germlined”) are the similar to those of the parental antibodies, and that 539C-M0038F01 Germlined has an improved IC50 as compared to the parental antibody.\n\n\n \n \n \n \nInhibitory activity of the germlined antibodies was tested in the HT-1080 zymogram assay. Results are shown in \nFIG. 5\n (lanes, from left to right, are no antibody, 100 nM antibody, 50 nM antibody, 10 nM antibody, 1 nM antibody, and 0.1 nM antibody). The ratio of pro-MMP-2:MMP-2 indicates the MMP-14 inhibitory activity of the antibody (higher ratios indicate greater inhibitory activity),\n\n\n \n \n\n\n\n\n\n\n\n\n\n\n\n\nTABLE 17\n\n\n\n\n\n\n \n\n\n\n\n\n\nSequences of Germlined Antibodies\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n>MMP-14-M0033H07 germline-Light chain\n\n\n\n\n\n\nMGWSCIILFLVATATGVHSDIQMTQSPSSLSASVGDRVTITCRASQGIRNFLAWYQQKPGKVPKLLIYGA\n\n\n\n\n\n\nSALQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNGVPLTFGGGTKVEIKRTVAAPSVFIFPPS\n\n\n\n\n\n\nDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKV\n\n\n\n\n\n\nYACEVTHQGLSSPVTKSFNRGEC\n\n\n\n\n\n\n(SEQ ID NO: 179)\n\n\n\n\n\n\n \n\n\n\n\n\n\n>MMP-14-M0033H07 germline-Heavy chain\n\n\n\n\n\n\nMGWSCIILFLVATATGAHSEVQLLESGGGLVQPGGSLRLSCAASGFTFSVYGMVWVRQAPGKGLEWVSVI\n\n\n\n\n\n\nSSSGGSTWYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARPFSRRYGVFDYWGQGTLVTVSSA\n\n\n\n\n\n\nSTKGPSVTPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV\n\n\n\n\n\n\nPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE\n\n\n\n\n\n\nVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL\n\n\n\n\n\n\nPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL\n\n\n\n\n\n\nDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK\n\n\n\n\n\n\n(SEQ ID NO: 180)\n\n\n\n\n\n\n \n\n\n\n\n\n\n>MMP-14-M0038f01 germline-Light chain\n\n\n\n\n\n\nMGWSCIILFLVATATGVHSDIQMTQSPSSLSASVGDRVTITCRASQSVGTYLNWYQQKPGKAPKLLIYAT\n\n\n\n\n\n\nSNLRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSIPRFTFGPGTKVDIKRTVAAPSVFIFPP\n\n\n\n\n\n\nSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHK\n\n\n\n\n\n\nVYACEVTHQSLSSPVTKSFNRGEC\n\n\n\n\n\n\n(SEQ ID NO: 181)\n\n\n\n\n\n\n \n\n\n\n\n\n\n>MMP-14-M0038f01 germline-Heavy chain\n\n\n\n\n\n\nMGWSCIILFLVATATGAHSEVQLLESGGGLVQPGGSLRLSCAASGFTFSLYSMNWVRQAPGKGLEWVSSI\n\n\n\n\n\n\nYSSGGSTLYADSVKGRFTISRDNSKNTLYLQMNSLREADTAVYYCARGRAFDIWGQGTMVTVSSASTKGP\n\n\n\n\n\n\nSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSL\n\n\n\n\n\n\nGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV\n\n\n\n\n\n\nVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE\n\n\n\n\n\n\nKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS\n\n\n\n\n\n\nFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK\n\n\n\n\n\n\n(SEQ ID NO: 182)\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \nExample 13\n\n\nInhibition of Tube Formation by MMP-14 Binding IgGs\n\n\n \n \n \nHuman umbilical vascular endothelium cells (HUVECs) were seeded into MATRIGEL™ basement membrane extract-coated 96 well plates at 20,000 or 40,000 cells in 100 μl/well. The seeded cells were incubated for 30 minutes, then the various test articles were added (vehicle control. M0038-F01 at concentrations ranging from 1 nM to 250 nM, or \nsuramin\n 8 mg/ml). The cells were incubated at 37° for 18 hours. 100 μl of calcein solution (8 μg/ml) was added 20 minutes prior to image capture. Representative photomicrographs are shown in \nFIG. 6A\n. Woe lengths were also quantified. Tube length measurements are summarized in \nFIG. 6B\n. M0038-F01 dose-dependently inhibits tube formation in the dose-range tested.\n\n\n \nExample 14\n\n\nInhibition of MDA-MB-231 Tumor Growth and Metastasis by MMP-14 Binding IgGs\n\n\n \n \n \nHuman breast cancer cells MDA-MB-231 cells transfected with green fluorescent protein (MDA-MB-231-GFP) were inoculated into the mammary fat pad of female BALB/c nu/nu mice with Matrigel. Animals were monitored for tumor growth, and at week 4-5 post tumor cell inoculation, animals with tumors of 30-50 mm\n3 \nwere selected, randomized and divided into experimental groups. Animals were treated with vehicle alone (control, n=9) doxorubicin (DOX, 5 mg/kg, administered weekly by intraperitoneal (IP) injection for 5 weeks, n=9, although one animal died during the experiment, between \nweeks\n 5 and 6), MMP-14 binding antibody M0038-F01 (10 mg/kg, administered on alternating days (Q2d) by IP injection for five weeks, n=8), or an IgG isotype control antibody specific for streptavidin (A2, administered 10 mg/kg, Q2d by IP injection for live weeks, n=8). Tumor volume was measured weekly, stalling at \nweek\n 5. Additionally, tissue samples of lung, liver, and spleen were taken to assess metastasis.\n\n\n \n \n \n \nTumor volume results are summarized in \nFIG. 7\n. Tumor volumes increased rapidly in animals treated with either vehicle or the isotype control (A2). Tumor growth was substantially inhibited in the animals treated with either DOX or M0038-F01.\n\n\n \n \n \n \nThere was a statistically significant reduction in lung and liver metastases in animals treated with DOX or M0038-F01 as compared to controls. Metastases to spleen were reduced in DOX and M0038-F01 treated annuals, but the difference was not statistically significant in this experiment.\n\n\n \n \n \n \nA dose-ranging experiment was performed to examine dose-response to MMP-14 binding antibody M0038-F01. Animals were inoculated with MDA-MB-231-GFP cells as described above, then selected and randomized, and divided into experimental groups of 8 animals each. Animals were treated with vehicle alone (control), DOX (5 mg/kg weekly by IP injection for 5 weeks), M0038-F01 (0.1, 1, or 10 mg/kg Q2d by IP injection for 5 weeks), or the IgG isotype control A2 (10 mg/kg Q2d by IP injection for live weeks). Tumor volume was measured weekly, starting at \nweek\n 5.\n\n\n \n \n \n \nResults from the dose-ranging experiment are summarized in \nFIG. 8\n. As in the previous experiment, tumor volumes increased rapidly in animals treated with either vehicle or the isotype control (A2). Tumor growth was reduced in all M0038-F01 treated animals, with the mg/kg dose being most effective, followed by the 1 mg/kg and 0.1 mg/kg doses.\n\n\n \n \n \n \nTumor tissue samples were collected on \nday\n 35 post-treatment for immunohistochemical analysis. Paraffin-embedded tissue samples were sectioned, stained with CD31 (Santa Cruz Biotechnology Inc., Santa Cruz, Calif., USA), Ki-67 (DAKO, Carpinteria, Calif., USA), MAPK, FAK, phosphoMAPK or phosphoFAK antibodies, visualized with biotinylated secondary antibodies using a VECTASTAINO ABC (Vector Laboratories Inc., Burlingame, Calif., USA), and lightly counterstained with haemotoxylin.\n\n\n \n \n \n \nImmunostaining was quantitated by computer-assisted image analysis et al., 2005, Oncogene, 24: 6657-66), While CD31 and KI67 levels were slightly reduced in doxorubincin-treated tumors as compared to both vehicle and IgG isotype (A2) controls, M0038-F01-treated tumors had statistically significant (p<0.05) reductions in both CD31 and KI67. These data are summarized in Table 18. M0038-F01-treated tumors also had significantly reduced levels of phospho-MAP kinase and phospho-FAK (2.4±0.7 and 4±1.2, respectively) as compared to controls (7.4±0.7; 6.9±0.9 A.U.), but total MAP kinase and FAK levels were essentially the same as in control tumors. Doxorubicin treated resulted in statistically significant reductions (p<0.05) in levels of total MAP kinase (5.8±1.9 A.U.) and FAK (6±1 A.U.) as well as phospho-MAP kinase (5.8±1.9 A.U.) and phospho-FAK (4±1.2 A.U.).\n\n\n \n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nTABLE 18\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nTreatment\n\n\nCD31\n\n\nKi67\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\nVehicle\n\n\n 5.2 ± 0.75\n\n\n  6 ± 1.38\n\n\n\n\n\n\n \n\n\nA2\n\n\n4.7 ± 0.7\n\n\n5.9 ± 1.64\n\n\n\n\n\n\n \n\n\nDOX\n\n\n4.08 ± 1.28\n\n\n5.2 ± 0.84\n\n\n\n\n\n\n \n\n\nM0038-F01\n\n\n2.0 ± 0.6\n\n\n2.4 ± 1.2 \n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n \nA dose-ranging experiment was performed to examine dose-response to MMP-14 binding antibody M0038-F01. Animals were inoculated with MDA-MB-23-GFP cells as described above, then selected and randomized, and divided into experimental groups or 8 animals each. Animals were treated with vehicle alone (control). DOX (5 mg/kg weekly by IP injection for 5 weeks), M0038-F01 (0.1, 1, or 10 mg/kg Q2d by IP injection for 5 weeks), or the IgG isotype control A2 (10 mg/kg Q2d by IP injection for five weeks). Tumor volume was measured weekly, starting at \nweek\n 5.\n\n\n \n \n \n \nResults from the dose-ranging experiment are summarized in \nFIG. 8\n. As in the previous experiment, tumor volumes increased rapidly in animals treated with either vehicle or the isotype control (A2). Tumor growth was reduced in all M0038-F01 treated animals, with the mg/kg dose being most effective, followed by the 1 mg/kg and 0.1 mg/kg doses.\n\n\n \nExample 15\n\n\nInhibition of MDA-MB-435 Breast Tumor Growth by MMP-14 Binding IgGs\n\n\n \n \n \nFragments of MDA-MB-435 GFP (MDA-MB-435 cells expressing green fluorescent protein) tumors were transplanted by surgical orthotopic implantation (SOI) into the right second mammary gland. Treatment was started on day 15 alter SOI when the volume of primary tumors reached about 85 mm\n3\n. Animals were treated with vehicle alone (Control, n=10), taxotere (10 mg/kg, administered QWx3, i.v., n=10), MMP-14 binding antibody M0038-F01 (0.1, 1, or 10 mg/kg, administered on alternating days (Q2d) by IP injection for five weeks, n=10), or an IgG isotype control antibody specific for streptavidin (A2, administered 10 mg/kg Q2d by IP injection for five weeks, n=10). Tumor volume was measured weekly, starting at \nweek\n 5.\n\n\n \n \n \n \nMice were sacrificed at day 61 after the start of the treatment and tumors (primary and metastases) were identified by fluorescent imaging. Additionally, primary tumors were excised and weighed. The tumor volume results are summarized in \nFIG. 9\n. The administration of 1 or 10 mg/kg doses of M0038-F01 resulted in a reduction of tumor volume as did administration of taxotere. Tumor mass results are summarized in Table 19 (asterisks indicate values that are significantly different (p≦0.05) compared to Control). Tumor mass results were comparable to tumor volume data. However, M0038-F01 was not effective in reducing lymph node or lung metastases in this experiment.\n\n\n \n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\nTABLE 19\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n \n\n\nGroup\n\n\nTumor Mass (± SD)\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n \n\n\nControl\n\n\n1.44 ± 0.85\n\n\n\n\n\n\n \n\n\nA2\n\n\n1.34 ± 0.66\n\n\n\n\n\n\n \n\n\nF01 0.1 mg/kg\n\n\n1.54 ± 0.91\n\n\n\n\n\n\n \n\n\n \nF01\n 1 mg/kg\n\n\n0.86 ± 0.21*\n\n\n\n\n\n\n \n\n\n \nF01\n 10 mg/kg\n\n\n0.82 ± 0.35*\n\n\n\n\n\n\n \n\n\nTaxotere\n\n\n0.59 ± 0.59*\n\n\n\n\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \nExample 6\n\n\nInhibition of B16 Melanoma Tumor Growth by MMP-14 Binding Antibodies\n\n\n \n \n \nB16F1 melanoma cells were implanted into Female C57/13L6 (CR) mice (4-6 Weeks old) mice by subcutaneous injection. Animals were monitored for tumor growth and, at \nday\n 11 post-implantation, animals were selected, randomized and divided into experimental groups. Animals were treated with vehicle alone (Control, n=8), doxorubicin (DOX, 5 mg/kg, administered weekly by intraperitoneal (IP) injection, n=8), MMP-14 binding antibody M0038-F01 (10, 1, or 0.1 mg/kg, administered on alternating days (Q2d) by IP injection, n=8), or an IgG isotype control antibody specific for streptavidin (A2, administered 10 mg/kg Q2d by IP injection, n=8).\n\n\n \n \n \n \nResults are summarized in \nFIG. 10A\n. All doses of M0038-F01 were effective in reducing tumor growth in this model, as was doxorubicin.\n\n\n \n \n \n \nMMP-14 binding antibodies were also tested in a model of melanoma metastasis. B16F1 cells were grown in culture, harvested at 85% confluence and inoculated at 5×10\n5 \ncells/mouse in 100 μl saline by tail vein injection. Treatment started on \nDay\n 1, post inoculation, for 14 days. Animals were treated with vehicle alone (Control, n=8), doxonibicin (DOX, 5 mg/kg, administered weekly by intraperitoneal (IP) injection, n=8), MMP-14 binding antibody M0038-F01 (F01, 10 mg/kg, administered on alternating days (Q2d) by IP injection, n=8), or an IgG isotype control antibody specific for streptavidin (A2, administered 10-mg/kg Q2d by IP injection, n=8). On day 15, animals were sacrificed and lungs taken, fixed, and analyzed for the number of metastases (nodules). Results are summarized in \nFIG. 10B\n. MMP-14 binding antibody substantially reduced the number of lung melanoma-tumors in a dose-dependent manner.\n\n\n \nExample 17\n\n\nInhibition of Prostate-Tumor Growth by MMP-14 Binding Antibodies\n\n\n \n \n \nPC3 prostate cancer cells were implanted into male nude mice by subcutaneous injection. Animals were monitored for tumor growth, and at \nweek\n 3 post tumor cell inoculation, animals with tumors of 50-100 mm\n3 \nwere selected, randomized and divided into experimental groups. Animals were treated with vehicle alone (Control, n=8), taxotere (10 mg/kg, administered weekly by IP injection, n=8), MMP-14 binding antibody M0038-F01 (10, 1, or 0.1 mg/kg, administered on alternating days (Q2d) by IP injection, n=8), or an IgG isotype control antibody specific for streptavidin (A2, administered 10 mg/kg Q2d, n=8). Tumor volume was measured weekly, starting at \nweek\n 3.\n\n\n \n \n \n \nResults from the dose-ranging experiment are summarized in \nFIG. 11\n. As in the previous experiment, tumor volumes increased rapidly in animals treated with either vehicle or the isotype control (A2). Tumor growth was reduced in all M0038-F01 treated animals, with the mg/kg dose being most effective, followed by the 1 mg/kg and 0.1 mg/kg doses. Taxotere was extremely effective in this model.\n\n\n \nExample 18\n\n\nInhibition of BT747 Breast Tumor Growth by MMP-14 Binding Antibodies\n\n\n \n \n \nFragments (approximately 1 mm\n2\n) of BT747 breast cancer tumor fragments were implanted into the flanks of female HRLN CB.17 SCID mice. Tumors were allowed to grow until they reached an average size of 80-120 mg, then animals were assorted into six experimental groups often animals each: vehicle alone (Vehicle), trastuzumab (HERCEPTINg. 20 mg/kg), MMP-14 binding antibody M0038-F01 (10, 1, or 0.1 mg/kg, administered on alternating days (Q2d)) or an IgG isotype control antibody specific for streptavidin (A2, 10 mg/kg Q2d). All groups were dosed by intraperitoneal (IP) injection. Tumor volume was measured biweekly.\n\n\n \n \n \n \nAdditionally, a seventh group of ten animals hearing large tumors (288 mm\n3\n) was selected for testing with a combination therapy (M0038-F01, 10 mg/kg Q2d, starting at \nday\n 3 plus trastuzumab, 20 mg/kg biweekly, starting at day 4).\n\n\n \n \n \n \nData from the small initial tumor size groups (i.e., initial tumor size 80-120 mm\n3\n) showed inhibition of tumor growth by MMP-14 binding antibody M0038-F01, with the highest dose resulting in the greatest inhibition of tumor growth. Trastuzumab inhibited tumor growth to an extent similar to 10 mg/kg M0038-F01. The effect of the combination of MMP-14 binding antibody M0038-F01 and trastuzumab on large tumors is unclear, as insufficient animals with large tumors were available to serve as controls for this group, however it was noted that the growth rate of tumors treated with M0038-F01 and trastuzumab was lower than the growth rate of controls of similar size (i.e., the vehicle, and A2 controls. Results are summarized graphically in \nFIG. 12\n.\n\n\n \nExample 19\n\n\nMMP-14 in Mouse Models Of Arthritis\n\n\n \n \n \nAntigen-induced arthritis, a model of rheumatoid arthritis, was induced by intraarticular injection of \nStreptococcus \ncell wall (SCW, 25 mg/6 ml) into the knee joints of C57B16 mice at \n \n \n \nday\n \n \n \n 0, 7, 14 and 21.\n\n\n \n \n \n \nMMP14 expression in acute phase SCW-induced arthritis (7 days after the first injection of SCW) was examined by immunohistochemical staining using M0038-F01. M0038-F01, but not an isotype-matched control, strongly stained synovial cells and chondrocytes as well as macrophages in joint exudate.\n\n\n \n \n \n \nMice were assorted into groups of six animals each and treated (by IP injection) with M0038-F01 (2, 6, or 10 mg/kg), a control isotype-matched antibody (control, 20 mg/ml), or etancrecpt (ENBREL®, 5 mg/ml) at \n \n \nday\n \n \n 13, 16, 20, and 23. Joint swelling (measured by technetium uptake) was measured at \n \nday\n \n 15, 16, 22, 23 and 28. M0038-F01 did not have an effect on joint swelling in this experiment.\n\n\n \n \n \n \nA number of embodiments attic invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims."
  },
  {
    "id": "EP2448920A1",
    "text": "Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics AbstractThe present invention relates to novel benzenesulfonamide compounds having a structure of formula (I), as well as to the method for synthesizing same and to the use thereof in pharmaceutical compositions to be used in human or veterinary medicine, as well as to the use thereof in cosmetic compositions. Claims\n\n\n\n\n\n\n \nRevendications \n claims\n\n\n\n\n\n\n\n\n \n1. Composé de formule générale (I) suivante : \n1. Compound of general formula (I) below:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \ndans laquelle \nin which\n\n\n\n\n\n\n \n R\n1\n représente un hydrogène, un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué, un radical - C(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, un radical C(O)OR4, R\n4\n ayant les significations données ci-après; \nR \n1\n is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aralkyl, substituted aralkyl, heteroaralkyl, substituted heteroaralkyl a radical - C (O) -R \n4\n , a radical -SO \n2\n -R \n4\n , a radical C (O) OR \n4\n , R \n4\n having the meanings given below;\n\n\n\n\n\n\n \nR\n2\n est un atome d'hydrogène ou un radical alkyle inférieur ; \nR \n2\n is a hydrogen atom or a lower alkyl radical;\n\n\n\n\n\n\n \n R\n3\n est un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétérocyclique, un radical hétérocyclique substitué, un radical cycloalkyle, un radical cycloalkyle substitué, un radical hétéroaryle, un radical hétéroaryle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué ; \nR \n3\n is an alkyl radical, a substituted alkyl radical, an alkenyl radical, a substituted alkenyl radical, an alkynyl radical, a substituted alkynyl radical, an aryl radical, a substituted aryl radical, an aralkyl radical, a substituted aralkyl radical or a radical. heterocyclic, a substituted heterocyclic radical, a cycloalkyl radical, a substituted cycloalkyl radical, a heteroaryl radical, a substituted heteroaryl radical, a heteroaralkyl radical, a substituted heteroaralkyl radical;\n\n\n\n\n\n\n \n R\n4\n est un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ; \nR \n4\n is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, aralkyl, substituted aralkyl;\n\n\n\n\n\n\n \nn peut prendre les valeurs de 0, 1 , 2 ou 3 ; \nn can take the values of 0, 1, 2 or 3;\n\n\n\n\n\n\n \nainsi que les sels d'addition des composés de formule générale (I) avec un acide pharmaceutiquement acceptable, les sels d'addition des composés de formule générale (I) avec une base pharmaceutiquement acceptable et les énantiomères des composés de formule générale (I). \nas well as the addition salts of the compounds of general formula (I) with a pharmaceutically acceptable acid, the addition salts of the compounds of general formula (I) with a pharmaceutically acceptable base and the enantiomers of the compounds of general formula (I) .\n\n\n\n\n\n\n\n\n\n\n \n2. Sel d'addition avec un acide pharmaceutiquement acceptable d'un composé selon la revendication 1 caractérisé en ce que l'acide pharmaceutiquement acceptable est choisi dans la liste constituée par l'acide chlorhydrique, l'acide bromhydrique, l'acide sulfurique, l'acide nitrique, l'acide phosphorique, l'acide acétique, l'acide trifluoroacétique, l'acide trichloroacétique, l'acide propionique, l'acide glycolique, l'acide pyruvique, l'acide succinique, l'acide benzoïque, l'acide cinnamique, l'acide mandélique, l'acide methanesulfonique, l'acide para-toluène sulfonique, l'acide salicylique, l'acide picrique, l'acide citrique, l'acide oxalique, l'acide tartrique, l'acide malonique, l'acide maléique, l'acide camphorsulfonique et l'acide fumarique.  \n2. Pharmaceutically acceptable acid addition salt of a compound according to claim 1, characterized in that the pharmaceutically acceptable acid is chosen from the list consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, trifluoroacetic acid, trichloroacetic acid, propionic acid, glycolic acid, pyruvic acid, succinic acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, para-toluene sulfonic acid, salicylic acid, picric acid, citric acid, oxalic acid, tartaric acid, malonic acid, maleic acid, camphorsulfonic acid and fumaric acid. \n\n\n\n\n\n\n\n\n\n\n \n3. Sel d'addition avec une base pharmaceutiquement acceptable d'un composé selon la revendication\n3. Addition salt with a pharmaceutically acceptable base of a compound according to claim\n\n\n\n\n\n\n \n1 caractérisé en ce que la base pharmaceutiquement acceptable est choisie dans la liste constituée par l'hydroxyde de potassium, l'hydroxyde de sodium, l'hydroxyde de lithium, l'hydroxyde de calcium, la methylamine, l'ethylamine, l'éthanolamine, la propylamine, l'isopropylamine, les 4 isomères de la butylamine, la diméthylamine, diethylamine, la diethanolamine, la dipropylamine, la diisopropylamine, la di n-butylamine, la pyrrolidine, la piperidine, la morpholine, la diethanol phenylamine, la trimethylamine, la triethylamine, la tripropylamine, la quinuclidine, la pyridine, la quinoline, l'isoquinoline, la lysine, l'arginine et l'ornithine. \n1 characterized in that the pharmaceutically acceptable base is selected from the list consisting of potassium hydroxide, sodium hydroxide, lithium hydroxide, calcium hydroxide, methylamine, ethylamine, ethanolamine , propylamine, isopropylamine, the 4 isomers of butylamine, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, diethanol phenylamine, trimethylamine , triethylamine, tripropylamine, quinuclidine, pyridine, quinoline, isoquinoline, lysine, arginine and ornithine.\n\n\n\n\n\n\n\n\n\n\n \n4. Composé selon l'une des revendications 1 à 3 caractérisé en ce que \n4. Compound according to one of claims 1 to 3 characterized in that\n\n\n\n\n\n\n \n R\n1\n représente un hydrogène, un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué, un radical -\nR \n1\n is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aralkyl, substituted aralkyl, heteroaralkyl, substituted heteroaralkyl , a radical -\n\n\n\n\n\n\n \nC(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, un radical C(O)OR4, R\n4\n ayant les significations données ci-après; \nC (O) -R \n4\n , a radical -SO \n2\n -R \n4\n , a radical C (O) OR \n4\n , R \n4\n having the meanings given below;\n\n\n\n\n\n\n \n R\n2\n est un atome d'hydrogène ou un radical alkyle inférieur ; \nR \n2\n is a hydrogen atom or a lower alkyl radical;\n\n\n\n\n\n\n \n R\n3\n est un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétérocyclique, un radical hétérocyclique substitué, un radical hétéroaryle, un radical hétéroaryle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué ; \nR \n3\n is aryl, substituted aryl, aralkyl, substituted aralkyl, heterocyclic, substituted heterocyclic, heteroaryl, substituted heteroaryl, heteroaralkyl, substituted heteroaralkyl;\n\n\n\n\n\n\n \n R\n4\n est un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ; \nR \n4\n is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, aralkyl, substituted aralkyl;\n\n\n\n\n\n\n \nn peut prendre les valeurs de 0, 1 , 2; \nn can take the values of 0, 1, 2;\n\n\n\n\n\n\n \nainsi que leurs sels d'addition avec un acide pharmaceutiquement acceptable, leurs sels d'addition avec une base pharmaceutiquement acceptable et les énantiomères desdits composés. \nas well as their addition salts with a pharmaceutically acceptable acid, their addition salts with a pharmaceutically acceptable base and the enantiomers of said compounds.\n\n\n\n\n\n\n\n\n\n\n \n5. Composé selon l'une des revendications 1 à 3 caractérisé en ce que \n5. Compound according to one of claims 1 to 3 characterized in that\n\n\n\n\n\n\n \n R\n1\n représente un hydrogène, un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical -C(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, R\n4\n ayant les significations données ci-après; \nR \n1\n represents a hydrogen, an alkyl radical, a substituted alkyl radical, an alkenyl radical, a substituted alkenyl radical, an alkynyl radical, a substituted alkynyl radical, an aralkyl radical, a substituted aralkyl radical or a -C (O) - radical; R \n4\n , a radical -SO \n2\n -R \n4\n , R \n4\n having the meanings given below;\n\n\n\n\n\n\n \nR\n2\n est un atome d'hydrogène ou un radical alkyle inférieur ; \nR \n2\n is a hydrogen atom or a lower alkyl radical;\n\n\n\n\n\n\n \n R\n3\n est un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétérocyclique, un radical hétérocyclique substitué, un radical hétéroaryle, un radical hétéroaryle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué ; \nR \n3\n is aryl, substituted aryl, aralkyl, substituted aralkyl, heterocyclic, substituted heterocyclic, heteroaryl, substituted heteroaryl, heteroaralkyl, substituted heteroaralkyl;\n\n\n\n\n\n\n \nR\n4\n est un radical alkyle, un radical alkyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ;  n peut prendre les valeurs de 1 ou 2; \nR \n4\n is an alkyl radical, a substituted alkyl radical, an aryl radical, a substituted aryl radical, an aralkyl radical, a substituted aralkyl radical;  n can take the values of 1 or 2;\n\n\n\n\n\n\n \nainsi que leurs sels d'addition avec un acide pharmaceutiquennent acceptable, leurs sels d'addition avec une base pharmaceutiquennent acceptable et les énantiomères desdits composés. \nas well as their addition salts with a pharmaceutically acceptable acid, their addition salts with a pharmaceutically acceptable base and the enantiomers of said compounds.\n\n\n\n\n\n\n\n\n\n\n \n6. Composé selon l'une des revendications 1 à 3 caractérisé en ce que \n6. Compound according to one of claims 1 to 3 characterized in that\n\n\n\n\n\n\n \n R\n1\n représente un radical alkyle, un radical alkyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical -C(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, R\n4\n ayant les significations données ci-après; \nR \n1\n represents an alkyl radical, a substituted alkyl radical, an aralkyl radical, a substituted aralkyl radical, a -C (O) -R \n4\n radical, a radical -SO \n2\n -R \n4\n , R \n4\n having the meanings given below. ;\n\n\n\n\n\n\n \nR\n2\n est un atome d'hydrogène ; \nR \n2\n is a hydrogen atom;\n\n\n\n\n\n\n \nR\n3\n est un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétérocyclique, un radical hétérocyclique substitué, un radical hétéroaryle, un radical hétéroaryle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué ; \nR \n3\n is aryl, substituted aryl, aralkyl, substituted aralkyl, heterocyclic, substituted heterocyclic, heteroaryl, substituted heteroaryl, heteroaralkyl, substituted heteroaralkyl;\n\n\n\n\n\n\n \nR\n4\n est un radical alkyle, un radical alkyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ; \nR \n4\n is an alkyl radical, a substituted alkyl radical, an aryl radical, a substituted aryl radical, an aralkyl radical, a substituted aralkyl radical;\n\n\n\n\n\n\n \nn prend la valeur de 1 ; \nn takes the value of 1;\n\n\n\n\n\n\n \nainsi que leurs sels d'addition avec un acide pharmaceutiquement acceptable, leurs sels d'addition avec une base pharmaceutiquement acceptable et les énantiomères desdits composés. \nas well as their addition salts with a pharmaceutically acceptable acid, their addition salts with a pharmaceutically acceptable base and the enantiomers of said compounds.\n\n\n\n\n\n\n\n\n\n\n \n7. Composé selon l'une des revendications 1 à 3 caractérisé en ce \n7. Compound according to one of claims 1 to 3 characterized in that\n\n\n\n\n\n\n \nR\n1\n représente un radical alkyle, un radical alkyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical -C(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, R\n4\n ayant les significations données ci-après; \nR \n1\n represents an alkyl radical, a substituted alkyl radical, an aralkyl radical, a substituted aralkyl radical, a -C (O) -R \n4\n radical, a radical -SO \n2\n -R \n4\n , R \n4\n having the meanings given below. ;\n\n\n\n\n\n\n \nR\n2\n est un atome d'hydrogène ; \nR \n2\n is a hydrogen atom;\n\n\n\n\n\n\n \n R\n3\n est un radical hétérocyclique, un radical hétérocyclique substitué, un radical hétéroaryle, un radical hétéroaryle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué ; \nR \n3\n is a heterocyclic radical, a substituted heterocyclic radical, a heteroaryl radical, a substituted heteroaryl radical, a heteroaralkyl radical, a substituted heteroaralkyl radical;\n\n\n\n\n\n\n \nR\n4\n est un radical alkyle, un radical alkyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ; \nR \n4\n is an alkyl radical, a substituted alkyl radical, an aryl radical, a substituted aryl radical, an aralkyl radical, a substituted aralkyl radical;\n\n\n\n\n\n\n \nn prend la valeur de 1 ; \nn takes the value of 1;\n\n\n\n\n\n\n \nainsi que leurs sels d'addition avec un acide pharmaceutiquement acceptable, leurs sels d'addition avec une base pharmaceutiquement acceptable et les énantiomères desdits composés. \nas well as their addition salts with a pharmaceutically acceptable acid, their addition salts with a pharmaceutically acceptable base and the enantiomers of said compounds.\n\n\n\n\n\n\n\n\n\n\n \n8. Composé selon l'une des revendications 1 à 3 caractérisé en ce que \n8. Compound according to one of claims 1 to 3 characterized in that\n\n\n\n\n\n\n \n R\n1\n représente un radical alkyle, un radical alkyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical -C(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, R\n4\n ayant les significations données ci-après; \nR \n1\n represents an alkyl radical, a substituted alkyl radical, an aralkyl radical, a substituted aralkyl radical, a -C (O) -R \n4\n radical, a radical -SO \n2\n -R \n4\n , R \n4\n having the meanings given below. ;\n\n\n\n\n\n\n \nR\n2\n est un atome d'hydrogène ; \nR \n2\n is a hydrogen atom;\n\n\n\n\n\n\n \n R\n3\n est un radical hétéroaryle, un radical hétéroaryle substitué, \nR \n3\n is a heteroaryl radical, a substituted heteroaryl radical,\n\n\n\n\n\n\n \n R\n4\n est un radical alkyle, un radical alkyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ; \nR \n4\n is an alkyl radical, a substituted alkyl radical, an aryl radical, a substituted aryl radical, an aralkyl radical, a substituted aralkyl radical;\n\n\n\n\n\n\n \nn prend la valeur de 1 ;  ainsi que leurs sels d'addition avec un acide pharmaceutiquement acceptable, leurs sels d'addition avec une base pharmaceutiquement acceptable et les énantiomères desdits composés. \nn takes the value of 1;  as well as their addition salts with a pharmaceutically acceptable acid, their addition salts with a pharmaceutically acceptable base and the enantiomers of said compounds.\n\n\n\n\n\n\n\n\n\n\n \n9. Composé selon l'une des revendications 1 à 8 choisi dans la liste constituée par les composés suivants : \n9. Compound according to one of claims 1 to 8 selected from the list consisting of the following compounds:\n\n\n\n\n\n\n \n 1 ) 3-[(4-but-2-ynyloxy-benzènesulfonyl)-méthyl-amino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-propionamide \n 1) 3 - [(4-But-2-ynyloxy-benzenesulfonyl) -methyl-amino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 2) (S)-3-(4-but-2-ynyloxy-benzènesulfonylamino)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)- propionamide \n 2) (S) -3- (4-But-2-ynyloxy-benzenesulfonylamino) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n3) (S)-3-(4-benzyloxy-benzènesulfonylamino)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)- propionamide \n3) (S) -3- (4-Benzyloxy-benzenesulfonylamino) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 4) (S)-3-[(4-benzyloxy-benzènesulfonyl)-méthyl-amino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-propionamide \n 4) (S) -3 - [(4-Benzyloxy-benzenesulfonyl) -methyl-amino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 5) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide \n 5) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n 6) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(naphthalen-1-ylméthoxy)- benzènesulfonylamino]-propionamide \n 6) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (naphthalen-1-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n 7) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-(4-propoxy-benzènesulfonylamino)- propionamide \n 7) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- (4-propoxy-benzenesulfonylamino) -propionamide\n\n\n\n\n\n\n \n8) (S)-3-[4-(3-cyano-benzyloxy)-benzènesulfonylamino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-propionamide \n8) (S) -3- [4- (3-cyano-benzyloxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 9) (S)-3-[4-(4-cyano-benzyloxy)-benzènesulfonylamino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-propionamide \n 9) (S) -3- [4- (4-cyano-benzyloxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 10) 4-{(S)-1-hydroxycarbamoyl-2-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-éthyl}- pipérazine-1-carboxylate de benzyle \n 10) Benzyl 4 - {(S) -1-hydroxycarbamoyl-2- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] ethyl} piperazine-1-carboxylate\n\n\n\n\n\n\n \n 11 ) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-phényl-pyridin-4-ylméthoxy)-benzène sulfonylamino]-propionamide \n 11) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-phenyl-pyridin-4-ylmethoxy) -benzene-sulfonylamino] -propionamide\n\n\n\n\n\n\n \n 12) (R)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzène sulfonylamino]-propionamide \n 12) (R) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzene-sulfonylamino] -propionamide\n\n\n\n\n\n\n \n13) (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-pipérazin-1-yl- propionamide \n13) (S) -N-Hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2-piperazin-1-yl-propionamide\n\n\n\n\n\n\n \n 14) Chlorhydrate de (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4- ylméthoxy)-benzène sulfonylamino]-propionamide \n 14) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzene-sulfonylamino] -propionamide hydrochloride\n\n\n\n\n\n\n \n 15) Di trifluoro acétate de 3-{4-[(S)-2-hydroxycarbamoyl-2-(4-méthanesulfonyl-pipérazin-1-yl)- éthylsulfamoyl]-phénoxyméthyl}-2-méthyl-indole-1-carboxylate de terbutyle \n 15) 3- {4 - [(S) -2-Hydroxycarbamoyl-2- (4-methanesulfonyl-piperazin-1-yl) -ethylsulfamoyl] -phenoxymethyl} -2-methylindole-1-carboxylate di trifluoroacetate tert-butyl\n\n\n\n\n\n\n \n 16) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide \n 16) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n 17) (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide  18) (S)-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)-benzène sulfonylannino]-propionannide \n17) (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide  18) (S) -2- [4- (4-Fluoro-benzyl) -piperazin-1-yl] -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzene-sulfonylannino] -propionannide\n\n\n\n\n\n\n \n 19) (S)-2-(4-éthyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n 19) (S) -2- (4-ethyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -propionanide\n\n\n\n\n\n\n \n20) (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylnnéthoxy)-benzènesulfonylannino]-2-[4-(4-trifluoronnéthyl- benzyl)-pipérazin-1-yl]-propionannide \n20) (S) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -2- [4- (4-trifluoromethyl-benzyl) -piperazin-1-yl] - propionannide\n\n\n\n\n\n\n \n 21 ) (S)-N-hydroxy-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)-benzène sulfonylamino]-propionannide \n 21) (S) -N-hydroxy-2- [4- (4-methyl-benzyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzene-sulfonylamino] -propionannide\n\n\n\n\n\n\n \n 22) (S)-3-[4-(benzo-isoxazol-3-ylnnéthoxy)-benzènesulfonylannino]-N-hydroxy-2-(4-nnéthanesulfonyl- pipérazin-1-yl)-propionannide \n 22) (S) -3- [4- (benzo-isoxazol-3-ylmethoxy) -benzenesulfonylannino] -N-hydroxy-2- (4-nnhanesulfonyl-piperazin-1-yl) -propionicid\n\n\n\n\n\n\n \n 23) (S)-N-hydroxy-2-(4-isobutyryl-pipérazin-1-yl)-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n 23) (S) -N-Hydroxy-2- (4-isobutyryl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] propionannide\n\n\n\n\n\n\n \n 24) (S)-N-hydroxy-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-l]-3-[4-(2-nnéthyl-quinolin-4- ylméthoxy)-benzènesulfonylannino]-propionannide \n 24) (S) -N-hydroxy-2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -3- [4- (2-methylquinolin-4-ylmethoxy)) -benzènesulfonylannino] -propionannide\n\n\n\n\n\n\n \n25) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-trifluoronnéthyl-pyrazolo[1 ,5-a]pyridin-3- ylméthoxy)-benzènesulfonylamino]-propionannide \n25) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino ] -propionannide\n\n\n\n\n\n\n \n 26) (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylnnéthoxy)-benzènesulfonylannino]-2-[4-(propane-2- sulfonyl)-pipérazin-1-yl]-propionannide \n 26) (S) -N-Hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -2- [4- (propane-2-sulfonyl) -piperazin-1-yl] - propionannide\n\n\n\n\n\n\n \n 27) (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy -3-[4-(2-trifluorométhyl-pyrazolo[1 ,5-a]pyridin-3- ylméthoxy)-benzènesulfonylannino]-propionannide \n 27) (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylannino ] -propionannide\n\n\n\n\n\n\n \n 28) (S)-2-(4-acétyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n 28) (S) -2- (4-Acetyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -propionanide\n\n\n\n\n\n\n \n 29) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-{propyl-[4-(quinolin-4-ylnnéthoxy)- benzènesulfonyl]-annino}-propionannide \n 29) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- {propyl- [4- (quinolin-4-ylmethoxy) -benzenesulfonyl] -annino} -propionanide\n\n\n\n\n\n\n \n30) (S)-2-(4-benzènesulfonyl-pipérazin-1-yl)-N-hydroxy-3-[4-(pyrazolo[1 ,5-a]pyridin-3-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n30) (S) -2- (4-Benzenesulfonyl-piperazin-1-yl) -N-hydroxy-3- [4- (pyrazolo [1,5-a] pyridin-3-ylmethoxy) benzenesulfonylannino] propionannide\n\n\n\n\n\n\n \n 31 ) (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy-3-[4-(1-nnéthyl-pipéridin-4-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n 31) (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (1-methyl-piperidin-4-ylmethoxy) -benzenesulfonylannino] -propionanide\n\n\n\n\n\n\n \n 32) (S)-2-[4-(4-fluoro-benzoyl)-pipérazin-1-yl]-N-hydroxy-3-[4-(3-nn-tolyl-propoxy)- benzènesulfonylamino]-propionannide \n 32) (S) -2- [4- (4-Fluoro-benzoyl) -piperazin-1-yl] -N-hydroxy-3- [4- (3-nn-tolyl-propoxy) -benzenesulfonylamino] -propionanide\n\n\n\n\n\n\n \n 33) (S)-N-hydroxy-3-[4-(2-méthyl-naphthalen-1-ylnnéthoxy)-benzènesulfonylannino]-2-(4-propionyl- pipérazin-1-yl)-propionannide \n 33) (S) -N-Hydroxy-3- [4- (2-methyl-naphthalen-1-ylmethoxy) -benzenesulfonylannino] -2- (4-propionyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 34) (S)-N-hydroxy-3-[4-(4-méthyl-pentyloxy)-benzènesulfonylannino]-2-(4-phénylacétyl-pipérazin-1-yl)- propionamide \n 34) (S) -N-hydroxy-3- [4- (4-methylpentyloxy) benzenesulfonylannino] -2- (4-phenylacetylpiperazin-1-yl) propionamide\n\n\n\n\n\n\n \n35) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-nnéthyl-pyridin-4-ylnnéthoxy)- benzènesulfonylamino]-propionannide \n35) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-pyridin-4-ylmethoxy) -benzenesulfonylamino] -propionanide\n\n\n\n\n\n\n \n 36) (S)-2-(3-acétyl-imidazolidin-1-yl)-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n 36) (S) -2- (3-Acetyl-imidazolidin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -propionanide\n\n\n\n\n\n\n \n 37) (S)-3-[4-(3,5-diméthyl-benzyloxy)-benzènesulfonylannino]-N-hydroxy-2-innidazolidin-1-yl- propionamide  38) (S)-N-hydroxy-2-(4-nnéthanesulfonyl-[1 ,4]-diazepan-1-yl)-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)- benzènesulfonylamino]-propionannide \n37) (S) -3- [4- (3,5-Dimethyl-benzyloxy) -benzenesulfonylannino] -N-hydroxy-2-innidazolidin-1-yl-propionamide  38) (S) -N-hydroxy-2- (4-nnhanesulfonyl- [1,4] diazepan-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] - propionannide\n\n\n\n\n\n\n \n 39) (S)-2-(4-benzyl-[1 ,4]-diazepan-1-yl)-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n 39) (S) -2- (4-Benzyl- [1,4] diazepan-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] - propionannide\n\n\n\n\n\n\n \n40) (S)-2-[1 ,4]-diazocan-1-yl-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)-benzènesulfonylannino]- propionamide. \n40) (S) -2- [1,4] -diazocan-1-yl-N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -propionamide.\n\n\n\n\n\n\n \n 41 ) (S)-N-hydroxy-3-[4-(2-méthyl-benzofuran-3-ylnnéthoxy)-benzènesulfonylannino]-2-[4-(propane-2- sulfonyl)-pipérazin-1-yl]-propionannide et \n 41) (S) -N-hydroxy-3- [4- (2-methyl-benzofuran-3-ylmethoxy) -benzenesulfonylannino] -2- [4- (propane-2-sulfonyl) -piperazin-1-yl] - propionannide and\n\n\n\n\n\n\n \n 42) (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-isopropyl-1 H-indol-3-ylméthoxy)- benzènesulfonylamino]-propionannide \n 42) (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-isopropyl-1H-indol-3-ylmethoxy) -benzenesulfonylamino] -propionanide\n\n\n\n\n\n\n\n\n\n\n \n10. Composé selon l'une des revendications 1 à 9 en tant que médicament. \n10. Compound according to one of claims 1 to 9 as a medicament.\n\n\n\n\n\n\n\n\n\n\n \n11. Composé selon l'une des revendications 1 à 9 pour le traitement de pathologies ou de désordres liés à une libération de TNFα. \n11. Compound according to one of claims 1 to 9 for the treatment of pathologies or disorders related to TNFα release.\n\n\n\n\n\n\n\n\n\n\n \n12. Composé selon l'une des revendications 1 à 9 en tant qu'inhibiteur de la production de TNFα. \n12. Compound according to one of claims 1 to 9 as an inhibitor of the production of TNFα.\n\n\n\n\n\n\n\n\n\n\n \n13. Composé selon l'une des revendications 1 à 9 en tant qu'inhibiteurs de l'enzyme TNFα-converting enzyme (TACE). \n13. Compound according to one of claims 1 to 9 as inhibitors of the enzyme TNFα-converting enzyme (TACE).\n\n\n\n\n\n\n\n\n\n\n \n14. Composé selon l'une des revendications 1 à 9 pour le traitement ou l'amélioration des désordres ou pathologies médiés par TACE. \n14. Compound according to one of claims 1 to 9 for the treatment or amelioration of disorders or pathologies mediated by TACE.\n\n\n\n\n\n\n\n\n\n\n \n15. Composé selon l'une des revendications 1 à 9 pour le traitement de maladies ou désordres impliquant une production de TNFα choisies parmi le choc septique, le choc hémodynamique, la malaria, les maladies intestinales inflammatoires (IBD) comme la maladie de Crohn et les colites ulcératives, les maladies osseuses inflammatoires, les infections mycobactériennes, la méningite, les maladies fibrotiques, les maladies cardiaques, l'attaque ischémique, le rejet de greffe, le cancer, l'athérosclérose, l'obésité, les maladies impliquant des phénomènes d'angiogénèse, les maladies auto-immunes, l'ostéoarthrite, l'arthrite rhumatoïde, la spondylarthrite ankylosante, l'arthrite chronique juvénile, la sclérose multiple, le HIV, le diabète melitus non insulino dépendant, les maladies allergiques, l'asthme, la maladie d'obstruction pulmonaire chronique (COPD) et l'inflammation occulaire.  \n15. Compound according to one of claims 1 to 9 for the treatment of diseases or disorders involving TNFα production selected from septic shock, hemodynamic shock, malaria, inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis, inflammatory bone diseases, mycobacterial infections, meningitis, fibrotic diseases, heart disease, ischemic attack, transplant rejection, cancer, atherosclerosis, obesity, diseases involving phenomena angiogenesis, autoimmune diseases, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, juvenile chronic arthritis, multiple sclerosis, HIV, non-insulin-dependent diabetes mellitus, allergic diseases, asthma , chronic obstructive pulmonary disease (COPD) and eye inflammation. \n\n\n\n\n\n\n\n\n\n\n \n16. Composé selon l'une des revendications 1 à 9 pour le traitement des maladies inflammatoires de la peau, du psoriasis, de la dermatite atopique et du rhumatisme psoriasique. \n16. Compound according to one of claims 1 to 9 for the treatment of inflammatory diseases of the skin, psoriasis, atopic dermatitis and psoriatic arthritis.\n\n\n\n\n\n\n\n\n\n\n \n17. Composé selon l'une des revendications 1 à 9 pour le traitement des pathologies neurologiques à caractère inflammatoire impliquant une production de TNFα choisies parmi la maladie d'Alzheimer, la maladie de Parkinson, les désordres parkinsoniens, la sclérose amyotrophique latérale, les maladies autoimmunes du système nerveux, les maladies autonomiques du système nerveux, les douleurs dorsales, l'œdème cérébral, les désordres cérébrovasculaires, la démence, les maladies autoimmunes de démyelination des fibres nerveuses du système nerveux, les neuropathies diabétiques, l'encéphalite, l'encéphalomyélite, l'épilepsie, le syndrome chronique de fatigue, l'artérite des cellules géantes, le syndrome Guillain-Barre, les maux de tête, la sclérose multiple, la neuralgie, les maladies du système nerveux périphérique, les polyneuropathies, la polyradiculoneuropathie, la radiculopathie, les paralysies respiratoires, les maladies des cordes spinales, le syndrome de Tourette, la vasculite du système nerveux centreux, les maladies d'Huntington et l'attaque cérébrale ; \n17. Compound according to one of claims 1 to 9 for the treatment of inflammatory neurological pathologies involving a production of TNFα selected from Alzheimer's disease, Parkinson's disease, parkinsonian disorders, amyotrophic lateral sclerosis, diseases autoimmune nervous system, autonomic diseases of the nervous system, back pain, cerebral edema, cerebrovascular disorders, dementia, autoimmune diseases of demyelination of nerve fibers of the nervous system, diabetic neuropathies, encephalitis, encephalomyelitis, epilepsy, chronic fatigue syndrome, giant cell arteritis, Guillain-Barre syndrome, headache, multiple sclerosis, neuralgia, diseases of the peripheral nervous system, polyneuropathies, polyradiculoneuropathy, radiculopathy, respiratory paralysis, spinal cord diseases, Tourette, vasculitis of the central nervous system, Huntington's disease and stroke; Description\n\n\n\n\n\n\n \n Nouveaux composés benzène-sulfonamides, leur procédé de synthèse et leur utilisation en médecine ainsi qu'en cosmétique \n New benzenesulphonamide compounds, their synthesis process and their use in medicine and cosmetics\n\n\n\n\n\n\n \n DOMAINE TECHNIQUE \n TECHNICAL AREA\n\n\n\n\n\n\n \nLa présente invention se rapporte à de nouveaux composés benzène-sulfonamides répondant à la formule générale (I) suivante : \nThe present invention relates to novel benzenesulphonamide compounds having the following general formula (I):\n\n\n\n\n\n\n \n \n\n ainsi qu'à leur procédé de synthèse et à leur utilisation dans des compositions pharmaceutiques destinées à un usage en médecine humaine ou vétérinaire. \n \n and their method of synthesis and their use in pharmaceutical compositions for use in human or veterinary medicine.\n\n\n\n\n\n\n \n Les composés de la présente invention agissent comme inhibiteurs de l'enzyme de conversion du TNFα encore appelée TACE. Ils sont de ce fait utiles dans le traitement des maladies pour lesquelles diminuer la production de TNFα est d'un grand intérêt. \n The compounds of the present invention act as inhibitors of the TNFα-converting enzyme also called TACE. They are therefore useful in the treatment of diseases for which the reduction of TNFα production is of great interest.\n\n\n\n\n\n\n \n La présente invention se rapporte également à l'utilisation des composés répondant à la formule générale (I) dans des compositions cosmétiques. \n The present invention also relates to the use of the compounds corresponding to the general formula (I) in cosmetic compositions.\n\n\n\n\n\n\n \nETATANTÉRIEUR DE LA TECHNIQUE \nSTATUS OF THE TECHNIQUE\n\n\n\n\n\n\n \nLes adamalysines (« ADAM » ou A Disintegrin and Metalloproteinase) sont une sous famille des enzymes métalloendopeptidases à zinc. Leur ectodomaine comporte un domaine protéasique dont l'activation dépend du zinc, un domaine disintégrine et un domaine riche en cystéines. A ce jour, au moins 30 ADAMs différentes ont été identifiées dont la première caractérisée a été ADAM17 encore appelée TACE (TNFα converting enzyme) [Gueydan C et al. Med.Sci 1997, 13, 83-88 ; Black R.A et al. Nature 1997, 385 :729-733 ; Moss et al. Nature 1997, 385 :733-736]. L'ARNm de TACE est présent dans de nombreux tissus et plus particulièrement au niveau des monocytes, des macrophages, des lymphocytes T mais aussi au niveau des kératinocytes par exemple. \nAdamalysins (\"ADAM\" or A Disintegrin and Metalloproteinase) are a sub-family of zinc metalloendopeptidase enzymes. Their ectodomain has a protease domain whose activation depends on zinc, a disintegrin domain and a domain rich in cysteines. To date, at least 30 different ADAMs have been identified, the first of which was characterized by ADAM17, also called TACE (TNFα converting enzyme) [Gueydan C et al. Med.Sci 1997, 13, 83-88; Black R.A et al. Nature 1997, 385: 729-733; Moss et al. Nature 1997, 385: 733-736]. TACE mRNA is present in many tissues and more particularly at the level of monocytes, macrophages, T lymphocytes, but also at the level of keratinocytes, for example.\n\n\n\n\n\n\n \n TACE est responsable de la coupure du pro-TNFα, protéine membranaire de 26 kDa, pour conduire à la libération du TNFα soluble, protéine de 17kDa, biologiquement active [Schlondorff et al. Biochem J. 2000, 347, 131-138]. Le TNFα soluble libéré par la cellule est capable d'agir sur des sites très éloignés du site de synthèse. \n\n Le TNFα est impliqué dans un grand nombre de processus biologiques pro-inflammatoires [Aggarwal et al, Eur. Cytokine Netw., 1996, 7 : 93-124]. Plusieurs études pharma∞logiques et cliniques ont montré de façon évidente que bloquer les effets du TNFα avec des anticorps spécifiques ou des biologiques anti-TNFα (Etanercept, Adalimumab, Infliximab) était bénéfique dans le traitement de maladies autoimmunes comme l'arthrite rhumatoide [Feldman et al. Lancet, 1994, 344, 1 105), le diabète mélitus non insulino dépendant [Lohmander L. S et al. Arthritis Rheum, 1993, 36, 1214-1222], la maladie de Crohn's [MacDonald et al. Clin. Exp. Immunol. 1990, 81 , 301]. \nTACE is responsible for the cleavage of pro-TNFα, a 26 kDa membrane protein, to lead to the release of soluble TNFα, a 17kDa protein, that is biologically active [Schlondorff et al. Biochem J. 2000, 347, 131-138]. The soluble TNFα released by the cell is able to act on sites far removed from the synthesis site.  TNFα is involved in a large number of pro-inflammatory biological processes [Aggarwal et al, Eur. Cytokine Netw., 1996, 7: 93-124]. Several pharmacological and clinical studies have clearly shown that blocking the effects of TNFα with specific antibodies or anti-TNFα biologics (Etanercept, Adalimumab, Infliximab) was beneficial in the treatment of autoimmune diseases such as rheumatoid arthritis [Feldman et al. Lancet, 1994, 344, 105), non-insulin dependent diabetes mellitus [Lohmander L. S et al. Arthritis Rheum, 1993, 36, 1214-1222], Crohn's disease [MacDonald et al. Clin. Exp. Immunol. 1990, 81, 301].\n\n\n\n\n\n\n \n Le TNFα joue également un rôle fondamental au cours du phénomène inflammatoire déclenché dans les lésions de psoriasis. Les taux sériques de TNFα sont élevés chez les patients psoriasiques [Mussi A et al. J. Biol. Regul. Homeost Agents, 1997, 11 , 115-118] ; les taux de TNFα sont également élevés dans les plaques même de psoriasis [Bonifati C. et al. Clin. Exp. Dermatol., 1994, 19, 383-387]. Les cellules clés de la physiopathologie du psoriasis sont les kératinocytes, les cellules dendritiques et certains lymphocytes T. L'interaction entre ces familles de cellules conduit à une cascade inflammatoire menant aux lésions caractéristiques du psoriasis avec libération de TNFα [Kupper TS, N. Engl. J. Med, 2003, 349, 1987-1990]. Des études cliniques pour le traitement de psoriasis en plaques modéré à sévère par les anti-TNFα biologiques (Etanercept, Adalimumab, Infliximab) ont démontré leur efficacité à la fois sur les lésions psoriasiques et sur la qualité de vie des patients [Ortonne JP, Annales de dermatologie et de vénéreologie, 2005, 132 (8-9 pt2), 4S6-9 et 2005, 132, 9S01-9S70]. \n TNFα also plays a fundamental role during the inflammatory process triggered in psoriasis lesions. Serum TNFα levels are elevated in psoriatic patients [Mussi A et al. J. Biol. Regul. Homeost Agents, 1997, 11, 115-118]; TNFα levels are also high in the same psoriasis plaques [Bonifati C. et al. Clin. Exp. Dermatol., 1994, 19, 383-387]. The key cells in the pathophysiology of psoriasis are keratinocytes, dendritic cells and certain T lymphocytes. The interaction between these families of cells leads to an inflammatory cascade leading to the characteristic lesions of psoriasis with release of TNFα [Kupper TS, N. Engl . J. Med, 2003, 349, 1987-1990]. Clinical studies for the treatment of moderate to severe plaque psoriasis by anti-TNFα agents (Etanercept, Adalimumab, Infliximab) have been shown to be effective in both psoriatic lesions and patients' quality of life [Ortonne JP, Annales Dermatology and Venereology, 2005, 132 (8-9 pt2), 4S6-9 and 2005, 132, 9S01-9S70].\n\n\n\n\n\n\n \nAinsi, les composés qui inhibent la production de TNFα sont d'un grand intérêt pour le traitement des maladies inflammatoires et des maladies impliquant une libération de TNFα. \nThus, compounds that inhibit the production of TNFα are of great interest for the treatment of inflammatory diseases and diseases involving TNFα release.\n\n\n\n\n\n\n \nEXPOSE DE L'INVENTION \nSUMMARY OF THE INVENTION\n\n\n\n\n\n\n \nNotre invention décrit donc de nouvelles molécules qui inhibent l'enzyme TACE (TNFα converting enzyme) et de ce fait, inhibent la sécrétion de TNFα soluble (forme active du TNFα) par les cellules. Ces nouvelles molécules sont donc des principes actifs potentiels pour le traitement des pathologies faisant intervenir une diminution ou une inhibition de la production de TNFα. \nOur invention therefore describes new molecules that inhibit the enzyme TACE (TNFα converting enzyme) and thereby inhibit the secretion of soluble TNFα (active form of TNFα) by the cells. These new molecules are therefore potential active ingredients for the treatment of pathologies involving a decrease or inhibition of TNFα production.\n\n\n\n\n\n\n \nA titre d'illustration, et de façon non limitative, ces pathologies sont par exemple le choc septique, le choc hémodynamique, la malaria, les maladies intestinales inflammatoires (IBD) comme la maladie de Crohn et les colites ulcératives, les maladies osseuses inflammatoires, les infections mycobactériennes, la méningite, les maladies fibrotiques, les maladies cardiaques, l'attaque ischémique, le rejet de greffe, le cancer, l'athérosclérose, l'obésité, les maladies impliquant des phénomènes d'angiogénèse, les maladies auto-immunes, l'ostéoarthrite, l'arthrite rhumatoïde, la spondylarthrite ankylosante, l'arthrite chronique juvénile, la sclérose multiple, le HIV, le diabète melitus non insulino dépendant, les maladies allergiques, l'asthme, la maladie d'obstruction pulmonaire chronique (COPD), l'inflammation occulaire, les maladies inflammatoires de la peau, le psoriasis, la dermatite atopique et le rhumatisme psoriasique. \n\n Ces molécules sont également des principes actifs potentiels pour le traitement de pathologies neurologiques à caractère inflammatoire pour lesquelles diminuer la production de TNFα serait d'un grand intérêt. Ces pathologies listées ci-après de façon non limitative sont par exemple la maladie d'Alzheimer, la maladie de Parkinson, les désordres parkinsoniens, la sclérose amyotrophique latérale, les maladies autoimmunes du système nerveux, les maladies autonomiques du système nerveux, les douleurs dorsales, l'œdème cérébral, les désordres cérébrovasculaires, la démence, les maladies autoimmunes de démyelination des fibres nerveuses du système nerveux, les neuropathies diabétiques, l'encéphalite, l'encéphalomyélite, l'épilepsie, le syndrome chronique de fatigue, l'artérite des cellules géantes, le syndrome Guillain-Barre, les maux de tête, la sclérose multiple, la neuralgie, les maladies du système nerveux périphérique, les polyneuropathies, la polyradiculoneuropathie, la radiculopathie, les paralysies respiratoires, les maladies des cordes spinales, le syndrome de Tourette, la vasculite du système nerveux centreux, les maladies d'Huntington et l'attaque cérébrale ; \nBy way of illustration, and in a nonlimiting manner, these pathologies are, for example, septic shock, hemodynamic shock, malaria, inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis, inflammatory bone diseases, mycobacterial infections, meningitis, fibrotic diseases, heart disease, ischemic attack, transplant rejection, cancer, atherosclerosis, obesity, diseases involving angiogenesis, autoimmune diseases , osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, juvenile chronic arthritis, multiple sclerosis, HIV, non-insulin-dependent diabetes mellitus, allergic diseases, asthma, chronic pulmonary obstruction disease ( COPD), eye inflammation, inflammatory skin diseases, psoriasis, atopic dermatitis and psoriatic arthritis.  These molecules are also potential active ingredients for the treatment of inflammatory neurological pathologies for which TNFα production would be of great interest. These pathologies listed hereafter without limitation are for example Alzheimer's disease, Parkinson's disease, parkinsonian disorders, amyotrophic lateral sclerosis, autoimmune diseases of the nervous system, autonomic diseases of the nervous system, back pain. , cerebral edema, cerebrovascular disorders, dementia, autoimmune diseases of demyelinating nerve fibers of the nervous system, diabetic neuropathies, encephalitis, encephalomyelitis, epilepsy, chronic fatigue syndrome, arteritis giant cells, Guillain-Barre syndrome, headaches, multiple sclerosis, neuralgia, diseases of the peripheral nervous system, polyneuropathies, polyradiculoneuropathy, radiculopathy, respiratory paralysis, spinal cord diseases, the syndrome of Tourette, vasculitis of the central nervous system, Huntington's disease and stroke ale;\n\n\n\n\n\n\n \nUne grande variété d'inhibiteurs de TACE est déjà connue comme indiqué ci-dessous. Toutefois, un grand nombre de ces inhibiteurs n'agit pas sélectivement sur l'enzyme TACE par rapport à d'autres enzymes de la famille des ADAMs et/ou de matrix métalloprotéinases (MMPs). \nA wide variety of TACE inhibitors is already known as indicated below. However, many of these inhibitors do not selectively act on the TACE enzyme over other enzymes in the family of ADAMs and / or matrix metalloproteinases (MMPs).\n\n\n\n\n\n\n \nOr, l'inhibition non sélective de ces familles d'enzymes induit des effets secondaires indésirables observés In Vivo. Par exemple, l'inhibition de MMP-1 (collagenase-1 ) a été associée aux problèmes de toxicité musculo-squelettique. \nHowever, the non-selective inhibition of these families of enzymes induces undesirable side effects observed in Vivo. For example, inhibition of MMP-1 (collagenase-1) has been associated with musculoskeletal toxicity problems.\n\n\n\n\n\n\n \n Comme inhibiteur non sélectif, on peut citer également l'Apratastat, inhibiteur connu et testé cliniquement en phase 2 pour le traitement de l'arthrite rhumatoïde (Curr Opin Investig Drugs. 2006 Nov;7(11 ), 1014-1019). Cet inhibiteur n'est pas sélectif de l'enzyme TACE par rapport à certaines MMPs (WO 00/44709 ; page 251 , table 10, exemple 61 ). \n As a non-selective inhibitor, there is also known Apratastat, a known inhibitor and clinically tested in phase 2 for the treatment of rheumatoid arthritis (Curr Opin Investig Drugs, Nov. 2006, 7 (11), 1014-1019). This inhibitor is not selective for the TACE enzyme with respect to certain MMPs (WO 00/44709, page 251, table 10, example 61).\n\n\n\n\n\n\n \nD'autres inhibiteurs de TACE également connus et faisant partie de la même famille que l'Apratastat, à savoir celle de dérivés benzène sulfonamides cycliques, ont été décrits dans WO 00/44709 et WO 97/18194. D'autres brevets (WO 96/00214, WO 97/22587) revendiquent des inhibiteurs de MMPs et/ou TACE pour lesquels la partie benzène sulfonamide est séparée de la fonction acide hydroxamique par un seul atome de carbone. Des publications décrivant ce type d'inhibiteurs de MMPs de façon plus large sont aussi celle de MacPherson et al. J. Med. Chem. 1997,40, 2525 et celle de Tamura et al. J. Med. Chem. 1998, 41 , 640. D'autres exemples d'inhibiteurs de MMPs/TACE pour lesquels la fonction sulfonamide est séparée de l'acide hydroxamique par un enchaînement de deux atomes de carbones formant un cycle sont décrits dans les brevets WO 98/16503, WO 98/16506, WO 98/16514 et WO 98/16520. D'autres exemples d'inhibiteurs de MMPs pour lesquels la fonction sulfonamide est séparée de l'acide hydroxamique par un enchaînement de deux atomes de carbones sont également décrits dans WO 2008/045671. \n\n Or, la demanderesse a maintenant découvert de manière inattendue et surprenante que de nouveaux composés de formule générale (I) présentent une très bonne activité inhibitrice de TACE et en particulier, inhibent l'enzyme TACE de façon sélective par rapport à d'autres ADAMs et MMPs. Ainsi, la présente invention concerne des composés de formule générale (I) suivante : \nOther TACE inhibitors also known and belonging to the same family as Apratastat, namely that of cyclic benzene sulfonamide derivatives, have been described in WO 00/44709 and WO 97/18194. Other patents (WO 96/00214, WO 97/22587) claim inhibitors of MMPs and / or TACE for which the benzene sulfonamide part is separated from the hydroxamic acid function by a single carbon atom. Publications describing this type of MMP inhibitors more broadly are also those of MacPherson et al. J. Med. Chem. 1997, 40, 2525 and that of Tamura et al. J. Med. Chem. 1998, 41, 640. Other examples of MMPs / TACE inhibitors for which the sulfonamide function is separated from the hydroxamic acid by a chain of two carbon atoms forming a ring are described in WO 98/16503, WO 98/16506, WO 98/16514 and WO 98/16520. Other examples of MMP inhibitors for which the sulfonamide function is separated from the hydroxamic acid by a two-carbon chain are also described in WO 2008/045671.  Now, the Applicant has now unexpectedly and surprisingly discovered that new compounds of general formula (I) exhibit a very good TACE inhibitory activity and in particular, selectively inhibit TACE enzyme compared to other ADAMs and MMPs. Thus, the present invention relates to compounds of general formula (I) below:\n\n\n\n\n\n\n \n \n\n dans laquelle : \n \n in which :\n\n\n\n\n\n\n \n R\n1\n représente un hydrogène, un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué, un radical - C(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, un radical C(O)OR4, R\n4\n ayant les significations données ci-après; \nR \n1\n is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aralkyl, substituted aralkyl, heteroaralkyl, substituted heteroaralkyl a radical - C (O) -R \n4\n , a radical -SO \n2\n -R \n4\n , a radical C (O) OR \n4\n , R \n4\n having the meanings given below;\n\n\n\n\n\n\n \nR\n2\n est un atome d'hydrogène ou un radical alkyle inférieur. \nR \n2\n is a hydrogen atom or a lower alkyl radical.\n\n\n\n\n\n\n \n R\n3\n est un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétérocyclique, un radical hétérocyclique substitué, un radical cycloalkyle, un radical cycloalkyle substitué, un radical hétéroaryle, un radical hétéroaryle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué ; \nR \n3\n is an alkyl radical, a substituted alkyl radical, an alkenyl radical, a substituted alkenyl radical, an alkynyl radical, a substituted alkynyl radical, an aryl radical, a substituted aryl radical, an aralkyl radical, a substituted aralkyl radical or a radical. heterocyclic, a substituted heterocyclic radical, a cycloalkyl radical, a substituted cycloalkyl radical, a heteroaryl radical, a substituted heteroaryl radical, a heteroaralkyl radical, a substituted heteroaralkyl radical;\n\n\n\n\n\n\n \n R\n4\n est un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ; \nR \n4\n is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, aralkyl, substituted aralkyl;\n\n\n\n\n\n\n \nn peut prendre les valeurs de 0, 1 , 2 ou 3 ; \nn can take the values of 0, 1, 2 or 3;\n\n\n\n\n\n\n \nainsi que les sels d'addition des composés de formule générale (I) avec un acide pharmaceutiquement acceptable, les sels d'addition des composés de formule générale (I) avec une base pharmaceutiquement acceptable et les énantiomères des composés de formule générale (I). \nas well as the addition salts of the compounds of general formula (I) with a pharmaceutically acceptable acid, the addition salts of the compounds of general formula (I) with a pharmaceutically acceptable base and the enantiomers of the compounds of general formula (I) .\n\n\n\n\n\n\n \nParmi les sels d'addition des composés de formule générale (I) avec un acide pharmaceutiquement acceptable, on peut citer de préférence les sels avec un acide organique ou avec un acide inorganique. \nAmong the addition salts of the compounds of general formula (I) with a pharmaceutically acceptable acid, there may be mentioned preferably the salts with an organic acid or with an inorganic acid.\n\n\n\n\n\n\n \n Les acides inorganiques appropriés sont par exemple les acides halohydriques comme l'acide chlorhydrique, l'acide bromhydrique, l'acide sulfurique, l'acide nitrique et l'acide phosphorique. \n\n Les acides organiques appropriés sont par exemple l'acide acétique, l'acide trifluoroacétique, l'acide trichloroacétique, l'acide propionique, l'acide glycolique, l'acide pyruvique, l'acide succinique, l'acide benzoïque, l'acide cinnamique, l'acide mandélique, l'acide methanesulfonique, l'acide para-toluène sulfonique, l'acide salicylique, l'acide picrique, l'acide citrique, l'acide oxalique, l'acide tartrique, l'acide malonique, l'acide maléique, l'acide camphorsulfonique et l'acide fumarique. \nSuitable inorganic acids are, for example, hydrohalic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid.  Examples of suitable organic acids are acetic acid, trifluoroacetic acid, trichloroacetic acid, propionic acid, glycolic acid, pyruvic acid, succinic acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, para-toluene sulfonic acid, salicylic acid, picric acid, citric acid, oxalic acid, tartaric acid, malonic acid, maleic acid, camphorsulfonic acid and fumaric acid.\n\n\n\n\n\n\n \nParmi les sels d'addition des composés de formule générale (I) avec une base pharmaceutiquement acceptable, on peut citer de préférence les sels avec une base organique ou avec une base inorganique. \nAmong the addition salts of the compounds of general formula (I) with a pharmaceutically acceptable base, there may be mentioned preferably salts with an organic base or with an inorganic base.\n\n\n\n\n\n\n \nLes bases inorganiques sont par exemple l'hydroxyde de potassium, l'hydroxyde de sodium, l'hydroxyde de lithium ou l'hydroxyde de calcium. \nThe inorganic bases are, for example, potassium hydroxide, sodium hydroxide, lithium hydroxide or calcium hydroxide.\n\n\n\n\n\n\n \n Les bases organiques appropriés comprennent les aminés et les amino-acides. Parmi les aminés, on peut citer par exemple les aminés primaires, secondaires ou tertiaires aliphatiques ou aromatiques comme la methylamine, l'ethylamine, l'éthanolamine, la propylamine, l'isopropylamine, les 4 isomères de la butylamine, la diméthylamine, diethylamine, la diethanolamine, la dipropylamine, la diisopropylamine, la di n-butylamine, la pyrrolidine, la piperidine, la morpholine, la diethanol phenylamine, la trimethylamine, la triethylamine, la tripropylamine, la quinuclidine, la pyridine, la quinoline ou l'isoquinoline. \n Suitable organic bases include amines and amino acids. Among the amines, mention may be made, for example, of primary, secondary or tertiary aliphatic or aromatic amines, such as methylamine, ethylamine, ethanolamine, propylamine, isopropylamine, the 4 isomers of butylamine, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, diethanol phenylamine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline or isoquinoline.\n\n\n\n\n\n\n \n Parmi les amino-acides, on peut citer par exemple la lysine, l'arginine et l'ornithine. \n Amino acids include, for example, lysine, arginine and ornithine.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical alkyle inférieur une chaîne hydrocarbonée saturée, linéaire ou ramifiée, comprenant de 1 à 4 atomes de carbone. \nAccording to the present invention, the term \"lower alkyl radical\" denotes a saturated hydrocarbon chain, linear or branched, comprising from 1 to 4 carbon atoms.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical alkyle une chaîne hydrocarbonée saturée, linéaire ou ramifiée, comprenant de 1 à 10 atomes de carbone. \nAccording to the present invention, the alkyl radical denotes a saturated hydrocarbon chain, linear or branched, comprising from 1 to 10 carbon atoms.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical alkenyle une chaîne hydrocarbonée insaturée, linéaire ou ramifiée comprenant de 2 à 10 atomes de carbone et comprenant une ou plusieurs doubles liaisons. \nAccording to the present invention, the term \"alkenyl radical\" denotes an unsaturated, linear or branched hydrocarbon-based chain comprising from 2 to 10 carbon atoms and comprising one or more double bonds.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical alkynyle une chaîne hydrocarbonée insaturée, linéaire ou ramifiée comprenant de 2 à 10 atomes de carbone et comprenant une ou plusieurs triples liaisons. Selon la présente invention, on désigne par radical alkyle substitué une chaîne hydrocarbonée saturée, linéaire ou ramifiée, comprenant de 1 à 10 atomes de carbone et substitué par un ou plusieurs radicaux choisis parmi un atome d'halogène, un radical alkoxyle, un radical hydroxyle. \nAccording to the present invention, alkynyl radical denotes a linear or branched unsaturated hydrocarbon chain comprising from 2 to 10 carbon atoms and comprising one or more triple bonds. According to the present invention, the term \"substituted alkyl radical\" denotes a linear or branched saturated hydrocarbon-based chain comprising from 1 to 10 carbon atoms and substituted by one or more radicals chosen from a halogen atom, an alkoxyl radical and a hydroxyl radical. .\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical alkenyle substitué une chaîne hydrocarbonée insaturée, linéaire ou ramifiée, comprenant de 2 à 10 atomes de carbone, comprenant une ou \n\n plusieurs doubles liaisons et substituée par un ou plusieurs radicaux choisis parmi un atome d'halogène, un radical alkoxyle et un radical hydroxyle. \nAccording to the present invention, the term \"substituted alkenyl radical\" denotes a linear or branched, unsaturated hydrocarbon-based chain comprising from 2 to 10 carbon atoms, comprising one or more  several double bonds and substituted by one or more radicals selected from a halogen atom, an alkoxyl radical and a hydroxyl radical.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical alkynyle substitué une chaîne hydrocarbonée insaturée, linéaire ou ramifiée, comprenant de 2 à 10 atomes de carbone, comprenant une ou plusieurs triples liaisons et substituée par un ou plusieurs radicaux choisis parmi un atome d'halogène, un radical alkoxyle et un radical hydroxyle. \nAccording to the present invention, the term \"substituted alkynyl radical\" denotes a linear or branched, unsaturated hydrocarbon-based chain comprising from 2 to 10 carbon atoms, comprising one or more triple bonds and substituted by one or more radicals chosen from a halogen atom, an alkoxyl radical and a hydroxyl radical.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par cycloalkyle une chaine hydrocarbonée, saturée, cyclique comprenant de 3 à 7 atomes de carbones. \nAccording to the present invention, cycloalkyl denotes a hydrocarbon chain, saturated, cyclic comprising from 3 to 7 carbon atoms.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par cycloalkyle substitué une chaine hydrocarbonée, saturée, cyclique comprenant de 3 à 7 atomes de carbones et substituée par un ou plusieurs radicaux choisis parmi un atome d'halogène, un radical alkoxyle et un radical hydroxyle. \nAccording to the present invention, the term \"substituted cycloalkyl\" denotes a hydrocarbon chain, saturated, cyclic comprising from 3 to 7 carbon atoms and substituted by one or more radicals chosen from a halogen atom, an alkoxyl radical and a hydroxyl radical.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical aryle, un cycle hydrocarboné aromatique ou deux cycles fusionnés hydrocarbonés aromatiques. \nAccording to the present invention, the term aryl radical, an aromatic hydrocarbon ring or two aromatic hydrocarbon fused rings.\n\n\n\n\n\n\n \n Les radicaux aryles préférés sont choisis parmi les radicaux phenyle et naphtyle. Selon la présente invention, on désigne par radical aryle substitué, un cycle ou deux cycles fusionnés hydrocarboné(s) aromatique(s) substitué(s) par un ou plusieurs groupes d'atomes choisis parmi un alkyle, un alkoxyle, un aryle, un halogène, un hydroxyle, un cyano, un trifluorométhyle et un nitro. \n The preferred aryl radicals are chosen from phenyl and naphthyl radicals. According to the present invention, the term \"substituted aryl radical\" denotes a ring or two fused aromatic hydrocarbon rings substituted with one or more groups of atoms chosen from alkyl, alkoxyl, aryl, halogen, hydroxyl, cyano, trifluoromethyl and nitro.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical aralkyle, un alkyle substitué par un aryle. \nAccording to the present invention, the term \"aralkyl radical\" denotes an alkyl substituted with an aryl.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical aralkyle substitué, un alkyle substitué par un aryle substitué. \nAccording to the present invention, the term \"substituted aralkyl radical\" denotes an alkyl substituted by a substituted aryl.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical hétérocyclique une chaîne hydrocarbonée cyclique ou polycyclique, saturée ou insaturée, comprenant un ou plusieurs hétéroatomes choisis parmi O, S et N. \nAccording to the present invention, the term \"heterocyclic radical\" denotes a cyclic or polycyclic hydrocarbon chain, saturated or unsaturated, comprising one or more heteroatoms chosen from O, S and N.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical hétérocyclique substitué, un radical hétérocyclique substitué par un ou plusieurs groupes d'atomes choisis parmi un alkyle, un alkoxyle, un halogène, un hydroxyle, un cyano, un trifluorométhyle et un nitro. \nAccording to the present invention, the term \"substituted heterocyclic radical\" denotes a heterocyclic radical substituted with one or more groups of atoms chosen from alkyl, alkoxyl, halogen, hydroxyl, cyano, trifluoromethyl and nitro.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical hétéroaryle, un radical hétérocyclique aromatique c'est-à-dire une chaîne hydrocarbonée cyclique ou polycyclique, aromatique, comprenant un ou plusieurs hétéroatomes choisis parmi O, S et N. \n\n Selon la présente invention, on désigne par radical hétéroaryle substitué, un radical hétéroaryle substitué par un ou plusieurs groupes d'atomes choisis par exemple parmi un alkyle, un alkoxy, un aryle, un aryle substitué, un halogène, un hydroxy, un cyano, un trifluorométhyle et un nitro. Selon la présente invention, on désigne par radical hétéroaralkyle, un radical alkyle substitué par un radical hétéroaryle. \nAccording to the present invention, the term \"heteroaryl radical\" denotes an aromatic heterocyclic radical, that is to say an aromatic cyclic or polycyclic hydrocarbon chain, comprising one or more heteroatoms chosen from O, S and N.  According to the present invention, the term \"substituted heteroaryl radical\" denotes a heteroaryl radical substituted with one or more groups of atoms selected for example from alkyl, alkoxy, aryl, substituted aryl, halogen, hydroxy, cyano, trifluoromethyl and nitro. According to the present invention, heteroaralkyl radical denotes an alkyl radical substituted by a heteroaryl radical.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical hétéroaralkyle substitué, un radical hétéroaralkyle substitué par un ou plusieurs groupes d'atomes choisis parmi un alkyle, un alkoxyle, un halogène, un hydroxyle, un cyano, un trifluorométhyle et un nitro. \nAccording to the present invention, the term \"substituted heteroaralkyl radical\" denotes a heteroaralkyl radical substituted with one or more groups of atoms chosen from an alkyl, an alkoxyl, a halogen, a hydroxyl, a cyano, a trifluoromethyl and a nitro.\n\n\n\n\n\n\n \nSelon la présente invention, on désigne par radical alkoxyle un atome d'oxygène substitué par un radical alkyle. Selon la présente invention, on désigne par atome d'halogène un atome de fluor, de chlore, de brome ou d'iode. \nAccording to the present invention, the term \"alkoxyl radical\" denotes an oxygen atom substituted by an alkyl radical. According to the present invention, the term \"halogen atom\" denotes a fluorine, chlorine, bromine or iodine atom.\n\n\n\n\n\n\n \nParmi les composés de formule générale (I) entrant dans le cadre de la présente invention, on peut notamment citer les composés suivants : \nAmong the compounds of general formula (I) within the scope of the present invention, there may be mentioned in particular the following compounds:\n\n\n\n\n\n\n \n1 ) 3-[(4-but-2-ynyloxy-benzènesulfonyl)-méthyl-amino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-propionamide \n1) 3 - [(4-But-2-ynyloxy-benzenesulfonyl) -methyl-amino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 2) (S)-3-(4-but-2-ynyloxy-benzènesulfonylamino)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)- propionamide \n 2) (S) -3- (4-But-2-ynyloxy-benzenesulfonylamino) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 3) (S)-3-(4-benzyloxy-benzènesulfonylamino)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)- propionamide \n 3) (S) -3- (4-Benzyloxy-benzenesulfonylamino) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 4) (S)-3-[(4-benzyloxy-benzènesulfonyl)-méthyl-amino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-propionamide \n 4) (S) -3 - [(4-Benzyloxy-benzenesulfonyl) -methyl-amino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 5) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide \n 5) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n6) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(naphthalen-1-ylméthoxy)- benzènesulfonylamino]-propionamide \n6) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (naphthalen-1-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n 7) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-(4-propoxy-benzènesulfonylamino)- propionamide \n 7) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- (4-propoxy-benzenesulfonylamino) -propionamide\n\n\n\n\n\n\n \n 8) (S)-3-[4-(3-cyano-benzyloxy)-benzènesulfonylamino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-propionamide \n 8) (S) -3- [4- (3-cyano-benzyloxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 9) (S)-3-[4-(4-cyano-benzyloxy)-benzènesulfonylamino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-propionamide \n 9) (S) -3- [4- (4-cyano-benzyloxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 10) 4-{(S)-1-hydroxycarbamoyl-2-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-éthyl}- pipérazine-1-carboxylate de benzyle \n\n 11 ) (S)-N-hydroxy-2-(4-nnéthanesulfonyl-pipérazin-1-yl)-3-[4-(2-phényl-pyridin-4-ylnnéthoxy)-benzène sulfonylannino]-propionannide \n10) Benzyl 4 - {(S) -1-hydroxycarbamoyl-2- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] ethyl} piperazine-1-carboxylate  11) (S) -N-Hydroxy-2- (4-acethanesulfonyl-piperazin-1-yl) -3- [4- (2-phenyl-pyridin-4-ylmethoxy) -benzene-sulfonylannino] -propionanide\n\n\n\n\n\n\n \n 12) (R)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)-benzène sulfonylamino]-propionannide \n 12) (R) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzene-sulfonylamino] -propionanide\n\n\n\n\n\n\n \n13) (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylnnéthoxy)-benzènesulfonylannino]-2-pipérazin-1-yl- propionamide \n13) (S) -N-Hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -2-piperazin-1-yl-propionamide\n\n\n\n\n\n\n \n 14) Chlorhydrate de (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-nnéthyl-quinolin-4- ylméthoxy)-benzène sulfonylannino]-propionannide \n 14) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzene-sulfonylannino] -propionanide hydrochloride\n\n\n\n\n\n\n \n 15) Di trifluoro acétate de 3-{4-[(S)-2-hydroxycarbamoyl-2-(4-méthanesulfonyl-pipérazin-1-yl)- éthylsulfamoyl]-phénoxyméthyl}-2-méthyl-indole-1-carboxylate de terbutyle \n 15) 3- {4 - [(S) -2-Hydroxycarbamoyl-2- (4-methanesulfonyl-piperazin-1-yl) -ethylsulfamoyl] -phenoxymethyl} -2-methylindole-1-carboxylate di trifluoroacetate tert-butyl\n\n\n\n\n\n\n \n 16) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(quinolin-4-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n 16) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (quinolin-4-ylmethoxy) -benzenesulfonylannino] propionannide\n\n\n\n\n\n\n \n 17) (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)- benzènesulfonylamino]-propionamide \n 17) (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n18) (S)-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)-benzène sulfonylannino]-propionannide \n18) (S) -2- [4- (4-Fluoro-benzyl) -piperazin-1-yl] -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzene-sulfonylannino] -propionannide\n\n\n\n\n\n\n \n 19) (S)-2-(4-éthyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n 19) (S) -2- (4-ethyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -propionanide\n\n\n\n\n\n\n \n 20) (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(4-trifluorométhyl- benzyl)-pipérazin-1-yl]-propionannide \n 20) (S) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (4-trifluoromethyl-benzyl) -piperazin-1-yl] - propionannide\n\n\n\n\n\n\n \n 21 ) (S)-N-hydroxy-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)-benzène sulfonylannino]-propionannide \n 21) (S) -N-hydroxy-2- [4- (4-methyl-benzyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzene-sulfonylannino] -propionannide\n\n\n\n\n\n\n \n 22) (S)-3-[4-(benzo-isoxazol-3-ylnnéthoxy)-benzènesulfonylannino]-N-hydroxy-2-(4-nnéthanesulfonyl- pipérazin-1-yl)-propionannide \n 22) (S) -3- [4- (benzo-isoxazol-3-ylmethoxy) -benzenesulfonylannino] -N-hydroxy-2- (4-nnhanesulfonyl-piperazin-1-yl) -propionicid\n\n\n\n\n\n\n \n23) (S)-N-hydroxy-2-(4-isobutyryl-pipérazin-1-yl)-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n23) (S) -N-Hydroxy-2- (4-isobutyryl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] propionannide\n\n\n\n\n\n\n \n 24) (S)-N-hydroxy-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-l]-3-[4-(2-nnéthyl-quinolin-4- ylméthoxy)-benzènesulfonylannino]-propionannide \n 24) (S) -N-hydroxy-2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -3- [4- (2-methylquinolin-4-ylmethoxy)) -benzènesulfonylannino] -propionannide\n\n\n\n\n\n\n \n 25) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-trifluoronnéthyl-pyrazolo[1 ,5-a]pyridin-3- ylméthoxy)-benzènesulfonylannino]-propionannide \n 25) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylannino ] -propionannide\n\n\n\n\n\n\n \n 26) (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylnnéthoxy)-benzènesulfonylannino]-2-[4-(propane-2- sulfonyl)-pipérazin-1-yl]-propionannide \n 26) (S) -N-Hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -2- [4- (propane-2-sulfonyl) -piperazin-1-yl] - propionannide\n\n\n\n\n\n\n \n 27) (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy -3-[4-(2-trifluorométhyl-pyrazolo[1 ,5-a]pyridin-3- ylméthoxy)-benzènesulfonylamino]-propionamide \n 27) (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino ] -propionamide\n\n\n\n\n\n\n \n28) (S)-2-(4-acétyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n28) (S) -2- (4-Acetyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -propionanide\n\n\n\n\n\n\n \n 29) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-{propyl-[4-(quinolin-4-ylnnéthoxy)- benzènesulfonyl]-annino}-propionannide \n 29) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- {propyl- [4- (quinolin-4-ylmethoxy) -benzenesulfonyl] -annino} -propionanide\n\n\n\n\n\n\n \n 30) (S)-2-(4-benzènesulfonyl-pipérazin-1-yl)-N-hydroxy-3-[4-(pyrazolo[1 ,5-a]pyridin-3-ylnnéthoxy)- benzènesulfonylamino]-propionamide \n\n 31 ) (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy-3-[4-(1-méthyl-pipéridin-4-ylméthoxy)- benzènesulfonylamino]-propionannide \n30) (S) -2- (4-Benzenesulfonyl-piperazin-1-yl) -N-hydroxy-3- [4- (pyrazolo [1,5-a] pyridin-3-ylmethoxy) benzenesulfonylamino] -propionamide  31) (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (1-methyl-piperidin-4-ylmethoxy) -benzenesulfonylamino] -propionanide\n\n\n\n\n\n\n \n 32) (S)-2-[4-(4-fluoro-benzoyl)-pipérazin-1-yl]-N-hydroxy-3-[4-(3-m-tolyl-propoxy)- benzènesulfonylannino]-propionannide \n 32) (S) -2- [4- (4-Fluoro-benzoyl) -piperazin-1-yl] -N-hydroxy-3- [4- (3-m-tolyl-propoxy) -benzenesulfonylannino] -propionanide\n\n\n\n\n\n\n \n33) (S)-N-hydroxy-3-[4-(2-méthyl-naphthalen-1-ylnnéthoxy)-benzènesulfonylannino]-2-(4-propionyl- pipérazin-1-yl)-propionannide \n33) (S) -N-Hydroxy-3- [4- (2-methyl-naphthalen-1-ylmethoxy) -benzenesulfonylannino] -2- (4-propionyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n 34) (S)-N-hydroxy-3-[4-(4-méthyl-pentyloxy)-benzènesulfonylannino]-2-(4-phénylacétyl-pipérazin-1-yl)- propionamide \n 34) (S) -N-hydroxy-3- [4- (4-methylpentyloxy) benzenesulfonylannino] -2- (4-phenylacetylpiperazin-1-yl) propionamide\n\n\n\n\n\n\n \n 35) (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-nnéthyl-pyridin-4-ylnnéthoxy)- benzènesulfonylamino]-propionannide \n 35) (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-pyridin-4-ylmethoxy) -benzenesulfonylamino] -propionanide\n\n\n\n\n\n\n \n 36) (S)-2-(3-acétyl-imidazolidin-1-yl)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylannino]-propionannide \n 36) (S) -2- (3-Acetyl-imidazolidin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -propionanide\n\n\n\n\n\n\n \n 37) (S)-3-[4-(3,5-diméthyl-benzyloxy)-benzènesulfonylannino]-N-hydroxy-2-innidazolidin-1-yl- propionamide \n 37) (S) -3- [4- (3,5-Dimethyl-benzyloxy) -benzenesulfonylannino] -N-hydroxy-2-innidazolidin-1-yl-propionamide\n\n\n\n\n\n\n \n38) (S)-N-hydroxy-2-(4-méthanesulfonyl-[1 ,4]diazepan-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylannino]-propionannide \n38) (S) -N-Hydroxy-2- (4-methanesulfonyl- [1,4] diazepan-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -propionanide\n\n\n\n\n\n\n \n 39) (S)-2-(4-benzyl-[1 ,4]diazepan-1-yl)-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)- benzènesulfonylannino]-propionannide \n 39) (S) -2- (4-Benzyl- [1,4] diazepan-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylannino] -propionanide\n\n\n\n\n\n\n \n 40) (S)-2-[1 ,4]diazocan-1-yl-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)-benzènesulfonylannino]- propionamide. \n 40) (S) -2- [1,4] diazocan-1-yl-N-hydroxy-3- [4- (2-methylquinolin-4-ylmethoxy) benzenesulfonylannino] propionamide.\n\n\n\n\n\n\n \n 41 ) (S)-N-hydroxy-3-[4-(2-méthyl-benzofuran-3-ylméthoxy)-benzènesulfonylamino]-2-[4-(propane-2- sulfonyl)-pipérazin-1-yl]-propionamide \n 41) (S) -N-hydroxy-3- [4- (2-methyl-benzofuran-3-ylmethoxy) -benzenesulfonylamino] -2- [4- (propane-2-sulfonyl) -piperazin-1-yl] - propionamide\n\n\n\n\n\n\n \n 42)(S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-isopropyl-1 H-indol-3-ylméthoxy)- benzènesulfonylamino]-propionamide \n 42) (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-isopropyl-1H-indol-3-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \nLes composés de formule générale (I) sont préparés selon le schéma réactionnel de la figure 1 présenté ci-dessous. \n\n\nThe compounds of general formula (I) are prepared according to the reaction scheme of FIG. 1 presented below. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nFigure 1 Selon la figure 1 , les composés (3) sont obtenus par réaction entre l'acide aminé (1) H-DAP(Boc)- OMe. HCI ou H-(D)-DAP(Boc)-OMe.HCI et le composé (2) (commercial ou préalablement préparé) en présence d'une base tertiaire organique comme la diisopropyléthylamine ou la triéthylamine à une température comprise entre 6O\n0\nC et 12O\n0\nC. Les composés (4) sont obtenus par déprotection de la fonction aminé des composés (3) selon des méthodes classiques comme par exemple l'utilisation d'une solution d'acide chlorhydrique dans l'isopropanol. \nFigure 1 According to Figure 1, the compounds (3) are obtained by reaction between the amino acid (1) H-DAP (Boc) - OMe. HCl or H- (D) -DAP (Boc) -OMe.HCl and the compound (2) (commercial or previously prepared) in the presence of an organic tertiary base such as diisopropylethylamine or triethylamine at a temperature between 60 \n°\n C. and 12O \n0\n C. The compounds (4) are obtained by deprotection of the amine function of the compounds (3) according to conventional methods such as for example the use of a solution of hydrochloric acid in isopropanol.\n\n\n\n\n\n\n \n Une réaction entre le composé (4) et le chlorure de 4-hydroxy-benzène sulfonyle O-protégé par un groupement benzyle par exemple (P = CH2-Ph) (5) en présence d'une base tertiaire comme par exemple la triéthylamine dans du dichlorométhane conduit au composé (6). Une N-alkylation de la fonction sulfonamide peut alors être réalisée par réaction avec un halogénure d'alkyle en présence d'une base comme par exemple du carbonate de potassium dans un solvant tel que du DMF pour conduire au dérivé (7). Le composé (8) est obtenu par déprotection selon les méthodes connues par l'homme de l'art pour déprotéger une fonction phénol. Le composé (9) est obtenu par alkylation de la fonction phénol du composé (8) par réaction avec un halogénure d'alkyle en présence d'une base comme par exemple du carbonate de césium dans de l'acétone ou par réaction de Mitsunobu avec un \n\n dérivé alcool primaire en présence de triphénylphosphine et de diisopropyl azodicarboxylate par exemple. Par réaction de saponification en présence d'une base comme l'hydroxyde de lithium en présence d'eau et de tétrahydrofuranne par exemple, le composé (10) est obtenu. Dans une dernière étape, le composé (11) est obtenu par couplage entre la O-(tert-butyldimethylsilyl)hydroxylamine par exemple et le dérivé (10) dans des conditions de couplage peptidique classiques, en utilisant par exemple comme agents de couplage le chlorhydrate de 1-(3-diméthylaminopropyl)-3- éthylcarbodiimide, l'hydroxybenzotriazole ou le TBTU, et comme base la triéthylamine ou la diisopropyléthylamine dans un solvant tel que le dichlorométhane ou le diméthylformamide. La déprotection de l'acide hydroxamique silylé intermédiairement formé se fait in situ ou par lavage avec une solution aqueuse légèrement acide pour conduire au composé (11). \nA reaction between the compound (4) and 4-hydroxy-benzenesulphonyl chloride O-protected with a benzyl group for example (P = CH 2 -Ph) (5) in the presence of a tertiary base such as for example triethylamine in dichloromethane leads to the compound (6). N-alkylation of the sulfonamide function can then be carried out by reaction with an alkyl halide in the presence of a base such as, for example, potassium carbonate in a solvent such as DMF to yield the derivative (7). The compound (8) is obtained by deprotection according to the methods known to those skilled in the art for deprotecting a phenol function. The compound (9) is obtained by alkylation of the phenol function of the compound (8) by reaction with an alkyl halide in the presence of a base such as, for example, cesium carbonate in acetone or by reaction of Mitsunobu with a  primary alcohol derivative in the presence of triphenylphosphine and diisopropyl azodicarboxylate for example. By saponification reaction in the presence of a base such as lithium hydroxide in the presence of water and tetrahydrofuran, for example, the compound (10) is obtained. In a final step, the compound (11) is obtained by coupling between O- (tert-butyldimethylsilyl) hydroxylamine for example and the derivative (10) under conventional peptide coupling conditions, using for example as coupling agents the hydrochloride. 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, hydroxybenzotriazole or TBTU, and as base triethylamine or diisopropylethylamine in a solvent such as dichloromethane or dimethylformamide. Deprotection of the silylated hydroxamic acid intermediate formed is carried out in situ or by washing with a slightly acidic aqueous solution to yield the compound (11).\n\n\n\n\n\n\n \nUne autre alternative pour l'obtention du composé (11) est présentée dans la figure 2 ci-dessous. \nAnother alternative for obtaining the compound (11) is shown in Figure 2 below.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n Figure 2 \n Figure 2\n\n\n\n\n\n\n \nSelon le schéma de synthèse de la figure 2, le dérivé (3) peut éventuellement être alkylé en présence d'une base telle que l'hydrure de sodium et d'un halogénure d'alkyle dans du diméthylformamide par exemple pour conduire au composé (12) à partir duquel le composé (13) est obtenu selon les méthodes classiques de déprotection des aminés comme par exemple l'utilisation d'une solution d'acide chlorhydrique dans l'isopropanol. \nAccording to the synthesis scheme of FIG. 2, the derivative (3) may optionally be alkylated in the presence of a base such as sodium hydride and an alkyl halide in dimethylformamide, for example to give the compound ( 12) from which the compound (13) is obtained according to the standard amine deprotection methods such as, for example, the use of a solution of hydrochloric acid in isopropanol.\n\n\n\n\n\n\n \n Le composé (14) est préalablement préparé à partir du sel de sodium de l'acide 4-hydroxy benzènesulfonique commercial par alkylation avec un halogénure d'alkyle en présence d'une base telle que l'hydroxyde de sodium par exemple dans un mélange de solvants comme l'isopropanol et l'eau par exemple. Le composé (15) est alors obtenu par réaction du dérivé (14) avec du chlorure d'oxalyle en présence de diméthylformamide dans du dichlorométhane par exemple. \n The compound (14) is prepared beforehand from the sodium salt of commercial 4-hydroxy benzenesulfonic acid by alkylation with an alkyl halide in the presence of a base such as sodium hydroxide for example in a mixture of solvents such as isopropanol and water for example. The compound (15) is then obtained by reaction of the derivative (14) with oxalyl chloride in the presence of dimethylformamide in dichloromethane for example.\n\n\n\n\n\n\n \nLe dérivé (9) est obtenu par réaction entre les composés (13) et (15) en présence d'une base comme la triéthylamine dans du dichlorométhane par exemple, \n\n Une voie de synthèse alternative pour l'obtention du composé (11) est également présentée dans la figure 3 ci-dessous. \nThe derivative (9) is obtained by reaction between the compounds (13) and (15) in the presence of a base such as triethylamine in dichloromethane, for example,  An alternative synthetic route for obtaining the compound (11) is also presented in Figure 3 below.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nFigure 3 Selon la figure 3, le composé (17) est obtenu par réaction entre l'acide aminé (1) H-DAP(Boc)- OMe. HCI ou H-(D)-DAP(Boc)-OMe.HCI et le composé (16) (préalablement préparé par réaction de la bis (2-chloroéthyl)amine par exemple et du bromure de benzyle en présence de carbonate de potassium dans l'acétonitrile) en présence d'une base tertiaire organique comme la diisopropyléthylamine à une température de 12O\n0\nC environ. Après déprotection de la fonction aminé, le composé (18) est condensé avec le chlorure de sulfonyle (15) pour conduire au dérivé (19). Une N- alkylation de la fonction sulfonamide peut alors être réalisée par réaction avec un halogénure d'alkyle en présence d'une base comme par exemple du carbonate de potassium dans un solvant tel que du DMF pour conduire au dérivé (20). Selon les conditions classiques d'hydrogénation du composé (20) en présence de palladium sur charbon dans un solvant tel que l'éthanol par exemple, le composé (21) est obtenu. Le composé (9) est obtenu selon les méthodes classiques de synthèse par exemple par réaction du composé (21) avec un chlorure d'acyle, ou un chlorure de sulfonyle en présence de triéthylamine, ou par réaction avec un halogénure d'alkyle en présence d'une base comme l'hydrure \n\n de sodium par exemple. Par réaction de saponification en présence d'une base comme l'hydroxyde de lithium en présence d'eau et de tétrahydrofuranne par exemple, le composé (10) est obtenu. Dans une dernière étape, le composé (11) est obtenu par couplage entre la O-(tert- butyldimethylsilyl)hydroxylamine par exemple et le dérivé (10) dans des conditions de couplage peptidique classiques, en utilisant par exemple comme agents de couplage le chlorhydrate de 1-(3- diméthylaminopropyl)-3-éthylcarbodiimide, l'hydroxybenzotriazole ou le TBTU, et comme base la triéthylamine ou la diisopropyléthylamine dans un solvant tel que le dichlorométhane ou le diméthylformamide. La déprotection de l'acide hydroxamique silylé intermédiairement formé se fait in situ ou par lavage avec une solution aqueuse acide pour conduire au composé (11). \nFigure 3 According to Figure 3, the compound (17) is obtained by reaction between the amino acid (1) H-DAP (Boc) - OMe. HCI or H- (D) -DAP (Boc) -OMe.HCl and the compound (16) (previously prepared by reaction of bis (2-chloroethyl) amine for example and benzyl bromide in the presence of potassium carbonate in acetonitrile) in the presence of an organic tertiary base such as diisopropylethylamine at a temperature of approximately 120 \n°\n C. After deprotection of the amine function, the compound (18) is condensed with the sulfonyl chloride (15) to yield the derivative (19). N-alkylation of the sulfonamide function can then be accomplished by reaction with an alkyl halide in the presence of a base such as, for example, potassium carbonate in a solvent such as DMF to yield the derivative (20). According to the conventional conditions of hydrogenation of the compound (20) in the presence of palladium on carbon in a solvent such as ethanol for example, the compound (21) is obtained. The compound (9) is obtained according to the conventional methods of synthesis, for example by reaction of the compound (21) with an acyl chloride, or a sulfonyl chloride in the presence of triethylamine, or by reaction with an alkyl halide in the presence a base like hydride  sodium for example. By saponification reaction in the presence of a base such as lithium hydroxide in the presence of water and tetrahydrofuran, for example, the compound (10) is obtained. In a last step, the compound (11) is obtained by coupling between O- (tert-butyldimethylsilyl) hydroxylamine for example and the derivative (10) under conventional peptide coupling conditions, using for example as coupling agents the hydrochloride. 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide, hydroxybenzotriazole or TBTU, and as base triethylamine or diisopropylethylamine in a solvent such as dichloromethane or dimethylformamide. The deprotection of the silylated hydroxamic acid intermediate formed is carried out in situ or by washing with an acidic aqueous solution to yield the compound (11).\n\n\n\n\n\n\n \nUne voie de synthèse alternative pour les composés avec R1 représentant un radical -(CO)-R\n4\n est décrite dans la figure 4. \nAn alternative synthetic route for compounds with R 1 representing a radical - (CO) -R \n4\n is described in Figure 4.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nFigure 4 \nFigure 4\n\n\n\n\n\n\n \nAprès déprotection de la fonction aminé du composé (17) suivant des conditions classiques d'hydrogénation en présence de palladium sur charbon dans un solvant tel que l'éthanol par exemple, le composé (22) est obtenu. Par réaction avec un chlorure d'acyle, R\n4\nCOCI en présence d'une base telle que la triéthylamine, le composé (23) est obtenu. Lorsque R\n2\n représente un radical alkyle inférieur, une N-alkylation du carbamate est alors réalisée par réaction avec un halogénure d'alkyle en présence d'une base comme par exemple du carbonate de potassium dans un solvant tel que du \n\n DMF pour conduire au dérivé (24). Par réaction de saponification en présence d'une base comme l'hydroxyde de lithium en présence d'eau et de tétrahydrofuranne par exemple, le composé (25) est préparé. Un couplage entre le chlorhydrate de O-allylhydroxylamine par exemple et le dérivé (25) permet d'obtenir le composé (26) dans des conditions de couplage peptidique classiques. Pour cela, on utilise par exemple le chlorhydrate de 1-(3-diméthylaminopropyl)-3-éthylcarbodiimide, l'hydroxybenzotriazole ou le TBTU comme agents de couplage, et la triéthylamine ou la diisopropyléthylamine comme base. La réaction s'effectue dans un solvant tel que le dichlorométhane ou le diméthylformamide. Après déprotection de la fonction aminé du composé (26) selon des méthodes classiques, le composé (27) est obtenu. Il est condensé avec le chlorure de sulfonyle (15) pour conduire au composé (28). Dans une dernière étape, le composé (29) est obtenu par déprotection de la fonction hydroxylamine du composé (28) selon des méthodes classiques comme par exemple le traitement par du tétrakis(triphénylphosphine)palladium (0) et du carbonate de potassium dans du méthanol. \nAfter deprotection of the amine function of the compound (17) according to conventional conditions of hydrogenation in the presence of palladium on carbon in a solvent such as ethanol for example, the compound (22) is obtained. By reaction with an acyl chloride, R \n4\n COCI in the presence of a base such as triethylamine, the compound (23) is obtained. When R \n2\n represents a lower alkyl radical, an N-alkylation of the carbamate is then carried out by reaction with an alkyl halide in the presence of a base such as, for example, potassium carbonate in a solvent such as  DMF to lead to the derivative (24). By saponification reaction in the presence of a base such as lithium hydroxide in the presence of water and tetrahydrofuran, for example, the compound (25) is prepared. A coupling between O-allylhydroxylamine hydrochloride for example and the derivative (25) makes it possible to obtain the compound (26) under conventional peptide coupling conditions. For this purpose, for example, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, hydroxybenzotriazole or TBTU are used as coupling agents, and triethylamine or diisopropylethylamine as the base. The reaction is carried out in a solvent such as dichloromethane or dimethylformamide. After deprotection of the amine function of the compound (26) according to conventional methods, the compound (27) is obtained. It is condensed with sulfonyl chloride (15) to yield compound (28). In a final step, the compound (29) is obtained by deprotection of the hydroxylamine function of the compound (28) according to standard methods, for example treatment with tetrakis (triphenylphosphine) palladium (0) and potassium carbonate in methanol. .\n\n\n\n\n\n\n \nSelon la présente invention, les composés de formule générale (I) préférés sont ceux pour lesquels : R\n1\n représente un hydrogène, un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué, un radical - C(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, un radical C(O)OR4, R\n4\n ayant les significations données ci-après; \nAccording to the present invention, the preferred compounds of general formula (I) are those for which: R \n1\n represents a hydrogen, an alkyl radical, a substituted alkyl radical, an alkenyl radical, a substituted alkenyl radical, an alkynyl radical or an alkynyl radical; substituted, an aralkyl radical, a substituted aralkyl radical, a heteroaralkyl radical, a substituted heteroaralkyl radical, a radical - C (O) -R \n4\n , a radical -SO \n2\n -R \n4\n , a radical C (O) OR \n4\n , R \n4\n having the meanings given below;\n\n\n\n\n\n\n \nR\n2\n est un atome d'hydrogène ou un radical alkyle inférieur. \nR \n2\n is a hydrogen atom or a lower alkyl radical.\n\n\n\n\n\n\n \n R\n3\n est un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétérocyclique, un radical hétérocyclique substitué, un radical hétéroaryle, un radical hétéroaryle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué ; \nR \n3\n is aryl, substituted aryl, aralkyl, substituted aralkyl, heterocyclic, substituted heterocyclic, heteroaryl, substituted heteroaryl, heteroaralkyl, substituted heteroaralkyl;\n\n\n\n\n\n\n \nR\n4\n est un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ; \nR \n4\n is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, aralkyl, substituted aralkyl;\n\n\n\n\n\n\n \nn peut prendre les valeurs de 0, 1 , 2; \nn can take the values of 0, 1, 2;\n\n\n\n\n\n\n \nainsi que leurs sels d'addition avec un acide pharmaceutiquement acceptable, leurs sels d'addition avec une base pharmaceutiquement acceptable et les énantiomères desdits composés. \nas well as their addition salts with a pharmaceutically acceptable acid, their addition salts with a pharmaceutically acceptable base and the enantiomers of said compounds.\n\n\n\n\n\n\n \nSelon la présente invention, les composés de formule générale (I) particulièrement préférés sont ceux pour lesquels : \nAccording to the present invention, the compounds of general formula (I) that are particularly preferred are those for which:\n\n\n\n\n\n\n \nR\n1\n représente un hydrogène, un radical alkyle, un radical alkyle substitué, un radical alkenyle, un radical alkenyle substitué, un radical alkynyle, un radical alkynyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical -C(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, R\n4\n ayant les significations données ci-après; \nR \n1\n represents a hydrogen, an alkyl radical, a substituted alkyl radical, an alkenyl radical, a substituted alkenyl radical, an alkynyl radical, a substituted alkynyl radical, an aralkyl radical, a substituted aralkyl radical or a -C (O) - radical; R \n4\n , a radical -SO \n2\n -R \n4\n , R \n4\n having the meanings given below;\n\n\n\n\n\n\n \nR\n2\n est un atome d'hydrogène ou un radical alkyle inférieur ; \n\n R\n3\n est un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétérocyclique, un radical hétérocyclique substitué, un radical hétéroaryle, un radical hétéroaryle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué ; \nR \n2\n is a hydrogen atom or a lower alkyl radical;  R \n3\n is aryl, substituted aryl, aralkyl, substituted aralkyl, heterocyclic, substituted heterocyclic, heteroaryl, substituted heteroaryl, heteroaralkyl, substituted heteroaralkyl;\n\n\n\n\n\n\n \nR\n4\n est un radical alkyle, un radical alkyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ; \nR \n4\n is an alkyl radical, a substituted alkyl radical, an aryl radical, a substituted aryl radical, an aralkyl radical, a substituted aralkyl radical;\n\n\n\n\n\n\n \nn peut prendre les valeurs de 1 ou 2; \nn can take the values of 1 or 2;\n\n\n\n\n\n\n \nainsi que leurs sels d'addition avec un acide pharmaceutiquennent acceptable, leurs sels d'addition avec une base pharmaceutiquennent acceptable et les énantiomères desdits composés. \nas well as their addition salts with a pharmaceutically acceptable acid, their addition salts with a pharmaceutically acceptable base and the enantiomers of said compounds.\n\n\n\n\n\n\n \nSelon la présente invention, les composés de formule générale (I) plus particulièrement préférés sont ceux pour lesquels : \nAccording to the present invention, the compounds of general formula (I) that are more particularly preferred are those for which:\n\n\n\n\n\n\n \n R\n1\n représente un radical alkyle, un radical alkyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical -C(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, R\n4\n ayant les significations données ci-après; \nR \n1\n represents an alkyl radical, a substituted alkyl radical, an aralkyl radical, a substituted aralkyl radical, a -C (O) -R \n4\n radical, a radical -SO \n2\n -R \n4\n , R \n4\n having the meanings given below. ;\n\n\n\n\n\n\n \nR\n2\n est un atome d'hydrogène, \nR \n2\n is a hydrogen atom,\n\n\n\n\n\n\n \n R\n3\n est un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué, un radical hétérocyclique, un radical hétérocyclique substitué, un radical hétéroaryle, un radical hétéroaryle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué ; \nR \n3\n is aryl, substituted aryl, aralkyl, substituted aralkyl, heterocyclic, substituted heterocyclic, heteroaryl, substituted heteroaryl, heteroaralkyl, substituted heteroaralkyl;\n\n\n\n\n\n\n \nR\n4\n est un radical alkyle, un radical alkyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ; \nR \n4\n is an alkyl radical, a substituted alkyl radical, an aryl radical, a substituted aryl radical, an aralkyl radical, a substituted aralkyl radical;\n\n\n\n\n\n\n \nn prend la valeur de 1 ; \nn takes the value of 1;\n\n\n\n\n\n\n \nainsi que leurs sels d'addition avec un acide pharmaceutiquement acceptable, leurs sels d'addition avec une base pharmaceutiquement acceptable et les énantiomères desdits composés. \nas well as their addition salts with a pharmaceutically acceptable acid, their addition salts with a pharmaceutically acceptable base and the enantiomers of said compounds.\n\n\n\n\n\n\n \nSelon la présente invention, les composés de formule générale (I) encore plus particulièrement préférés sont ceux pour lesquels : \nAccording to the present invention, the compounds of general formula (I) still more particularly preferred are those for which:\n\n\n\n\n\n\n \n R\n1\n représente un radical alkyle, un radical alkyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical -C(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, R\n4\n ayant les significations données ci-après; \nR \n1\n represents an alkyl radical, a substituted alkyl radical, an aralkyl radical, a substituted aralkyl radical, a -C (O) -R \n4\n radical, a radical -SO \n2\n -R \n4\n , R \n4\n having the meanings given below. ;\n\n\n\n\n\n\n \nR\n2\n est un atome d'hydrogène, \nR \n2\n is a hydrogen atom,\n\n\n\n\n\n\n \n R\n3\n est un radical hétérocyclique, un radical hétérocyclique substitué, un radical hétéroaryle, un radical hétéroaryle substitué, un radical hétéroaralkyle, un radical hétéroaralkyle substitué ; \nR \n3\n is a heterocyclic radical, a substituted heterocyclic radical, a heteroaryl radical, a substituted heteroaryl radical, a heteroaralkyl radical, a substituted heteroaralkyl radical;\n\n\n\n\n\n\n \n R\n4\n est un radical alkyle, un radical alkyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ; \nR \n4\n is an alkyl radical, a substituted alkyl radical, an aryl radical, a substituted aryl radical, an aralkyl radical, a substituted aralkyl radical;\n\n\n\n\n\n\n \nn prend la valeur de 1 ; \nn takes the value of 1;\n\n\n\n\n\n\n \nainsi que leurs sels d'addition avec un acide pharmaceutiquement acceptable, leurs sels d'addition avec une base pharmaceutiquement acceptable et les énantiomères desdits composés. \n\n Selon la présente invention, les composés de formule générale (I) les plus particulièrement préférés sont ceux pour lesquels : \nas well as their addition salts with a pharmaceutically acceptable acid, their addition salts with a pharmaceutically acceptable base and the enantiomers of said compounds.  According to the present invention, the compounds of general formula (I) most particularly preferred are those for which:\n\n\n\n\n\n\n \n R\n1\n représente un radical alkyle, un radical alkyle substitué, un radical aralkyle, un radical aralkyle substitué, un radical -C(O)-R\n4\n, un radical -SO\n2\n-R\n4\n, R\n4\n ayant les significations données ci-après; \nR \n1\n represents an alkyl radical, a substituted alkyl radical, an aralkyl radical, a substituted aralkyl radical, a -C (O) -R \n4\n radical, a radical -SO \n2\n -R \n4\n , R \n4\n having the meanings given below. ;\n\n\n\n\n\n\n \nR\n2\n est un atome d'hydrogène, \nR \n2\n is a hydrogen atom,\n\n\n\n\n\n\n \n R\n3\n est un radical hétéroaryle, un radical hétéroaryle substitué, \nR \n3\n is a heteroaryl radical, a substituted heteroaryl radical,\n\n\n\n\n\n\n \n R\n4\n est un radical alkyle, un radical alkyle substitué, un radical aryle, un radical aryle substitué, un radical aralkyle, un radical aralkyle substitué ; \nR \n4\n is an alkyl radical, a substituted alkyl radical, an aryl radical, a substituted aryl radical, an aralkyl radical, a substituted aralkyl radical;\n\n\n\n\n\n\n \nn prend la valeur de 1 ; \nn takes the value of 1;\n\n\n\n\n\n\n \nainsi que leurs sels d'addition avec un acide pharmaceutiquement acceptable, leurs sels d'addition avec une base pharmaceutiquement acceptable et les énantiomères desdits composés. \nas well as their addition salts with a pharmaceutically acceptable acid, their addition salts with a pharmaceutically acceptable base and the enantiomers of said compounds.\n\n\n\n\n\n\n \nLes composés selon l'invention présentent une très bonne activité inhibitrice de TACE et en particulier, ils inhibent l'enzyme TACE de façon sélective par rapport à d'autres ADAMs et MMPs. Cette activité inhibitrice de l'enzyme TACE est mesurée dans un test enzymatique et quantifiée par la mesure d'une IC\n50\n (concentration d'inhibiteur nécessaire pour obtenir 50% d'inhibition de l'enzyme TACE), comme décrit dans l'exemple 28. Les composés de la présente invention présentent une IC\n50\n pour TACE inférieure ou égale à 10μM et plus particulièrement inférieure ou égale à 1μM. De façon avantageuse, les composés de la présente invention présentent une IC\n50\n pour TACE inférieure ou égale à 0,5μM. \nThe compounds according to the invention have a very good TACE inhibitory activity and in particular, they inhibit the TACE enzyme selectively compared with other ADAMs and MMPs. This inhibitory activity of the enzyme TACE is measured in an enzymatic test and quantified by the measurement of an IC \n50\n (concentration of inhibitor necessary to obtain 50% inhibition of the TACE enzyme), as described in the example 28. The compounds of the present invention have an IC \n50\n for TACE of less than or equal to 10 μM and more particularly less than or equal to 1 μM. Advantageously, the compounds of the present invention have an IC \n50\n for TACE of less than or equal to 0.5 μM.\n\n\n\n\n\n\n \n De façon avantageuse, ces composés sont également très sélectifs de TACE par rapport aux autres ADAMs et MMPs (test décrit dans l'exemple 29): leur activité inhibitrice est au moins 10 fois plus importante pour TACE que pour d'autres ADAMs et MMPs (c'est-à-dire que la valeur de l'IC\n50\n pour TACE est au moins 10 fois plus petite que celle pour d'autres ADAMs et MMPs), et plus avantageusement au moins 100 fois plus importante. \nAdvantageously, these compounds are also very selective for TACE compared to other ADAMs and MMPs (test described in Example 29): their inhibitory activity is at least 10-fold greater for TACE than for other ADAMs and MMPs ( i.e., the IC \n50 value\n for TACE is at least 10 times smaller than that for other ADAMs and MMPs), and more preferably at least 100 times greater.\n\n\n\n\n\n\n \nTACE (TNFα-Converting Enzyme) catalyse la formation du TNF-alpha soluble à partir de la protéine précurseur (TNFα transmembranaire) liée aux membranes de certaines cellules. Le TNFαest une cytokine pro-inflammatoire qui est connue pour jouer un rôle dans de nombreuses pathologies à caractère inflammatoire. \nTACE (TNFα-Converting Enzyme) catalyzes the formation of soluble TNF-alpha from the precursor protein (transmembrane TNFα) bound to the membranes of certain cells. TNFα is a pro-inflammatory cytokine that is known to play a role in many inflammatory diseases.\n\n\n\n\n\n\n \n L'invention vise donc l'utilisation d'au moins un composé de formule générale (I) tel que défini ci- dessus pour le traitement de pathologies ou de désordres liés à une libération de TNFα. Un inhibiteur de l'enzyme TACE de formule générale (I) diminue la production de TNFα. De ce fait, il est utile pour le traitement de pathologies liées à une libération de TNFα. \n The invention therefore relates to the use of at least one compound of general formula (I) as defined above for the treatment of pathologies or disorders related to TNFα release. An inhibitor of the enzyme TACE of general formula (I) decreases the production of TNFα. Therefore, it is useful for the treatment of pathologies related to TNFα release.\n\n\n\n\n\n\n \nL'invention vise aussi l'utilisation d'au moins un composé de formule générale (I) tel que défini ci- dessus pour la préparation d'une composition pharmaceutique ou cosmétique dans laquelle ledit composé a une activité inhibitrice de l'enzyme TACE. \nThe invention also relates to the use of at least one compound of general formula (I) as defined above for the preparation of a pharmaceutical or cosmetic composition in which said compound has an inhibitory activity of the enzyme TACE.\n\n\n\n\n\n\n \n Elle vise donc l'utilisation d'au moins un composé de formule générale (I) tel que défini ci-dessus pour le traitement de pathologies ou de désordres qui sont améliorés par l'inhibition de l'enzyme TACE. \n\n L'invention concerne également une méthode de traitement thérapeutique (humain ou animal) ou cosmétique, consistant en l'administration ou l'application d'une composition pharmaceutique ou cosmétique comprenant Je44t un composé de formule générale (I) en tant qu'inhibiteur de TACE et de ce fait en tant qu'inhibiteur de la production de TNFα soluble. \nIt therefore aims at the use of at least one compound of general formula (I) as defined above for the treatment of pathologies or disorders which are improved by the inhibition of the enzyme TACE.  The invention also relates to a method of therapeutic treatment (human or animal) or cosmetic, consisting of the administration or the application of a pharmaceutical or cosmetic composition comprising a compound of general formula (I) as inhibitor of TACE and thereby as an inhibitor of the production of soluble TNFα.\n\n\n\n\n\n\n \nAinsi, l'invention concerne l'utilisation d'au moins un composé de formule générale (I) tel que défini ci- dessus pour le traitement de pathologies ou de désordres liés à une production de TNFα. \nThus, the invention relates to the use of at least one compound of general formula (I) as defined above for the treatment of pathologies or disorders related to TNFα production.\n\n\n\n\n\n\n \nL'invention concerne également l'utilisation d'un composé de formule générale (I) tel que défini ci- dessus pour la préparation d'un médicament destiné au traitement de pathologies pour lesquelles diminuer la production de TNFα serait d'un grand intérêt. \nThe invention also relates to the use of a compound of general formula (I) as defined above for the preparation of a medicament for the treatment of pathologies for which the reduction of TNFα production would be of great interest.\n\n\n\n\n\n\n \n En effet, les composés utilisés selon l'invention sont particulièrement appropriés au traitement et à la prévention des désordres / maladies tels que les maladies inflammatoires listées ci-après mais non limitatives comme le choc septique, le choc hémodynamique, la malaria, les maladies intestinales inflammatoires (IBD) comme la maladie de Crohn et les colites ulcératives, les maladies osseuses inflammatoires, les infections mycobactériennes, la méningite, les maladies fibrotiques, les maladies cardiaques, l'athérosclérose, l'obésité, l'attaque ischémique, le rejet de greffe, le cancer, les maladies impliquant des phénomènes d'angiogénèse, les maladies auto-immunes, l'ostéoarthrite, l'arthrite rhumatoïde, la spondylarthrite ankylosante, l'arthrite chronique juvénile, la sclérose multiple, le HIV, le diabète melitus non insulino dépendant, les maladies allergiques, l'asthme, la maladie d'obstruction pulmonaire chronique (COPD), les maladies inflammatoires de la peau, le psoriasis, la dermatite atopique et le rhumatisme psoriasique. \n Indeed, the compounds used according to the invention are particularly suitable for the treatment and prevention of disorders / diseases such as the inflammatory diseases listed below but not limiting such as septic shock, hemodynamic shock, malaria, intestinal diseases Inflammatory diseases (IBD) such as Crohn's disease and ulcerative colitis, inflammatory bone diseases, mycobacterial infections, meningitis, fibrotic diseases, heart disease, atherosclerosis, obesity, ischemic attack, rejection of transplantation, cancer, diseases involving angiogenesis phenomena, autoimmune diseases, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, juvenile chronic arthritis, multiple sclerosis, HIV, diabetes melitus non dependent insulin, allergic diseases, asthma, chronic pulmonary obstruction disease (COPD), inflammatory diseases of skin, psoriasis, atopic dermatitis and psoriatic arthritis.\n\n\n\n\n\n\n \n Ces molécules sont également des principes actifs potentiels pour le traitement de pathologies neurologiques à caractère inflammatoire pour lesquelles diminuer la production de TNFα serait d'un grand intérêt. Ces pathologies listées ci-après de façon non limitative sont par exemple la maladie d'Alzheimer, la maladie de Parkinson, les désordres parkinsoniens, la sclérose amyotrophique latérale, les maladies autoimmunes du système nerveux, les maladies autonomiques du système nerveux, les douleurs dorsales, l'œdème cérébral, les désordres cérébrovasculaires, la démence, les maladies autoimmunes de démyelination des fibres nerveuses du système nerveux, les neuropathies diabétiques, l'encéphalite, l'encéphalomyélite, l'épilepsie, le syndrome chronique de fatigue, l'artérite des cellules géantes, le syndrome Guillain-Barre, les maux de tête, la sclérose multiple, la neuralgie, les maladies du système nerveux périphérique, les polyneuropathies, la polyradiculoneuropathie, la radiculopathie, les paralysies respiratoires, les maladies des cordes spinales, le syndrome de Tourette, la vasculite du système nerveux centreux, les maladies d'Huntington et l'attaque cérébrale ; \n These molecules are also potential active ingredients for the treatment of inflammatory neurological pathologies for which TNFα production would be of great interest. These pathologies listed hereafter without limitation are for example Alzheimer's disease, Parkinson's disease, parkinsonian disorders, amyotrophic lateral sclerosis, autoimmune diseases of the nervous system, autonomic diseases of the nervous system, back pain. , cerebral edema, cerebrovascular disorders, dementia, autoimmune diseases of demyelinating nerve fibers of the nervous system, diabetic neuropathies, encephalitis, encephalomyelitis, epilepsy, chronic fatigue syndrome, arteritis giant cells, Guillain-Barre syndrome, headaches, multiple sclerosis, neuralgia, diseases of the peripheral nervous system, polyneuropathies, polyradiculoneuropathy, radiculopathy, respiratory paralysis, spinal cord diseases, the syndrome of Tourette, vasculitis of the central nervous system, Huntington's disease and stroke ale;\n\n\n\n\n\n\n \nL'invention concerne l'utilisation d'un composé de formule générale (I) tel que défini ci-dessus pour la préparation d'un médicament destiné au traitement de pathologies à caractère inflammatoire dans lesquelles le TNFα est impliqué. \n\n L'invention concerne l'utilisation d'un composé de formule générale (I) tel que défini ci-dessus pour la préparation d'un médicament destiné au traitement de maladies inflammatoires de la peau, du psoriasis, de la dermatite atopique ou du rhumatisme psoriasique ; La présente invention a aussi pour objet une composition pharmaceutique destinée notamment au traitement des affections susmentionnées, et qui est caractérisée par le fait qu'elle comprend, dans un support pharmaceutiquement acceptable et compatible avec le mode d'administration retenu pour cette composition, au moins un composé de formule générale (I). Ce composé de formule générale (I) peut également se présenter sous une de ses formes énantiomériques ou sous la forme d'un de ses sels pharmaceutiquement acceptables. \nThe invention relates to the use of a compound of general formula (I) as defined above for the preparation of a medicament for the treatment of inflammatory diseases in which TNFα is involved.  The invention relates to the use of a compound of general formula (I) as defined above for the preparation of a medicament for the treatment of inflammatory skin diseases, psoriasis, atopic dermatitis or rheumatism. psoriatic; The subject of the present invention is also a pharmaceutical composition intended in particular for the treatment of the abovementioned affections, and which is characterized in that it comprises, in a pharmaceutically acceptable carrier and compatible with the mode of administration chosen for this composition, at least a compound of general formula (I). This compound of general formula (I) may also be in one of its enantiomeric forms or in the form of a pharmaceutically acceptable salt thereof.\n\n\n\n\n\n\n \nOn va maintenant donner, à titre d'illustration et sans aucun caractère limitatif, plusieurs exemples de préparation de composés actifs de formule (I) selon l'invention, ainsi que des résultats d'activité biologiques de tels composés. \nSeveral examples of the preparation of active compounds of formula (I) according to the invention, as well as biological activity results for such compounds, will now be given by way of illustration and without any limiting character.\n\n\n\n\n\n\n \nEXEMPLES DE RÉALISATION \nEXAMPLES OF REALIZATION\n\n\n\n\n\n\n \nLes composés de formule générale (I) sont caractérisés par analyse RMN du proton sur un appareil Advanced 400MHz Bruker. \nThe compounds of general formula (I) are characterized by proton NMR analysis on an Advanced 400MHz Bruker apparatus.\n\n\n\n\n\n\n \nExemple 1 : 3-[(4-but-2-ynyloxy-benzènesulfonyl)-méthyl-amino]-N-hydroxy-2-(4- méthanesulfonyl-pipérazin-1-yl)-propionamide. \nExample 1: 3 - [(4-But-2-ynyloxy-benzenesulfonyl) methyl-amino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide.\n\n\n\n\n\n\n \n1-1 : 2-(4-tert-butoxycarbonyl-pipérazin-1-yl)-malonate de diméthyle \n1-1: Dimethyl 2- (4-tert-butoxycarbonyl-piperazin-1-yl) -malonate\n\n\n\n\n\n\n \n19,5g (141 mmoles) de carbonate de potassium puis 19,5ml (134 mmoles) de diméthylbromomalonate sont additionnés à une solution de 25g (134 mmoles) de pipérazine 1- carboxylate de tertbutyle dans 300ml d'acétonitrile. Le milieu réactionnel est agité à température ambiante pendant 24h puis filtré pour éliminer les sels insolubles et concentré sous vide. Le résidu brut obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane/acétate d'éthyle 70/30. 41g (97%) de 2-(4-tert-butoxycarbonyl-pipérazin-1-yl)-malonate de diméthyle sont obtenus sous forme d'une huile claire . \n19.5 g (141 mmol) of potassium carbonate and 19.5 ml (134 mmol) of dimethylbromomalonate are added to a solution of 25 g (134 mmol) of tertbutyl piperazine-1-carboxylate in 300 ml of acetonitrile. The reaction medium is stirred at ambient temperature for 24 hours and then filtered to remove the insoluble salts and concentrated in vacuo. The crude residue obtained is purified by chromatography on silica gel eluting with a 70/30 heptane / ethyl acetate mixture. 41 g (97%) of dimethyl 2- (4-tert-butoxycarbonyl-piperazin-1-yl) -malonate are obtained in the form of a clear oil.\n\n\n\n\n\n\n \n1-2 : 2-(4-tert-butoxycarbonyl-pipérazin-1-yl)-2-(1,3-dioxo-1,3-dihydro-isoindol-2-ylméthyl)-malonate de diméthyle: \n1-2: Dimethyl 2- (4-tert-butoxycarbonyl-piperazin-1-yl) -2- (1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl) -malonate:\n\n\n\n\n\n\n \n3,5g (87 mmoles) d'hydrure de sodium sont additionnés par portions à une solution de 25g (87 mmoles) de 2-(4-tert-butoxycarbonyl-piperazin-1-yl)-malonate de diméthyle dans 250ml de tétrahydrofuranne refroidie à 2\n0\nC. Le milieu réactionnel est agité à température ambiante pendant 30 minutes puis ramené à 2\n0\nC avant addition goutte à goutte de 21g (87 mmoles) de 2-bromométhyl- isoindole-1 ,3-dione dans 200ml de tétrahydrofuranne. Le milieu réactionnel est agité à température \n\n ambiante pendant 2Oh, traité par addition de 500ml d'eau puis extrait à l'acétate d'éthyle. La phase organique est séchée sur sulfate de magnésium, filtrée et concentrée sous vide. \n3.5 g (87 mmol) of sodium hydride are added in portions to a solution of 25 g (87 mmol) of dimethyl 2- (4-tert-butoxycarbonyl-piperazin-1-yl) -malonate in 250 ml of cooled tetrahydrofuran at 20 \n°\n C. The reaction mixture is stirred at ambient temperature for 30 minutes and then brought back to 20 \n°\n C. before adding dropwise 21 g (87 mmol) of 2-bromomethylisoindole-1,3-dione in 200 ml of tetrahydrofuran. The reaction medium is stirred at room temperature  ambient for 2Oh, treated by addition of 500ml of water and then extracted with ethyl acetate. The organic phase is dried over magnesium sulfate, filtered and concentrated in vacuo.\n\n\n\n\n\n\n \nLe produit brut obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane/acétate d'éthyle 70/30. 27,5g (73%) de 2-(4-tert-Butoxycarbonyl-piperazin-1-yl)-2-(1 ,3-dioxo- 1 ,3-dihydro-isoindol-2-ylmethyl)-malonate de diméthyle sont obtenus sous forme d'un solide blanc . \nThe crude product obtained is purified by chromatography on silica gel eluted with a 70/30 heptane / ethyl acetate mixture. 27.5 g (73%) of dimethyl 2- (4-tert-butoxycarbonyl-piperazin-1-yl) -2- (1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl) -malonate are obtained in the form of a white solid.\n\n\n\n\n\n\n \n1-3: 2-aminométhyl-2-(4-tert-butoxycarbonyl-piperazin-1-yl)-malonate de diméthyle \nDimethyl 1-3: 2-aminomethyl-2- (4-tert-butoxycarbonyl-piperazin-1-yl) -malonate\n\n\n\n\n\n\n \n Une solution de 2,9ml (64 mmoles) d'hydrazine hydrate dans 8ml de méthanol est additionnée à une solution de 27,5g (58 mmoles) de 2-(4-tert-butoxycarbonyl-pipérazin-1-yl)-2-(1 ,3-dioxo-1 ,3-dihydro- isoindol-2-ylméthyl)-malonate de diméthyle dans 300ml de méthanol préalablement refroidie à -5\n0\nC. Le milieu réactionnel est agité de -5\n0\nC à température ambiante pendant 3h. Après évaporation et addition de 300ml d'eau, le milieu réactionnel est extrait à l'acétate d'éthyle. Les phases organiques sont lavées avec une solution aqueuse saturée d'hydrogénocarbonate de sodium, séchées sur sulfate de magnésium, filtrées, évaporées. Le résidu obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane / acétate d'éthyle 8/2 puis augmentation de la polarité jusqu'à un mélange acétate d'éthyle / méthanol 90/10. 10g (50%) de 2-aminométhyl-2-(4-tert-butoxycarbonyl- piperazin-1-yl)-malonate de diméthyle sont ainsi obtenus sous forme d'une huile claire. \nA solution of 2.9 ml (64 mmol) of hydrazine hydrate in 8 ml of methanol is added to a solution of 27.5 g (58 mmol) of 2- (4-tert-butoxycarbonyl-piperazin-1-yl) -2- (1,3-dioxo-1,3-dihydroisoindol-2-ylmethyl) dimethyl malonate in 300 ml of methanol previously cooled to -5 \n°\n C. The reaction medium is stirred at -5 \n°\n C. at room temperature for 3 hours. . After evaporation and addition of 300 ml of water, the reaction medium is extracted with ethyl acetate. The organic phases are washed with a saturated aqueous solution of sodium hydrogencarbonate, dried over magnesium sulphate, filtered and evaporated. The residue obtained is purified by chromatography on silica gel eluted with heptane / ethyl acetate mixture 8/2 and then increasing the polarity to a 90/10 ethyl acetate / methanol mixture. 10 g (50%) of dimethyl 2-aminomethyl-2- (4-tert-butoxycarbonylpiperazin-1-yl) -malonate are thus obtained in the form of a clear oil.\n\n\n\n\n\n\n \n1-4: 2-(4-tert-butoxycarbonyl-pipérazin-1-yl)-2-[(4-but-2-ynyloxybenzènesulfonylamino)-méthyl]- malonate de diméthyle \n1-4: Dimethyl 2- (4-tert-butoxycarbonyl-piperazin-1-yl) -2 - [(4-but-2-ynyloxybenzenesulfonylamino) methyl] malonate\n\n\n\n\n\n\n \n 1 ,1 ml (8 mmoles) de triéthylamine puis 1 ,8ml (7 mmoles) de chlorure de 4-but-2-ynyloxy- benzènesulfonyle sont additionnés sur une solution de 2,5g (7 mmoles) de 2-aminométhyl-2-(4-tert- butoxycarbonyl-piperazin-1-yl)-malonate de diméthyle dans 30ml de dichlorométhane. Le milieu réactionnel est agité à température ambiante pendant 2 heures puis concentré sous vide. Le produit brut obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane/acétate d'éthyle 70/30. 2,1g (51 %) de 2-(4-tert-butoxycarbonyl-pipérazin-1-yl)-2-[(4-but-2-ynyloxy- benzènesulfonylamino)-méthyl]-malonate de diméthyle sont obtenus sous forme d'un solide blanc. \n 1.1 ml (8 mmol) of triethylamine and then 1.8 ml (7 mmol) of 4-but-2-ynyloxybenzenesulfonyl chloride are added to a solution of 2.5 g (7 mmol) of 2-aminomethyl-2- Dimethyl (4-tert-butoxycarbonyl-piperazin-1-yl) -malonate in 30 ml of dichloromethane. The reaction medium is stirred at room temperature for 2 hours and then concentrated in vacuo. The crude product obtained is purified by chromatography on silica gel eluted with a 70/30 heptane / ethyl acetate mixture. 2.1 g (51%) of dimethyl 2- (4-tert-butoxycarbonyl-piperazin-1-yl) -2 - [(4-but-2-ynyloxy-benzenesulfonylamino) methyl] dimalonate are obtained in the form of a white solid.\n\n\n\n\n\n\n \n1-5: 2-[(4-but-2-ynyloxy-benzènesulfonylamino)-méthyl]-2-piperazin-1-yl-malonate de diméthyle 2,8ml d'acide trifluoroacétique sont additionnés sur une solution de 2,1g ( 4 mmoles) de 2-(4-tert- butoxycarbonyl-piperazin-1-yl)-2-[(4-but-2-ynyloxybenzènesulfonylamino)-méthyl]-malonate de diméthyle dilué dans 30ml de dichlorométhane. Après agitation à température ambiante pendant 24h, une solution aqueuse saturée d'hydrogénocarbonate de sodium est additionnée jusqu'à pH=8 et le milieu réactionnel est extrait par du dichlorométhane. Les phases organiques sont rassemblées, lavées à l'eau, séchées sur sulfate de magnésium puis filtrées et évaporées. 1 ,7g (98%) de 2-[(4-but- 2-ynyloxy-benzènesulfonylamino)-méthyl]-2-pipérazin-1-yl-malonate de diméthyle sont obtenus sous forme d'un solide blanc. \nDimethyl 1-5: 2 - [(4-but-2-ynyloxy-benzenesulfonylamino) -methyl] -2-piperazin-1-yl-malonate 2.8 ml of trifluoroacetic acid are added to a solution of 2.1 g ( 4 mmol) of dimethyl 2- (4-tert-butoxycarbonyl-piperazin-1-yl) -2 - [(4-but-2-ynyloxybenzenesulfonylamino) methyl] dimalonate diluted in 30 ml of dichloromethane. After stirring at room temperature for 24 hours, a saturated aqueous solution of sodium hydrogencarbonate is added until pH = 8 and the reaction medium is extracted with dichloromethane. The organic phases are combined, washed with water, dried over magnesium sulphate and then filtered and evaporated. 1.7 g (98%) of dimethyl 2 - [(4-but-2-ynyloxy-benzenesulfonylamino) methyl] -2-piperazin-1-yl-malonate are obtained as a white solid.\n\n\n\n\n\n\n \n1-6: 2-[(4-but-2-ynyloxy-benzènesulfonylamino)-méthyl]-2-(4-méthanesulfonyl-pipérazin-1-yl)- malonate de diméthyle \n\n 0,6ml (4 mmoles) de triéthylamine puis 0,3ml (4 mmoles) de chlorure de méthanesulfonyle sont additionnés sur une solution de 1 ,6g (4 mmoles) de 2-[(4-but-2-ynyloxy-benzènesulfonylamino)- méthyl]-2-piperazin-1-yl-malonate de diméthyle dilué dans 30ml de dichlorométhane. Le milieu réactionnel est ensuite agité à température ambiante pendant 3h puis évaporé à sec. Le résidu brut est purifié par chromatographie sur gel de silice élue avec un mélange dichlorométhane/méthanol 99/1. 1 ,1g (58%) de 2-[(4-but-2-ynyloxy-benzènesulfonylamino)-méthyl]-2-(4-méthanesulfonyl- piperazin-1-yl)-malonate de diméthyle sont obtenus sous forme d'un solide blanc. \nDimethyl 1-6: 2 - [(4-but-2-ynyloxy-benzenesulfonylamino) methyl] -2- (4-methanesulfonyl-piperazin-1-yl) malonate  0.6 ml (4 mmol) of triethylamine and then 0.3 ml (4 mmol) of methanesulfonyl chloride are added to a solution of 1.6 g (4 mmol) of 2 - [(4-but-2-ynyloxy-benzenesulfonylamino) - dimethyl methyl] -2-piperazin-1-yl-malonate diluted in 30ml of dichloromethane. The reaction medium is then stirred at room temperature for 3 h and then evaporated to dryness. The crude residue is purified by chromatography on silica gel eluted with a 99/1 dichloromethane / methanol mixture. 1.1 g (58%) of dimethyl 2 - [(4-but-2-ynyloxy-benzenesulfonylamino) -methyl] -2- (4-methanesulfonyl-piperazin-1-yl) -malonate are obtained in the form of a white solid.\n\n\n\n\n\n\n \n1-7: 2-{(4-but-2-ynyloxy-benzènesulfonyl)-méthyl-amino]-méthyl}-2-(4-méthanesulfonyl-pipérazin-1-yl) malonate de diméthyle \nDimethyl 1-7: 2 - {(4-but-2-ynyloxy-benzenesulfonyl) methyl-amino] -methyl} -2- (4-methanesulfonyl-piperazin-1-yl) malonate\n\n\n\n\n\n\n \n 120mg (0,9 mmoles) de carbonate de potassium puis 56μl (0,9 mmoles) d'iodure de méthyle sont additionnés à une solution de 400mg ( 0,8 mmoles) de 2-[(4-but-2-ynyloxy-benzènesulfonylamino)- méthyl]-2-(4-méthanesulfonyl-pipérazin-1-yl)-malonate de diméthyle dans 10ml de diméthylformamide. Le milieu réactionnel est ensuite agité à température ambiante pendant 18h puis hydrolyse par addition d'eau et extrait à l'acétate d'éthyle. Les phases organiques sont lavées par de l'eau puis séchées sur sulfate de magnésium, filtrées et concentrées sous vide. Le produit brut obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane/acétate d'éthyle 50/50. 410mg (100%) de 2-{[(4-but-2-ynyloxy-benzènesulfonyl)-méthyl-amino]-méthyl}-2-(4-méthanesulfonyl- pipérazin-1-yl)-malonate de diméthyle sont obtenus sous forme d'un solide blanc. \n 120 mg (0.9 mmol) of potassium carbonate and then 56 μl (0.9 mmol) of methyl iodide are added to a solution of 400 mg (0.8 mmol) of 2 - [(4-but-2-ynyloxy) dimethylformamide (dimethylformamide) benzenesulfonylamino) methyl) -2- (4-methanesulfonyl-piperazin-1-yl) -malonate in 10 ml of dimethylformamide. The reaction medium is then stirred at room temperature for 18 h and then hydrolyzed by adding water and extracted with ethyl acetate. The organic phases are washed with water and then dried over magnesium sulfate, filtered and concentrated in vacuo. The crude product obtained is purified by chromatography on silica gel eluted with a 50/50 heptane / ethyl acetate mixture. 410 mg (100%) of dimethyl 2 - {[(4-but-2-ynyloxy-benzenesulfonyl) methyl-amino] -methyl} -2- (4-methanesulfonyl-piperazin-1-yl) -malonate are obtained under form of a white solid.\n\n\n\n\n\n\n \n1-8: acide 3-[(4-but-2-ynyloxy-benzènesulfonyl)-méthyl-amino]-2-(4-méthanesulfonyl-piperazin-1-yl)- propanoïque \n1-8: 3 - [(4-But-2-ynyloxy-benzenesulfonyl) -methyl-amino] -2- (4-methanesulfonyl-piperazin-1-yl) -propanoic acid\n\n\n\n\n\n\n \n 1 ,7ml (1 ,7 mmoles) d'une solution aqueuse d'hydroxyde de sodium de concentration 1 M sont additionnés sur une solution de 270mg (0,5 mmoles) de 2-{[(4-but-2-ynyloxy-benzènesulfonyl)-méthyl- amino]-méthyl}-2-(4-méthanesulfonyl-pipérazin-1-yl) malonate de diméthyle dans 7ml de tétrahydrofuranne et 2ml de méthanol. Le milieu réactionnel est agité à 4O\n0\nC pendant 15h puis ramené à pH=6 par l'addition d'une solution aqueuse d'acide chlorohydrique de concentration 1 M. Après évaporation sous vide des solvants, le produit précipite. Le résidu obtenu est repris dans 5ml d'eau et agité pendant 30min jusqu'à précipitation. Le produit est filtré, rincé à l'eau puis séché sous vide. 200mg (87%) d'acide 3-[(4-but-2-ynyloxy-benzènesulfonyl)-méthyl-amino]-2-(4-méthanesulfonyl- pipérazin-1-yl)-propanoique sont obtenus sous forme d'un solide blanc. \n1.7 ml (1.7 mmol) of a 1M aqueous solution of sodium hydroxide are added to a solution of 270 mg (0.5 mmol) of 2 - {[(4-but-2-ynyloxy) dimethyl benzenesulfonyl) methyl-amino-methyl-2- (4-methanesulfonyl-piperazin-1-yl) malonate in 7 ml of tetrahydrofuran and 2 ml of methanol. The reaction medium is stirred at 40 \n°\n C. for 15 hours and then brought to pH = 6 by the addition of a 1M aqueous solution of hydrochloric acid. After evaporation of the solvents under vacuum, the product precipitates. The residue obtained is taken up in 5 ml of water and stirred for 30 min until precipitation. The product is filtered, rinsed with water and then dried under vacuum. 200 mg (87%) of 3 - [(4-but-2-ynyloxy-benzenesulfonyl) methyl-amino] -2- (4-methanesulfonyl-piperazin-1-yl) -propanoic acid are obtained in the form of a white solid.\n\n\n\n\n\n\n \n1-9: 3-[(4-but-2-ynyloxy-benzènesulfonyl)-méthyl-amino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-propionamide \n1-9: 3 - [(4-But-2-ynyloxy-benzenesulfonyl) -methyl-amino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n63mg ( 0,5 mmoles) de 1-hydroxybenzotriazole puis 88mg (0,5 mmoles) de chlorhydrate de 1-éthyl-3- (3-diméthylaminopropyl)carbodiimide sont ajoutés à une solution de 200mg (0,4 mmoles) d' acide 3- [(4-but-2-ynyloxy-benzènesulfonyl)-méthyl-amino]-2-(4-méthanesulfonyl-piperazin-1-yl)-propanoïque dans 6ml de diméthylformamide. Le milieu réactionnel est agité 10min à température ambiante puis 68mg (0,5 mmoles) de O-tert-butyldiméthysilylhydroxylamine sont ajoutés . Le milieu réactionnel est ensuite agité à température ambiante pendant 24h, hydrolyse par l'addition de 2ml d'une solution \n\n aqueuse d'acide citrique 5% et agité pendant 30 minutes supplémentaires. Après extraction à l'acétate d'éthyle, la phase organique est lavée à l'eau, séchée sur sulfate de magnésium, filtrée et concentrée. Le résidu brut est purifié par chromatographie sur gel de silice élue avec un mélange dichlorométhane/méthanol 95/5. 100mg (50%) de 3-[(4-but-2-ynyloxy-benzènesulfonyl)-méthyl- amino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-propionamide sont obtenus sous forme d'un solide blanc de point de fusion 86\n0\nC. \n63 mg (0.5 mmol) of 1-hydroxybenzotriazole and then 88 mg (0.5 mmol) of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride are added to a solution of 200 mg (0.4 mmol) of acid. 3 - [(4-But-2-ynyloxy-benzenesulfonyl) methyl-amino] -2- (4-methanesulfonyl-piperazin-1-yl) -propanoic acid in 6 ml of dimethylformamide. The reaction medium is stirred for 10 min at room temperature and then 68 mg (0.5 mmol) of O-tert-butyldimethylsilylhydroxylamine are added. The reaction medium is then stirred at ambient temperature for 24 h, hydrolyzed by the addition of 2 ml of a solution  aqueous citric acid 5% and stirred for a further 30 minutes. After extraction with ethyl acetate, the organic phase is washed with water, dried over magnesium sulfate, filtered and concentrated. The crude residue is purified by chromatography on silica gel eluted with a 95/5 dichloromethane / methanol mixture. 100mg (50%) of 3 - [(4-but-2-ynyloxy-benzenesulfonyl) -methylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide are obtained in the form of a white solid with a melting point of 86 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 1 ,91 (s, 3H); 2,63-2,68 (m, 2H); 2,72 (s, 3H); 2,72-2,75 (m, 2H); 2,92 (s, 3H); 3,05-3,15 (m, 5H); 3,30-3,38 (m, 2H); 4,93 (s, 2H); 7,24 (d, J=6,8Hz, 2H); 7,79 (d, J=6,8Hz, 2H); 9,06 (s, 1 H); 10.77 (s, 1 H). \n \n1\n H NMR (δ, DMSO): 1.91 (s, 3H); 2.63-2.68 (m, 2H); 2.72 (s, 3H); 2.72-2.75 (m, 2H); 2.92 (s, 3H); 3.05-3.15 (m, 5H); 3.30-3.38 (m, 2H); 4.93 (s, 2H); 7.24 (d, J = 6.8 Hz, 2H); 7.79 (d, J = 6.8 Hz, 2H); 9.06 (s, 1H); 10.77 (s, 1H).\n\n\n\n\n\n\n \nExemple 2: (S)-3-(4-but-2-ynyloxy-benzènesulfonylamino)-N-hydroxy-2-(4-méthanesulfonyl- pipérazin-1 -yl)-propionamide. 2-1: Sel de sodium de l'acide 4-but-2-ynyloxy-benzènesulfonique \nExample 2: (S) -3- (4-but-2-ynyloxy-benzenesulfonylamino) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide. 2-1: Sodium salt of 4-but-2-ynyloxy-benzenesulfonic acid\n\n\n\n\n\n\n \n 50g (370 mmoles) de 1-bromo-but-2-yne sont additionnés sur une solution de 43g (185 mmoles) de sel de sodium de l'acide 4-hydroxy-benzènesulfonique commercial et de 185ml (185 mmoles) d'une solution aqueuse d'hydroxyde de sodium de concentration 1 M dans 800ml d'isopropanol. Le milieu réactionnel est chauffé à 7O\n0\nC pendant 18h. \n50 g (370 mmol) of 1-bromo-but-2-yne are added to a solution of 43 g (185 mmol) of sodium salt of commercial 4-hydroxy-benzenesulphonic acid and 185 ml (185 mmol) of a 1 M aqueous sodium hydroxide solution in 800 ml of isopropanol. The reaction medium is heated at 70 \n°\n C. for 18 h.\n\n\n\n\n\n\n \nAprès évaporation de l'isopropanol, le produit obtenu est filtré, rincé à l'isopropanol et à l'éther diéthylique puis séché sous vide. 46g (100%) du sel de sodium de l'acide 4-but-2-ynyloxy- benzènesulfonique sont obtenus sous forme d'un solide blanc . \nAfter evaporation of the isopropanol, the product obtained is filtered, rinsed with isopropanol and diethyl ether and then dried under vacuum. 46 g (100%) of the sodium salt of 4-but-2-ynyloxybenzenesulfonic acid are obtained in the form of a white solid.\n\n\n\n\n\n\n \n2.2: Chlorure de 4-but-2-ynyloxy-benzènesulfonyle \n2.2: 4-but-2-ynyloxybenzenesulfonyl chloride\n\n\n\n\n\n\n \n30g (107 mmoles) du sel de sodium de l'acide 4-but-2-ynyloxy-benzènesulfonique dans 120ml de diméthylformamide sont additionnés goutte à goutte à une solution de 28ml (321 mmoles) de chlorure d'oxalyle dans 120ml de dichlorométhane, préalablement refroidie à -1O\n0\nC puis le milieu réactionnel est agité à température ambiante pendant 18h. 800ml de glace sont additionnés et le milieu est extrait à l'acétate d'éthyle. Les phases organiques sont rassemblées, lavées à l'eau, séchées de sulfate de magnésium, filtrées et concentrées sous vide. 22g (84%) de chlorure de 4-but-2-ynyloxy- benzènesulfonyle sous la forme d'un solide beige . \n30 g (107 mmol) of the sodium salt of 4-but-2-ynyloxybenzenesulfonic acid in 120 ml of dimethylformamide are added dropwise to a solution of 28 ml (321 mmol) of oxalyl chloride in 120 ml of dichloromethane, previously cooled to -1O \n0\n C and the reaction medium is stirred at room temperature for 18h. 800 ml of ice are added and the medium is extracted with ethyl acetate. The organic phases are combined, washed with water, dried magnesium sulfate, filtered and concentrated in vacuo. 22g (84%) of 4-but-2-ynyloxybenzenesulfonyl chloride as a beige solid.\n\n\n\n\n\n\n \n2.3: N, N-bis-(2-chloro-éthyl)-méthanesulfonamide \n2.3: N, N-bis- (2-chloro-ethyl) -methanesulfonamide\n\n\n\n\n\n\n \n 8,6ml (62 mmoles) de triéthylamine sont additionnés à une solution de 5g (28 mmoles) du chlorhydrate de bis-(2-chloroéthyl)-amine dans 60ml de dichlorométhane. Les sels de chlorure de triéthylammonium précipitent et sont filtrés . 2,4ml (31 mmoles) de chlorure de méthanesulfonyle sont alors additionnés au filtrat obtenu et le milieu réactionnel est agité à température ambiante pendant 3h. Après addition d'eau, le produit est extrait au dichlorométhane. La phase organique est lavée à l'eau, séchée sur sulfate de magnésium, filtrée et concentrée. 5,8g (94%) de N,N-bis-(2-chloro-éthyl)- méthanesulfonamide sont obtenus sous forme d'un solide beige. \n\n 2.4: (S)-3-tert-butoxycarbonylamino-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle Dans un tube de Schlenk, une solution de 5g (20 mmoles) de chlorhydrate de (S)-2-amino-3-tert- butoxycarbonylamino-propanoate de méthyle et 4,3g (20 mmoles) de N,N-bis-(2-chloro-éthyl)- méthanesulfonamide dans 65ml de N,N-Diisopropyléthylamine est chauffée à 127\n0\nC sous forte agitation pendant 18h. Après addition d'eau, le produit est extrait à l'acétate d'éthyle. Les phases organiques sont rassemblées, lavées à l'eau, séchées sur sulfate de magnésium, filtrées et concentrées sous vide. Le produit brut obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane / acétate d'éthyle 50/50. 3,3g (46%) de (S)-3-tert-butoxycarbonylamino-2- (4-méthanesulfonyl-piperazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n8.6 ml (62 mmol) of triethylamine are added to a solution of 5 g (28 mmol) of bis (2-chloroethyl) -amine hydrochloride in 60 ml of dichloromethane. The triethylammonium chloride salts precipitate and are filtered. 2.4 ml (31 mmol) of methanesulfonyl chloride are then added to the filtrate obtained and the reaction mixture is stirred at ambient temperature for 3 h. After addition of water, the product is extracted with dichloromethane. The organic phase is washed with water, dried over magnesium sulfate, filtered and concentrated. 5.8 g (94%) of N, N-bis- (2-chloro-ethyl) -methanesulfonamide are obtained in the form of a beige solid.  2.4: (S) -3-tert-butoxycarbonylamino-2- (4-methanesulfonyl-piperazin-1-yl) -propionic acid methyl ester In a Schlenk tube, a solution of 5 g (20 mmol) of (S) -hydrochloride Methyl 2-amino-3-tert-butoxycarbonylamino-propanoate and 4.3 g (20 mmol) of N, N-bis- (2-chloro-ethyl) methanesulfonamide in 65 ml of N, N-diisopropylethylamine is heated to 127 \n°\n C. C with vigorous stirring for 18h. After addition of water, the product is extracted with ethyl acetate. The organic phases are combined, washed with water, dried over magnesium sulfate, filtered and concentrated in vacuo. The crude product obtained is purified by chromatography on silica gel eluted with a 50/50 heptane / ethyl acetate mixture. 3.3 g (46%) of methyl (S) -3-tert-butoxycarbonylamino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate are obtained in the form of a white solid.\n\n\n\n\n\n\n \n2.5: Chlorhydrate de (S)-3-amino-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle\n2.5: Methyl (S) -3-amino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate hydrochloride\n\n\n\n\n\n\n \n15ml d'une solution d'acide chlorhydrique dans l'isopropanol de concentration 5-6N sont additionnés goutte à goutte à une solution de 2,7g (7,4 mmoles) de (S)-3-tert-butoxycarbonylamino-2-(4- méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle dans 30ml de méthanol. Le milieu réactionnel est agité à 4O\n0\nC pendant 2h, concentré sous vide puis repris dans 20ml de méthanol et 150ml d'éther diéthylique. Le produit précipite, est filtré sous vide, rincé à l'éther diéthylique puis séché sous vide. 2,3g (100%) du chlorhydrate de (S)-3-amino-2-(4-méthanesulfonyl-piperazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n15 ml of a solution of hydrochloric acid in isopropanol of concentration 5-6N are added dropwise to a solution of 2.7 g (7.4 mmol) of (S) -3-tert-butoxycarbonylamino-2- ( 4-methyl methanesulfonyl-piperazin-1-yl) -propanoate in 30 ml of methanol. The reaction medium is stirred at 40 \n°\n C. for 2 h, concentrated in vacuo and then taken up in 20 ml of methanol and 150 ml of diethyl ether. The product precipitates, is filtered under vacuum, rinsed with diethyl ether and then dried under vacuum. 2.3 g (100%) of methyl (S) -3-amino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate hydrochloride are obtained in the form of a white solid.\n\n\n\n\n\n\n \n2.6: (S)-3-(4-but-2-ynyloxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate méthyle \n2.6: (S) -3- (4-But-2-ynyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate methyl\n\n\n\n\n\n\n \n 0,3ml (2 mmoles) de triéthylamine et 270mg (1 mmole) de chlorure de 4-but-2-ynyloxy- benzènesulfonyle (préparé comme décrit en 2.2) sont additionnés sur une solution de 300mg (1 mmole) du chlorhydrate de (S)-3-amino-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle (préparé comme décrit en 2.5) dans 8ml de dichlorométhane. Après agitation à température ambiante pendant 18h,de l'eau est additionné et le milieu réactionnel est extrait au dichlorométhane. Les phases organiques sont lavées à l'eau, séchées sur sulfate de magnésium, filtrées et concentrés. Le produit brut obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane / acétate d'éthyle 50/50. 400mg (85%) de (S)-3-(4-but-2-ynyloxy-benzènesulfonylamino)-2-(4- méthanesulfonyl-piperazin-1-yl)-propanoate de méthyle sous forme d'un solide blanc. \n 0.3 ml (2 mmol) of triethylamine and 270 mg (1 mmol) of 4-but-2-ynyloxybenzenesulfonyl chloride (prepared as described in 2.2) are added to a solution of 300 mg (1 mmol) of the hydrochloride salt of Methyl 3-amino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate (prepared as described in 2.5) in 8 ml of dichloromethane. After stirring at room temperature for 18 h, water is added and the reaction mixture is extracted with dichloromethane. The organic phases are washed with water, dried over magnesium sulphate, filtered and concentrated. The crude product obtained is purified by chromatography on silica gel eluted with a 50/50 heptane / ethyl acetate mixture. 400 mg (85%) of methyl (S) -3- (4-but-2-ynyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate as a white solid.\n\n\n\n\n\n\n \n2.7: acide (S)-3-(4-but-2-ynyloxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-piperazin-1-yl)- propanoïque \n2.7: (S) -3- (4-But-2-ynyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) propanoic acid\n\n\n\n\n\n\n \n1 ,3ml (1 ,3 mmoles) d'une solution aqueuse d'hydroxyde de lithium de concentration 1 M sont additionnés sur une solution de 400mg (0,8 mmoles) de (S)-3-(4-but-2-ynyloxy- benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle dilué dans 10ml de tétrahydrofuranne préalablement refroidie à O\n0\nC. Le milieu réactionnel est agité à température ambiante pendant 2Oh. Après évaporation à sec, 1 ,5ml d'une solution aqueuse d'acide acétique de concentration 1 M sont additionnés pour obtenir un pH= 6. Le produit précipite, est filtré, rincé à l'eau \n\n puis à l'éther diéthylique et séché sous vide. 340mg (89%) d'acide (S)-3-(4-but-2-ynyloxy- benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoïque sont obtenus sous forme d'un solide blanc. 2.8: (S)-3-(4-but-2-ynyloxy-benzènesulfonylamino)-N-hydroxy-2-(4-méthanesulfonyl-piperazin-1-yl)- propionamide \n1, 3 ml (1.3 mmol) of a 1M aqueous solution of lithium hydroxide are added to a solution of 400 mg (0.8 mmol) of (S) -3- (4-but-2- Methyl ynyloxybenzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate diluted in 10 ml of tetrahydrofuran previously cooled to 0 \n°\n C. The reaction medium is stirred at room temperature for 20 h. After evaporation to dryness, 1.5 ml of an aqueous solution of acetic acid of 1 M concentration are added to obtain a pH = 6. The product precipitates, is filtered, rinsed with water  then with diethyl ether and dried under vacuum. 340 mg (89%) of (S) -3- (4-but-2-ynyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) propanoic acid are obtained in the form of a white solid. . 2.8: (S) -3- (4-but-2-ynyloxy-benzenesulfonylamino) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) propionamide\n\n\n\n\n\n\n \n 120mg ( 0,9 mmoles) de 1-hydroxybenzotriazole et 170mg (0,9 mmoles) du chlorhydrate de 1-éthyl-3- (3-diméthylaminopropyl)carbodiinnide sont ajoutés à une solution de 340mg (0,7 mmoles) d' acide (S)- 3-(4-but-2-ynyloxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoïque dans 8ml de diméthylformamide. Le milieu réactionnel est agité 30min puis 120mg (0,8 mmoles) de O-tert- butyldiméthysilyl-hydroxylamine dans 3ml de diméthylformamide sont additionnés. Le milieu réactionnel est ensuite agité à température ambiante pendant 2Oh puis hydrolyse par 2ml d'eau et 2ml d'une solution aqueuse 5% d'acide citrique. Après agitation pendant 30min, une solution aqueuse saturée d'hydrogénocarbonate de sodium est ajoutée jusqu'à pH=8 puis le milieu réactionnel est extrait par de l'acétate d'éthyle. La phase organique est séchée sur sulfate de magnésium, filtrée et concentrée. Le résidu est repris dans du dichlorométhane, filtré puis séché sous vide. 80mg (23%) de (S)-3-(4-but-2-ynyloxy-benzènesulfonylamino)-N-hydroxy-2-(4-méthanesulfonyl-piperazin-1-yl)- propionamide sont obtenus sous forme d'un solide blanc de point de fusion 15O\n0\nC. \n120 mg (0.9 mmol) of 1-hydroxybenzotriazole and 170 mg (0.9 mmol) of 1-ethyl-3- (3-dimethylaminopropyl) carbodiinnide hydrochloride are added to a solution of 340 mg (0.7 mmol) of acid. (S) - 3- (4-But-2-ynyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoic acid in 8 ml of dimethylformamide. The reaction medium is stirred for 30 minutes and then 120 mg (0.8 mmol) of O-tert-butyldimethylsilyl-hydroxylamine in 3 ml of dimethylformamide are added. The reaction medium is then stirred at room temperature for 20 h and then hydrolyzed with 2 ml of water and 2 ml of a 5% aqueous solution of citric acid. After stirring for 30 min, a saturated aqueous solution of sodium hydrogencarbonate is added until pH = 8 and the reaction medium is extracted with ethyl acetate. The organic phase is dried over magnesium sulfate, filtered and concentrated. The residue is taken up in dichloromethane, filtered and dried under vacuum. 80 mg (23%) of (S) -3- (4-but-2-ynyloxy-benzenesulfonylamino) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide are obtained in the form of a white solid of melting point 15O \n0\n C.\n\n\n\n\n\n\n \nRMN \n1\nH (δ, DMSO) : 1 ,86 (s, 3H); 2,55 (m, 4H); 2,83 (s, 3H); 2,85-2,88 (m, 1 H); 2,97-3,00 (m, 3H); 3,00-3,06 (m, 2H); 3,10-3,12 (t, J=4,8Hz, 1 H); 4,86 (s, 2H); 7,15 (d, J=9,2Hz, 2H); 7,51 (s, 1 H); 7,75 (d, J=9,2Hz, 2H); 8,94 (s, 1 H); 10,6 (s, 1 H). \n \n1\n H NMR (δ, DMSO): 1, 86 (s, 3H); 2.55 (m, 4H); 2.83 (s, 3H); 2.85-2.88 (m, 1H); 2.97-3.00 (m, 3H); 3.00-3.06 (m, 2H); 3.10-3.12 (t, J = 4.8 Hz, 1H); 4.86 (s, 2H); 7.15 (d, J = 9.2 Hz, 2H); 7.51 (s, 1H); 7.75 (d, J = 9.2 Hz, 2H); 8.94 (s, 1H); 10.6 (s, 1H).\n\n\n\n\n\n\n \nExemple 3 : (S)-3-(4-benzyloxy-benzenesulfonylamino)-N-hydroxy-2-(4-methanesulfonyl- piperazin-1 -yl)-propionamide. \nExample 3: (S) -3- (4-Benzyloxy-benzenesulfonylamino) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide.\n\n\n\n\n\n\n \n3.1 : N,N-bis-(2-chloro-éthyl)-méthanesulfonamide \n3.1: N, N-bis- (2-chloro-ethyl) -methanesulfonamide\n\n\n\n\n\n\n \n 14,3ml (185 mmoles) de chlorure de méthane sulfonyle sont ajoutés lentement à une solution de 15g (84 mmoles) de chlorhydrate de bis(2-chloroéthylamine) commercial et 26ml (185 mmoles) de triéthylamine dans 200ml de dichlorométhane et 70ml de tétrahydrofuranne préalablement agitée pendant 15min puis filtrée pour enlever le chlorure de triéthylammonium. Le milieu réactionnel est ensuite agité à température ambiante pendant 18h, extrait au dichlorométhane, lavé à l'eau. La phase organique est séchée sur sulfate de magnésium, filtrée, évaporée. Le résidu obtenu est lavé à l'éther diisopropylique, filtré puis séché sous vide. 15,3g (82%) de N,N-bis-(2-chloro-éthyl)- méthanesulfonamide sont obtenus sous forme d'un solide. \n 14.3 ml (185 mmol) of methanesulfonyl chloride are slowly added to a solution of 15 g (84 mmol) of commercial bis (2-chloroethylamine) hydrochloride and 26 ml (185 mmol) of triethylamine in 200 ml of dichloromethane and 70 ml of tetrahydrofuran previously stirred for 15 min and then filtered to remove triethylammonium chloride. The reaction medium is then stirred at ambient temperature for 18 h, extracted with dichloromethane and washed with water. The organic phase is dried over magnesium sulphate, filtered and evaporated. The residue obtained is washed with diisopropyl ether, filtered and then dried under vacuum. 15.3 g (82%) of N, N-bis- (2-chloro-ethyl) -methanesulfonamide are obtained in the form of a solid.\n\n\n\n\n\n\n \n3.2 : (S)-3-tert-butoxycarbonylamino-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle\n3.2: Methyl (S) -3-tert-butoxycarbonylamino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate\n\n\n\n\n\n\n \nUne solution de 9,6g (44 mmoles) de N,N-bis-(2-chloro-éthyl)-méthanesulfonamide et de 11 ,1g (44 mmoles) de chlorhydrate de 2-amino-3-tert-butoxy-propanoate de méthyle dans 90ml de diisopropyléthylamine est chauffée à 127\n0\nC pendant 18h. Le milieu réactionnel est évaporé à sec. 31g de résidu brut sont obtenus et purifiés par chromatographie sur gel de silice élues avec un mélange \n\n heptane / acétate d'éthyle 9/1 puis augmentation de la polarité jusqu'à 4/6. 5,5g (35%) de (S)-3-tert- butoxycarbonylamino-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle sont obtenus. \nA solution of 9.6 g (44 mmol) of N, N-bis- (2-chloro-ethyl) -methanesulfonamide and 11.1 g (44 mmol) of 2-amino-3-tert-butoxy-propanoate hydrochloride. methyl in 90 ml of diisopropylethylamine is heated at 127 \n0\n C for 18h. The reaction medium is evaporated to dryness. 31 g of crude residue are obtained and purified by chromatography on silica gel eluted with a mixture  heptane / ethyl acetate 9/1 and then increase the polarity up to 4/6. 5.5 g (35%) of methyl (S) -3-tert-butoxycarbonylamino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate are obtained.\n\n\n\n\n\n\n \n3.3: dichlorhydrate de (S)-3-Amino-2-(4-methanesulfonyl-piperazin-1-yl)-propanoate de méthyle Une solution de 4g (11 mmoles) de (S)-3-tert-butoxycarbonylamino-2-(4-méthanesulfonyl-pipérazin-1- yl)-propanoate de méthyle (préparé comme décrit dans l'exemple 2.4) dans 40ml de méthanol et 20ml d'une solution d'acide chlorhydrique dans l'isopropanol de concentration 5 ou 6M est agitée à 4O\n0\nC pendant 18h puis concentrée sous vide. Le résidu obtenu est repris dans 200ml d'éther diéthylique, filtré puis séché sous vide. 3,5g (94%) du dichlorhydrate de (S)-3-amino-2-(4- méthanesulfonyl-piperazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'un solide beige. \n3.3: Methyl (S) -3-Amino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate dihydrochloride A solution of 4 g (11 mmol) of (S) -3-tert-butoxycarbonylamino-2- Methyl (4-methanesulfonyl-piperazin-1-yl) -propanoate (prepared as described in Example 2.4) in 40 ml of methanol and 20 ml of a solution of hydrochloric acid in isopropanol of concentration 5 or 6M is stirred at 40 \n°\n C. for 18 h and then concentrated under vacuum. The residue obtained is taken up in 200 ml of diethyl ether, filtered and dried under vacuum. 3.5 g (94%) of methyl (S) -3-amino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate dihydrochloride are obtained in the form of a beige solid.\n\n\n\n\n\n\n \n3.4 : sel de sodium de l'acide 4-benzyloxy-benzènesulfonique \n3.4: sodium salt of 4-benzyloxybenzenesulfonic acid\n\n\n\n\n\n\n \n 64ml (539 mmoles) de bromure de benzyle sont additionnés à une solution de 50g (215 mmoles) de sel de sodium de l'acide 4-hydroxy-benzènesulfonique dihydraté dans 700ml d'isopropanol et 250ml (250 mmoles) d'une solution aqueuse d'hydroxyde de sodium de concentration 1 M. Le milieu réactionnel est chauffé à 7O\n0\nC pendant 2Oh. Après concentration sous vide de l'isopropanol, le produit précipite et est filtré. 61g (100%) de sel de sodium de l'acide 4-benzyloxy-benzènesulfonique sont obtenus sous forme d'un solide blanc . 3.5 : chlorure de 4-benzyloxy-benzènesulfonyle \n64 ml (539 mmol) of benzyl bromide are added to a solution of 50 g (215 mmol) of sodium salt of 4-hydroxy-benzenesulfonic acid dihydrate in 700 ml of isopropanol and 250 ml (250 mmol) of an aqueous solution 1 M concentration of sodium hydroxide. The reaction medium is heated at 70 \n°\n C. for 20 h. After concentration of the isopropanol under vacuum, the product precipitates and is filtered. 61 g (100%) of sodium salt of 4-benzyloxybenzenesulfonic acid are obtained in the form of a white solid. 3.5: 4-Benzyloxybenzenesulfonyl chloride\n\n\n\n\n\n\n \n Une solution de 55ml (639 mmoles) de chlorure d'oxalyle dans 250ml de dichlorométhane est additionnée goutte à goutte à une solution de 61g (213 mmoles) de sel de sodium de l'acide A- benzyloxy-benzènesulfonique dans 200ml de diméthylformamide, en maintenant la température entre -2O\n0\nC et -1O\n0\nC. Après addition, le milieu réactionnel est lentement ramené à température ambiante puis agité pendant 18h, versé sur de la glace et extrait à l'acétate d'éthyle. La phase organique est lavée par de l'eau, par une solution aqueuse saturée de chlorure de sodium et concentrée sous vide. 54g (89%) de chlorure de 4-benzyloxy-benzènesulfonyle sont obtenus sous forme d'un solide blanc . \nA solution of 55 ml (639 mmol) of oxalyl chloride in 250 ml of dichloromethane is added dropwise to a solution of 61 g (213 mmol) of sodium salt of A-benzyloxy-benzenesulfonic acid in 200 ml of dimethylformamide, now the temperature between -2O \n0\n C and -1O \n0\n C. After addition, the reaction medium is slowly brought to room temperature and then stirred for 18h, poured on ice and extracted with ethyl acetate. The organic phase is washed with water, with a saturated aqueous solution of sodium chloride and concentrated in vacuo. 54 g (89%) of 4-benzyloxy-benzenesulfonyl chloride are obtained in the form of a white solid.\n\n\n\n\n\n\n \n3.6: (S)-3-(4-benzyloxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle \n3.6: Methyl (S) -3- (4-benzyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate\n\n\n\n\n\n\n \n 1 ,1 ml (7,8 mmoles) de triéthylamine puis 730mg ( 2,6 mmoles) de chlorure de 4-benzyloxy- benzènesulfonyle dans 8ml de dichlorométhane sont additionnés à une solution de 800mg ( 2,4 mmoles) de dichlorhydrate de (S)-3-amino-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle dans 20ml de dichlorométhane et le milieu réactionnel est agité à température ambiante pendant 3h . Après addition d'eau, le produit est extrait au dichlorométhane. La phase organique est lavée à l'eau , séchée sur sulfate de magnésium, filtrée et concentrée. \n 1.1 ml (7.8 mmol) of triethylamine and then 730 mg (2.6 mmol) of 4-benzyloxybenzenesulfonyl chloride in 8 ml of dichloromethane are added to a solution of 800 mg (2.4 mmol) of dihydrochloride. ) -3-amino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate in 20ml of dichloromethane and the reaction medium is stirred at room temperature for 3h. After addition of water, the product is extracted with dichloromethane. The organic phase is washed with water, dried over magnesium sulfate, filtered and concentrated.\n\n\n\n\n\n\n \n Le résidu obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane/ acétate d'éthyle 8/2. 0,9g (75%) de (S)-3-(4-benzyloxy-benzènesulfonylamino)-2-(4-méthanesulfonyl- piperazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n\n 3.7 : acide (S)-3-(4-benzyloxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-piperazin-1-yl)- propanoique \nThe residue obtained is purified by chromatography on silica gel eluted with a heptane / ethyl acetate mixture 8/2. 0.9 g (75%) of methyl (S) -3- (4-benzyloxy-benzenesulfonylamino) -2- (4-methanesulfonylpiperazin-1-yl) -propanoate are obtained in the form of a white solid.  3.7: (S) -3- (4-Benzyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) propanoic acid\n\n\n\n\n\n\n \n 2,6ml ( 2,6 mmoles) d'une solution aqueuse d'hydroxyde de lithium de concentration 1 M sont additionnés à une solution de 900mg (1 ,8 mmoles) de (S)-3-(4-benzyloxy-benzènesulfonylamino)-2- (4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle dans 20ml de tétrahydrofurane et 0,5ml d'eau. Le milieu réactionnel est agité à température ambiante pendant 18h puis le THF est évaporé sous vide. 2,8ml d'une solution aqueuse d'acide acétique de concentration 1 M puis 30ml d'eau sont additionnés et le produit précipite. La suspension est agitée 30min à 100\n0\nC puis ramenée à température ambiante, filtrée et séchée sous vide. 750mg (86%) d' acide (S)-3-(4-benzyloxy- benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoique sont obtenus sous forme d'un solide blanc. \n2.6 ml (2.6 mmol) of a 1 M aqueous solution of lithium hydroxide are added to a solution of 900 mg (1.8 mmol) of (S) -3- (4-benzyloxy-benzenesulfonylamino) Methyl 2- (4-methanesulfonyl-piperazin-1-yl) -propanoate in 20 ml of tetrahydrofuran and 0.5 ml of water. The reaction medium is stirred at ambient temperature for 18 h and then the THF is evaporated under vacuum. 2.8 ml of a 1 M aqueous solution of acetic acid and then 30 ml of water are added and the product precipitates. The suspension is stirred for 30 min at 100 \n°\n C. and then brought to ambient temperature, filtered and dried under vacuum. 750 mg (86%) of (S) -3- (4-benzyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoic acid are obtained in the form of a white solid.\n\n\n\n\n\n\n \n3.8 : (S)-3-(4-benzyloxy-benzènesulfonylamino)-N-hydroxy-2-(4-méthanesulfonyl- pipérazin-1 -yl)-propionamide \n3.8: (S) -3- (4-Benzyloxy-benzenesulfonylamino) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n224mg ( 1 ,7 mmoles) de 1-hydroxybenzotriazole et 318mg (1 ,7 mmoles) du chlorhydrate de 1-éthyl- 3-(3-diméthylaminopropyl) carbodiimide sont additionnés successivement à 750mg (1 ,5 mmoles) d'acide (S)-3-(4-benzyloxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-piperazin-1-yl)-propanoique dans 20ml de diméthylformamide. Après agitation à température ambiante pendant 20min, une solution de 244mg (1 ,7 mmoles) de O-tert-butyldiméthylsilylhydroxylamine dans 3ml de diméthylformamide est ajoutée. Le milieu réactionnel est ensuite agité à température ambiante pendant 18h puis 2ml d'une solution aqueuse saturée d'hydrogénocarbonate de sodium et enfin 2ml d'eau sont ajoutés. Après extraction à l'acétate d'éthyle, la phase organique est lavée avec une solution aqueuse saturée d'hydrogénocarbonate de sodium, séchée sur sulfate de magnésium, filtrée et concentrée. Le résidu brut obtenu est repris dans 15ml d'acétate d'éthyle , chauffé à 7O\n0\nC puis ramené à température ambiante, filtré, séché sous vide. \n224 mg (1, 7 mmol) of 1-hydroxybenzotriazole and 318 mg (1.7 mmol) of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride are successively added to 750 mg (1.5 mmol) of ) -3- (4-Benzyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoic acid in 20 ml of dimethylformamide. After stirring at ambient temperature for 20 min, a solution of 244 mg (1.7 mmol) of O-tert-butyldimethylsilylhydroxylamine in 3 ml of dimethylformamide is added. The reaction medium is then stirred at ambient temperature for 18 h and then 2 ml of a saturated aqueous solution of sodium hydrogencarbonate and finally 2 ml of water are added. After extraction with ethyl acetate, the organic phase is washed with a saturated aqueous solution of sodium hydrogencarbonate, dried over magnesium sulfate, filtered and concentrated. The crude residue obtained is taken up in 15 ml of ethyl acetate, heated at 70 \n°\n C. and then brought to ambient temperature, filtered and dried under vacuum.\n\n\n\n\n\n\n \n 300mg (34%) de (S)-3-(4-benzyloxy-benzènesulfonylamino)-N-hydroxy-2-(4-méthanesulfonyl- pipérazin-1-yl)-propionamide sont obtenus sous forme d'un solide blanc de point de fusion 165\n0\nC. RMN \n1\nH (δ, DMSO) : 2,40-2,50 (m, 2H); 2,50-2,60 (m, 2H); 2,84 (s, 3H), 3,00-3,05 (m, 4H); 3,06-3,09 (m, 2H); 3,34 (s, 1 H); 5,19 (s, 2H); 7,19 (d, J=8,4Hz, 2H); 7,30-7,34 (m, 1 H); 7,35-7,47 (m, 5H); 7,73 (d, J=8,4Hz, 2H); 8,93 (s, 1 H); 10,65 (s, 1 H). \n300 mg (34%) of (S) -3- (4-benzyloxy-benzenesulfonylamino) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide are obtained in the form of a white point solid. melting 165 \n0\n C. \n1\n H NMR (δ, DMSO): 2.40-2.50 (m, 2H); 2.50-2.60 (m, 2H); 2.84 (s, 3H), 3.00-3.05 (m, 4H); 3.06-3.09 (m, 2H); 3.34 (s, 1H); 5.19 (s, 2H); 7.19 (d, J = 8.4Hz, 2H); 7.30-7.34 (m, 1H); 7.35-7.47 (m, 5H); 7.73 (d, J = 8.4Hz, 2H); 8.93 (s, 1H); 10.65 (s, 1H).\n\n\n\n\n\n\n \nExemple 4 : (S)-3-[(4-benzyloxy-benzènesulfonyl)-méthyl-amino]-N-hydroxy- 2-(4-méthanesulfonyl-pipérazin-1-yl)-propionamide. 4.1: (S)-3-[(4-benzyloxy-benzènesulfonyl)-méthyl-amino]-2-(4-méthanesulfonyl-pipérazin-1-yl)- propanoate de méthyle \nExample 4: (S) -3 - [(4-Benzyloxy-benzenesulfonyl) -methyl-amino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide. 4.1: Methyl (S) -3 - [(4-benzyloxy-benzenesulfonyl) methyl-amino] -2- (4-methanesulfonyl-piperazin-1-yl) propanoate\n\n\n\n\n\n\n \n 300mg (1 ,9 mmoles) de carbonate de potassium puis 0,2ml (3,1 mmoles) d' iodure de méthyle sont additionnés sur une solution de 800mg (1 ,6 mmoles) de (S)-3-(4-benzyloxy-benzènesulfonylamino)-2- (4-methanesulfonyl-pipérazin-1-yl)-propanoate méthyle (préparé comme décrit en 3.6) dans 15ml de diméthylformamide. Le milieu réactionnel est ensuite agité à température ambiante pendant 2Oh, \n\n hydrolyse puis dilué par de l'acétate d'éthyle. Le produit est extrait à l'acétate d'éthyle. Les phases organiques sont lavées avec de l'eau, séchées sur sulfate de magnésium et filtrées. \n300 mg (1, 9 mmol) of potassium carbonate and then 0.2 ml (3.1 mmol) of methyl iodide are added to a solution of 800 mg (1, 6 mmol) of (S) -3- (4-benzyloxy) benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate methyl (prepared as described in 3.6) in 15 ml of dimethylformamide. The reaction medium is then stirred at room temperature for 20 h,  hydrolyzed and then diluted with ethyl acetate. The product is extracted with ethyl acetate. The organic phases are washed with water, dried over magnesium sulphate and filtered.\n\n\n\n\n\n\n \nLe filtrat est concentré sous vide pour donner 820mg (100%) de (S)-3-(4-benzyloxy- benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate méthyle sous la forme d'un solide blanc. \nThe filtrate is concentrated in vacuo to give 820 mg (100%) of (S) -3- (4-benzyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate methyl as a solution. white solid.\n\n\n\n\n\n\n \n4.2: acide (S)-3-[(4-benzyloxy-benzènesulfonyl)-méthyl-amino]-2-(4-méthanesulfonyl-pipérazin-1-yl)- propanoique: \n4.2: (S) -3 - [(4-Benzyloxy-benzenesulfonyl) -methyl-amino] -2- (4-methanesulfonyl-piperazin-1-yl) -propanoic acid:\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 820mg (1 ,6 mmoles) de (S)-3-[(4-benzyloxy- benzènesulfonyl)-méthyl-amino]-2-(4-méthanesulfonyl-pipérazin-1-yl)- propanoate de méthyle, 720mg (90%) d' acide (S)-3-[(4-benzyloxy-benzènesulfonyl)-méthyl-amino]-2-(4-méthanesulfonyl-pipérazin-1- yl)-propanoique sont obtenus sous forme d'un solide blanc. \n In a manner analogous to Example 3.7, from 820 mg (1.6 mmol) of (S) -3 - [(4-benzyloxy-benzenesulfonyl) methyl-amino] -2- (4-methanesulfonyl-piperazin-1) methyl-propanoate, 720mg (90%) of (S) -3 - [(4-benzyloxy-benzenesulfonyl) -methyl-amino] -2- (4-methanesulfonyl-piperazin-1-yl) - propanoic are obtained in the form of a white solid.\n\n\n\n\n\n\n \n4.3: (S)-3-[(4-benzyloxy-benzènesulfonyl)-méthyl-amino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin- 1-yl)-propionamide \n4.3: (S) -3 - [(4-Benzyloxy-benzenesulfonyl) -methyl-amino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 720mg (1 ,4 mmoles) d' acide (S)-3-[(4- benzyloxy-benzènesulfonyl)-méthyl-amino]-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoique, 360mg (49%) de (S)-3-[(4-benzyloxy-benzènesulfonyl)-méthyl-amino]-N-hydroxy-2-(4-méthanesulfonyl- pipérazin-1-yl)-propionamide sont obtenus sous forme d'un solide blanc de point de fusion 11O\n0\nC. RMN \n1\nH (δ, DMSO) : 2,58-2,63 (m, 2H); 2,65 (s, 3H); 2,67-2,73 (m, 2H); 2,86 (s, 3H); 2,98-3,05 (m, 4H); 3,05-3,09 (m, 1 H); 3,24-3,25 (m, 1 H); 3,28-3,31 (m, 1 H); 5,21 (s, 2H); 7,24 (d, J=8,9Hz, 2H); 7,34-7,44 (\nm\n, 3H); 7,48 (d, J=7,2Hz, 2H); 7,72 (d, J=8,9Hz, 2H); 8,99 (s, 1 H); 10,69 (s, 1 H). \nIn a manner analogous to Example 3.8, from 720 mg (1.4 mmol) of (S) -3 - [(4-benzyloxy-benzenesulfonyl) methyl-amino] -2- (4-methanesulfonyl) piperazine 1-yl) propanoic acid, 360 mg (49%) of (S) -3 - [(4-benzyloxy-benzenesulfonyl) methyl-amino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) ) -propionamide are obtained in the form of a white solid of melting point 110 \n°\n C. \n1\n H NMR (δ, DMSO): 2.58-2.63 (m, 2H); 2.65 (s, 3H); 2.67-2.73 (m, 2H); 2.86 (s, 3H); 2.98-3.05 (m, 4H); 3.05-3.09 (m, 1H); 3.24-3.25 (m, 1H); 3.28-3.31 (m, 1H); 5.21 (s, 2H); 7.24 (d, J = 8.9Hz, 2H); 7.34-7.44 ( \nm\n , 3H); 7.48 (d, J = 7.2 Hz, 2H); 7.72 (d, J = 8.9Hz, 2H); 8.99 (s, 1H); 10.69 (s, 1H).\n\n\n\n\n\n\n \nExemple 5 : (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4- ylméthoxy)-benzènesulfonylamino]-propionamide. \nExample 5: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n5.1 : (S)-3-(4-hydroxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle \n5.1: Methyl (S) -3- (4-hydroxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate\n\n\n\n\n\n\n \nUne solution de 2,0g (3,9 mmoles) de (S)-3-(4-benzyloxy-benzènesulfonylamino)-2-(4- méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle (préparé comme décrit dans l'exemple 3.6) dans 60ml d'éthanol, 30ml de dioxanne et 0,5ml d'acide acétique glacial est dégazée sous flux d'azote puis 200mg (10% massique) de palladium sur charbon 10% en suspension dans 3ml de dioxanne sont additionnés. Le milieu réactionnel est placé sous une atmosphère d'hydrogène et agité à température ambiante pendant 18h. Après filtration sur célite, le filtrat est hydrolyse puis le produit est extrait à l'acétate d'éthyle. La phase organique est lavée à l'eau puis par une solution aqueuse saturée de chlorure de sodium, séchée sur sulfate de magnésium, filtrée, concentrée sous vide. 1 ,65g (100%) de (S)-3-(4-hydroxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n\n 5.2 : (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylaminoj-propanoate de méthyle \nA solution of 2.0 g (3.9 mmol) of methyl (S) -3- (4-benzyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate (prepared as described in US Pat. Example 3.6) in 60 ml of ethanol, 30 ml of dioxane and 0.5 ml of glacial acetic acid is degassed under a stream of nitrogen and then 200 mg (10% by mass) of palladium on carbon 10% suspended in 3 ml of dioxane are added . The reaction medium is placed under a hydrogen atmosphere and stirred at room temperature for 18 h. After filtration on celite, the filtrate is hydrolyzed and the product is extracted with ethyl acetate. The organic phase is washed with water and then with saturated aqueous sodium chloride solution, dried over magnesium sulfate, filtered and concentrated in vacuo. 1.65 g (100%) of methyl (S) -3- (4-hydroxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate are obtained in the form of a white solid.  5.2: Methyl (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) benzenesulfonylamino] -propanoate\n\n\n\n\n\n\n \n 280mg (0,85 mmoles) de carbonate de césium suivis de 160mg (0,85 mmoles) de 4-chlorométhyl-2- méthyl-quinoline et de 15mg d' iodure de potassium sont additionnés sur une solution de 300mg (0,71 mmoles) de (S)-3-(4-Hydroxy-benzenesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)- propanoate de méthyle dans 10ml d'acétone. Le milieu réactionnel est agité à température ambiante pendant 18h, filtré, concentré sous vide. Le produit brut est purifié par chromatographie sur gel de silice élue avec un mélange heptane/acétate d'éthyle 40/60. 130mg (32%) de (S)-2-(4- méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]- propanoate de méthyle sont obtenus sous la forme d'un solide blanc. \n 280 mg (0.85 mmol) of cesium carbonate followed by 160 mg (0.85 mmol) of 4-chloromethyl-2-methyl-quinoline and 15 mg of potassium iodide are added to a solution of 300 mg (0.71 mmol). ) methyl (S) -3- (4-hydroxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate in 10 ml of acetone. The reaction medium is stirred at room temperature for 18 h, filtered, concentrated in vacuo. The crude product is purified by chromatography on silica gel eluted with a 40/60 heptane / ethyl acetate mixture. 130 mg (32%) of methyl (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoate are obtained under the shape of a white solid.\n\n\n\n\n\n\n \n5.3 : acide (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoique \n5.3: (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 130mg (0,2 mmoles) de (S)-2-(4-méthanesulfonyl- pipéridin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle, 120mg (99%) d' acide (S)-2-(4-méthanesulfonyl-pipéridin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoique sont obtenus sous forme d'un solide blanc. \n Analogous to Example 3.7, from 130 mg (0.2 mmol) of (S) -2- (4-methanesulfonylpiperidin-1-yl) -3- [4- (2-methyl-quinolin) Methyl 4-ylmethoxy) -benzenesulfonylamino] -propanoate, 120mg (99%) (S) -2- (4-methanesulfonyl-piperidin-1-yl) -3- [4- (2-methyl-quinolin) 4-ylmethoxy) benzenesulfonylamino] propanoic acid are obtained in the form of a white solid.\n\n\n\n\n\n\n \n5.4 : (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylaminoj-propionamide \n5.4: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 123mg (0,2 mmoles) d'acide (S)-2-(4- méthanesulfonyl-piperazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]- propanoique, 90mg (69%) de (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl- quinolin-4-ylméthoxy)-benzènesulfonylamino]-propionamide sont obtenus sous forme d'un solide de point de fusion 185\n0\nC. \nIn a similar manner to Example 3.8, from 123 mg (0.2 mmol) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl) -2- quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoic acid, 90mg (69%) of (S) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl) -2- quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide are obtained in the form of a solid with a melting point of 185 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,54-2,60 (m, 4H); 2,72 (s, 3H); 2,88 (s, 3H), 2,88-2,93 (m, 1 H); 3,01-3,05 (m, 1 H); 3,06-3,12 (m, 4H); 3,13-3,16 (t, J=7Hz, 1 H); 5,76 (s, 2H); 7,38 (d, J=8Hz, 2H); 7,57 (s, 1 H); 7,61- 7,66 (m, 2H); 7,78-7,85 (m, 3H); 8,02 (d, J=8,2Hz, 1 H); 8,15 (d, J= 8,2Hz, 1 H); 8,98 (s, 1 H); 10,71 (s, 1 H). \n \n1\n H NMR (δ, DMSO): 2.54-2.60 (m, 4H); 2.72 (s, 3H); 2.88 (s, 3H), 2.88-2.93 (m, 1H); 3.01-3.05 (m, 1H); 3.06-3.12 (m, 4H); 3.13-3.16 (t, J = 7 Hz, 1H); 5.76 (s, 2H); 7.38 (d, J = 8Hz, 2H); 7.57 (s, 1H); 7.61-7.66 (m, 2H); 7.78-7.85 (m, 3H); 8.02 (d, J = 8.2 Hz, 1H); 8.15 (d, J = 8.2 Hz, 1H); 8.98 (s, 1H); 10.71 (s, 1H).\n\n\n\n\n\n\n \nExemple 6 : (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(naphthalen-1- ylméthoxy)-benzènesulfonylamino]-propionamide. \nExample 6: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (naphthalen-1-ylmethoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n6.1 : (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoate de méthyle \n6.1: Methyl (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) benzenesulfonylamino] -propanoate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 5.2, à partir de 160mg (0,9 mmoles) de 4-chlorométhyl-2-méthyl- quinoline et de 300mg (0,7 mmoles) de (S)-3-(4-hydroxy-benzènesulfonylamino)- 2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle (préparé comme décrit en 5.1 ), 130mg (32%) de (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n\n 6.2 : acide (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(naphthalen-1-ylméthoxy)- benzènesulfonylaminoj-propanoique \nAnalogous to Example 5.2, starting from 160 mg (0.9 mmol) of 4-chloromethyl-2-methylquinoline and 300 mg (0.7 mmol) of (S) -3- (4-hydroxy) benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate (prepared as described in 5.1), 130mg (32%) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) Methyl 3- [4- (2-methyl-quinolin-4-ylmethoxy) benzenesulfonylamino] -propanoate are obtained as a white solid.  6.2: (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (naphthalen-1-ylmethoxy) -benzenesulfonylamino] propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 240mg (0,6 mmoles) de (S)-2-(4-méthanesulfonyl- pipérazin-1-yl)-3-[4-(naphthalen-1-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle, 210mg (91 %) d' acide (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(naphthalen-1-ylméthoxy)- benzènesulfonylamino]-propanoique sont obtenus sous forme d'un solide blanc. \n Analogous to Example 3.7, from 240 mg (0.6 mmol) of (S) -2- (4-methanesulfonylpiperazin-1-yl) -3- [4- (naphthalen-1-ylmethoxy)) Methyl benzenesulfonylamino] propanoate, 210 mg (91%) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (naphthalen-1-ylmethoxy) benzenesulfonylamino] - propanoic are obtained in the form of a white solid.\n\n\n\n\n\n\n \n6.3 : (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(naphthalen-1-ylméthoxy)- benzènesulfonylamino]-propionamide \n6.3: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (naphthalen-1-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 210mg (0,4 mmoles) d'acide (S)-2-(4- méthanesulfonyl-pipérazin-1-yl)-3-[4-(naphthalen-1-ylméthoxy)-benzènesulfonylamino]-propanoique, 70mg (33%) de (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(naphthalen-1-ylméthoxy)- benzènesulfonylamino]-propionamide sont obtenus sous forme d'un solide beige de point de fusion 148\n0\nC. \nAnalogous to Example 3.8, from 210 mg (0.4 mmol) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (naphthalen-1-yl) acid). ylmethoxy) -benzenesulfonylamino] -propanoic acid, 70mg (33%) of (S) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (naphthalen-1-ylmethoxy) benzenesulfonylamino) ] -propionamide are obtained in the form of a beige solid with a melting point of 148 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,45 (m, 2H); 2,60 (m, 2H); 2,85 (s, 3H); 2,90-3,05 (m, 4H); 3,06-3,15 (m, 2H); 3,35 (s, 1 H); 5,66 (s, 2H); 7,30 (d, J=8,4Hz, 2H); 7,50-7,60 (m, 4H); 7,70 (d, J=6,2Hz, 1 H); 7,77 (d, J=8.2Hz, 2H); 7,95-8,05 (m, 2H); 8,10 (d, J=6,4Hz, 1 H); 8,94 (s, 1 H); 10,70 (s, 1 H). \n \n1\n H NMR (δ, DMSO): 2.45 (m, 2H); 2.60 (m, 2H); 2.85 (s, 3H); 2.90-3.05 (m, 4H); 3.06-3.15 (m, 2H); 3.35 (s, 1H); 5.66 (s, 2H); 7.30 (d, J = 8.4Hz, 2H); 7.50-7.60 (m, 4H); 7.70 (d, J = 6.2 Hz, 1H); 7.77 (d, J = 8.2 Hz, 2H); 7.95-8.05 (m, 2H); 8.10 (d, J = 6.4Hz, 1H); 8.94 (s, 1H); 10.70 (s, 1H).\n\n\n\n\n\n\n \nExemple 7 : (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-(4-propoxy- benzènesulfonylamino)-propionamide. 7.1 : (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-(4-propoxy-benzènesulfonylamino)-propanoate de méthyle \nExample 7: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- (4-propoxy-benzenesulfonylamino) -propionamide. 7.1: Methyl (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- (4-propoxy-benzenesulfonylamino) -propanoate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 5.2, à partir de 0,1 ml (1 ,3 mmoles) de 1-bromopropane et de 400mg (0,95 mmoles) de (S)-3-(4-hydroxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1- yl)-propanoate de méthyle (préparé comme décrit en 5.1 ) , 220mg (50%) de (S)-2-(4-méthanesulfonyl- pipérazin-1-yl)-3-(4-propoxy-benzènesulfonylamino)-propanoate de méthyle sont obtenus sous forme d'une huile incolore. \n In a similar manner to Example 5.2, from 0.1 ml (1.3 mmol) of 1-bromopropane and 400 mg (0.95 mmol) of (S) -3- (4-hydroxy-benzenesulfonylamino) - Methyl 2- (4-methanesulfonyl-piperazin-1-yl) -propanoate (prepared as described in 5.1), 220 mg (50%) of (S) -2- (4-methanesulfonylpiperazin-1-yl) -3 Methyl (4-propoxybenzenesulfonylamino) propanoate are obtained in the form of a colorless oil.\n\n\n\n\n\n\n \n7.2 : acide (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-(4-propoxy-benzènesulfonylamino)- propanoique \n7.2: (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- (4-propoxy-benzenesulfonylamino) -propanoic acid\n\n\n\n\n\n\n \nDe manière analogue à l'exemple 3.7, à partir de 220mg (0,5 mmoles) de (S)-2-(4-méthanesulfonyl- pipérazin-1-yl)-3-(4-propoxy-benzènesulfonylamino)-propanoate de méthyle, 190mg (90%) d' acide (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-(4-propoxy-benzènesulfonylamino)-propanoique sont obtenus sous forme d'un solide blanc. \n\n7.3 : (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-(4-propoxy-benzènesulfonylamino)- propionamide \nIn a similar manner to Example 3.7, from 220 mg (0.5 mmol) of (S) -2- (4-methanesulfonylpiperazin-1-yl) -3- (4-propoxy-benzenesulfonylamino) -propanoate. methyl, 190 mg (90%) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- (4-propoxy-benzenesulfonylamino) -propanoic acid are obtained in the form of a white solid.  7.3: (S) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- (4-propoxy-benzenesulfonylamino) -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 190mg (0,4 mmoles) d'acide (S)-2-(4- méthanesulfonyl-pipérazin-1-yl)-3-(4-propoxy-benzènesulfonylamino)-propanoique, 30mg (16%) de (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-(4-propoxy-benzènesulfonylamino)- propionamide sont obtenus sous forme d'un solide blanc de point de fusion 137\n0\nC. \nIn a similar manner to Example 3.8, from 190 mg (0.4 mmol) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- (4-propoxy-benzenesulfonylamino) - Propane, 30 mg (16%) of (S) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- (4-propoxy-benzenesulfonylamino) -propionamide are obtained in the form of a white solid. melting point 137 \n°\n C.\n\n\n\n\n\n\n \nRMN \n1\nH (δ, DMSO) : 0,91 (t, J=7,3Hz, 3H); 1 ,63-1 ,73 (m, 2H); 2,45 (m, 2H); 2,55 (m, 2H); 2,77 (s, 3H); 2,82 (m, 1 H); 2,83-2,95 (m, 4H); 2,95-3,05 (m, 2H); 3,94 (t, J=6,4Hz, 2H); 7,03 (d, J=8,7Hz, 2H); 7,38 (m, 1 H); 7,65 (d, J=8,7Hz, 2H); 8,85 (s, 1 H); 10,58 (s, 1 H). \n \n1\n H NMR (δ, DMSO): 0.91 (t, J = 7.3 Hz, 3H); 1.63-1.73 (m, 2H); 2.45 (m, 2H); 2.55 (m, 2H); 2.77 (s, 3H); 2.82 (m, 1H); 2.83-2.95 (m, 4H); 2.95-3.05 (m, 2H); 3.94 (t, J = 6.4Hz, 2H); 7.03 (d, J = 8.7 Hz, 2H); 7.38 (m, 1H); 7.65 (d, J = 8.7 Hz, 2H); 8.85 (s, 1H); 10.58 (s, 1H).\n\n\n\n\n\n\n \nExemple 8 : (S)-3-[4-(3-cyano-benzyloxy)-benzènesulfonylamino]-N-hydroxy-2-(4- méthanesulfonyl-pipérazin-1-yl)-propionamide. \nExample 8: (S) -3- [4- (3-cyano-benzyloxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide.\n\n\n\n\n\n\n \n8.1 : (S)-3-[4-(3-cyano-benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1-yl)- propanoate de méthyle \n8.1: Methyl (S) -3- [4- (3-cyano-benzyloxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin-1-yl) propanoate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 5.2, à partir de 205mg (1 mmole) de 3-(bromométhyl)benzonitrile et de 400mg (0,95 mmoles) de (S)-3-(4-hydroxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin- 1-yl)-propanoate de méthyle (préparé comme décrit dans l'exemple 5.1 ), 295mg (58%) de (S)-3-[4-(3- cyano-benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n In a similar manner to Example 5.2, from 205 mg (1 mmol) of 3- (bromomethyl) benzonitrile and 400 mg (0.95 mmol) of (S) -3- (4-hydroxy-benzenesulfonylamino) -2- Methyl (4-methanesulfonyl-piperazin-1-yl) -propanoate (prepared as described in Example 5.1), 295 mg (58%) of (S) -3- [4- (3-cyano-benzyloxy) -benzenesulfonylamino) Methyl 2- (4-methanesulfonyl-piperazin-1-yl) -propanoate are obtained as a white solid.\n\n\n\n\n\n\n \n8.2 : acide (S)-3-[4-(3-cyano-benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1-yl)- propanoique \n8.2: (S) -3- [4- (3-cyano-benzyloxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin-1-yl) -propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 295mg (0,5 mmoles) de (S)-3-[4-(3-cyano- benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle, 270mg (94%) d'acide (S)-3-[4-(3-cyano-benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl- pipérazin-1-yl)-propanoique sont obtenus sous forme d'un solide blanc. \n In a similar manner to Example 3.7, from 295 mg (0.5 mmol) of (S) -3- [4- (3-cyano-benzyloxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin-1) Methyl-propanoate, 270 mg (94%) of (S) -3- [4- (3-cyano-benzyloxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin-1-yl) - propanoic are obtained in the form of a white solid.\n\n\n\n\n\n\n \n8.3 : (S)-3-[4-(4-cyano-benzyloxy)-benzènesulfonylamino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin- 1-yl)-propionamide \n8.3: (S) -3- [4- (4-cyano-benzyloxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 264mg (0,5 mmoles) d'acide (S)-3-[4-(3-cyano- benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoique, 107mg (40%) de (S)-3-[4-(3-cyano-benzyloxy)-benzènesulfonylamino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-propionamide sont obtenus sous forme d'une poudre beige de point de fusion 108\n0\nC. \nAnalogously to Example 3.8, from 264 mg (0.5 mmol) of (S) -3- [4- (3-cyano-benzyloxy) -benzenesulfonylamino] -2- (4-methanesulfonyl) piperazine 1-yl) -propanoic acid, 107mg (40%) of (S) -3- [4- (3-cyano-benzyloxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) ) -propionamide are obtained in the form of a beige powder with a melting point of 108 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,55 (m, 4H); 2,84 (s, 3H); 2,95-3,05 (m, 4H); 3,10 (t, J=6,4Hz, 1 H); 3,34 (m;\n \n1\n H NMR (δ, DMSO): 2.55 (m, 4H); 2.84 (s, 3H); 2.95-3.05 (m, 4H); 3.10 (t, J = 6.4Hz, 1H); 3.34 (m;\n\n\n\n\n\n\n \n2H); 5,26 (s, 2H); 7,22 (d, J=8,6Hz, 2H); 7,50 (s, 1 H); 7,64 (t, J=7,6Hz, 1 H); 7,76 (d, J=8,6Hz, 2H);\n2H); 5.26 (s, 2H); 7.22 (d, J = 8.6 Hz, 2H); 7.50 (s, 1H); 7.64 (t, J = 7.6 Hz, 1H); 7.76 (d, J = 8.6 Hz, 2H);\n\n\n\n\n\n\n \n7,83 (t, J=8Hz, 2H); 7,96 (s, 1 H); 8,93 (s, 1 H); 10,66 (s, 1 H). \n\n Exemple 9 : (S)-3-[4-(4-cyano-benzyloxy)-benzènesulfonylamino]-N-hydroxy-2-(4- méthanesulfonyl-pipérazin-1-yl)-propionamide. \n7.83 (t, J = 8Hz, 2H); 7.96 (s, 1H); 8.93 (s, 1H); 10.66 (s, 1H).  Example 9: (S) -3- [4- (4-cyano-benzyloxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide.\n\n\n\n\n\n\n \n9.1 : (S)-3-[4-(4-cyano-benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1-yl)- propanoate de méthyle \n9.1: Methyl (S) -3- [4- (4-cyano-benzyloxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin-1-yl) propanoate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 5.2, à partir de 400mg (1 mmole) de (S)-3-(4-hydroxy- benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle (préparé comme décrit en 5.1 ) et de 205mg (1 ,1 mmoles) de 4-(bromométhyl)benzonitrile, 229mg (45%) de (S)-3-[4-(4- cyano-benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n In a manner similar to Example 5.2, from 400 mg (1 mmol) of methyl (S) -3- (4-hydroxybenzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate ( prepared as described in 5.1) and 205 mg (1.1 mmol) of 4- (bromomethyl) benzonitrile, 229 mg (45%) of (S) -3- [4- (4-cyano-benzyloxy) benzenesulfonylamino] -2 Methyl (4-methanesulfonyl-piperazin-1-yl) -propanoate are obtained in the form of a white solid.\n\n\n\n\n\n\n \n9.2 : acide (S)-3-[4-(4-cyano-benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1-yl)- propanoique \n9.2: (S) -3- [4- (4-cyano-benzyloxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin-1-yl) -propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 229mg (0,4 mmoles) de (S)-3-[4-(4-cyano- benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle, 202mg (91 %) d'acide (S)-3-[4-(4-cyano-benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl- pipérazin-1-yl)-propanoique sont obtenus sous forme d'un solide blanc. \n Analogous to Example 3.7, from 229 mg (0.4 mmol) of (S) -3- [4- (4-cyano-benzyloxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin-1) Methyl-propanoate, 202 mg (91%) of (S) -3- [4- (4-cyano-benzyloxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin-1-yl) - propanoic are obtained in the form of a white solid.\n\n\n\n\n\n\n \n9.3 : (S)-3-[4-(4-cyano-benzyloxy)-benzènesulfonylamino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin- 1-yl)-propionamide \n9.3: (S) -3- [4- (4-cyano-benzyloxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir d'acide 197mg (0,4 mmoles) de (S)-3-[4-(4-cyano- benzyloxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-piperazin-1-yl)-propanoique, 81 mg (40%) de (S)-3-[4-(4-cyano-benzyloxy)-benzènesulfonylamino]-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)- propionamide sont obtenus sous forme d'une poudre beige de point de fusion 109\n0\nC. \nAnalogously to Example 3.8, from 197 mg (0.4 mmol) of (S) -3- [4- (4-cyano-benzyloxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin) -1-yl) -propanoic acid, 81 mg (40%) of (S) -3- [4- (4-cyano-benzyloxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1- yl) - propionamide are obtained in the form of a beige powder of melting point 109 \n°\n C.\n\n\n\n\n\n\n \nRMN \n1\nH (δ, DMSO) : 2,50-2,60 (m, 4H); 2,84 (s, 3H); 2,96 -3,01 (m, 4H); 3,09 (t, J=7Hz, 1 H); 3,34 (s, 2H); 5,32 (s, 2H); 7,22 (d, J=8,8Hz, 2H); 7,50 (m, 1 H); 7,66 (d, J=8,1 Hz, 2H); 7,75 (d, J=8,8Hz, 2H); 7,89 (d, J=8,1 Hz, 2H); 8,93 (s, 1 H); 10,66 (s, 1 H). \n \n1\n H NMR (δ, DMSO): 2.50-2.60 (m, 4H); 2.84 (s, 3H); 2.96 - 3.01 (m, 4H); 3.09 (t, J = 7Hz, 1H); 3.34 (s, 2H); 5.32 (s, 2H); 7.22 (d, J = 8.8 Hz, 2H); 7.50 (m, 1H); 7.66 (d, J = 8.1Hz, 2H); 7.75 (d, J = 8.8 Hz, 2H); 7.89 (d, J = 8.1Hz, 2H); 8.93 (s, 1H); 10.66 (s, 1H).\n\n\n\n\n\n\n \nExemple 10 : 4-{(S)-1-hydroxycarbamoyl-2-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzène sulfonylamino]-éthyl}-pipérazine-1-carboxylate de benzyle. \nExample 10 Benzyl 4 - {(S) -1-hydroxycarbamoyl-2- [4- (2-methyl-quinolin-4-ylmethoxy) -benzene sulfonylamino] -ethyl} -piperazine-1-carboxylate.\n\n\n\n\n\n\n \n10.1 : bis-(2-chloroéthyl)-carbamate de benzyle \n10.1: Benzyl bis (2-chloroethyl) carbamate\n\n\n\n\n\n\n \n 13,2ml (92 mmoles) de chloroformate de benzyle sont ajoutés lentement à une solution, refroidie à O\n0\nC, de 15g (84 mmoles) de chlorhydrate de bis(2-chloroéthylamine), 26ml (185 mmoles) de triéthylamine dans 200ml de dichlorométhane et 70ml de tétrahydrofuranne préalablement agitée pendant 15min puis filtrée pour enlever le chlorure de triéthylammonium. Le milieu réactionnel est agité à température ambiante pendant 18h. Après addition d'eau, le milieu réactionnel est extrait à l'acétate d'éthyle. La phase organique est séchée sur sulfate de magnésium, filtrée, évaporée. 20g de résidu brut sont obtenus et purifiés par chromatographie sur gel de silice élues avec un mélange \n\n heptane / acétate d'éthyle 8/2. 6g (26%) de bis-(2-chloroéthyl)-carbamate de benzyle sont ainsi obtenus. \n13.2 ml (92 mmol) of benzyl chloroformate are slowly added to a solution, cooled to 0 \n°\n C., of 15 g (84 mmol) of bis (2-chloroethylamine) hydrochloride, 26 ml (185 mmol) of triethylamine in 200 ml of dichloromethane and 70 ml of tetrahydrofuran previously stirred for 15 min and then filtered to remove triethylammonium chloride. The reaction medium is stirred at ambient temperature for 18 h. After addition of water, the reaction medium is extracted with ethyl acetate. The organic phase is dried over magnesium sulphate, filtered and evaporated. 20 g of crude residue are obtained and purified by chromatography on silica gel eluted with a mixture  heptane / ethyl acetate 8/2. 6 g (26%) of benzyl bis- (2-chloroethyl) carbamate are thus obtained.\n\n\n\n\n\n\n \n10.2 : 4-((S)-2-tert-butoxycarbonylamino-1-méthoxycarbonyl-éthyl)-pipérazine-1 -carboxylate de benzyle \n10.2: 4 - ((S) -2-tert-butoxycarbonylamino-1-methoxycarbonyl-ethyl) -piperazine-1-benzylcarboxylate\n\n\n\n\n\n\n \n Une solution de 5,5g (20 mmoles) de bis-(2-chloroéthyl)-carbamate de benzyle et 5,1g (20 mmoles) de chlorhydrate de 2-amino-3-tert-butoxy-propanoate de méthyle dans 40ml de diisopropyléthylamine est chauffée à 127\n0\nC pendant 18h. Après refroidissement, le milieu réactionnel est évaporé à sec. 17g de résidu brut sont obtenus et purifiés par chromatographie sur gel de silice élues avec un mélange heptane / acétate d'éthyle 9/1 jusqu'à 4/6. 1 ,6g (19%) de 4-((S)-2-tert-butoxycarbonylamino-1- méthoxycarbonyl-éthyl)-pipérazine-1-carboxylate de benzyle. \nA solution of 5.5 g (20 mmol) of benzyl bis (2-chloroethyl) carbamate and 5.1 g (20 mmol) of methyl 2-amino-3-tert-butoxy-propanoate hydrochloride in 40 ml of diisopropylethylamine is heated at 127 \n0\n C for 18h. After cooling, the reaction medium is evaporated to dryness. 17 g of crude residue are obtained and purified by chromatography on silica gel eluted with a heptane / ethyl acetate mixture 9/1 to 4/6. 1, 6g (19%) of benzyl 4 - ((S) -2-tert-butoxycarbonylamino-1-methoxycarbonyl-ethyl) -piperazine-1-carboxylate.\n\n\n\n\n\n\n \n10.3 : dichlorhydrate de 4-(2-amino-1-méthoxycarbonyl-éthyl)-pipérazine-1-carboxylate de benzyle Une solution de 1 ,45g (3,4 mmoles) de 4-((S)-2-tert-butoxycarbonylamino-1-méthoxycarbonyl-éthyl)- pipérazine-1-carboxylate de benzyle dans 3,5ml d'une solution d'acide chlorhydrique dans l'isopropanol de concentration 5-6N et 10ml de méthanol est chauffée à 4O\n0\nC pendant 3h puis évaporée. Le résidu est repris dans l'éther diéthylique, filtré. 1 ,2g (90%) de dichlorhydrate de 4-(2- amino-1-méthoxycarbonyl-éthyl)-pipérazine-1-carboxylate de benzyle sont obtenus sous forme d'un solide. \n10.3: Benzyl 4- (2-amino-1-methoxycarbonyl-ethyl) -piperazine-1-carboxylate dihydrochloride A solution of 1.45 g (3.4 mmol) of 4 - ((S) -2-tert-butoxycarbonylamino Benzyl 1-methoxycarbonyl-ethyl) -piperazine-1-carboxylate in 3.5 ml of a solution of hydrochloric acid in isopropanol of concentration 5-6N and 10 ml of methanol is heated at 40 \n°\n C. for 3 h and then evaporated . The residue is taken up in diethyl ether, filtered. 1.2 g (90%) of benzyl 4- (2-amino-1-methoxycarbonyl-ethyl) -piperazine-1-carboxylate dihydrochloride are obtained in the form of a solid.\n\n\n\n\n\n\n \n10.4 : 4-[(S)-2-(4-hydroxy-benzènesulfonylamino)-1-méthoxycarbonyl-éthyl]-pipérazine-1-carboxylate de benzyle \nBenzyl 10,4: 4 - [(S) -2- (4-hydroxy-benzenesulfonylamino) -1-methoxycarbonyl-ethyl] -piperazine-1-carboxylate\n\n\n\n\n\n\n \n 2,1 ml (15 mmoles) de triéthylamine puis 920mg (5 mmoles) de chlorure de 4-hydroxy- benzènesulfonyle dans 20ml de dichlorométhane sont additionnés goutte à goutte à une solution de 1 ,1g (3 mmoles) de dichlorhydrate de 4-(2-amino-1-méthoxycarbonyl-éthyl)-pipérazine-1-carboxylate de benzyle dans 30ml de dichlorométhane, préalablement refroidie à O\n0\nC. Le milieu réactionnel est ensuite agité à température ambiante pendant 18h. Après addition d'eau, le milieu réactionnel est extrait par du dichlorométhane. La phase organique est à l'eau puis séchée sur sulfate de magnésium, filtrée et concentrée sous vide. Le résidu brut obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane/acétate d'éthyle 50/50. 60mg (46%) de 4-[2-(4-hydroxy- benzènesulfonylamino)-1-méthoxycarbonyl-éthyl]-pipérazine-1-carboxylate de benzyle sont obtenus sous forme d'un solide blanc. \n2.1 ml (15 mmol) of triethylamine and then 920 mg (5 mmol) of 4-hydroxybenzenesulfonyl chloride in 20 ml of dichloromethane are added dropwise to a solution of 1.1 g (3 mmol) of dihydrochloride of Benzyl 2-amino-1-methoxycarbonyl-ethyl) -piperazine-1-carboxylate in 30 ml of dichloromethane, previously cooled to 0 \n°\n C. The reaction medium is then stirred at ambient temperature for 18 hours. After addition of water, the reaction medium is extracted with dichloromethane. The organic phase is with water then dried over magnesium sulfate, filtered and concentrated under vacuum. The crude residue obtained is purified by chromatography on silica gel eluted with a 50/50 heptane / ethyl acetate mixture. 60 mg (46%) of benzyl 4- [2- (4-hydroxybenzenesulfonylamino) -1-methoxycarbonyl-ethyl] -piperazine-1-carboxylate are obtained as a white solid.\n\n\n\n\n\n\n \n10.5 : 4-{(S)-1-méthoxycarbonyl-2-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-éthyl}- pipérazine-1 -carboxylate de benzyle \nBenzyl 10.5: 4 - {(S) -1-methoxycarbonyl-2- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -ethyl} piperazine-1-carboxylate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 5.2, à partir de 260mg (1 ,4 mmoles) de 4-chlorométhyl-2-méthyl- quinoline et de 600mg (1 ,3 mmoles) de 4-[(S)-2-(4-hydroxy-benzènesulfonylamino)-1- méthoxycarbonyl-éthyl]-pipérazine-1 -carboxylate de benzyle, 320mg (40%) de 4-{(S)-1- méthoxycarbonyl-2-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-éthyl}-pipérazine-1- carboxylate de benzyle sont obtenus sous forme d'un solide blanc. \n\n 10.6 : 4-{(S)-1-carboxy-2-[4-(2-méthyl-quinolin-4-ylméthoxy benzènesulfonylamino]-éthyl}-pipérazine- 1 -carboxylate de benzyle \nIn a similar manner to Example 5.2, from 260 mg (1.4 mmol) of 4-chloromethyl-2-methylquinoline and 600 mg (1.3 mmol) of 4 - [(S) -2- (4 benzylated-hydroxy-benzenesulfonylamino) -1-methoxycarbonyl-ethyl] -piperazine-1-carboxylate, 320mg (40%) of 4 - {(S) -1-methoxycarbonyl-2- [4- (2-methyl-quinolin)} Benzyl 4-ylmethoxy) -benzenesulfonylamino] -ethyl} -piperazine-1-carboxylate are obtained as a white solid.  Benzyl 10.6: 4 - {(S) -1-carboxy-2- [4- (2-methyl-quinolin-4-ylmethoxybenzenesulfonylamino] -ethyl} -piperazine-1-carboxylate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 160mg (0,25 mmoles) de 4-{(S)-1-méthoxycarbonyl- 2-[4-(2-méthylquinolin-4-ylméthoxy)-benzènesulfonylamino]-éthyl}-pipérazine-1 -carboxylate de benzyle, 135mg (87%) de 4-{(S)-1-carboxy-2-[4-(2-méthyl-quinolin-4-ylméthoxy benzènesulfonylamino]-éthyl}-pipérazine-1-carboxylate de benzyle sont obtenus sous forme d'un solide beige. 10.7 : 4-{(S)-1-hydroxycarbamoyl-2-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-ethyl}- piperazine-1 -carboxylate de benzyle \n Analogously to Example 3.7, from 160 mg (0.25 mmol) of 4 - {(S) -1-methoxycarbonyl-2- [4- (2-methylquinolin-4-ylmethoxy) -benzenesulfonylamino] -ethyl } -piperazine-1-benzylcarboxylate, 135mg (87%) of 4 - {(S) -1-carboxy-2- [4- (2-methyl-quinolin-4-ylmethoxy) benzenesulfonylamino] -ethyl} -piperazine Benzyl 1-carboxylate is obtained in the form of a beige solid 10.7: 4 - {(S) -1-hydroxycarbamoyl-2- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -ethyl} benzyl piperazine-1-carboxylate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 135mg (0,2 mmoles) de 4-{(S)-1-carboxy-2-[4-(2- méthyl-quinolin-4-ylméthoxy benzènesulfonylamino]-éthyl}-pipérazine-1 -carboxylate de benzyle, 115mg (82%) de 4-{(S)-1-hydroxycarbamoyl-2-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-éthyl}-pipérazine-1-carboxylate de benzyle sont obtenus sous forme d'un solide blanc de point de fusion 162\n0\nC. \nIn a similar manner to Example 3.8, from 135 mg (0.2 mmol) of 4 - {(S) -1-carboxy-2- [4- (2-methyl-quinolin-4-ylmethoxy-benzenesulfonylamino] -ethyl} } -piperazine-1-benzylcarboxylate, 115mg (82%) 4 - {(S) -1-hydroxycarbamoyl-2- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -ethyl} - Benzyl piperazine-1-carboxylate are obtained in the form of a white solid having a melting point of 162 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,35-2,45 (m, 4H); 2,70 (s, 3H); 2,80-2,90 (m, 1 H); 2,95-3,05 (m, 1 H); 3-05-3,10 (m, 1 H); 3,25-3,40 (m, 4H); 5,05 (s, 2H); 5,74 (s, 2H); 7,29-7,40 (m, 7H); 7,55 (m, 1 H); 7,60-7,70 (m, 2H); 7,79 (d, J=8,8Hz, 3H); 8,01 (d, J=8Hz, 1 H); 8,14 (d, J=8Hz, 1 H); 8,91 (s, 1 H); 10,67 (s, 1 H). \n \n1\n H NMR (δ, DMSO): 2.35-2.45 (m, 4H); 2.70 (s, 3H); 2.80-2.90 (m, 1H); 2.95-3.05 (m, 1H); 3-05-3.10 (m, 1H); 3.25-3.40 (m, 4H); 5.05 (s, 2H); 5.74 (s, 2H); 7.29-7.40 (m, 7H); 7.55 (m, 1H); 7.60-7.70 (m, 2H); 7.79 (d, J = 8.8 Hz, 3H); 8.01 (d, J = 8Hz, 1H); 8.14 (d, J = 8 Hz, 1H); 8.91 (s, 1H); 10.67 (s, 1H).\n\n\n\n\n\n\n \nExemple 11 : (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-phényl-pyridin-4- ylméthoxy)-benzènesulfonylamino]-propionamide. \nExample 11: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-phenyl-pyridin-4-ylmethoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n11.1 : (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-phényl-pyridin-4-ylméthoxy)- benzènesulfonylaminoj-propanoate de méthyle \n11.1: Methyl (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-phenyl-pyridin-4-ylmethoxy) -benzenesulfonylamino] -propanoate\n\n\n\n\n\n\n \n 0,23ml (1 ,4 mmoles) de diéthylazodicarboxylate sont ajoutés lentement à une solution de 400mg (0,9 mmoles) de (S)-3-(4-hydroxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle (préparé comme décrit dans l'exemple 5.1) , 193mg (1 ,0 mmole) de (2-phényl-pyridin-4- yl)-méthanol et 373mg (1 ,4 mmoles) de triphénylphosphine dans 4ml de tétrahydrofuranne. Le mélange réactionnel est agité une heure à température ambiante puis évaporé à sec. Le résidu obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane/acétate d'éthyle 60/40. 318mg (57%) de (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-phényl-pyridin-4- ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle sont obtenus sous forme d'une poudre blanche. \n 0.23 ml (1.4 mmol) of diethylazodicarboxylate are added slowly to a solution of 400 mg (0.9 mmol) of (S) -3- (4-hydroxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1) Methyl-propanoate (prepared as described in Example 5.1), 193 mg (1.0 mmol) of (2-phenyl-pyridin-4-yl) -methanol and 373 mg (1.4 mmol) of triphenylphosphine in 4ml of tetrahydrofuran. The reaction mixture is stirred for one hour at ambient temperature and then evaporated to dryness. The residue obtained is purified by chromatography on silica gel eluted with a 60/40 heptane / ethyl acetate mixture. 318 mg (57%) of methyl (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-phenyl-pyridin-4-ylmethoxy) -benzenesulfonylamino] -propanoate are obtained under form of a white powder.\n\n\n\n\n\n\n \n712 : acide (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-phényl-pyridin-4-ylméthoxy)- benzènesulfonylamino]-propanoique \n712: (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-phenyl-pyridin-4-ylmethoxy) -benzenesulfonylamino] -propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 317mg (0,5 mmoles) de (S)-2-(4-méthanesulfonyl- pipérazin-1-yl)-3-[4-(2-phényl-pyridin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle, \n\n 298mg (96%) d'acide (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-phényl-pyridin-4-ylméthoxy)- benzènesulfonylannino]-propanoique sont obtenus sous forme d'un solide blanc. \nAnalogous to Example 3.7, from 317 mg (0.5 mmol) of (S) -2- (4-methanesulfonylpiperazin-1-yl) -3- [4- (2-phenylpyridin) Methyl 4-ylmethoxy) -benzenesulfonylamino] -propanoate  298 mg (96%) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-phenyl-pyridin-4-ylmethoxy) -benzenesulfonylannino] -propanoic acid are obtained under form of a white solid.\n\n\n\n\n\n\n \n11.3 : (S)-N-hydroxy-2-(4-méthanesulfonyl-piperazin-1-yl)-3-[4-(2-phenyl-pyridin-4-ylmethoxy)- benzenesulfonylaminoj-propionamide \n11.3: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-phenyl-pyridin-4-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 293mg (0,5 mmoles) d'acide (S)-2-(4- méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-phényl-pyridin-4-ylméthoxy)-benzènesulfonylamino]- propanoique, 64mg (21 %) de (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-phényl- pyridin-4-ylméthoxy)-benzènesulfonylamino]-propionamide sont obtenus sous forme d'une poudre blanche de point de fusion 100\n0\nC. \nIn a similar manner to Example 3.8, from 293 mg (0.5 mmol) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-phenyl) -2- pyridin-4-ylmethoxy) -benzenesulfonylamino] -propanoic acid, 64mg (21%) of (S) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-phenyl) pyridin-4-ylmethoxy) -benzenesulfonylamino] -propionamide are obtained in the form of a white powder having a melting point of 100 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,52-2,59 (m, 4H); 2,84 (s, 3H); 2,85-2,90 (m, 1 H); 2,90-3,00 (m, 1 H); 3,00-3,08 (m, 4H); 3,10 (t, J=7,0Hz, 1 H); 5,35 (s, 2H); 7,26 (d, J=8,9Hz, 2H); 7,42 (m, 1 H); 7,45-7,55 (m, 4H); 7,78 (d, J=8,8Hz, 2H); 8,03 (s, 1 H); 8,10 (d, J=7,0Hz, 2H); 8,69 (d, J=5,0Hz, 1 H); 8,93 (s, 1 H); 10,66 (s, 1 H). \n \n1\n H NMR (δ, DMSO): 2.52-2.59 (m, 4H); 2.84 (s, 3H); 2.85-2.90 (m, 1H); 2.90-3.00 (m, 1H); 3.00-3.08 (m, 4H); 3.10 (t, J = 7.0 Hz, 1H); 5.35 (s, 2H); 7.26 (d, J = 8.9Hz, 2H); 7.42 (m, 1H); 7.45-7.55 (m, 4H); 7.78 (d, J = 8.8 Hz, 2H); 8.03 (s, 1H); 8.10 (d, J = 7.0 Hz, 2H); 8.69 (d, J = 5.0 Hz, 1H); 8.93 (s, 1H); 10.66 (s, 1H).\n\n\n\n\n\n\n \nExemple 12 : (R)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4- ylméthoxy)-benzènesulfonylamino]-propionamide. \nExample 12: (R) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n12.1 : (R)-3-tert-butoxycarbonylamino-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle De manière analogue à l'exemple 3.2, à partir de 3,8g (17 mmoles) de N,N-bis-(2-chloro-éthyl)- méthanesulfonamide (préparé comme décrit en 3.1 ) et 4g (16 mmoles) de chlorhydrate de 2- (R) amino-3-tert-butoxy-propanoate de méthyle commercial, 2,6g (46%) de (R)-3-tert- butoxycarbonylamino-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'un solide jaune clair. \n12.1: Methyl (R) -3-tert-butoxycarbonylamino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate Analogously to Example 3.2, from 3.8 g (17 mmol) of N N-bis- (2-chloroethyl) methanesulfonamide (prepared as described in 3.1) and 4g (16 mmol) of commercial methyl 2- (R) amino-3-tert-butoxypropanoate hydrochloride, 2, 6 g (46%) of methyl (R) -3-tert-butoxycarbonylamino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate are obtained in the form of a light yellow solid.\n\n\n\n\n\n\n \n12.2 : dichlorhydrate de (R)-3-amino-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle\n12.2: Methyl (R) -3-amino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate dihydrochloride\n\n\n\n\n\n\n \nDe manière analogue à l'exemple 3.3, à partir de 2,5g ( 7 mmoles) de (R)-3-tert-butoxycarbonylamino- 2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle, 2,3g (100%) du dichlorhydrate de (R)-3- amino-2-(4-méthanesulfonyl-piperazin-1-yl)-propanoate de méthyle sont obtenus. \nIn a similar manner to Example 3.3, from 2.5 g (7 mmol) of methyl (R) -3-tert-butoxycarbonylamino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate, 2, 3 g (100%) of methyl (R) -3-amino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate dihydrochloride are obtained.\n\n\n\n\n\n\n \n12.3 : (R)-3-(4-benzyloxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle \n12.3: Methyl (R) -3- (4-benzyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.6, à partir de 2,4g (8,4 mmoles) de chlorure de 4-benzyloxy- benzènesulfonyle (préparé comme décrit dans l'exemple 3.5) et de 2,3g (7,6 mmoles) de dichlorhydrate de (R)-3-amino-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle, 3g (77%) de (R)-3-(4-benzyloxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'un solide. \n In a similar manner to Example 3.6, from 2.4 g (8.4 mmol) of 4-benzyloxybenzenesulfonyl chloride (prepared as described in Example 3.5) and 2.3 g (7.6 mmol) of methyl (R) -3-amino-2- (4-methanesulfonyl-piperazin-1-yl) -propanoate dihydrochloride, 3 g (77%) of (R) -3- (4-benzyloxy-benzenesulfonylamino) -2 Methyl (4-methanesulfonyl-piperazin-1-yl) -propanoate are obtained in the form of a solid.\n\n\n\n\n\n\n \n12.4 : (R)-3-(4-hydroxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle \n\n De manière analogue à l'exemple 5.1 , à partir de 3g (5,9 mmoles) de (R)-3-(4-benzyloxy- benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle, 2g (80%) de (R)- 3-(4-hydroxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n12.4: Methyl (R) -3- (4-hydroxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate  In a manner similar to Example 5.1, starting from 3 g (5.9 mmol) of (R) -3- (4-benzyloxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate. methyl, 2g (80%) of (R) - 3- (4-hydroxy-benzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate are obtained in the form of a white solid.\n\n\n\n\n\n\n \n12.5 : (R) -2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylaminoj-propanoate de méthyle \n12.5: Methyl-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 5.2, à partir de 1g (2,4 mmoles) de (R)-3-(4-hydroxy- benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle et de 500mg (2,6 mmoles) de 4-chlorométhyl-2-méthylquinoline, 740mg (53%) de (R) -2-(4-méthanesulfonyl-pipérazin- 1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle sont obtenus sous forme d'un solide. \n In a manner similar to Example 5.2, from 1 g (2.4 mmol) of (R) -3- (4-hydroxybenzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate. methyl and 500 mg (2.6 mmol) of 4-chloromethyl-2-methylquinoline, 740 mg (53%) of (R) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2) methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoate are obtained in the form of a solid.\n\n\n\n\n\n\n \n12.6 : acide (R) -2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoique \n12.6: (R) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 740mg (1 ,3 mmoles) de (R) -2-(4-méthanesulfonyl- pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle, 622mg (86%) d' acide (R) -2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoique sont obtenus. \n Analogous to Example 3.7, from 740 mg (1.3 mmol) of (R) -2- (4-methanesulfonylpiperazin-1-yl) -3- [4- (2-methyl-quinolin) Methyl 4-ylmethoxy) -benzenesulfonylamino] -propanoate, 622 mg (86%) of (R) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin) 4-ylmethoxy) benzenesulfonylamino] propanoic acid are obtained.\n\n\n\n\n\n\n \n12.7 : (R)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylaminoj-propionamide \n12.7: (R) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 620mg (1 ,1 mmoles) d'acide (R) -2-(4- méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]- propanoique, 465mg (73%) de (R)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-méthyl- quinolin-4-ylméthoxy)-benzènesulfonylamino]-propionamide sont obtenus sous forme d'un solide blanc. \n In a manner analogous to Example 3.8, from 620 mg (1.1 mmol) of (R) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl) -2- quinolin-4-ylmethoxy) -benzenesulfonylamino] propanoic acid, 465 mg (73%) of (R) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl) -2- quinolin-4-ylmethoxy) -benzenesulfonylamino] propionamide are obtained in the form of a white solid.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2.53 (m, 4H); 2,68 (s, 3H); 2,84 (s, 3H); 2,85 (m, 2H); 2,95-3,05 (m, 4H); 3,10 (m, 1 H); 5,72 (s, 2H); 7,35 (d, J=8,8Hz, 2H); 7,52 (m, 1 H); 7,57-7,62 (m, 2H); 7,75-7,82 (m, 3H); 7,98 (d, J=8,4Hz, 1 H); 8,11 (d, J=8,16Hz, 1 H); 8,93 (s, 1 H); 10,70 (s, 1 H). \n \n1\n H NMR (δ, DMSO): 2.53 (m, 4H); 2.68 (s, 3H); 2.84 (s, 3H); 2.85 (m, 2H); 2.95-3.05 (m, 4H); 3.10 (m, 1H); 5.72 (s, 2H); 7.35 (d, J = 8.8 Hz, 2H); 7.52 (m, 1H); 7.57-7.62 (m, 2H); 7.75-7.82 (m, 3H); 7.98 (d, J = 8.4Hz, 1H); 8.11 (d, J = 8.16 Hz, 1H); 8.93 (s, 1H); 10.70 (s, 1H).\n\n\n\n\n\n\n \nExemple 13 : (S)-N-Hydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-benzenesulfonylamino]- 2-piperazin-1 -yl-propionamide. \nExample 13: (S) -N-Hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2-piperazin-1-yl-propionamide.\n\n\n\n\n\n\n \n13.1 : 4-{(S)-1-hydroxycarbamoyl-2-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-éthyl}- pipérazine-1 -carboxylate de benzyle: \nBenzyl 13.1: 4 - {(S) -1-hydroxycarbamoyl-2- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] ethyl} piperazine-1-carboxylate:\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 135mg ( 0,2 mmoles) de 4-{(S)-1-carboxy-2-[4-(2- méthyl-quinolin-4-ylméthoxybenzènesulfonylamino]-éthyl}-pipérazine-1 -carboxylate de benzyle (préparé comme décrit en 10.6), 1 15mg (82%) de 4-{(S)-1-hydroxycarbamoyl-2-[4-(2-méthyl-quinolin- \n\n 4-ylméthoxy)-benzènesulfonylannino]-éthyl}-pipérazine-1-carboxylate de benzyle sont obtenus sous forme d'un solide blanc de point de fusion 162\n0\nC. \nIn a similar manner to Example 3.8, from 135 mg (0.2 mmol) of 4 - {(S) -1-carboxy-2- [4- (2-methyl-quinolin-4-ylmethoxybenzenesulfonylamino] -ethyl} benzyl -piperazine-1-carboxylate (prepared as described in 10.6), 15mg (82%) of 4 - {(S) -1-hydroxycarbamoyl-2- [4- (2-methyl-quinolin)}  Benzyl 4-ylmethoxy) -benzenesulfonylannino] ethyl} -piperazine-1-carboxylate are obtained in the form of a white solid having a melting point of 162 \n°\n C.\n\n\n\n\n\n\n \n13.2 : (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-pipérazin-1-yl- propionamide \n13.2: (S) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2-piperazin-1-yl-propionamide\n\n\n\n\n\n\n \n 90mg (0,15 mmoles) de 4-{(S)-1-hydroxycarbamoyl-2-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-éthyl}-pipérazine-1-carboxylate de benzyle sont placés en solution dans 5ml de dichlorométhane et 5ml d' acide trifluoroacétique. Le milieu réactionnel est ensuite agité à température ambiante pendant 96h. Après évaporation de l'acide trifluoroacétique, le résidu est repris 5ml de la solution aqueuse saturée d'hydrogénocarbonate de sodium et extrait au n-butanol. La phase organique est lavée à l'eau puis par une solution aqueuse saturée de chlorure de sodium, séchée sur sulfate de magnésium filtrée et concentrée sous vide. Le produit brut obtenu est repris dans un mélange heptane/acétate d'éthyle 50/50, agité pendant 1 h puis filtré et séché sous vide. 50mg (70%) de (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-pipérazin-1-yl- propionamide sont obtenus sous forme d'un solide beige de point de fusion 225\n0\nC. \n90 mg (0.15 mmol) of benzyl 4 - {(S) -1-hydroxycarbamoyl-2- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -ethyl} -piperazine-1-carboxylate are placed in solution in 5 ml of dichloromethane and 5 ml of trifluoroacetic acid. The reaction medium is then stirred at room temperature for 96h. After evaporation of the trifluoroacetic acid, the residue is taken up in 5 ml of saturated aqueous sodium hydrogencarbonate solution and extracted with n-butanol. The organic phase is washed with water and then with a saturated aqueous solution of sodium chloride, dried over magnesium sulfate filtered and concentrated in vacuo. The crude product obtained is taken up in a 50/50 heptane / ethyl acetate mixture, stirred for 1 h, then filtered and dried under vacuum. 50 mg (70%) of (S) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2-piperazin-1-yl-propionamide are obtained in the form of a beige solid of melting point 225 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,35-2,45 (m, 4H); 2,67 (s, 3H); 2,70 (m, 4H); 2,80-3,00 (m, 2H); 3,15 (s, 1 H); 5,72 (s, 2H); 7,35 (d, J=8,6Hz, 2H); 7,70-7,80 (m, 3H); 7,98 (d, J=8,4Hz, 1 H); 8,12 (d, J=8,2Hz, 1 H). \n \n1\n H NMR (δ, DMSO): 2.35-2.45 (m, 4H); 2.67 (s, 3H); 2.70 (m, 4H); 2.80-3.00 (m, 2H); 3.15 (s, 1H); 5.72 (s, 2H); 7.35 (d, J = 8.6 Hz, 2H); 7.70-7.80 (m, 3H); 7.98 (d, J = 8.4Hz, 1H); 8.12 (d, J = 8.2 Hz, 1H).\n\n\n\n\n\n\n \nExemple 14 : chlorhydrate de (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2- méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propionamide. \nExample 14: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide hydrochloride.\n\n\n\n\n\n\n \n0,2ml (1 ,3 mmoles) d'une solution d'acide chlorhydrique dans l'isopropanol de concentration 5-6N sont ajoutés à une solution de 301 mg (0,5 mmoles) de (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin- 1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propionamide (préparé comme décrit dans l'exemple 14) dans 10ml d'isopropanol. Après agitation à température ambiante pendant 1 h, le produit précipite. Par filtration, 927mg du chlorhydrate de (S)-N-hydroxy-2-(4-méthanesulfonyl- pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propionamide sont obtenus sous forme d'une poudre blanche. Ce solide est recristallisé dans un mélange isopropanol- eau 30ml / 5ml. 176mg (52%) du chlorhydrate de (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)- 3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propionamide sont obtenus sous forme d'une poudre blanche de point de fusion 209\n0\nC. \n0.2 ml (1.3 mmol) of a solution of hydrochloric acid in isopropanol of concentration 5-6N are added to a solution of 301 mg (0.5 mmol) of (S) -N-hydroxy-2 (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide (prepared as described in Example 14) in 10 ml of isopropanol. After stirring at room temperature for 1 hour, the product precipitates. By filtration, 927 mg of (S) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide hydrochloride are obtained in the form of a white powder. This solid is recrystallized from an isopropanol / water mixture 30 ml / 5 ml. 176 mg (52%) of (S) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) - 3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] hydrochloride propionamide are obtained in the form of a white powder having a melting point of 209 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,67 (m, 4H); 2,87 (s, 3H); 2,93 (s, 3H); 3,00-3,15 (m, 4H); 3,22 (m, 1 H); 3,35- 3,90 (m, 2H); 5,94 (s, 2H); 7,42 (d, J=8,7Hz, 2H); 7,64 (m, 1 H); 7,83-7,90 (m, 3H); 7,98 (m, 1 H); 8,05 (m, 1 H); 8,30 (d, J=7,6Hz; 1 H); 8,38 (d, J=8,5Hz, 1 H); 9,00 (m, 1 H); 10,75 (m, 1 H). \n \n1\n H NMR (δ, DMSO): 2.67 (m, 4H); 2.87 (s, 3H); 2.93 (s, 3H); 3.00-3.15 (m, 4H); 3.22 (m, 1H); 3.35- 3.90 (m, 2H); 5.94 (s, 2H); 7.42 (d, J = 8.7 Hz, 2H); 7.64 (m, 1H); 7.83-7.90 (m, 3H); 7.98 (m, 1H); 8.05 (m, 1H); 8.30 (d, J = 7.6 Hz, 1H); 8.38 (d, J = 8.5 Hz, 1H); 9.00 (m, 1H); 10.75 (m, 1H).\n\n\n\n\n\n\n \nExemple 15 : 3-{4-[(S)-2-hydroxycarbamoyl-2-(4-méthanesulfonyl-pipérazin-1-yl)- éthylsulfamoyl]-phénoxyméthyl}-2-méthyl-indole-1-carboxylate de tert-butyle , di trifluoroacétate. \n\n 15.1 : 3-{4-[(S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-2-méthoxycarbonyl-éthylsulfamoyl]- phénoxyméthyl}-2-méthyl-indole-1-carboxylate de tert-butyle \nExample 15: tert-Butyl 3- {4 - [(S) -2-hydroxycarbamoyl-2- (4-methanesulfonyl-piperazin-1-yl) -ethylsulfamoyl] -phenoxymethyl} -2-methylindole-1-carboxylate , di trifluoroacetate.  15.1: tert-butyl 3- {4 - [(S) -2- (4-methanesulfonyl-piperazin-1-yl) -2-methoxycarbonyl-ethylsulfamoyl] phenoxymethyl} -2-methylindole-1-carboxylate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 11.1 , à partir de 400mg (0,95 mmoles) de (S)-3-(4-hydroxy- benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle (préparé comme décrit dans l'exemple 5.1 ) et de 248mg (0,95 mmoles) de 3-hydroxyméthyl-2-méthyl-indole-1- carboxylate de tert-butyle commercial, 326mg (52%) de 3-{4-[(S)-2-(4-méthanesulfonyl-pipérazin-1-yl)- 2-méthoxycarbonyl-éthylsulfamoyl]-phénoxyméthyl}-2-méthyl-indole-1-carboxylate de tert-butyle sont obtenus sous forme d'une poudre beige. 15.2 : 3-{4-[(S)-2-carboxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-éthylsulfamoyl]-phénoxymethyl}-2- méthyl-indole-1 -carboxylate de tert-butyle \n In a manner analogous to Example 11.1, from 400 mg (0.95 mmol) of (S) -3- (4-hydroxybenzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate. methyl (prepared as described in Example 5.1) and 248 mg (0.95 mmol) of commercial tert-butyl 3-hydroxymethyl-2-methyl-indole-1-carboxylate, 326 mg (52%) of 3- {4 Tert-Butyl [(S) -2- (4-methanesulfonyl-piperazin-1-yl) -2-methoxycarbonyl-ethylsulfamoyl] -phenoxymethyl} -2-methyl-indole-1-carboxylate are obtained in the form of a beige powder. 15.2: 3- {4 - [(S) -2-carboxy-2- (4-methanesulfonyl-piperazin-1-yl) -ethylsulfamoyl] -phenoxymethyl} -2-methylindole-1-tert-butylcarboxylate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 325mg (0,5 mmoles) de 3-{4-[(S)-2-(4- méthanesulfonyl-pipérazin-1-yl)-2-méthoxycarbonyl-éthylsulfamoyl]-phénoxyméthyl}-2-méthyl-indole- 1 -carboxylate de tert-butyle, 179mg (100%) de 3-{4-[(S)-2-carboxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-éthylsulfamoyl]-phénoxyméthyl}-2-méthyl-indole-1 -carboxylate de tert-butyle sont obtenus sous forme d'une poudre jaune. \n Analogous to Example 3.7, from 325 mg (0.5 mmol) of 3- {4 - [(S) -2- (4-methanesulfonyl-piperazin-1-yl) -2-methoxycarbonyl-ethylsulfamoyl] tert-Butylphenylphenol-2-methyl-indole-1-carboxylate, 179 mg (100%) of 3- {4 - [(S) -2-carboxy-2- (4-methanesulfonyl-piperazin-1-yl) tert-butyl-ethylsulfamoyl] -phenoxymethyl-2-methyl-indole-1-carboxylate are obtained in the form of a yellow powder.\n\n\n\n\n\n\n \n15.3 : Ditrifluoroacétate de 3-{4-[(S)-2-hydroxycarbamoyl-2-(4-méthanesulfonyl-pipérazin-1-yl)- éthylsulfamoyl]-phénoxymethyl}-2-méthyl-indole-1 -carboxylate de tert-butyle \n15.3: 3- {4 - [(S) -2-Hydroxycarbamoyl-2- (4-methanesulfonyl-piperazin-1-yl) -ethylsulfamoyl] -phenoxymethyl} -2-methylindole-1-carboxylate trifluoroacetate of tert- butyl\n\n\n\n\n\n\n \n45mg (0,3 mmoles) de O-tert-butyldiméthylsilylhydroxylamine en solution dans 1 ml de diméthylformamide sont ajoutés à une solution de 179mg (0,3 mmoles) de 3-{4-[(S)-2-carboxy-2-(4- méthanesulfonyl-pipérazin-1-yl)-éthylsulfamoyl]-phénoxymethyl}-2-méthyl-indole-1 -carboxylate de tert- butyle, 41 mg (0,3 mmoles) de 1-hydroxybenzotriazole et 58mg (0,3 mmoles) du chlorhydrate de 1- éthyl-3-(3-diméthylaminopropyl) carbodiimide dans 3ml de diméthylformamide. Le mélange réactionnel est agité 18h à température ambiante. Après addition d'eau puis extraction à l'acétate d'éthyle, les phases organiques sont rassemblées, lavées avec une solution saturée d'hydrogénocarbonate de sodium puis séchées sur sulfate de sodium, filtrées et évaporées. Le résidu est purifié par HPLC préparative (colonne Gemini C6 phenyl, 150x3mm, 3μm ; détecteur UV : 190- 420nm ; débit : 0 ,3ml/mn ; solvant A : CH\n3\nCN + 0,02% acide trifluoroacétique ; solvant B : eau + 0,02% acide trifluoroacétique). \n45 mg (0.3 mmol) of O-tert-butyldimethylsilylhydroxylamine dissolved in 1 ml of dimethylformamide are added to a solution of 179 mg (0.3 mmol) of 3- {4 - [(S) -2-carboxy-2- Tert-butyl (4-methanesulfonyl-piperazin-1-yl) -ethylsulfamoyl] -phenoxymethyl-2-methyl-indole-1-carboxylate, 41 mg (0.3 mmol) of 1-hydroxybenzotriazole and 58 mg (0.3 mmol) of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride in 3 ml of dimethylformamide. The reaction mixture is stirred for 18h at room temperature. After addition of water and extraction with ethyl acetate, the organic phases are combined, washed with saturated sodium hydrogencarbonate solution and then dried over sodium sulfate, filtered and evaporated. The residue is purified by preparative HPLC (Gemini C6 phenyl column, 150x3mm, 3μm, UV detector: 190-420nm, flow rate: 0.3ml / min, solvent A: CH \n3\n CN + 0.02% trifluoroacetic acid, solvent B: water + 0.02% trifluoroacetic acid).\n\n\n\n\n\n\n \nGradient : \nGradient:\n\n\n\n\n\n\n \n Temps Composition \n Composition time\n\n\n\n\n\n\n \n 0.0 min A = 5% B = 95% \n 0.0 min A = 5% B = 95%\n\n\n\n\n\n\n \n 20.0 min A = 98% B = 2% \n 20.0 min A = 98% B = 2%\n\n\n\n\n\n\n \n30.0 min A = 98% B = 2% \n30.0 min A = 98% B = 2%\n\n\n\n\n\n\n \n Temps de rétention : 14,6mn, M + 1 = 666,1. \n Retention time: 14.6 min, M + 1 = 666.1.\n\n\n\n\n\n\n \n Après concentration des différentes fractions, 21 mg (10%) de ditrifluoroacétate de 3-{4-[(S)-2- hydroxycarbamoyl-2-(4-méthanesulfonyl-pipérazin-1-yl)-éthylsulfamoyl]-phénoxyméthyl}-2-méthyl- indole-1 -carboxylate de tert-butyle sont obtenus. \n\n Exemple 16 : (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(quinolin-4-yl méthoxy)-benzènesulfonylamino]-propionamide. \nAfter concentration of the various fractions, 21 mg (10%) of 3- {4 - [(S) -2-hydroxycarbamoyl-2- (4-methanesulfonyl-piperazin-1-yl) -ethylsulfamoyl] -phenoxymethyl} ditrifluoroacetate 1-methyl-indole-1-tert-butylcarboxylate are obtained.  Example 16: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n16.1 : (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(quinolin-4-ylméthoxy)-benzènesulfonylamino]- propanoate de méthyle \n16.1: Methyl (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 5.2, à partir de 440mg (2,5 mmoles) de 4-chlorométhyl-quinoline et de 950mg (2,2 mmoles) de (S)-3-(4-hydroxy-benzènesulfonylamino)-2-(4-méthanesulfonyl-piperazin- 1-yl)-propanoate de méthyle (préparé comme décrit en 5.1 ), 550mg (43%) de (S)-2-(4- méthanesulfonyl-pipérazin-1-yl)-3-[4-(quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle sont obtenus sous forme d'une huile incolore. \n In a manner analogous to Example 5.2, starting with 440 mg (2.5 mmol) of 4-chloromethylquinoline and 950 mg (2.2 mmol) of (S) -3- (4-hydroxy-benzenesulfonylamino) -2 Methyl (4-methanesulfonyl-piperazin-1-yl) -propanoate (prepared as described in 5.1), 550 mg (43%) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- Methyl 4- (quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoate are obtained as a colorless oil.\n\n\n\n\n\n\n \n16.2 : acide (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoïque \n16.2: (S) -2- (4-Methanesulfonyl-piperazin-1-yl) -3- [4- (quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 550mg (1 ,0 mmole) de (S)-2-(4-méthanesulfonyl- pipérazin-1-yl)-3-[4-(quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle, 450mg (83%) d' acide (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoïque sont obtenus sous forme d'un solide blanc . \n Analogous to Example 3.7, from 550 mg (1.0 mmol) of (S) -2- (4-methanesulfonylpiperazin-1-yl) -3- [4- (quinolin-4-ylmethoxy)). methyl benzenesulfonylamino] propanoate, 450 mg (83%) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (quinolin-4-ylmethoxy) benzenesulfonylamino] - propanoic are obtained in the form of a white solid.\n\n\n\n\n\n\n \n16.3 : (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(quinolin-4-ylméthoxy)- benzènesulfonylaminoj-propionamide \n16.3: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 450mg (0,8 mmoles) d' acide (S)-2-(4- méthanesulfonyl-pipérazin-1-yl)-3-[4-(quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoïque 260mg (56%) de (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide sont obtenus sous forme d'un solide blanc de point de fusion 18O\n0\nC. \nIn a manner similar to Example 3.8, from 450 mg (0.8 mmol) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (quinolin-4-) ylmethoxy) -benzenesulfonylamino] -propanoic acid 260mg (56%) (S) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (quinolin-4-ylmethoxy) benzenesulfonylamino] -propionamide are obtained in the form of a white solid of melting point 18O \n0\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,52-2,54 (m, 4H); 2,84 (s, 3H); 2,87 (m, 1 H); 2,97 (m, 1 H); 2,98-3,05 (m, 4H), 3,11 (t, J=7Hz, 1 H); 5,78 (s, 2H); 7,34 (d, J=8,8Hz, 2H); 7,52 (m, 1 H); 7,66-7,72 (m, 2H); 7,78-7,84 (m, 3H); 8,10 (d, J=8,3Hz, 1 H); 8,19 (d, J=8,2Hz, 1 H); 8,93 (s, 1 H); 8,94 (s, 1 H); 10,67 (s, 1 H). Exemple 17 : (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide. \n \n1\n H NMR (δ, DMSO): 2.52-2.54 (m, 4H); 2.84 (s, 3H); 2.87 (m, 1H); 2.97 (m, 1H); 2.98-3.05 (m, 4H), 3.11 (t, J = 7Hz, 1H); 5.78 (s, 2H); 7.34 (d, J = 8.8 Hz, 2H); 7.52 (m, 1H); 7.66-7.72 (m, 2H); 7.78-7.84 (m, 3H); 8.10 (d, J = 8.3 Hz, 1H); 8.19 (d, J = 8.2 Hz, 1H); 8.93 (s, 1H); 8.94 (s, 1H); 10.67 (s, 1H). Example 17: (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n 17.1 : Sel de sodium de l'acide 4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonique \n 17.1: Sodium salt of 4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonic acid\n\n\n\n\n\n\n \n 100g (438 mmoles) du chlorhydrate de 4-chlorométhyl-2-méthyl-quinoline sont additionnés sur une solution de 77g (395 mmoles) du sel de sodium de l'acide 4-hydroxy-benzènesulfonique et de 84ml (84 mmoles) d'une solution aqueuse d'hydroxyde de sodium de concentration 1 M dans 800ml d'isopropanol. Le milieu réactionnel est chauffé à 7O\n0\nC pendant 5h puis à 4O\n0\nC pendant 18h. \n100 g (438 mmol) of 4-chloromethyl-2-methyl-quinoline hydrochloride are added to a solution of 77 g (395 mmol) of the sodium salt of 4-hydroxy-benzenesulfonic acid and 84 ml (84 mmol) of an aqueous solution of 1 M sodium hydroxide in 800 ml of isopropanol. The reaction medium is heated at 70 \n°\n C. for 5 h and then at 40 \n°\n C. for 18 h.\n\n\n\n\n\n\n \nAprès évaporation de l'isopropanol, le produit obtenu est filtré, rincé à l'isopropanol et à l'éther diéthylique puis séché sous vide. 114g (75%) du sel de sodium de l'acide 4-(2-méthyl-quinolin-4- ylméthoxy)-benzènesulfonique sont obtenus sous forme d'un solide blanc . \n\n17.2 : Chlorure de 4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonyle \nAfter evaporation of the isopropanol, the product obtained is filtered, rinsed with isopropanol and diethyl ether and then dried under vacuum. 114 g (75%) of the sodium salt of 4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonic acid are obtained as a white solid.  17.2: 4- (2-Methyl-quinolin-4-ylmethoxy) -benzenesulfonyl chloride\n\n\n\n\n\n\n \n 76g (216 mmoles) du sel de sodium de l'acide 4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonique dans 500ml de diméthylformamide sont additionnés goutte à goutte à une solution de 55ml (649 mmoles) de chlorure d'oxalyle dans 100ml de dichlorométhane, préalablement refroidie à -1O\n0\nC. Après addition, le milieu réactionnel est agité à température ambiante pendant 18h. Le milieu réactionnel est ensuite versé dans 11 de glace puis extrait à l'acétate d'éthyle. Les phases organiques sont rassemblées, lavées à l'eau puis avec une solution aqueuse saturée de chlorure de sodium, séchées de sulfate de magnésium, filtrées et concentrées sous vide. 77g (92%) du chlorhydrate de chlorure de 4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonyle sont obtenus sous forme d'un solide beige . \n76 g (216 mmol) of the sodium salt of 4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonic acid in 500 ml of dimethylformamide are added dropwise to a solution of 55 ml (649 mmol) of sodium chloride. oxalyl in 100ml of dichloromethane, previously cooled to -1O \n0\n C. After addition, the reaction mixture is stirred at room temperature for 18h. The reaction medium is then poured into ice and then extracted with ethyl acetate. The organic phases are combined, washed with water and then with saturated aqueous sodium chloride solution, dried over magnesium sulfate, filtered and concentrated in vacuo. 77 g (92%) of 4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonyl chloride hydrochloride are obtained as a beige solid.\n\n\n\n\n\n\n \n17.3 : benzyl-bis-(2-chloro-éthyl)-amine \n17.3: benzyl-bis- (2-chloro-ethyl) -amine\n\n\n\n\n\n\n \n 21g (152 mmoles) de carbonate de potassium puis 8ml (67 mmoles) de bromure de benzyle sont ajoutés à une solution de 10g (56 mmoles) de chlorhydrate de bis-(2-chloro-éthyl)-amine dans 130ml d'acétonitrile puis le milieu réactionnel est chauffé à 6O\n0\nC pendant 24h. Après filtration, le filtrat est concentré sous vide. Le résidu brut est purifié par chromatographie sur gel de silice élue avec un mélange heptane/acétate d'éthyle 90/10 pour donner 8,5g (65%) de benzyl-bis-(2-chloro-éthyl)-amine. \n21 g (152 mmol) of potassium carbonate and then 8 ml (67 mmol) of benzyl bromide are added to a solution of 10 g (56 mmol) of bis (2-chloroethyl) amine hydrochloride in 130 ml of acetonitrile then the reaction medium is heated at 60 \n°\n C. for 24 hours. After filtration, the filtrate is concentrated in vacuo. The crude residue is purified by chromatography on silica gel eluted with a 90/10 heptane / ethyl acetate mixture to give 8.5 g (65%) of benzyl-bis- (2-chloro-ethyl) -amine.\n\n\n\n\n\n\n \n17.4 : (S)-2-(4-benzyl-pipérazin-1-yl)-3-tert-butoxycarbonylamino-propanoate de méthyle \n17.4: methyl (S) -2- (4-benzylpiperazin-1-yl) -3-tert-butoxycarbonylamino-propanoate\n\n\n\n\n\n\n \nUne solution de 5,9g (23 mmoles) du chlorhydrate de (S)-2-amino-3-tert-butoxycarbonylamino- propanoate de méthyle commercial et de 9,6g (23 mmoles) de benzyl-bis-(2-chloro-éthyl)-amine dans 50ml de N,N-diisopropyléthylamine est chauffée à 127\n0\nC pendant 3h30. Après évaporation de la N, N- diisopropyléthylamine, le milieu réactionnel est hydrolyse puis extrait par de l'acétate d'éthyle. La phase organique est lavée par une solution aqueuse d'hydroxyde de sodium de concentration 1 N, par de l'eau puis séchée sur sulfate de magnésium, filtrée et concentrée sous vide. Le produit brut obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane/acétate d'éthyle 50/50. 8,9g (64%) de (S)-2-(4-benzyl-pipérazin-1-yl)-3-tert-butoxycarbonylamino-propanoate de méthyle sont obtenus sous forme d'une huile jaune. 17.5 : trichlorhydrate de (S)-3-amino-2-(4-benzyl-pipérazin-1-yl)-propanoate de méthyle \nA solution of 5.9 g (23 mmol) of commercial methyl (S) -2-amino-3-tert-butoxycarbonylaminopropanoate hydrochloride and 9.6 g (23 mmol) of benzyl-bis (2-chloro) ethyl) amine in 50 ml of N, N-diisopropylethylamine is heated at 127 \n°\n C. for 3 h 30 min. After evaporation of the N, N-diisopropylethylamine, the reaction medium is hydrolyzed and then extracted with ethyl acetate. The organic phase is washed with an aqueous sodium hydroxide solution of 1 N concentration, with water then dried over magnesium sulfate, filtered and concentrated in vacuo. The crude product obtained is purified by chromatography on silica gel eluted with a 50/50 heptane / ethyl acetate mixture. 8.9 g (64%) of methyl (S) -2- (4-benzyl-piperazin-1-yl) -3-tert-butoxycarbonylamino-propanoate are obtained in the form of a yellow oil. 17.5: Methyl (S) -3-amino-2- (4-benzylpiperazin-1-yl) -propanoate trihydrochloride\n\n\n\n\n\n\n \n 8,9g ( 23,5 mmoles) de (S)-2-(4-benzyl-pipérazin-1-yl)-3-tert-butoxycarbonylamino-propanoate de méthyle sont placés en solution dans 60ml de méthanol et dans 20ml d'acide chlorhydrique isopropanolique de concentration 5-6N . Le milieu réactionnel est agité à 4O\n0\nC pendant 18h puis concentré sous vide. 9,0g (100%) du trichlorhydrate de (S)-3-amino-2-(4-benzyl-pipérazin-1-yl)- propanoate de méthyle sont obtenus sous forme d'un solide beige. \n8.9 g (23.5 mmol) of methyl (S) -2- (4-benzyl-piperazin-1-yl) -3-tert-butoxycarbonylamino-propanoate are placed in solution in 60 ml of methanol and in 20 ml of isopropanolic hydrochloric acid 5-6N concentration. The reaction medium is stirred at 40 \n°\n C. for 18 h and then concentrated in vacuo. 9.0 g (100%) of methyl (S) -3-amino-2- (4-benzylpiperazin-1-yl) -propanoic trihydrochloride are obtained in the form of a beige solid.\n\n\n\n\n\n\n \n17.6 : (S)-2-(4-benzyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]- propanoate de méthyle. \n17.6: (S) -2- (4-Benzyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionic acid methyl ester.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.6, à partir de 1 ,0g (2,6 mmoles) du trichlorhydrate de (S)-3-amino- 2-(4-benzyl-pipérazin-1-yl)-propanoate de méthyle et de 1 ,1g (2,8 mmoles) de chlorure de 4-(2- \n\n méthyl-quinolin-4-ylméthoxy)-benzènesulfonyle sous forme de chlorohydrate, 750mg (50%) de (S)-2- (4-benzyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle sont obtenus sous forme d'un solide beige. 17.7 : acide (S)-2-(4-benzyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylaminoj-propanoïque. \nAnalogously to Example 3.6, from 1.0 g (2.6 mmol) of methyl (S) -3-amino-2- (4-benzylpiperazin-1-yl) -propanoate trihydrochloride and of 1.1 g (2.8 mmol) of 4- (2-  methyl-quinolin-4-ylmethoxy) -benzenesulfonyl chlorohydrate form, 750mg (50%) (S) -2- (4-benzyl-piperazin-1-yl) -3- [4- (2-methyl-quinoline) Methyl 4-ylmethoxy) -benzenesulfonylamino] -propanoate are obtained as a beige solid. 17.7: (S) -2- (4-Benzyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] propanoic acid.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 750mg (1 ,3 mmoles) de (S)-2-(4-benzyl-pipérazin-1- yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle, 680mg (93%) d'acide (S)-2-(4-benzyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]- propanoïque sont obtenus sous forme d'un solide blanc. \n In a similar manner to Example 3.7, from 750 mg (1.3 mmol) of (S) -2- (4-benzylpiperazin-1-yl) -3- [4- (2-methyl-quinolin) Methyl 4-ylmethoxy) -benzenesulfonylamino] -propanoate, 680 mg (93%) of (S) -2- (4-benzylpiperazin-1-yl) -3- [4- (2-methyl-quinolin) 4-ylmethoxy) -benzenesulfonylamino] propanoic acid are obtained in the form of a white solid.\n\n\n\n\n\n\n \n17.8 : (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide. \n17.8: (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 680mg (1 ,2 mmoles) d'acide (S)-2-(4-benzyl- pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoique, 250mg\n In a similar manner to Example 3.8, from 680 mg (1.2 mmol) of (S) -2- (4-benzylpiperazin-1-yl) -3- [4- (2-methyl) -2- quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoic, 250mg\n\n\n\n\n\n\n \n(36%) de (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide sont obtenus sous forme d'un solide blanc de point de fusion\n(36%) (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide are obtained in the form of a white solid of melting point\n\n\n\n\n\n\n \n188\n0\nC. \n188 \n0\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,33 (m, 4H); 2,49 (m, 4H); 2,73 (s, 3H); 2,80-2,90 (m, 1 H); 3,00-3,10 (m, 2H); 2,46 (m, 2H); 5,77 (s, 2H); 7,25-7,40 (m, 7H); 7,50(m, 1 H); 7,61-7,67 (m, 2H); 7,78-7,85 (m, 3H); 8,04\n \n1\n H NMR (δ, DMSO): 2.33 (m, 4H); 2.49 (m, 4H); 2.73 (s, 3H); 2.80-2.90 (m, 1H); 3.00-3.10 (m, 2H); 2.46 (m, 2H); 5.77 (s, 2H); 7.25-7.40 (m, 7H); 7.50 (m, 1H); 7.61-7.67 (m, 2H); 7.78-7.85 (m, 3H); 8.04\n\n\n\n\n\n\n \n(d, J=8Hz, 1 H); 8,17 (d, J=8,2Hz, 1 H); 8,95 (s, 1 H); 10,65 (s, 1 H). \n(d, J = 8Hz, 1H); 8.17 (d, J = 8.2 Hz, 1H); 8.95 (s, 1H); 10.65 (s, 1H).\n\n\n\n\n\n\n \nExemple 18 : (S)-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-N-hydroxy-3-[4-(2-méthyl-quinolin-4- ylméthoxy)-benzènesulfonylamino]-propionamide. \nExample 18: (S) -2- [4- (4-Fluoro-benzyl) -piperazin-1-yl] -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n18.1 : bis-(2-chloro-éthyl)-(4-fluoro-benzyl)-amine \n18.1: bis- (2-chloro-ethyl) - (4-fluoro-benzyl) -amine\n\n\n\n\n\n\n \n De manière analogue à l'exemple 17.3, à partir de 5g (28 mmoles) du chlorhydrate de bis-(2-chloro- éthyl)-amine et de 3,8ml (31 mmoles) de 1-bromométhyl-4-fluoro-benzène, 6,9g (98%) de bis-(2- chloro-éthyl)-(4-fluoro-benzyl)-amine sont obtenus. \n In a similar manner to Example 17.3, from 5 g (28 mmol) of bis (2-chloroethyl) amine hydrochloride and 3.8 ml (31 mmol) of 1-bromomethyl-4-fluoro-benzene 6.9 g (98%) of bis- (2-chloro-ethyl) - (4-fluoro-benzyl) -amine are obtained.\n\n\n\n\n\n\n \n18.2 : (S)-3-tert-butoxycarbonylamino-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-propanoate de méthyle\n18.2: Methyl (S) -3-tert-butoxycarbonylamino-2- [4- (4-fluoro-benzyl) -piperazin-1-yl] -propanoate\n\n\n\n\n\n\n \nDe manière analogue à l'exemple 17.4, à partir de 7,1g (28 mmoles) du chlorhydrate de (S)-2-amino- 3-tert-butoxycarbonylamino-propanoate de méthyle et de 6,9g (28 mmoles) de bis-(2-chloro-éthyl)-(4- fluoro-benzyl)-amine, 5,3g (48%) de (S)-3-tert-butoxycarbonylamino-2-[4-(4-fluoro-benzyl)-pipérazin-1- yl]-propanoate de méthyle sont obtenus sous forme d'une huile. \nIn a manner analogous to Example 17.4, starting from 7.1 g (28 mmol) of methyl (S) -2-amino-3-tert-butoxycarbonylamino-propanoate hydrochloride and 6.9 g (28 mmol) of bis - (2-chloro-ethyl) - (4-fluoro-benzyl) -amine, 5.3 g (48%) of (S) -3-tert-butoxycarbonylamino-2- [4- (4-fluoro-benzyl) - Methyl piperazin-1-yl] -propanoate is obtained in the form of an oil.\n\n\n\n\n\n\n \n18.3 : trichlorhydrate de (S)-3-amino-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-propanoate de méthyle\n18.3: Methyl (S) -3-amino-2- [4- (4-fluoro-benzyl) -piperazin-1-yl] -propanoate trihydrochloride\n\n\n\n\n\n\n \nDe manière analogue à l'exemple 17.5, à partir de 5,3g (13,4 mmoles) de (S)-3-tert- butoxycarbonylamino-2-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propanoate de méthyle, 5,4g (100%) de \n\n trichlorhydrate de (S)-3-amino-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-propanoate de méthyle sont obtenus sous forme d'un solide beige. \nAnalogous to Example 17.5, from 5.3 g (13.4 mmol) of (S) -3-tert-butoxycarbonylamino-2- [4- (4-fluoro-benzyl) -piperazin-1-yl) ] methylpropanoate, 5.4g (100%) of  Methyl (S) -3-amino-2- [4- (4-fluoro-benzyl) -piperazin-1-yl] -propanoate trihydrochloride are obtained as a beige solid.\n\n\n\n\n\n\n \n18.4 : (S)-2-[4-(4-fluoro-benzyl)-piperazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylaminoj-propanoate de méthyle \n18.4 Methyl (S) -2- [4- (4-fluoro-benzyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.6, à partir de 1 ,5g ( 3,7 mmoles) du trichlorhydrate de (S)-3- amino-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-propanoate de méthyle et de 1 ,6g (4, I mmoles) de chlorure de 4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonyle chlorohydrate (préparé comme décrit en 17.2), 1 ,0g (46%) de (S)-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n Analogously to Example 3.6, from 1.5 g (3.7 mmol) of (S) -3-amino-2- [4- (4-fluoro-benzyl) -piperazin-1-yl trihydrochloride Methyl propanoate and 1.6 g (4.1 mmol) of 4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonyl chloride hydrochloride (prepared as described in 17.2), 1.0 g (46%) Methyl (S) -2- [4- (4-fluoro-benzyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoate are obtained in the form of a white solid.\n\n\n\n\n\n\n \n18.5 : acide (S)-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoïque \n18.5: (S) -2- [4- (4-Fluoro-benzyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 1 ,1g (1 ,7 mmoles) de (S)-2-[4-(4-fluoro-benzyl)- pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle 1 ,0g (100%) d'acide (S)-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoïque sont obtenus sous forme d'un solide blanc. \n Analogous to Example 3.7, from 1.1 g (1.7 mmol) of (S) -2- [4- (4-fluoro-benzyl) -piperazin-1-yl] -3- [4] Methyl (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] propanoate 1.0 g (100%) of (S) -2- [4- (4-fluoro-benzyl) -piperazin-1- (4-fluoro-benzyl) -piperazin) yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) benzenesulfonylamino] propanoic acid are obtained as a white solid.\n\n\n\n\n\n\n \n18.6 : (S)-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylaminoj-propionamide \n18.6: (S) -2- [4- (4-Fluoro-benzyl) -piperazin-1-yl] -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, 990mg (1 ,7 mmoles) d'acide (S)-2-[4-(4-fluoro-benzyl)- pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoique, 330mg\n Analogous to Example 3.8, 990 mg (1.7 mmol) of (S) -2- [4- (4-fluoro-benzyl) -piperazin-1-yl] -3- [4- methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] propanoic acid, 330mg\n\n\n\n\n\n\n \n(33%) de (S)-2-[4-(4-fluoro-benzyl)-pipérazin-1-yl]-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide sont obtenus sous forme d'un solide blanc de point de fusion 18O\n0\nC. \n(33%) (S) -2- [4- (4-Fluoro-benzyl) -piperazin-1-yl] -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) - benzenesulfonylamino] -propionamide are obtained in the form of a white solid of melting point 18O \n0\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,20-2-30 (m, 4H); 2,35-2,45 (m, 4H); 2,66 (s, 3H); 2,72-2,80 (m, 1 H); 2,87-3,00 (m, 2H); 3,38 (s, 2H); 5,70 (s, 2H); 7,10 (t, J=8,8Hz, 2H); 7,26-7,33 (m, 4H); 7,56-7,60(m, 2H); 7,73- 7,78 (m, 3H); 7,97 (d, J=8,4Hz, 1 H); 8,10 (d, J=8,2Hz, 1 H). Exemple 19 : (S)-2-(4-éthyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-yl-méthoxy)- benzènesulfonylamino]-propionamide. \n \n1\n H NMR (δ, DMSO): 2,20-2-30 (m, 4H); 2.35-2.45 (m, 4H); 2.66 (s, 3H); 2.72-2.80 (m, 1H); 2.87-3.00 (m, 2H); 3.38 (s, 2H); 5.70 (s, 2H); 7.10 (t, J = 8.8 Hz, 2H); 7.26-7.33 (m, 4H); 7.56-7.60 (m, 2H); 7.73-7.78 (m, 3H); 7.97 (d, J = 8.4Hz, 1H); 8.10 (d, J = 8.2 Hz, 1H). Example 19: (S) -2- (4-Ethyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-yl-methoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n19.1 : bis-(2-chloro-éthyl)-éthyl-amine \n19.1: bis- (2-chloro-ethyl) -ethyl-amine\n\n\n\n\n\n\n \n 24ml (330 mmoles) de chlorure de thionyle sont additionnés goutte à goutte à une solution de 20g (150 mmoles) de 2-[éthyl-(2-hydroxy-éthyl)-amino]-éthanol dans 200ml de dichlorométhane préalablement refroidie à O\n0\nC puis le milieu réactionnel est agité à température ambiante pendant 2Oh. Après addition d'une solution aqueuse saturée d'hydrogénocarbonate de sodium, le produit est extrait au dichlorométhane. La phase organique obtenue est ensuite lavée à l'eau, séchée sur sulfate de magnésium, filtrée et concentrée sous vide. 19,5g (76%) de bis-(2-chloro-éthyl)-éthyl-amine sous la forme d'une huile. \n\n 19.2 : (S)-3-tert-butoxycarbonylamino-2-(4-éthyl-pipérazin-1-yl)-propanoate de méthyle\n24 ml (330 mmol) of thionyl chloride are added dropwise to a solution of 20 g (150 mmol) of 2- [ethyl- (2-hydroxyethyl) amino] ethanol in 200 ml of dichloromethane previously cooled to \n0.degree.\n And then the reaction medium is stirred at room temperature for 20 h. After addition of a saturated aqueous sodium hydrogencarbonate solution, the product is extracted with dichloromethane. The organic phase obtained is then washed with water, dried over magnesium sulfate, filtered and concentrated in vacuo. 19.5 g (76%) of bis (2-chloroethyl) ethylamine in the form of an oil.  19.2: Methyl (S) -3-tert-butoxycarbonylamino-2- (4-ethyl-piperazin-1-yl) -propanoate\n\n\n\n\n\n\n \nUne solution de 5,0g (19,6 mmoles) de chlorhydrate de (S)-2-amino-3-tert-butoxycarbonylannino- propanoate de méthyle commercial et 3,3g (19,6 mmoles) de bis-(2-chloro-éthyl)-éthyl-amine dans 50ml de N,N-diisopropyléthylamine est chauffée à 127\n0\nC pendant 5h. Après évaporation d'un maximum de diisopropyléthylamine, le milieu réactionnel est dilué par de l'acétate d'éthyle, lavé avec une solution aqueuse d'hydroxyde de sodium de concentration 1 N. La phase organique obtenue est ensuite lavée à l'eau, séchée sur sulfate de magnésium, filtrée et concentrée sous vide. Le produit brut obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane / acétate d'éthyle 30/70. 2,5g (40%) de (S)-3-tert-butoxycarbonylamino-2-(4-éthyl-pipérazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'une huile. \nA solution of 5.0 g (19.6 mmol) of commercial methyl (S) -2-amino-3-tert-butoxycarbonylaminopropanoate hydrochloride and 3.3 g (19.6 mmol) of bis (2-chloro) -ethyl-ethyl-amine in 50ml of N, N-diisopropylethylamine is heated at 127 \n0\n C for 5h. After evaporation of a maximum of diisopropylethylamine, the reaction medium is diluted with ethyl acetate, washed with an aqueous solution of sodium hydroxide of 1N concentration. The organic phase obtained is then washed with water, dried over magnesium sulphate, filtered and concentrated in vacuo. The crude product obtained is purified by chromatography on silica gel eluted with a 30/70 heptane / ethyl acetate mixture. 2.5 g (40%) of methyl (S) -3-tert-butoxycarbonylamino-2- (4-ethyl-piperazin-1-yl) -propanoate are obtained in the form of an oil.\n\n\n\n\n\n\n \n19.3 : trichlorhydrate de (S)-3-amino-2-(4-éthyl-pipérazin-1-yl)-propanoate de méthyle \n19.3: methyl (S) -3-amino-2- (4-ethyl-piperazin-1-yl) -propanoic trihydrochloride\n\n\n\n\n\n\n \n 2,5g (7,9 mmoles) de (S)-3-tert-butoxycarbonylamino-2-(4-éthyl-pipérazin-1-yl)-propanoate de méthyle sont placés dans 20ml de méthanol et 10ml d'acide chlorhydrique isopropanolique de concentration 5-6N. Le milieu réactionnel est chauffé à 4O\n0\nC pendant 3h puis évaporé à sec. Le résidu est repris dans 50ml d'éthanol, agité 1 h à température ambiante puis filtré. 1 ,4g (54%) de trichlorhydrate de (S)-3-amino-2-(4-éthyl-pipérazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'un solide beige. \n2.5 g (7.9 mmol) of methyl (S) -3-tert-butoxycarbonylamino-2- (4-ethyl-piperazin-1-yl) -propanoate are placed in 20 ml of methanol and 10 ml of isopropanol hydrochloric acid. 5-6N concentration. The reaction medium is heated at 40 \n°\n C. for 3 h and then evaporated to dryness. The residue is taken up in 50 ml of ethanol, stirred for 1 h at room temperature and then filtered. 1.4 g (54%) of methyl (S) -3-amino-2- (4-ethyl-piperazin-1-yl) -propanoic trihydrochloride are obtained in the form of a beige solid.\n\n\n\n\n\n\n \n19.4 : (S)-2-(4-éthyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]- propanoate de méthyle \n19.4 Methyl (S) -2- (4-ethyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.6, à partir de 700mg ( 2,1 mmoles) du trichlorhydrate de (S)-3- amino-2-(4-éthyl-pipérazin-1-yl)-propanoate de méthyle et de 900mg (2,3 mmoles) du chlorhydrate de chlorure de 4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonyle (préparé comme décrit en 17.2), 740mg (67%) de (S)-2-(4-éthyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n In a manner analogous to Example 3.6, from 700 mg (2.1 mmol) of methyl (S) -3-amino-2- (4-ethyl-piperazin-1-yl) -propanoic trihydrochloride and 900 mg of (2.3 mmol) 4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonyl chloride hydrochloride (prepared as described in 17.2), 740 mg (67%) of (S) -2- (4-ethyl) Methyl -piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoate are obtained in the form of a white solid.\n\n\n\n\n\n\n \n19.5 : acide ((S)-2-(4-éthyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoïque \n19.5: ((S) -2- (4-ethyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir 740mg (1 ,4 mmoles) de (S)-2-(4-éthyl-pipérazin-1-yl)-3- [4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle, 630mg (87%) d'acide ((S)-2-(4-éthyl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]- propanoïque sont obtenus sous forme d'un solide blanc. \n Analogously to Example 3.7, from 740 mg (1.4 mmol) of (S) -2- (4-ethyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4) Methyl (methoxy) -benzenesulfonylamino] -propanoate, 630 mg (87%) of ((S) -2- (4-ethyl-piperazin-1-yl) -3- [4- (2-methyl-quinolin) 4-ylmethoxy) -benzenesulfonylamino] propanoic acid are obtained in the form of a white solid.\n\n\n\n\n\n\n \n19.6 : (S)-2-(4-éthyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylaminoj-propionamide \n19.6: (S) -2- (4-ethyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 630mg (1 ,2 mmoles) d'acide (S)-2-(4-éthyl- pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoique, 60mg (8%) \n\n de (S)-2-(4-éthyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-nnéthyl-quinolin-4-ylnnéthoxy)-benzène- sulfonylamino]-propionannide sont obtenus sous forme d'un solide blanc de point de fusion 15O\n0\nC. RMN \n1\nH (δ, DMSO) : 2,49 (s, 3H); 2,55-2,65 (m, 2H); 2,69 (s, 3H); 2,70-2,90 (m, 6H); 2,90-3,00 (m, 2H); 3,13 (t, J=7,3Hz, 1 H); 3,20-3,35 (m, 2H); 3,36 (s, 2H); 5,72 (s, 2H); 7,35 (d, J=8,9Hz, 2H); 7,58- 7,62 (m, 3H); 7,74-7,81 (m, 3H); 7,98 (d, J=7,9Hz, 1 H); 8,12 (d, J=8,3Hz, 1 H); 9,03 (s, 1 H), 10,82 (s, 1 H). \nIn a similar manner to Example 3.8, from 630 mg (1.2 mmol) of (S) -2- (4-ethylpiperazin-1-yl) -3- [4- (2-methyl) -2- quinolin-4-ylmethoxy) -benzenesulfonylamino] propanoic acid, 60mg (8%)  (S) -2- (4-ethyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionannide are obtained in the form of a white solid of melting point 150 \n°\n C. \n1\n H NMR (δ, DMSO): 2.49 (s, 3H); 2.55-2.65 (m, 2H); 2.69 (s, 3H); 2.70-2.90 (m, 6H); 2.90-3.00 (m, 2H); 3.13 (t, J = 7.3 Hz, 1H); 3.20-3.35 (m, 2H); 3.36 (s, 2H); 5.72 (s, 2H); 7.35 (d, J = 8.9Hz, 2H); 7.58-7.62 (m, 3H); 7.74-7.81 (m, 3H); 7.98 (d, J = 7.9Hz, 1H); 8.12 (d, J = 8.3 Hz, 1H); 9.03 (s, 1H), 10.82 (s, 1H).\n\n\n\n\n\n\n \nExemple 20 : (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]- 2-[4-(4-trifluorométhyl-benzyl)-pipérazin-1-yl]-propionamide. \nExample 20: (S) -N-Hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- (4- (4-trifluoromethyl-benzyl) -piperazin-1-yl] -propionamide.\n\n\n\n\n\n\n \n20.1 : bis-(2-chloro-éthyl)-(4-thfluorométhyl-benzyl)-amine \n20.1: bis- (2-chloro-ethyl) - (4-thfluoromethyl-benzyl) -amine\n\n\n\n\n\n\n \n De manière analogue à l'exemple 32.3, à partir 5,0g (28 mmoles) du chlorhydrate bis-(2-chloro-éthyl)- amine et de 7,4g (31 mmoles) de 1-bromométhyl-4-trifluorométhyl-benzène, 5g (59%) d'un mélange de bis-(2-chloro-éthyl)-(4-trifluorométhyl-benzyl)-amine sont obtenus sous forme d'une huile incolore. \n In a similar manner to Example 32.3, starting from 5.0 g (28 mmol) of bis (2-chloroethyl) amine hydrochloride and 7.4 g (31 mmol) of 1-bromomethyl-4-trifluoromethylbenzene. 5 g (59%) of a mixture of bis- (2-chloro-ethyl) - (4-trifluoromethyl-benzyl) -amine are obtained in the form of a colorless oil.\n\n\n\n\n\n\n \n20.2 : (S)-3-tert-butoxycarbonylamino-2-[4-(4-thfluorométhyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle \n20.2: Methyl (S) -3-tert-butoxycarbonylamino-2- [4- (4-thfluoromethyl-benzyl) -piperazin-1-yl] -propanoate\n\n\n\n\n\n\n \n Une solution de 4,2g (16,5 mmoles) du chlorhydrate de (S)-2-amino-3-tert-butoxycarbonylamino- propanoate de méthyle et 4,95g (16,5 mmoles) de bis-(2-chloro-éthyl)-(4-trifluorométhyl-benzyl)-amine dans 25ml de N,N-Diisopropyléthylamine est chauffée à 127\n0\nC pendant 6h. Après évaporation d'un maximum de diisopropyléthylamine, le milieu réactionnel est dilué avec de l'acétate d'éthyle et lavé par une solution aqueuse d'hydroxyde de sodium de concentration 1 N. La phase organique obtenue est lavée à l'eau, séchée sur sulfate de magnésium, filtrée et concentrée sous vide. Le résidu brut est purifié par chromatographie sur gel de silice élue avec un mélange heptane / acétate d'éthyle 60/40. 4,0g (55%) de (S)-3-tert-butoxycarbonylamino-2-[4-(4-trifluorométhyl-benzyl)-pipérazin-1-yl]- propanoate de méthyle sont obtenus sous forme d'une huile. \nA solution of 4.2 g (16.5 mmol) of methyl (S) -2-amino-3-tert-butoxycarbonylaminopropanoate hydrochloride and 4.95 g (16.5 mmol) of bis (2-chloro) ethyl) - (4-trifluoromethyl-benzyl) -amine in 25ml of N, N-Diisopropylethylamine is heated at 127 \n0\n C for 6h. After evaporation of a maximum of diisopropylethylamine, the reaction medium is diluted with ethyl acetate and washed with a 1N aqueous solution of sodium hydroxide. The organic phase obtained is washed with water and dried. on magnesium sulfate, filtered and concentrated in vacuo. The crude residue is purified by chromatography on silica gel eluted with a 60/40 heptane / ethyl acetate mixture. 4.0 g (55%) of methyl (S) -3-tert-butoxycarbonylamino-2- [4- (4-trifluoromethyl-benzyl) -piperazin-1-yl] -propanoate are obtained in the form of an oil.\n\n\n\n\n\n\n \n20.3 : trichlorhydrate de (S)-3-amino-2-[4-(4-thfluorométhyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle \n20.3: Methyl (S) -3-amino-2- [4- (4-thfluoromethyl-benzyl) -piperazin-1-yl] -propanoate trihydrochloride\n\n\n\n\n\n\n \nDe manière analogue à l'exemple 17.5, à partir de 4g (9,1 mmoles) de (S)-3-tert- butoxycarbonylamino-2-[4-(4-trifluorométhyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle, 3,8g (93%) de trichlorhydrate de (S)-3-amino-2-[4-(4-trifluorométhyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle sont obtenus sous la forme d'un solide beige. 20.4 : (S)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(4-trifluorométhyl-benzyl)- pipérazin-1 -yl]-propanoate de méthyle \nAnalogously to Example 17.5, from 4 g (9.1 mmol) of (S) -3-tert-butoxycarbonylamino-2- [4- (4-trifluoromethyl-benzyl) -piperazin-1-yl] - methyl propanoate, 3.8 g (93%) of methyl (S) -3-amino-2- [4- (4-trifluoromethyl-benzyl) -piperazin-1-yl] -propanoate trihydrochloride are obtained in the form of a beige solid. Methyl 20.4: (S) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (4-trifluoromethyl-benzyl) piperazin-1-yl] propanoate\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.6, à partir de 1 ,0g ( 2,2 mmoles ) de trichlorhydrate de (S)-3- amino-2-[4-(4-trifluorométhyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle et de 1 ,2g (3,1 mmoles) de chlorhydrate de chlorure de 4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonyle (préparé comme décrit dans l'exemple 17.2), 910mg (65%) de (S)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- \n\n benzènesulfonylannino]-2-[4-(4-trifluoronnéthyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \nIn a similar manner to Example 3.6, from 1.0 g (2.2 mmol) of (S) -3-amino-2- [4- (4-trifluoromethyl-benzyl) -piperazin-1-yl) dihydrochloride ] -methyl propanoate and 1.2 g (3.1 mmol) of 4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonyl chloride hydrochloride (prepared as described in Example 17.2), 910 mg (65%). %) of (S) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -  Benzenesulfonylannino] -2- [4- (4-trifluoromethyl-benzyl) -piperazin-1-yl] -propanoate are obtained in the form of a white solid.\n\n\n\n\n\n\n \n20.5 : acide (S)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(4-thfluorométhyl- benzyl)-pipérazin-1-yl]propanoïque \n20.5: (S) -3- [4- (2-Methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (4-thfluoromethyl-benzyl) -piperazin-1-yl] propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 910mg (1 ,4 mmoles) de (S)-3-[4-(2-méthyl-quinolin-\n In a similar manner to Example 3.7, from 910 mg (1.4 mmol) of (S) -3- [4- (2-methyl-quinolin)\n\n\n\n\n\n\n \n4-ylméthoxy)-benzènesulfonylamino]-2-[4-(4-trifluorométhyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle, 790mg (88%) d'acide (S)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-\nMethyl 4-ylmethoxy) -benzenesulfonylamino] -2- [4- (4-trifluoromethyl-benzyl) -piperazin-1-yl] -propanoate, 790 mg (88%) of (S) -3- [4- 2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4-\n\n\n\n\n\n\n \n(4-trifluorométhyl-benzyl)-pipérazin-1-yl]propanoïque sont obtenus sous forme d'un solide blanc. \n(4-Trifluoromethyl-benzyl) -piperazin-1-yl] propanoic acid are obtained in the form of a white solid.\n\n\n\n\n\n\n \n20.6 : (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(4- trifluorométhyl-benzyl)-pipérazin-1-yl]-propionamide \n20.6: (S) -N-Hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (4-trifluoromethyl-benzyl) -piperazin-1-yl] - propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 790mg (1 ,2 mmoles) d'acide (S)-3-[4-(2-méthyl- quinolin-4-ylméthoxy)benzènesulfonylamino]-2-[4-(4-trifluorométhyl-benzyl)-pipérazin-1-yl]- propanoique, 550mg (68%) de (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-2-[4-(4-trifluorométhyl-benzyl)-pipérazin-1-yl]-propionamide sont obtenus sous forme d'un solide blanc de point de fusion 148\n0\nC. \nIn a manner analogous to Example 3.8, starting from 790 mg (1.2 mmol) of (S) -3- [4- (2-methylquinolin-4-ylmethoxy) benzenesulfonylamino] -2- [4- (4-Trifluoromethyl-benzyl) -piperazin-1-yl] -propanoic acid, 550 mg (68%) of (S) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) benzenesulfonylamino] -2- [4- (4-Trifluoromethyl-benzyl) -piperazin-1-yl] -propionamide are obtained in the form of a white solid with a melting point of 148 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,21 (m, 4H); 2,38 (m, 4H); 2,58 (s, 3H); 2,69-2,75 (m, 1 H); 2,85-2,93 (m, 1 H);\n \n1\n H NMR (δ, DMSO): 2.21 (m, 4H); 2.38 (m, 4H); 2.58 (s, 3H); 2.69-2.75 (m, 1H); 2.85-2.93 (m, 1H);\n\n\n\n\n\n\n \n2,93-2,98 (m, 1 H); 3,42 (s, 2H); 5,63 (s, 2H); 7,25 (d, J=9Hz, 2H); 7,40 (d, J=8Hz, 3H); 7,47-7,53 (m, 2H); 7,57 (d, J=8,1 Hz, 2H); 7,65-7,72 (m, 3H); 7,90 (d, J=7,9Hz, 1 H); 8,03 (d, J=7,8Hz, 1 H); 8,83 (s,\n2.93-2.98 (m, 1H); 3.42 (s, 2H); 5.63 (s, 2H); 7.25 (d, J = 9Hz, 2H); 7.40 (d, J = 8Hz, 3H); 7.47-7.53 (m, 2H); 7.57 (d, J = 8.1 Hz, 2H); 7.65-7.72 (m, 3H); 7.90 (d, J = 7.9 Hz, 1H); 8.03 (d, J = 7.8 Hz, 1H); 8.83 (s,\n\n\n\n\n\n\n \n1 H), 10,56 (s, 1 H). \n1H), 10.56 (s, 1H).\n\n\n\n\n\n\n \nExemple 21 : (S)-N-hydroxy-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4- ylméthoxy)-benzènesulfonylamino]-propionamide. \nExample 21: (S) -N-Hydroxy-2- [4- (4-methyl-benzyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n21.1 : bis-(2-chloro-éthyl)-(4-méthyl-benzyl)-amine \n21.1: bis- (2-chloro-ethyl) - (4-methyl-benzyl) -amine\n\n\n\n\n\n\n \n De manière analogue à l'exemple 17.3, à partir de 5,0g (28 mmoles) du chlorhydrate de bis-(2-chloro- éthyl)-amine et de 5,7g (31 mmoles) de 1-bromométhyl-4-méthyl-benzène, 4,9g (71 %) de bis-(2- chloro-éthyl)-(4-méthyl-benzyl)-amine sont obtenus. \n In a similar manner to Example 17.3, starting from 5.0 g (28 mmol) of bis (2-chloroethyl) amine hydrochloride and 5.7 g (31 mmol) of 1-bromomethyl-4-methyl benzene, 4.9 g (71%) of bis- (2-chloro-ethyl) - (4-methyl-benzyl) -amine are obtained.\n\n\n\n\n\n\n \n212 : (S)-3-tert-butoxycarbonylamino-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle De manière analogue à l'exemple 17.4, à partir de 5,1g (20 mmoles) du chlorhydrate de (S)-2-amino- 3-tert-butoxycarbonylamino-propanoate de méthyle commercial et de 4,9g (20 mmoles) de bis-(2- chloro-éthyl)-(4-méthyl-benzyl)-amine, 4,1g (53%) de (S)-3-tert-butoxycarbonylamino-2-[4-(4-méthyl- benzyl)-pipérazin-1-yl]-propanoate de méthyle sont obtenus sous forme d'une huile. 13 : trichlorhydrate de (S)-3-amino-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle\n212: Methyl (S) -3-tert-butoxycarbonylamino-2- [4- (4-methyl-benzyl) -piperazin-1-yl] -propanoate Analogously to Example 17.4, starting from 5.1 g (20 mmol) commercial methyl (S) -2-amino-3-tert-butoxycarbonylamino-propanoate hydrochloride and 4.9 g (20 mmol) bis (2-chloro-ethyl) - (4-methyl); benzyl) -amine, 4.1 g (53%) of methyl (S) -3-tert-butoxycarbonylamino-2- [4- (4-methylbenzyl) piperazin-1-yl] -propanoate are obtained in the form of of an oil. 13: Methyl (S) -3-amino-2- [4- (4-methyl-benzyl) -piperazin-1-yl] -propanoate trihydrochloride\n\n\n\n\n\n\n \nDe manière analogue à l'exemple 19.3, à partir de 4,1g (10,5 mmoles) de (S)-3-tert- butoxycarbonylamino-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle, 3,95g (94%) de \n\n trichlorhydrate de (S)-3-amino-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle sont obtenus sous forme d'un solide crème. \nAnalogous to Example 19.3, from 4.1 g (10.5 mmol) of (S) -3-tert-butoxycarbonylamino-2- [4- (4-methyl-benzyl) -piperazin-1-yl) ] -methyl propanoate, 3.95g (94%) of  Methyl (S) -3-amino-2- [4- (4-methyl-benzyl) -piperazin-1-yl] -propanoate trihydrochloride are obtained as a cream solid.\n\n\n\n\n\n\n \n214 : (S)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(4-méthyl-benzyl)- pipérazin-1 -yl]-propanoate de méthyle. \n214: Methyl (S) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (4-methyl-benzyl) piperazin-1-yl] -propanoate.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.6, à partir de 1 ,0g (2,5 mmoles) du trichlorhydrate de (S)-3- amino-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle et de 1 ,3g (3,5 mmoles) de chlorhydrate de chlorure de 4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonyle (préparé comme décrit dans l'exemple 17.2), 950mg (63%) de (S)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n In a similar manner to Example 3.6, from 1.0 g (2.5 mmol) of (S) -3-amino-2- [4- (4-methyl-benzyl) -piperazin-1-yl trihydrochloride ] -methyl propanoate and 1.3 g (3.5 mmol) of 4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonyl chloride hydrochloride (prepared as described in Example 17.2), 950 mg (63%). %) Methyl (S) -3- [4- (2-methyl-quinolin-4-ylmethoxy) benzenesulfonylamino] -2- [4- (4-methyl-benzyl) -piperazin-1-yl] -propanoate are obtained in the form of a white solid.\n\n\n\n\n\n\n \n215 : acide ((S)-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoïque. \n215: ((S) -2- [4- (4-methyl-benzyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoic acid.\n\n\n\n\n\n\n \nDe manière analogue à l'exemple 3.7, à partir de 950mg (1 ,6 mmoles) de (S)-2-[4-(4-méthyl-benzyl)- pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]- propanoate de méthyle, 880mg (95%) d'acide ((S)-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoïque sont obtenus sous forme d'un solide crème. 216 : (S)Η-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(4-méthyl- benzyl)-pipérazin-1-yl]-propionamide. \nAnalogous to Example 3.7, from 950 mg (1.6 mmol) of (S) -2- [4- (4-methyl-benzyl) -piperazin-1-yl] -3- [4- ( Methyl 2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoate, 880 mg (95%) of ((S) -2- [4- (4-methyl-benzyl) -piperazin-1-yl] 3- [4- (2-Methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoic acid are obtained in the form of a cream solid 216: (S) Η-hydroxy-3- [4- (2-methyl) -quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (4-methylbenzyl) piperazin-1-yl] propionamide.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 880mg (1 ,5 mmoles) d'acide (S)-3-[4-(2-méthyl- quinolin-4-ylméthoxy)benzènesulfonylamino]-2-[4-(4-méthyl-benzyl)-pipérazin-1-yl]-propanoique, 150mg (17%) de (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(4- méthyl-benzyl)-pipérazin-1-yl]-propionamide sont obtenus sous forme d'un solide blanc de point de fusion 17O\n0\nC. \nIn a manner similar to Example 3.8, starting from 880 mg (1.5 mmol) of (S) -3- [4- (2-methylquinolin-4-ylmethoxy) benzenesulfonylamino] -2- [4- (4-methyl-benzyl) -piperazin-1-yl] -propanoic acid, 150 mg (17%) of (S) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (4-methyl-benzyl) -piperazin-1-yl] -propionamide are obtained in the form of a white solid with a melting point of 170 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,25 (m, 4H); 2,25 (s, 3H); 2,43 (m, 4H); 2,67 (s, 3H); 2,80 (m, 1 H); 2,95-3,05 (m, 2H); 3,37 (m, 2H); 5,71 (s, 2H); 7,10 (q, J=8Hz, 4H); 7,33 (d, J=8,9Hz, 2H); 7,43 (m, 1 H); 7,56-7,61 (m, 2H); 7,73-7,79 (m, 3H); 7,98 (d, J=8,3Hz, 1 H); 8,1 1 (d, J=8,2Hz, 1 H); 8,89 (s, 1 H); 10,59 (s, 1 H). \n \n1\n H NMR (δ, DMSO): 2.25 (m, 4H); 2.25 (s, 3H); 2.43 (m, 4H); 2.67 (s, 3H); 2.80 (m, 1H); 2.95-3.05 (m, 2H); 3.37 (m, 2H); 5.71 (s, 2H); 7.10 (q, J = 8Hz, 4H); 7.33 (d, J = 8.9Hz, 2H); 7.43 (m, 1H); 7.56-7.61 (m, 2H); 7.73-7.79 (m, 3H); 7.98 (d, J = 8.3 Hz, 1H); 8.1 (d, J = 8.2 Hz, 1H); 8.89 (s, 1H); 10.59 (s, 1H).\n\n\n\n\n\n\n \nExemple 22 : (S)-3-[4-(benzoisoxazol-3-ylméthoxy)-benzènesulfonylamino]-N-hydroxy-2- (4-méthanesulfonyl-pipérazin-1-yl)-propionamide. \nExample 22: (S) -3- [4- (benzoisoxazol-3-ylmethoxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -propionamide.\n\n\n\n\n\n\n \n22.1 : Benzoisoxazol-3-yl-méthanol. \n22.1 Benzoisoxazol-3-yl-methanol.\n\n\n\n\n\n\n \n589mg (3,0 mmoles) de 1 ,2-benzoisoxazole-3-carboxylate d'éthyle en solution dans 10ml de tétrahydrofuranne sont ajoutés à une suspension de 129mg (3,5 mmoles) d'hydrure de lithium aluminium dans 5ml de tétrahydrofuranne. Le mélange réactionnel est agité une heure à 6O\n0\nC puis traité par l'addition goutte à goutte de 2ml de méthanol, filtré sur célite, rincé à l'acétate d'éthyle. Les phases organiques sont rassemblées, séchées sur sulfate de sodium et évaporées. Le résidu obtenu \n\n est purifié par chromatographie sur gel de silice élue avec un mélange heptane/acétate d'éthyle 60/40. 180mg (39%) de benzoisoxazol-3-yl-méthanol sont obtenus sous forme d'un solide blanc. \n589 mg (3.0 mmol) of ethyl 1,2-benzoisoxazole-3-carboxylate dissolved in 10 ml of tetrahydrofuran are added to a suspension of 129 mg (3.5 mmol) of lithium aluminum hydride in 5 ml of tetrahydrofuran. The reaction mixture is stirred for 1 hour at 60 \n°\n C. and then treated with the dropwise addition of 2 ml of methanol, filtered through celite and rinsed with ethyl acetate. The organic phases are combined, dried over sodium sulphate and evaporated. The residue obtained  is purified by chromatography on silica gel eluted with a 60/40 heptane / ethyl acetate mixture. 180 mg (39%) of benzoisoxazol-3-yl-methanol are obtained in the form of a white solid.\n\n\n\n\n\n\n \n22.2 : (S)-3-[4-(benzoisoxazol-3-ylméthoxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1- yl)-propanoate de méthyle. \n22.2: (S) -3- [4- (benzoisoxazol-3-ylmethoxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin-1-yl) -propionic acid methyl ester.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 11.1 , à partir de 494mg (1 ,2 mmoles) de (S)-3-(4-hydroxy- benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle (préparé comme décrit en 5.1 ) et de 175mg (1 ,2 mmoles) de benzoisoxazol-3-yl-méthanol, 459mg (71 %) de (S)-3-[4- (benzoisoxazol-3-ylméthoxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'une huile. \n In a manner analogous to Example 11.1, starting from 494 mg (1.2 mmol) of (S) -3- (4-hydroxybenzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate. methyl (prepared as described in 5.1) and 175 mg (1.2 mmol) of benzoisoxazol-3-yl-methanol, 459 mg (71%) of (S) -3- [4- (benzoisoxazol-3-ylmethoxy) -benzenesulfonylamino) Methyl 2- (4-methanesulfonyl-piperazin-1-yl) -propanoate are obtained as an oil.\n\n\n\n\n\n\n \n22.3 : acide (S)-3-[4-(benzoisoxazol-3-ylméthoxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl- pipérazin-1 -yl)-propanoique. \n22.3: (S) -3- [4- (benzoisoxazol-3-ylmethoxy) -benzenesulfonylamino] -2- (4-methanesulfonylpiperazin-1-yl) propanoic acid.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 458mg (0,8 mmoles) de (S)-3-[4-(benzoisoxazol-3- ylméthoxy)-benzènesulfonylamino]-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle, 283mg (63%) d'acide (S)-3-[4-(benzoisoxazol-3-ylméthoxy)-benzènesulfonylamino]-2-(4- méthanesulfonyl-pipérazin-1-yl)-propanoique sont obtenus sous forme d'un solide blanc. \n Analogous to Example 3.7, starting from 458 mg (0.8 mmol) of (S) -3- [4- (benzoisoxazol-3-ylmethoxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin-1) Methyl-propanoate, 283 mg (63%) of (S) -3- [4- (benzoisoxazol-3-ylmethoxy) -benzenesulfonylamino] -2- (4-methanesulfonyl-piperazin-1-yl) - propanoic are obtained in the form of a white solid.\n\n\n\n\n\n\n \n22.4 : (S)-3-[4-(benzoisoxazol-3-ylméthoxy)-benzènesulfonylamino]-N-hydroxy-2-(4-méthanesulfonyl- pipérazin-1 -yl)-propionamide. \n22.4: (S) -3- [4- (benzoisoxazol-3-ylmethoxy) benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonylpiperazin-1-yl) propionamide.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 283mg (0,5 mmoles) d'acide (S)-3-[4- (benzoisoxazol-3-ylméthoxy)-benzènesulfonylamino]-2-(4-éthanesulfonyl-pipérazin-1-yl)-propanoique, 231 mg (80%) de (S)-3-[4-(benzoisoxazol-3-ylméthoxy)-benzènesulfonylamino]-N-hydroxy-2-(4- méthanesulfonyl-pipérazin-1-yl)-propionamide sont obtenus sous forme d'un solide beige de point de fusion 107\n0\nC. \nIn a similar manner to Example 3.8, from 283 mg (0.5 mmol) of (S) -3- [4- (benzoisoxazol-3-ylmethoxy) -benzenesulfonylamino] -2- (4-ethanesulfonyl) piperazine -1-yl) -propanoic acid, 231 mg (80%) of (S) -3- [4- (benzoisoxazol-3-ylmethoxy) -benzenesulfonylamino] -N-hydroxy-2- (4-methanesulfonyl-piperazin-1- yl) -propionamide are obtained in the form of a beige solid with a melting point of 107 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,53-2,55 (m, 4H); 2,88 (s, 3H); 2,90-2,93 (m, 2H); 3,00-3,10 (m, 4H); 3,13 (t, J=6,9Hz,1 H); 5,77 (s, 2H); 7,35 (d, J=8,8Hz, 2H); 7,49 (t, J=7,5Hz, 1 H); 7,57 (m, 1 H); 7,75 (t, J=7,4Hz, 1 H); 7,78-7,87 (m, 3H); 8,01 (d, J=8Hz, 1 H); 8,96 (m, 1 H); 10,67 (m, 1 H). Exemple 23 : (S)-N-hydroxy-2-(4-isobutyryl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide. \n \n1\n H NMR (δ, DMSO): 2.53-2.55 (m, 4H); 2.88 (s, 3H); 2.90-2.93 (m, 2H); 3.00-3.10 (m, 4H); 3.13 (t, J = 6.9Hz, 1H); 5.77 (s, 2H); 7.35 (d, J = 8.8 Hz, 2H); 7.49 (t, J = 7.5Hz, 1H); 7.57 (m, 1H); 7.75 (t, J = 7.4 Hz, 1H); 7.78-7.87 (m, 3H); 8.01 (d, J = 8Hz, 1H); 8.96 (m, 1H); 10.67 (m, 1H). Example 23: (S) -N-Hydroxy-2- (4-isobutyryl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n23.1 : (S)-3-tert-butoxycarbonylamino-2-pipérazin-1-yl-propanoate de méthyle. \n23.1: Methyl (S) -3-tert-butoxycarbonylamino-2-piperazin-1-yl-propanoate.\n\n\n\n\n\n\n \n 2g (25% massique) de palladium sur charbon 10% sont additionnés à une solution de 8g (21 mmoles) de (S)-2-(4-benzyl-pipérazin-1-yl)-3-tert-butoxycarbonylamino-propanoate de méthyle (préparé comme décrit dans l'exemple 17.4) dans 120ml d'éthanol, préalablement dégazée sous flux d'azote. Le milieu réactionnel est ensuite placé sous une pression atmosphérique d'hydrogène pendant 24h puis filtré sur célite et abondamment rincé au dichlorométhane. Après concentration sous vide, 6,1g (100%) de (S)-3-tert-butoxycarbonylamino-2-pipérazin-1-yl-propanoate de méthyle sont obtenus. \n 2 g (25% by weight) of 10% palladium on carbon are added to a solution of 8 g (21 mmol) of (S) -2- (4-benzyl-piperazin-1-yl) -3-tert-butoxycarbonylamino-propanoate. methyl (prepared as described in Example 17.4) in 120 ml of ethanol, previously degassed under a stream of nitrogen. The reaction medium is then placed under atmospheric pressure of hydrogen for 24 h and then filtered through Celite and thoroughly rinsed with dichloromethane. After concentration under vacuum, 6.1 g (100%) of methyl (S) -3-tert-butoxycarbonylamino-2-piperazin-1-ylpropanoate are obtained.\n\n\n\n\n\n\n \n23.2 : (S)-3-tert-butoxycarbonylamino-2-(4-isobutyryl-pipérazin-1-yl)-propanoate de méthyle. \n\n 1 ,2ml ( 8,3 mmoles) de triéthylamine puis 0,8ml (7,6 mmoles) de chlorure d'isobutyryle sont additionnés à une solution de 2,0g ( 6,9 mmoles) de (S)-3-tert-butoxycarbonylamino-2-pipérazin-1-yl- propanoate de méthyle dans 20ml de dichlorométhane, préalablement refroidie à O\n0\nC. Après agitation à température ambiante pendant 1 h30, de l'eau est additionnée. Le milieu réactionnel est extrait au dichlorométhane. La phase organique est lavée à l'eau, séchée sur sulfate de magnésium, filtrée et concentrée sous vide. Le résidu brut obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane / acétate d'éthyle 50/50. 2,0g (81 %) de ((S)-3-tert-butoxycarbonylamino-2-(4- isobutyryl-pipérazin-1-yl)-propanoate de méthyle sont obtenus sous forme d'une huile incolore. 23.3 : acide (S)-3-tert-butoxycarbonylamino-2-(4-isobutyryl-pipérazin-1-yl)-propanoïque. \n23.2: Methyl (S) -3-tert-butoxycarbonylamino-2- (4-isobutyryl-piperazin-1-yl) -propanoate.  1.2 ml (8.3 mmol) of triethylamine and 0.8 ml (7.6 mmol) of isobutyryl chloride are added to a solution of 2.0 g (6.9 mmol) of (S) -3-tert- methyl butoxycarbonylamino-2-piperazin-1-yl-propanoate in 20 ml of dichloromethane, previously cooled to 0 \n°\n C. After stirring at room temperature for 1 h 30, water is added. The reaction medium is extracted with dichloromethane. The organic phase is washed with water, dried over magnesium sulfate, filtered and concentrated in vacuo. The crude residue obtained is purified by chromatography on silica gel eluted with a 50/50 heptane / ethyl acetate mixture. 2.0 g (81%) of methyl ((S) -3-tert-butoxycarbonylamino-2- (4-isobutyryl-piperazin-1-yl) -propanoate are obtained in the form of a colorless oil. S) -3-tert-butoxycarbonylamino-2- (4-isobutyryl-piperazin-1-yl) propanoic acid.\n\n\n\n\n\n\n \n 10ml (10 mmoles) d'une solution aqueuse d'hydroxyde de lithium de concentration 1 N sont additionnés à une solution de 2,0g (5,6 mmoles) de (S)-3-tert-butoxycarbonylamino-2-(4-isobutyryl- pipérazin-1-yl)-propanoate de méthyle dans 40ml de tétrahydrofuranne et 8ml d'eau puis le milieu réactionnel est agité à température ambiante pendant 2Oh. Après addition d'une solution aqueuse d'acide acétique de concentration 1 N, le produit est extrait au n-butanol. La phase organique est séchée sur sulfate de magnésium, filtrée, concentrée sous vide. 1 ,5g (78%) d'acide (S)-3-tert- butoxycarbonylamino-2-(4-isobutyryl-pipérazin-1-yl)propanoïque sont obtenus sous forme d'un solide blanc. 23.4 : (S)-2-allyloxycarbamoyl-2-(4-isobutyryl-pipérazin-1-yl)-éthyl]-carbamate de tert-butyle. \n 10 ml (10 mmol) of a 1 N aqueous solution of lithium hydroxide are added to a solution of 2.0 g (5.6 mmol) of (S) -3-tert-butoxycarbonylamino-2- (4- methyl isobutyryl-piperazin-1-yl) -propanoate in 40 ml of tetrahydrofuran and 8 ml of water and then the reaction medium is stirred at ambient temperature for 20 h. After addition of a 1N aqueous solution of acetic acid, the product is extracted with n-butanol. The organic phase is dried over magnesium sulfate, filtered and concentrated in vacuo. 1.5 g (78%) of (S) -3-tert-butoxycarbonylamino-2- (4-isobutyryl-piperazin-1-yl) propanoic acid are obtained as a white solid. 23.4: (S) -2-allyloxycarbamoyl-2- (4-isobutyryl-piperazin-1-yl) -ethyl] -carbamate tert-butyl ester.\n\n\n\n\n\n\n \n 1 ,4g (4,4 mmoles) de O-(benzotriazol-1-yl)-N,N, N',N'-tétraméthyluroniumtétrafluoroborate puis 2,3ml (13,1 mmoles) de diisopropyléthylamine sont ajoutés à une solution de 1 ,5g (4,4 mmoles) d'acide (S)- 3-tert-butoxycarbonylamino-2-(4-isobutyryl-pipérazin-1-yl)-propanoïque dans 20ml de diméthylformamide. Après agitation à température ambiante pendant 15min, une solution de 500mg (4,6 mmoles) de chlorhydrate de O-allyl-hydroxylamine et de 0,8ml (4,6 mmoles) de diisopropyléthylamine dans 10ml de diméthylformamide est ajoutée. Le milieu réactionnel est agité à température ambiante pendant 2Oh, hydrolyse par une solution aqueuse saturée d'hydrogénocarbonate de sodium puis dilué par de l'acétate d'éthyle. La phase organique est lavée par une solution aqueuse saturée de chlorure de sodium, séchée sur sulfate de magnésium, filtrée et concentrée sous vide. 1 ,45g (83%) de [(S)-2-allyloxycarbamoyl-2-(4-isobutyryl-pipérazin-1-yl)-éthyl]- carbamate de tert-butyle sont obtenus sous forme d'une huile incolore. \n 1.4 g (4.4 mmol) of O- (benzotriazol-1-yl) -N, N, N ', N'-tetramethyluroniumtetrafluoroborate and then 2.3 ml (13.1 mmol) of diisopropylethylamine are added to a solution of 1 5 g (4.4 mmol) of (S) -3-tert-butoxycarbonylamino-2- (4-isobutyryl-piperazin-1-yl) -propanoic acid in 20 ml of dimethylformamide. After stirring at room temperature for 15 min, a solution of 500 mg (4.6 mmol) of O-allyl-hydroxylamine hydrochloride and 0.8 ml (4.6 mmol) of diisopropylethylamine in 10 ml of dimethylformamide is added. The reaction medium is stirred at ambient temperature for 20 h, hydrolyzed with a saturated aqueous solution of sodium hydrogencarbonate and then diluted with ethyl acetate. The organic phase is washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, filtered and concentrated in vacuo. 1.45 g (83%) of tert-butyl [(S) -2-allyloxycarbamoyl-2- (4-isobutyryl-piperazin-1-yl) -ethyl] carbamate are obtained in the form of a colorless oil.\n\n\n\n\n\n\n \n23.5 : dichlorhydrate de (S)-N-allyloxy-3-amino-2-(4-isobutyryl-pipérazin-1-yl)-propionamide. \n23.5: (S) -N-Allyloxy-3-amino-2- (4-isobutyryl-piperazin-1-yl) -propionamide dihydrochloride.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 19.3, à partir de 1 ,45g (3,6 mmoles) de [(S)-2-allyloxycarbamoyl-2- (4-isobutyryl-pipérazin-1-yl)-éthyl]-carbamate de tert-butyle, 1 ,4g (100%) de dichlorhydrate de (S)-N- allyloxy-3-amino-2-(4-isobutyryl-pipérazin-1-yl)-propionamide sont obtenus sous forme d'un solide blanc. \n Analogous to Example 19.3, from 1.45 g (3.6 mmol) of [(S) -2-allyloxycarbamoyl-2- (4-isobutyryl-piperazin-1-yl) -ethyl] -carbamate from tert-butyl, 1.4 g (100%) of (S) -N-allyloxy-3-amino-2- (4-isobutyryl-piperazin-1-yl) -propionamide dihydrochloride are obtained in the form of a white solid .\n\n\n\n\n\n\n \n23.6 : (S)-N-allyloxy-2-(4-isobutyryl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide. \n\n 1 ,9g (5,1 mmoles) du chlorhydrate de chlorure de 4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonyle chlorohydrate (préparé comme décrit en 32.2) sont ajoutés à une solution de 1 ,3g (3,6 mmoles) de dichlorhydrate de (S)-N-allyloxy-3-amino-2-(4-isobutyryl-pipérazin-1-yl)- propionamide, 2,0ml (14,5 mmoles) de triéthylamine dans 15ml de dichlorométhane et 15ml de diméthylformamide , préalablement refroidie à O\n0\nC. Le milieu réactionnel est ensuite agité de O\n0\nC à température ambiante pendant 3h. Après addition d'eau, le milieu réactionnel est extrait au dichlorométhane. La phase organique est lavée par une solution aqueuse d'hydrogénocarbonate de sodium saturée, par de l'eau, séchée sur sulfate de magnésium, filtrée et concentrée. \n23.6: (S) -N-Allyloxy-2- (4-isobutyryl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide.  1. 9 g (5.1 mmol) of 4- (2-methyl-quinolin-4-ylmethoxy) benzenesulfonyl chloride hydrochloride hydrochloride (prepared as described in 32.2) are added to a solution of 1.3 g (3.6 g). mmol) of (S) -N-allyloxy-3-amino-2- (4-isobutyryl-piperazin-1-yl) propionamide dihydrochloride, 2.0ml (14.5 mmol) of triethylamine in 15ml of dichloromethane and 15ml of dimethylformamide, previously cooled to 0 \n°\n C. The reaction medium is then stirred at 0 \n°\n C. at ambient temperature for 3 hours. After addition of water, the reaction medium is extracted with dichloromethane. The organic phase is washed with saturated aqueous sodium hydrogen carbonate solution, with water, dried over magnesium sulfate, filtered and concentrated.\n\n\n\n\n\n\n \nLe résidu brut obtenu est purifié par chromatographie sur colonne de silice élue avec un mélange dichlorométhane/ méthanol 97/3. 900mg (41 %) de (S)-N-allyloxy-2-(4-isobutyryl-pipérazin-1-yl)-3-[4- (2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propionamide sont obtenus sous forme d'un solide blanc. \nThe crude residue obtained is purified by chromatography on a silica column eluted with a 97/3 dichloromethane / methanol mixture. 900mg (41%) of (S) -N-allyloxy-2- (4-isobutyryl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide are obtained in the form of a white solid.\n\n\n\n\n\n\n \n23.7 : (S)-N-hydroxy-2-(4-isobutyryl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propionamide. \n23.7: (S) -N-hydroxy-2- (4-isobutyryl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n 33mg (0,06 mmoles) de palladium tétrakis triphénylphosphine puis 920mg (6,6 mmoles) de carbonate de potassium sont additionnés à une solution de 670mg (1 ,1 mmoles) de (S)-N-allyloxy-2-(4- isobutyryl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propionamide dans 15ml de méthanol puis le milieu réactionnel est chauffé à reflux pendant 8h. Après addition d'acétate d'éthyle, le milieu réactionnel est lavé par une solution aqueuse d'hydrogénocarbonate de sodium saturée. La phase organique est ensuite lavée par de l'eau, séchée sur sulfate de magnésium, filtrée et concentrée. Le produit brut est repris dans 6ml d'éthanol et 12 ml d'eau puis chauffé à 8O\n0\nC jusqu'à solubilisation. Après refroidissement, la cristallisation est amorcée par évaporation d'un minimum d'éthanol. 120mg de produit sont obtenus par filtration et purifiés par chromatographie sur couche mince de silice préparative, élues avec un mélange dichlorométhane / méthanol 97/3. \n33 mg (0.06 mmol) of palladium tetrakis triphenylphosphine and then 920 mg (6.6 mmol) of potassium carbonate are added to a solution of 670 mg (1.1 mmol) of (S) -N-allyloxy-2- (4- isobutyryl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide in 15 ml of methanol and the reaction medium is refluxed for 8 h. After addition of ethyl acetate, the reaction medium is washed with saturated aqueous sodium hydrogen carbonate solution. The organic phase is then washed with water, dried over magnesium sulfate, filtered and concentrated. The crude product is taken up in 6 ml of ethanol and 12 ml of water and then heated at 80 \n°\n C. until solubilization. After cooling, the crystallization is initiated by evaporation of a minimum of ethanol. 120 mg of product are obtained by filtration and purified by preparative silica thin layer chromatography, eluted with a 97/3 dichloromethane / methanol mixture.\n\n\n\n\n\n\n \n 20mg (3%) de (S)-N-hydroxy-2-(4-isobutyryl-pipérazin-1-yl)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylaminoj-propionamide sont finalement obtenus sous forme d'un solide beige. \n 20 mg (3%) of (S) -N-hydroxy-2- (4-isobutyryl-piperazin-1-yl) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide are finally obtained in the form of a beige solid.\n\n\n\n\n\n\n \nRMN \n1\nH (δ, DMSO) : 0,84 (s, 3H); 0,85 (s, 3H); 2,30-2,44 (m, 2H); 2,52 (m, 2H); 2,67 (s, 3H); 2,77 (m, 1 H); 2,85 (m, 2H); 2,95 (m, 1 H); 3,35 (m, 4H); 5,71 (s, 2H); 7,33 (d, J=8,9Hz, 2H); 7,43 (m, 1 H); 7,55- 7,62 (m, 2H); 7,72-7,82 (m, 3H); 7,98 (d, J=8,4Hz, 1 H); 8,11 (d, J=8,2Hz, 1 H); 8,96 (m, 1 H); 10,67 (m, 1 H). \n \n1\n H NMR (δ, DMSO): 0.84 (s, 3H); 0.85 (s, 3H); 2.30-2.44 (m, 2H); 2.52 (m, 2H); 2.67 (s, 3H); 2.77 (m, 1H); 2.85 (m, 2H); 2.95 (m, 1H); 3.35 (m, 4H); 5.71 (s, 2H); 7.33 (d, J = 8.9Hz, 2H); 7.43 (m, 1H); 7.55-7.62 (m, 2H); 7.72-7.82 (m, 3H); 7.98 (d, J = 8.4Hz, 1H); 8.11 (d, J = 8.2 Hz, 1H); 8.96 (m, 1H); 10.67 (m, 1H).\n\n\n\n\n\n\n \nExemple 24 : (S)-N-hydroxy-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-l]-3-[4-(2-méthyl- quinolin-4-ylméthoxy)-benzènesulfonylamino]-propionamide. \nExample 24: (S) -N-Hydroxy-2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -3- [4- (2-methylquinolin-4-ylmethoxy) ) benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n24.1 : (S)-3-tert-butoxycarbonylamino-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle. \n24.1: Methyl (S) -3-tert-butoxycarbonylamino-2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -propanoate.\n\n\n\n\n\n\n \n 479mg (3,0 mmoles) de chlorure de 2-méthyl-propane-1-sulfonyle sont additionnés à une solution de\n 479 mg (3.0 mmol) of 2-methyl-propane-1-sulfonyl chloride are added to a solution of\n\n\n\n\n\n\n \n800mg (2,8 mmoles) de (S)-3-tert-butoxycarbonylamino-2-pipérazin-1-yl-propanoate de méthyle (préparé comme décrit dans l'exemple 23.1 ), 775μl (5,5 mmoles) de triéthylamine dans 8ml de dichlorométhane, préalablement refroidie à O\n0\nC. Le milieu réactionnel est agité à température \n\n ambiante pendant 18h puis de l'eau est additionnée et le milieu est extrait au dichlorométhane. La phase organique est lavée à l'eau, séchée sur sulfate de magnésium, filtrée et concentrée. Le résidu obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane / acétate d'éthyle 5/5. 785mg (71 %) de (S)-3-tert-butoxycarbonylamino-2-[4-(2-méthyl-propane-1-sulfonyl)- pipérazin-1-yl]-propanoate de méthyle sont obtenus sous forme d'une huile incolore. \n800 mg (2.8 mmol) of methyl (S) -3-tert-butoxycarbonylamino-2-piperazin-1-ylpropanoate (prepared as described in Example 23.1), 775 μl (5.5 mmol) of triethylamine in 8 ml of dichloromethane, previously cooled to 0 \n°\n C. The reaction medium is stirred at room temperature  ambient for 18h then water is added and the medium is extracted with dichloromethane. The organic phase is washed with water, dried over magnesium sulfate, filtered and concentrated. The residue obtained is purified by chromatography on silica gel eluted with a heptane / ethyl acetate mixture 5/5. 785 mg (71%) of methyl (S) -3-tert-butoxycarbonylamino-2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -propanoate are obtained in the form of a colorless oil.\n\n\n\n\n\n\n \n24.2 : dichlorhydrate de (S)-3-amino-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle. \n24.2: Methyl (S) -3-amino-2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -propanoate dihydrochloride.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.3, à partir de 785mg (1 ,9 mmoles) de (S)-3-tert- butoxycarbonylamino-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle,\n In a similar manner to Example 3.3, from 785 mg (1.9 mmol) of (S) -3-tert-butoxycarbonylamino-2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1 methyl-methylpropanoate,\n\n\n\n\n\n\n \n621 mg (85%) de dichlorhydrate de (S)-3-amino-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-yl]- propanoate de méthyle sont obtenus sous forme d'un solide. \n621 mg (85%) of methyl (S) -3-amino-2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -propanoate dihydrochloride are obtained in the form of a solid.\n\n\n\n\n\n\n \n24.3 : (S)-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-propanoate de méthyle. \n24.3: (S) -2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] - methyl propanoate.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.6, à partir de 621 mg (1 ,6 mmoles) de dichlorhydrate de (S)-3- amino-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle et de 876mg (2,3 mmoles) de chlorhydrate de chlorure de 4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonyle (préparé comme décrit dans l'exemple 17.2), 643mg (64%) de (S)-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin- 1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle \n In a manner similar to Example 3.6, from 621 mg (1.6 mmol) of (S) -3-amino-2- [4- (2-methyl-propane-1-sulfonyl) -piperazin) dihydrochloride were used. Methyl 1-yl] -propanoate and 876 mg (2.3 mmol) of 4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonyl chloride hydrochloride (prepared as described in Example 17.2), 643 mg ( 64%) of (S) -2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino) ] -methyl propanoate\n\n\n\n\n\n\n \nsont obtenus sous forme d'une huile. \nare obtained in the form of an oil.\n\n\n\n\n\n\n \n24.4 : acide (S)-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4- ylméthoxy)-benzènesulfonylamino]-propanoique. \n24.4: (S) -2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] acid propanoic acid.\n\n\n\n\n\n\n \nDe manière analogue à l'exemple 3.7, à partir de 643mg (1 ,0 mmole) de (S)-2-[4-(2-méthyl-propane- 1-sulfonyl)-pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle, 395mg (63%) d' acide (S)-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-yl]-3-[4-(2-méthyl- quinolin-4-ylméthoxy)-benzènesulfonylamino]-propanoique sont obtenus sous forme d'un solide blanc. 24.5 : (S)-N-hydroxy-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4- ylméthoxy)-benzènesulfonylamino]-propionamide. \nIn a similar manner to Example 3.7, from 643 mg (1.0 mmol) of (S) -2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -3- Methyl 4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoate, 395 mg (63%) of (S) -2- [4- (2-methyl-propane-1-sulfonyl) acid) -piperazin-1-yl] -3- [4- (2-methylquinolin-4-ylmethoxy) benzenesulfonylamino] propanoic acid are obtained as a white solid. 24.5: (S) -N-hydroxy-2- [4- (2-methyl-propane-1-sulfonyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy)); benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 390mg (0,6 mmoles) d'acide (S)-2-[4-(2-méthyl- propane-1-sulfonyl)-pipérazin-1-yl]-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]- propanoique, 12mg (3%) de (S)-N-hydroxy-2-[4-(2-méthyl-propane-1-sulfonyl)-pipérazin-1-yl]-3-[4-(2- méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-propionamide sont obtenus sous forme d'un solide blanc. \n In a manner similar to Example 3.8, from 390 mg (0.6 mmol) of (S) -2- [4- (2-methylpropane-1-sulfonyl) -piperazin-1-yl] - 3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propanoic acid, 12 mg (3%) of (S) -N-hydroxy-2- [4- (2-methyl-propane-1-yl) sulfonyl) -piperazin-1-yl] -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -propionamide are obtained as a white solid.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 1 ,01 (d, J=6,7Hz, 6H); 2,05 (m, 1 H); 2,49 (m, 4H); 2,67 (s, 3H); 2,86 (d, J=6,6Hz, 2H); 3,00-3,10 (m, 6H); 3,31 (m, 1 H); 5,71 (s, 2H); 7,34 (d, J=8,9Hz, 2H); 7,52 (m, 1 H); 7,57 (m, 2H); 7,76-7,80 (m, 3H); 7,98 (d, J=8,2Hz, 1 H); 8,10 (m, 1 H); 8,93 (s, 1 H); 10,66 (s, 1 H). \n\n Exemple 25 : (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-trifluorométhyl- pyrazolo[1,5-α]pyridin-3-ylméthoxy)-benzènesulfonylamino]-propionamide. \n \n1\n H NMR (δ, DMSO): 1, 01 (d, J = 6.7Hz, 6H); 2.05 (m, 1H); 2.49 (m, 4H); 2.67 (s, 3H); 2.86 (d, J = 6.6Hz, 2H); 3.00-3.10 (m, 6H); 3.31 (m, 1H); 5.71 (s, 2H); 7.34 (d, J = 8.9Hz, 2H); 7.52 (m, 1H); 7.57 (m, 2H); 7.76-7.80 (m, 3H); 7.98 (d, J = 8.2 Hz, 1H); 8.10 (m, 1H); 8.93 (s, 1H); 10.66 (s, 1H).  Example 25: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n25.1 : 2-thfluorométhyl-pyrazolo[1,5-a]pyhdine-3-carboxylate d'éthyle. \n25.1: ethyl 2-thfluoromethyl-pyrazolo [1,5-a] pyhdine-3-carboxylate.\n\n\n\n\n\n\n \nUne solution de 2,1g (38 mmoles) de KOH dans 20ml d'eau puis 6,7g (30 mmoles) d'iodure de 1- amino-pyridinium sont ajoutés à une solution de 2,5g (15 mmoles) de 4,4,4-trifluoro-but-2-ynoate d'éthyle dans 25ml de dichlorométhane. Après agitation à température ambiante pendant 5h, de l'eau est additionnée et le milieu réactionnel est extrait au dichlorométhane. La phase organique est lavée à l'eau, séchée sur sulfate de magnésium, filtrée et concentrée. Le résidu obtenu est purifié par chromatographie sur gel de silice élue avec un mélange heptane / acétate d'éthyle 8/2. 2,8g (73%) de 2-trifluorométhyl-pyrazolo[1 ,5-α]pyridine-3-carboxylate d'éthyle sont obtenus sous forme d'un solide jaune. \nA solution of 2.1 g (38 mmol) of KOH in 20 ml of water and then 6.7 g (30 mmol) of 1-amino-pyridinium iodide are added to a solution of 2.5 g (15 mmol) of 4, Ethyl 4,4-trifluoro-but-2-ynoate in 25 ml of dichloromethane. After stirring at room temperature for 5 hours, water is added and the reaction mixture is extracted with dichloromethane. The organic phase is washed with water, dried over magnesium sulfate, filtered and concentrated. The residue obtained is purified by chromatography on silica gel eluted with a heptane / ethyl acetate mixture 8/2. 2.8 g (73%) of ethyl 2-trifluoromethyl-pyrazolo [1,5-a] pyridine-3-carboxylate are obtained in the form of a yellow solid.\n\n\n\n\n\n\n \n25.2 : (2-thfluorométhyl-pyrazolo[1 , 5-a]pyhdin-3-yl)-méthanol. \n25.2: (2-thfluoromethyl-pyrazolo [1,5-a] pyhdin-3-yl) -methanol.\n\n\n\n\n\n\n \nUne solution de 2,8g (11 mmoles) de 2-trifluorométhyl-pyrazolo[1 ,5-α]pyridine-3-carboxylate d'éthyle dans 50ml de tétrahydrofuranne est additionnée goutte à goutte à une suspension de 0,5g (12 mmoles) d'hydrure d'aluminium et de lithium dans 45ml de tétrahydrofuranne. Le milieu réactionnel est ensuite agité à 7O\n0\nC pendant 3h. Après addition goutte à goutte de 2,5ml de méthanol puis de 1 ,8ml d'une solution aqueuse d'hydroxyde de sodium de concentration 2N, le milieu réactionnel est agité 20mn à température ambiante puis filtré. Le filtrat est séché sur sulfate de magnésium, filtré et concentré sous vide. 2,3g (100%) de (2-trifluorométhyl-pyrazolo[1 ,5-α]pyridin-3-yl)-méthanol sont obtenus sous forme d'un solide. \nA solution of 2.8 g (11 mmol) of ethyl 2-trifluoromethyl-pyrazolo [1,5-a] pyridine-3-carboxylate in 50 ml of tetrahydrofuran is added dropwise to a suspension of 0.5 g (12 mmol ) of aluminum hydride and lithium in 45ml of tetrahydrofuran. The reaction medium is then stirred at 70 \n°\n C. for 3 hours. After dropwise addition of 2.5 ml of methanol and then 1.8 ml of a 2N aqueous solution of sodium hydroxide, the reaction medium is stirred for 20 minutes at ambient temperature and then filtered. The filtrate is dried over magnesium sulfate, filtered and concentrated in vacuo. 2.3 g (100%) of (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-yl) -methanol are obtained in the form of a solid.\n\n\n\n\n\n\n \n25.3 : (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-thfluorométhyl-pyrazolo[1, 5-a]pyridin-3- ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle. \n25.3: (S) -2- (4-Methanesulfonyl-piperazin-1-yl) -3- [4- (2-thfluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino] propanoate methyl.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 11.1 , à partir de 800mg (1 ,9 mmoles) de (S)-3-(4-hydroxy- benzènesulfonylamino)-2-(4-méthanesulfonyl-pipérazin-1-yl)-propanoate de méthyle (préparé comme décrit en 5.1 ) et de 540mg (2,5 mmoles) de (2-trifluorométhyl-pyrazolo[1 ,5-α]pyridin-3-yl)-méthanol, 380mg (32%) de (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-trifluorométhyl-pyrazolo[1 ,5- a]pyridin-3-ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \n In a manner analogous to Example 11.1, from 800 mg (1.9 mmol) of (S) -3- (4-hydroxybenzenesulfonylamino) -2- (4-methanesulfonyl-piperazin-1-yl) -propanoate. methyl (prepared as described in 5.1) and 540 mg (2.5 mmol) of (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-yl) -methanol, 380 mg (32%) of (S) - Methyl 2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino] -propanoate are obtained in the form of a white solid.\n\n\n\n\n\n\n \n25.4 : acide (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-thfluorométhyl-pyrazolo[1,5-α]pyhdin-3- ylméthoxy)-benzènesulfonylamino]-propanoique. \n25.4: (S) -2- (4-Methanesulfonyl-piperazin-1-yl) -3- [4- (2-thfluoromethyl-pyrazolo [1,5-a] pyhdin-3-ylmethoxy) -benzenesulfonylamino] -propanoic acid .\n\n\n\n\n\n\n \nDe manière analogue à l'exemple 3.7, à partir de 380mg (0,6 mmoles) de (S)-2-(4-méthanesulfonyl- pipérazin-1-yl)-3-[4-(2-trifluorométhyl-pyrazolo[1 ,5-α]pyridin-3-ylméthoxy)-benzènesulfonylamino]- propanoate de méthyle, 237mg (64%) d' acide (S)-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2- trifluorométhyl-pyrazolo[1 ,5-α]pyridin-3-ylméthoxy)-benzènesulfonylamino]-propanoique \nAnalogously to Example 3.7, from 380 mg (0.6 mmol) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-trifluoromethyl-pyrazolo [ Methyl 1, 5-α] pyridin-3-ylmethoxy) -benzenesulfonylamino] -propanoate, 237 mg (64%) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4] - (2-Trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino] -propanoic\n\n\n\n\n\n\n \nsont obtenus sous forme d'un solide blanc. \n\n25.5: (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-thfluorométhyl-pyrazolo[1,5- a]pyridin-3-ylméthoxy)-benzènesulfonylamino]-propionamide. \nare obtained in the form of a white solid.  25.5: (S) -N-Hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-thfluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino ] -propionamide.\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 230mg (0,4 mmoles) d'acide (S)-2-(4- méthanesulfonyl-pipérazin-1-yl)-3-[4-(2-trifluorométhyl-pyrazolo[1 ,5-α]pyridin-3-ylméthoxy)- benzènesulfonylamino]-propanoique, 9mg (4%) de (S)-N-hydroxy-2-(4-méthanesulfonyl-pipérazin-1- yl)-3-[4-(2-trifluorométhyl-pyrazolo[1 ,5-α]pyridin-3-ylméthoxy)-benzènesulfonylamino]-propionamide sous forme d'un solide blanc. \n In a manner similar to Example 3.8, from 230 mg (0.4 mmol) of (S) -2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-trifluoromethyl) -2- pyrazolo [1,5-a] pyridin-3-ylmethoxy) benzenesulfonylamino] propanoic acid, 9mg (4%) of (S) -N-hydroxy-2- (4-methanesulfonyl-piperazin-1-yl) -3- [4- (2-Trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino] -propionamide as a white solid.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,51-2,54 (m, 4H); 2,84 (s, 3H); 2,95 (m, 1 H); 2,97-3,04 (m, 4H); 3,10 (m, 1 H); 3,32 (m, 1 H); 5,45 (s, 2H); 7,20-7,25 (m, 3H); 7,49-7,51 (m, 2H); 7,76 (d, J=8,8Hz, 2H); 8,04 (m, 1 H); 8,87 (d, J=7Hz, 2H); 8,90 (m, 1 H). \n \n1\n H NMR (δ, DMSO): 2.51-2.54 (m, 4H); 2.84 (s, 3H); 2.95 (m, 1H); 2.97-3.04 (m, 4H); 3.10 (m, 1H); 3.32 (m, 1H); 5.45 (s, 2H); 7.20-7.25 (m, 3H); 7.49-7.51 (m, 2H); 7.76 (d, J = 8.8 Hz, 2H); 8.04 (m, 1H); 8.87 (d, J = 7Hz, 2H); 8.90 (m, 1H).\n\n\n\n\n\n\n \nExemple 26 : (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4- (propane-2-sulfonyl)-pipérazin-1-yl]-propionamide. 26.1 : (S)-3-tertbutoxycarbonylamino-2-[4-(propane-2-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle De manière analogue à l'exemple 20.2, à partir de 800mg (2,8 mmoles) de (S)-3- tertbutoxycarbonylamino-2-pipérazin-1-yl-propanoate de méthyle (préparé comme décrit dans l'exemple 23.1 ) et de 342μl (3,1 mmoles) de chlorure de propane-2-sulfonyle, 700mg (64%) de (S)-3- tertbutoxycarbonylamino-2-[4-(propane-2-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle sont obtenus sous forme d'une huile. \nExample 26: (S) -N-Hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (propane-2-sulfonyl) -piperazin-1-yl] -propionamide. 26.1: Methyl (S) -3-tertbutoxycarbonylamino-2- [4- (propan-2-sulfonyl) -piperazin-1-yl] -propanoate Analogous to Example 20.2, from 800 mg (2.8 g) mmol) of methyl (S) -3-tert-butoxycarbonylamino-2-piperazin-1-yl-propanoate (prepared as described in Example 23.1) and 342 μl (3.1 mmol) of propane-2-sulphonyl chloride, 700 mg (64%) of methyl (S) -3-tert-butoxycarbonylamino-2- [4- (propane-2-sulfonyl) -piperazin-1-yl] -propanoate are obtained in the form of an oil.\n\n\n\n\n\n\n \n26.2 : dichlorhydrate de (S)-3-amino-2-[4-(propane-2-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle De manière analogue à l'exemple 3.3, à partir de 700mg (1 ,8 mmoles) (S)-3-tertbutoxycarbonylamino- 2-[4-(propane-2-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle, 620mg (86%) du dichlorhydrate de (S)-3-amino-2-[4-(propane-2-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle sont obtenus sous forme d'une huile. \n26.2: Methyl (S) -3-amino-2- [4- (propan-2-sulfonyl) -piperazin-1-yl] -propanoate dihydrochloride Analogous to Example 3.3, starting from 700 mg (1 Methyl (S) -3-tert-butoxycarbonylamino-2- [4- (propane-2-sulfonyl) -piperazin-1-yl] -propanoate, 620 mg (86%) of the (S) -3-dihydrochloride. Methyl amino-2- [4- (propane-2-sulfonyl) -piperazin-1-yl] -propanoate are obtained as an oil.\n\n\n\n\n\n\n \n26.3 : (S)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(propane-2-sulfonyl)- pipérazin-1 -yl]-propanoate de méthyle \n26.3: Methyl (S) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (propan-2-sulfonyl) piperazin-1-yl] -propanoate\n\n\n\n\n\n\n \nDe manière analogue à l'exemple 17.6, à partir de 620mg (1 ,5 mmoles) de dichlorhydrate de (S)-3- amino-2-[4-(propane-2-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle et de 830mg (2,1 mmoles) de chlorhydrate de chlorure de 4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonyle (préparé comme décrit dans l'exemple 17.2), 505mg (54%) de (S)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)- benzènesulfonylamino]-2-[4-(propane-2-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \nIn a manner similar to Example 17.6, from 620 mg (1.5 mmol) of (S) -3-amino-2- [4- (propane-2-sulfonyl) -piperazin-1-yl] dihydrochloride, methyl propanoate and 830 mg (2.1 mmol) of 4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonyl chloride hydrochloride (prepared as described in Example 17.2), 505 mg (54%) of Methyl 3- (4- (2-methyl-quinolin-4-ylmethoxy) benzenesulfonylamino] -2- [4- (propan-2-sulfonyl) -piperazin-1-yl] -propanoate are obtained in the form of of a white solid.\n\n\n\n\n\n\n \n26.4 : acide (S)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(propane-2- sulfonyl)-pipérazin-1-yl]-propanoique \n26.4: (S) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (propane-2-sulfonyl) -piperazin-1-yl] -propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 505mg (0,8 mmoles) de (S)-3-[4-(2-méthyl-quinolin- 4-ylméthoxy)-benzènesulfonylamino]-2-[4-(propane-2-sulfonyl)-pipérazin-1-yl]-propanoate de méthyle, \n\n135mg (27%) d' acide (S)-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(propane- 2-sulfonyl)-pipérazin-1-yl]-propanoique sont obtenus sous forme d'un solide blanc. \nAnalogous to Example 3.7, from 505 mg (0.8 mmol) of (S) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- ( methyl propane-2-sulfonyl) -piperazin-1-yl] -propanoate,  135mg (27%) of (S) -3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (propane-2-sulfonyl) -piperazin-1-yl) ] -propanoic are obtained in the form of a white solid.\n\n\n\n\n\n\n \n26.5 : (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(propane-2- sulfonyl)-pipérazin-1-yl]-propionamide \n26.5: (S) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino] -2- [4- (propane-2-sulfonyl) -piperazin-1-yl] - propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 135mg (0,2 mmoles) d'acide (S)-3-[4-(2-méthyl- quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4-(propane-2-sulfonyl)-pipérazin-1-yl]-propanoique, 24mg (17%) de (S)-N-hydroxy-3-[4-(2-méthyl-quinolin-4-ylméthoxy)-benzènesulfonylamino]-2-[4- (propane-2-sulfonyl)-pipérazin-1-yl]-propionamide sont obtenus sous forme d'un solide blanc. \n Analogously to Example 3.8, from 135 mg (0.2 mmol) of (S) -3- [4- (2-methylquinolin-4-ylmethoxy) benzenesulfonylamino] -2- [4] - (propan-2-sulfonyl) -piperazin-1-yl] propanoic acid, 24 mg (17%) of (S) -N-hydroxy-3- [4- (2-methyl-quinolin-4-ylmethoxy) -benzenesulfonylamino) ] -2- [4- (propane-2-sulfonyl) -piperazin-1-yl] -propionamide are obtained as a white solid.\n\n\n\n\n\n\n \nRMN \n1\nH (δ, DMSO) : 1 ,19 (d, J=6,8Hz, 6H); 2,45 (m, 4H); 2,68 (s, 3H); 2,80-2,90 (m, 1 H); 2,95-3,15 (m, 6H); 3,29 (m, 1 H); 5,72 (s, 2H); 7,34 (d, J=8,9Hz, 2H); 7,52 (m, 1 H); 7,57 (m, 2H); 7,76-7,80 (m, 3H); 7,98 (d, J=8,2Hz, 1 H); 8,10 (d, J=8,1 Hz, 1 H); 8,93 (s, 1 H); 10,66 (s, 1 H). \n \n1\n H NMR (δ, DMSO): 1.19 (d, J = 6.8 Hz, 6H); 2.45 (m, 4H); 2.68 (s, 3H); 2.80-2.90 (m, 1H); 2.95-3.15 (m, 6H); 3.29 (m, 1H); 5.72 (s, 2H); 7.34 (d, J = 8.9Hz, 2H); 7.52 (m, 1H); 7.57 (m, 2H); 7.76-7.80 (m, 3H); 7.98 (d, J = 8.2 Hz, 1H); 8.10 (d, J = 8.1 Hz, 1H); 8.93 (s, 1H); 10.66 (s, 1H).\n\n\n\n\n\n\n \nExemple 27 : (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy -3-[4-(2-trifluorométhyl-pyrazolo[1,5- α]pyridin-3-ylméthoxy)-benzènesulfonylamino]-propionamide. \nExample 27: (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) benzenesulfonylamino] -propionamide.\n\n\n\n\n\n\n \n27.1 : chlorure de 4-hydroxy-benzènesulfonyle \n27.1: 4-hydroxy-benzenesulfonyl chloride\n\n\n\n\n\n\n \n Une solution de 7g (30 mmoles) du sel de sodium de l'acide 4-hydroxy-benzènesulfonique dihydrate dans 40ml de diméthylformamide est additionnée goutte à goutte à une solution de 15,5ml (181 mmoles) de chlorure d'oxalyle dans 120ml de dichlorométhane refroidie à -3O\n0\nC. Le milieu réactionnel est lentement ramené à température ambiante puis agité à température ambiante pendant 18h. Après addition de 200ml de glace, le milieu réactionnel est extrait à l'acétate d'éthyle. La phase organique est lavée par de l'eau, par une solution aqueuse saturée de chlorure de sodium, séchée sur sulfate de magnésium, filtrée et concentrée. 6,2g (100%) de chlorure de 4-hydroxy-benzènesulfonyle sont obtenus sous forme d'une huile incolore. \nA solution of 7 g (30 mmol) of the sodium salt of 4-hydroxy-benzenesulphonic acid dihydrate in 40 ml of dimethylformamide is added dropwise to a solution of 15.5 ml (181 mmol) of oxalyl chloride in 120 ml of dichloromethane cooled to -30 \n°\n C. The reaction medium is slowly brought to ambient temperature and then stirred at ambient temperature for 18 hours. After addition of 200 ml of ice, the reaction medium is extracted with ethyl acetate. The organic phase is washed with water, with a saturated aqueous solution of sodium chloride, dried over magnesium sulfate, filtered and concentrated. 6.2 g (100%) of 4-hydroxy-benzenesulfonyl chloride are obtained in the form of a colorless oil.\n\n\n\n\n\n\n \n27.2 : (S)-2-(4-benzyl-pipérazin-1-yl)-3-(4-hydroxy-benzènesulfonylamino)-propanoate de méthyle\n27.2: methyl (S) -2- (4-benzylpiperazin-1-yl) -3- (4-hydroxy-benzenesulfonylamino) propanoate\n\n\n\n\n\n\n \nDe manière analogue à l'exemple 3.6, à partir de 5,8g (30 mmoles) de chlorure de 4-hydroxy- benzènesulfonyle et de 7,7g (20 mmoles) de trichlorhydrate de (S)-3-amino-2-(4-benzyl-pipérazin-1- yl)-propanoate de méthyle (préparé comme décrit dans l'exemple 17.5), 2,25g (27%) de (S)-2-(4- benzyl-pipérazin-1-yl)-3-(4-hydroxy-benzènesulfonylamino)-propanoate de méthyle sont obtenus sous forme d'un solide blanc. \nIn a similar manner to Example 3.6, from 5.8 g (30 mmol) of 4-hydroxybenzenesulfonyl chloride and 7.7 g (20 mmol) of (S) -3-amino-2- ( Methyl 4-benzyl-piperazin-1-yl) -propanoate (prepared as described in Example 17.5), 2.25 g (27%) of (S) -2- (4-benzyl-piperazin-1-yl) Methyl 3- (4-hydroxy-benzenesulfonylamino) propanoate are obtained as a white solid.\n\n\n\n\n\n\n \n27.3 : (S)-2-(4-benzyl-pipérazin-1-yl)-3-[4-(2-trifluorométhyl-pyrazolo[1,5-a]pyridin-3-ylméthoxy)- benzènesulfonylamino]-propanoate de méthyle \n27.3: (S) -2- (4-Benzyl-piperazin-1-yl) -3- [4- (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino] propanoate methyl\n\n\n\n\n\n\n \n De manière analogue à l'exemple 11.1 , à partir de 500mg (1 ,1 mmoles) de (S)-2-(4-benzyl-pipérazin- 1-yl)-3-(4-hydroxy-benzènesulfonylamino)-propanoate de méthyle, et de 370mg (1 ,7 mmoles) de (2- trifluorométhyl-pyrazolo[1 ,5-α]pyridin-3-yl)-méthanol (préparé comme décrit dans l'exemple 25.2), 350mg (50%) de (S)-2-(4-benzyl-pipérazin-1-yl)-3-[4-(2-trifluorométhyl-pyrazolo[1 ,5-α]pyridin-3- \n\n ylméthoxy)-benzènesulfonylamino]-propanoate de méthyle sont obtenus sous forme d'une huile incolore. \nIn a manner analogous to Example 11.1, from 500 mg (1.1 mmol) of (S) -2- (4-benzyl-piperazin-1-yl) -3- (4-hydroxy-benzenesulfonylamino) -propanoate. methyl, and 370mg (1.7 mmol) of (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-yl) -methanol (prepared as described in Example 25.2), 350mg (50%) of (S) -2- (4-Benzyl-piperazin-1-yl) -3- [4- (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-  Methyl ylmethoxy) -benzenesulfonylamino] -propanoate are obtained as a colorless oil.\n\n\n\n\n\n\n \n27.4 : acide (S)-2-(4-benzyl-pipérazin-1-yl)-3-[4-(2-trifluorométhyl-pyrazolo[1,5-α]pyridin-3-ylméthoxy)- benzènesulfonylamino]-propanoïque \n27.4: (S) -2- (4-Benzyl-piperazin-1-yl) -3- [4- (2-trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino] propanoic acid\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.7, à partir de 350mg (0,5 mmoles) de (S)-2-(4-benzyl-pipérazin-1- yl)-3-[4-(2-trifluorométhyl-pyrazolo[1 ,5-α]pyridin-3-ylméthoxy)-benzènesulfonylamino]- propanoate de méthyle, 165mg (48%) d' acide (S)-2-(4-benzyl-pipérazin-1-yl)-3-[4-(2-trifluorométhyl-pyrazolo[1 ,5- α]pyridin-3-ylméthoxy)-benzènesulfonylamino]-propanoïque sont obtenus sous forme d'un solide blanc. \n Analogous to Example 3.7, from 350 mg (0.5 mmol) of (S) -2- (4-benzyl-piperazin-1-yl) -3- [4- (2-trifluoromethyl-pyrazolo [ Methyl 1,5-α] pyridin-3-ylmethoxy) -benzenesulfonylamino] propanoate, 165 mg (48%) of (S) -2- (4-benzylpiperazin-1-yl) -3- [4] (2-Trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino] -propanoic acid are obtained in the form of a white solid.\n\n\n\n\n\n\n \n27.5 : (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-thfluorométhyl-pyrazolo[1,5-α]pyhdin-3- ylméthoxy)-benzènesulfonylamino]-propionamide \n27.5: (S) -2- (4-Benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-thfluoromethyl-pyrazolo [1,5-a] pyhdin-3-ylmethoxy) -benzenesulfonylamino ] -propionamide\n\n\n\n\n\n\n \n De manière analogue à l'exemple 3.8, à partir de 165mg (0,3 mmoles) d'acide (S)-2-(4-benzyl- pipérazin-1-yl)-3-[4-(2-trifluorométhyl-pyrazolo[1 ,5-α]pyridin-3-ylméthoxy)-benzènesulfonylamino]- propanoique, 50mg (29%) de (S)-2-(4-benzyl-pipérazin-1-yl)-N-hydroxy-3-[4-(2-trifluorométhyl- pyrazolo[1 ,5-α]pyridin-3-ylméthoxy)-benzènesulfonylamino]-propionamide sont obtenus sous forme d'un solide blanc de point de fusion 138\n0\nC. \nAnalogously to Example 3.8, from 165 mg (0.3 mmol) of (S) -2- (4-benzylpiperazin-1-yl) -3- [4- (2-trifluoromethyl) -2- pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino] propanoic acid, 50 mg (29%) of (S) -2- (4-benzyl-piperazin-1-yl) -N-hydroxy-3- [4- (2-Trifluoromethyl-pyrazolo [1,5-a] pyridin-3-ylmethoxy) -benzenesulfonylamino] -propionamide are obtained in the form of a white solid having a melting point of 138 \n°\n C.\n\n\n\n\n\n\n \n RMN \n1\nH (δ, DMSO) : 2,20 (m, 4H); 2,38 (m, 4H); 2,65-2,75 (m, 1 H); 2,86-2,98 (m, 2H); 3,35 (m, 2H); 5,37 (s, 2H); 7,10-7,25 (m, 8H); 7,35-7,44 (m, 2H); 7,68 (d, J=8,9Hz, 2H); 7,98 (d, J=9Hz, 1 H); 8,81\n \n1\n H NMR (δ, DMSO): 2.20 (m, 4H); 2.38 (m, 4H); 2.65-2.75 (m, 1H); 2.86-2.98 (m, 2H); 3.35 (m, 2H); 5.37 (s, 2H); 7.10-7.25 (m, 8H); 7.35-7.44 (m, 2H); 7.68 (d, J = 8.9Hz, 2H); 7.98 (d, J = 9Hz, 1H); 8.81\n\n\n\n\n\n\n \n(m, 2H); 10,52 (s, 1 H). \n(m, 2H); 10.52 (s, 1H).\n\n\n\n\n\n\n \nExemple 28 : Test enzymatique d'inhibition de TACE. Description du test \nExample 28 Enzymatic Test for TACE Inhibition Description of the test\n\n\n\n\n\n\n \n Les produits sont solubilisés dans du DMSO à une concentration de 10 mM. Une dilution sérielle de raison 3 sur 10 points est effectuée de façon à avoir une gamme de concentration allant de 10 μM à 0,5 nM final. \n The products are solubilized in DMSO at a concentration of 10 mM. A serial dilution of 3 out of 10 points is carried out so as to have a concentration range from 10 μM to 0.5 nM final.\n\n\n\n\n\n\n \nL'enzyme TACE est une production interne (réalisée selon la publication « protein Eng Des Sel 2006, 19., 155-161 ») et, est ajouté de façon à avoir un signal équivalent à 6 fois le bruit de fond en 2h à 37\n0\nC. La réaction s'effectue en milieu tamponné Tris 50 mM, 4% de glycérol, pH7,4. Le substrat fluorescent est MCA-Pro-Leu-Ala-Val-(Dpa)-Arg-Ser-Ser-Arg-NH2 (R&D System référence :ES003). Le substrat est clivé par l'enzyme entre l'alanine et la valine libérant ainsi un peptide fluorescent (excitation : 320nm, émission : 420nm). Le substrat est utilisé à 40μM. la réaction est réalisée dans un volume final de 10μl (4μl inhibiteur, 4μl substrat, 2μl enzyme) dans une plaque de 384 puits low volume (Corning référence : 3676). La plaque est incubée 2h à température ambiante, puis lue en fluorescence au Pherastar (BMG labtech). L\n1\nIC\n50\n est déterminée en utilisant un logiciel de traitement mathématique (XLfit). \n\n Test des produits \nThe TACE enzyme is an internal production (carried out according to the publication \"protein Eng Des Sel 2006, 19., 155-161\") and is added so as to have a signal equivalent to 6 times the background noise in 2 hours at 37. \n0\n C. The reaction is performed in 50 mM Tris buffered medium, 4% glycerol, pH 7.4. The fluorescent substrate is MCA-Pro-Leu-Ala-Val- (Dpa) -Arg-Ser-Ser-Arg-NH2 (R & D System reference: ES003). The substrate is cleaved by the enzyme between alanine and valine thus releasing a fluorescent peptide (excitation: 320 nm, emission: 420 nm). The substrate is used at 40 μM. the reaction is carried out in a final volume of 10 μl (4 μl inhibitor, 4 μl substrate, 2 μl enzyme) in a plate of 384 low-volume wells (Corning reference: 3676). The plate is incubated for 2 hours at room temperature and then read in fluorescence with Pherastar (BMG labtech). L \n1\n IC \n50\n is determined using mathematical processing software (XLfit).  Product testing\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n Sur la base des résultats obtenus dans le test enzymatique TACE décrit ci-dessus, les composés revendiqués dans la présente invention sont des inhibiteurs de l'enzyme TNF-alpha converting enzyme (TACE) et de ce fait peuvent être des principes actifs potentiels pour le traitement de pathologies pour lesquelles diminuer la production de TNF alpha serait d'un grand intérêt. \n Based on the results obtained in the TACE enzymatic assay described above, the compounds claimed in the present invention are inhibitors of the enzyme TNF-alpha converting enzyme (TACE) and therefore may be potential active ingredients for treatment of diseases for which to decrease the production of TNF alpha would be of great interest.\n\n\n\n\n\n\n \nExemple 29 : test de sélectivité \nExample 29: selectivity test\n\n\n\n\n\n\n \nPrincipe du test : \nPrinciple of the test:\n\n\n\n\n\n\n \n Les molécules sont testées en dose réponse sur les enzymes suivants MMP1 , MMP3, MMP9, ADAM9 et ADAM10 suivant le même protocole que celui décrit pour l'enzyme TACE dans l'exemple 28 mais avec des substrats différents (MMP R&D System référence :P126-990 et ADAM R&D System référence :ES003). \n The molecules are tested in dose response on the following enzymes MMP1, MMP3, MMP9, ADAM9 and ADAM10 according to the same protocol as that described for the enzyme TACE in Example 28 but with different substrates (MMP R & D System reference: P126- 990 and ADAM R & D System Reference: ES003).\n\n\n\n\n\n\n \nLes enzymes sont achetées chez Calbiochem \nEnzymes are bought at Calbiochem\n\n\n\n\n\n\n \nTest des produits : \nProduct testing:\n\n\n\n\n\n\n \nIC50 (nM) \n\n\n\n\n\nIC50 (nM) \n \n\n\n\n\n\n\n \nSur la base des résultats obtenus dans le test de sélectivité décrit ci-dessus, ces composés sont également très sélectifs de TACE par rapport aux autres ADAMs et MMPs, c'est-à-dire qu'ils présentent des IC\n50\n pour d'autres ADAMs ou MMPs au moins 10 fois supérieures à celle obtenue pour TACE, et plus avantageusement au moins 100 fois supérieures. \nOn the basis of the results obtained in the selectivity test described above, these compounds are also very selective for TACE compared to other ADAMs and MMPs, ie they have IC \n50\n for others. ADAMs or MMPs at least 10 times higher than that obtained for TACE, and more preferably at least 100 times higher.\n\n\n\n\n\n\n \n Or, dans la mesure où il est connu que l'inhibition non sélective de ces familles d'enzymes induit des effets secondaires indésirables observés In Vivo, l'inhibition sélective de TACE par rapport à ces autres enzymes devrait permettre de réduire des effets secondaires indésirables lors de l'administration de ces molécules pour le traitement de pathologies pour lesquelles diminuer la production de TNF alpha serait d'un grand intérêt. \n\n However, since it is known that the non-selective inhibition of these families of enzymes induces undesirable side effects observed in vivo, the selective inhibition of TACE relative to these other enzymes should make it possible to reduce undesirable side effects. during the administration of these molecules for the treatment of pathologies for which to decrease the production of TNF alpha would be of great interest."
  }
]